A substance that inhibits or prevents the proliferation of neoplasms.
| Member | Definition | Class |
|---|
| (-)-gallocatechin gallate | A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of (-)-gallocatechin. A natural product found in found in green tea. | (-)-gallocatechin gallate |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | A pyridopyrimidine that is pyrido[2,3-d]pyrimidine which is substituted at positions 2 and 4 by (3S)-3-methylmorpholin-4-yl groups and at position 5 by a 3-(hydroxymethyl)-4-methoxyphenyl group. It is an mTOR complex 1/2 (mTORC1/2) dual inhibitor [mTOR = mammalian target of rapamycin]. | AZD-8055 |
| 1-methyltryptophan | A tryptophan derivative that is tryptophan carrying a single methyl substituent at position 1 on the indole. | 1-methyltryptophan |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions. | 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose |
| 1'-acetoxychavicol acetate | An acetate ester that is chavicol acetate substituted by an acetoxy group at position 1'. | 1'-acetoxychavicol acetate |
| 10-propargyl-10-deazaaminopterin | A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma. | pralatrexate |
| 10058-F4 | A member of the class of thiazolidinones that is 2-sulfanylidene-1,3-thiazolidin-4-one which is substituted at position 5 by a (4-ethylphenyl)methylidene group. It is a cell permeable inhibitor of c-Myc-Max dimerization and exhibits antitumour effects in vivo. It downregulates c-Myc expression and upregulates CDK inhibitors, p21 and p27 resulting in the inhibition of proliferation, induction of apoptosis and cell cycle arrest in G0/G1 phase. | 10058-F4 |
| 13(S)-HODE | An HODE (hydroxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroxy group is at position 13 (with S-configuration). | 13(S)-HODE |
| 2-(4-morpholinoanilino)-6-cyclohexylaminopurine | A member of the class of purines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by a [4-(morpholin-4-yl)phenyl]nitrilo group and a cyclohexylamino group, respectively. | reversine |
| 2-fluoroadenine | An organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine. | 2-fluoroadenine |
| 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile | A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued). | AZD1080 |
| 2-hydroxy-9-cis-octadecenoic acid | A 2-hydroxy fatty acid that is oleic acid which carries a hydroxy group at position 2. It is an orally bioavailable synthetic hydroxylated fatty acid which modulates the lipid content of cancer cell membranes and induces cell cycle arrest and apoptosis in several cancer cell lines. | 2-hydroxyoleic acid |
| 2-hydroxyacetanilide | A member of the class of phenols that is 2-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. A positional isomer of paracetamol which possesses anti-inflammatory, anti-arthritic and anti-platelet aggregation properties. | 2-acetamidophenol; 2'-Hydroxyacetanilide |
| 2-methoxyestradiol | A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2. | 2-methoxy-17beta-estradiol |
| 2,2'-thiodiethanol | A diol that is pentane-1,5-diol in which the methylene group at position 3 is replaced by a sulfur atom | thiodiglycol |
| 2,3-dihydro-3beta-O-sulfate withaferin A | A withanolide that is 2,3-dihydrowithaferin A substituted by a sulfoxy group at position 3. Isolated from Physalis longifolia, it exhibits antineoplastic activity. | 2,3-dihydro-3beta-O-sulfate withaferin A |
| 2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 2, 3, 6 and 8, an isoprenyl group at position 1 and a 2-methylbut-3-en-2-yl group at position 5. It is isolated from the root barks of Cudrania tricuspidata and exhibits cytotoxicity towards human cancer cell lines. | cudratricusxanthone A |
| 2,5-dihydroxybenzyl alcohol | An aromatic primary alcohol that is benzyl alcohol substituted by hydroxy groups at positions 2 and 5. | gentisyl alcohol |
| 2,6-diaminopurine | A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups. | 9H-purine-2,6-diamine |
| 2'-methoxykurarinone | A dimethoxyflavanone that is (2S)-(-)-kurarinone in which the hydroxy group at position 2' is replaced by a methoxy group. Isolated from the roots of Sophora flavescens, it exhibits cytotoxicity against human myeloid leukemia HL-60 cells. | (2S)-2'-methoxykurarinone |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor. | BGJ-398 |
| 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one | A member of the class of pyridines that is pyridine substituted by a 3-oxo-3-(pyridin-4-yl)prop-1-en-1-yl group at position 3. An inhibitor of PFKFB3 kinase, an enzyme with a key role in glycolysis. | 3PO |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation. | [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol; lificiguat |
| 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine; rac-crizotinib |
| 3,3'-di-o-methylquercetin | A dimethoxyflavone that is quercetin in which the hydroxy groups at position 3 and 3' have been replaced by methoxy groups. It has been isolated from several plant species and exhibits anti-bacterial and anti-cancer properties. | 3,3'-dimethylquercetin |
| 3,3'-diindolylmethane | | 3,3'-diindolylmethane |
| 3,3',4,5'-tetrahydroxystilbene | A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5. | piceatannol |
| 3,4-dihydroxyphenylethanol | A member of the class of catechols that is benzene-1,2-diol substituted by a 2-hydroxyethyl group at position 4. Isolated from Olea europaea, it exhibits antioxidant and antineoplastic activities. | hydroxytyrosol |
| 3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside | A monosaccharide derivative that consists of 4-(hydroxymethyl)-2,6-dimethoxyphenol attached to a beta-D-glucopyranosyl residue at position 1 via a glycosidic linkage. Isolated from Acacia mearnsii it exhibits cytotoxic activity. | 3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside |
| 3,7-dihydroxytropolone | A cyclic ketone that is tropolone in which the hydrogens at positions 3 and 7 are substituted by hydroxy groups. It is isolated from the soil bacterium Streptomyces tropolofaciens strain K611-97. | 3,7-dihydroxytropolone |
| 3'-deoxyadenosine 5'-triphosphate | | cordycepin triphosphate |
| 3',4',7-trihydroxyisoflavone | A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'. | 3',4',7-trihydroxyisoflavone |
| 3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by a hydroxy group at position 3, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits cytotoxic, anticholinergic and antiserotonergic activities. | zhankuic acid B |
| 3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by hydroxy groups at positions 3 and 12, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha,12alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits antineoplastic activity. | zhankuic acid C |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR). | arotinoid acid |
| 4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide | A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines. | 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease. | TDZD-8 |
| 4-carbamoylimidazolium 5-olate | A hydroxyimidazole that is 5-hydroxyimidazole in which the hydrogen at position 4 is replaced by an aminocarbonyl group. | 5-hydroxyimidazole-4-carboxamide |
| 4-iodo-6-phenylpyrimidine | A member of the class of pyrimidines carrying iodo and phenyl substituents at positions 4 and 6 respectively. | 4-iodo-6-phenylpyrimidine |
| 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol | A terpineol that is 1-menthene carrying a hydroxy substituent at position 4. | 4-terpineol |
| 4-methyl-5-pentylbenzene-1,3-diol | A resorcinol having methyl and pentyl groups at positions 4 and 5 respectively. | 4-methyl-5-pentylbenzene-1,3-diol |
| 4-methylumbelliferyl glucuronide | A beta-D-glucosiduronic acid having a 4-methylumbelliferyl substituent at the anomeric position. A hyaluronan synthesis inhibitor, it is anti-tumourigenic for various malignant tumours. | 4-methylumbelliferone beta-D-glucuronide |
| 4-oxoretinol | A retinoid that is all-trans-retinol in which the hydrogens at position 4 have been replaced by an oxo group. | all-trans-4-oxoretinol |
| 4-phenylbutyric acid | A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation. | 4-phenylbutyric acid |
| 4'-demethyldesoxypodophyllotoxin | A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 4-hydroxy-3,5-dimethoxyphenyl group. | 4'-demethyldeoxypodophyllotoxin |
| 4'-demethylepipodophyllotoxin | An organic heterotetracyclic compound that is the 9- epimer of 4'-demethylpodophyllotoxin. | 4'-demethylepipodophyllotoxin |
| 4'-hydroxychalcone | A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4'. | 4'-hydroxychalcone |
| 4alpha-methylergosta-8,24(28)-dien-3,7,11-trione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by a methyl group at position 4 and oxo groups at positions 3, 7 and 11 (the 4alpha,5alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits cytotoxic and anti-inflammatory activity. | zhankuic acid A |
| 5-(3-methyl-1-triazeno)imidazole-4-carboxamide | A monocarboxylic acid amide that is dacarbazine in which one of the methyl groups is replaced by a hydrogen. It is the active metabolite of dacarbazine, and is also produced by spontaneous hydrolysis of temozolomide in the body. | MTIC |
| 5-(n,n-hexamethylene)amiloride | A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. | 5-(N,N-hexamethylene)amiloride |
| 5-(tetradecyloxy)-2-furancarboxylic acid | A member of the class of furans that is 2-furoic acid in which the hydrogen at position 5 is replaced by a tetradecyloxy group. | 5-(tetradecyloxy)-2-furoic acid |
| 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride | A hydrochloride obtained by combining tipiracil with one equivalent of hydrochloric acid. Used in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. | tipiracil hydrochloride |
| 5-heptadecylresorcinol | A 5-alkylresorcinol that is resorcinol which is substituted by a heptadecyl group at position 5. It is found in wheat bran. | 5-heptadecylresorcinol |
| 5-o-methylembelin | A member of the class of monohydroxy-1,4-benzoquinones that is embelin in which the hydroxy group at position 5 is replaced by a methoxy group. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antileishmanial activity as well as inhibitory activity towards hepatitis C protease. | 5-O-methyl embelin |
| 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one | A member of the class of chromones that is 4H-chromen-4-one in which the hydrogens at positions 2,5,7 and 8 are replaced by methyl, hydroxy, hydroxy, and (3S,4R)-3-hydroxy-1-methylpiperidin-4-yl groups, respectively. It is an alkaloid initially isolated from Amoora rohituka and is a precursor of the anti-cancer compound flavopiridol. | rohitukine |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6. | oroxylin A |
| 5,7,3'-trihydroxy-3,4'-dimethoxyflavone | A dimethoxyflavone that is the 3,4'-dimethyl ether derivative of quercetin. Isolated from Combretum quadrangulare, it exhibits antineoplastic activity. | quercetin 3,4'-dimethyl ether |
| 6-anilino-5,8-quinolinedione | A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group. | 6-anilino-5,8-quinolinedione |
| 6-azauridine-5'-monophosphate | A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of uridine 5'-monophosphate. | 6-azauridine 5'-monophosphate |
| 6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene | | (+)-halomon |
| 6-hydroxytaxol | A taxane diterpenoid that consists of paclitaxel bearing an additional hydroxy substituent at the 6alpha-position. | 6-hydroxypaclitaxel |
| 6-methoxyspirotryprostatin b | An indole alkaloid isolated from a marine-derived fungal strain Aspergillus sydowii PFW1-13 and has been shown to exhibit cytotoxic activity. | 6-methoxyspirotryprostatin B |
| 6-methylthiohexyl isothiocyanate | A isothiocyanate that is hexane in which two of the terminal methyl hydrogens at positions 1 and 6 have been replaced by isothiocyanato and methylsulfanyl groups. | 1-isothiocyanato-6-(methylsulfanyl)hexane |
| 7,8-dihydroxyflavanone | A dihydroxyflavanone with hydroxy substituents at positions 7 and 8. Isolated from the seeds of Alpinia katsumadai, it acts as a an inhibitor for Jun-Fos-DNA complex formation and exhibits antineoplastic activity. | 7,8-dihydroxyflavanone |
| 7,8-dihydroxyflavone | A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's. | 7,8-dihydroxyflavone |
| 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine | A member of the class of 6-aminopurines that is 2-fluoroadenine carrying additional 2-chloro-3,4,5-trimethoxybenzyl and pent-4-yn-1-yl substituents at positions 8 and 9 respectively. | 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine |
| 9-arabinofuranosylguanine | A purine nucleoside in which guanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. It inhibits DNA synthesis and causes cell death. | 9-beta-D-arabinofuranosylguanine |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | A member of the class of prostaglandins J that is prosta-5,9,12-trien-1-oic acid carrying oxo and hydsroxy substituents at positions 11 and 15 respectively (the 5Z,12E,15S-stereoisomer). | 13,14-dihydro-Delta(12)-prostaglandin J2 |
| 9-hydroxyellipticine | A organic heterotetracyclic compound that is ellipticine in which the hydrogen at position 9 has been replaced by a hydroxy group. | 9-hydroxyellipticine |
| 9-methoxycanthin-6-one | An indole alkaloid that is the 9-methoxy derivative of canthin-6-one. Isolated from Eurycoma longifolia and Simaba multiflora, it exhibits cytotoxic activity towards human cancer cell lines. | 9-methoxycanthin-6-one |
| 9,11-linoleic acid | An octadeca-9,11-dienoic acid having 9-trans,11-trans-stereochemistry. | (9E,11E)-octadecadienoic acid |
| abarelix | A polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence. | abarelix |
| abiraterone | A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. | abiraterone |
| abiraterone acetate | A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. | abiraterone acetate |
| abt 869 | A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 2-fluoro-5-methylphenyl group, while the other is substituted by a p-(3-amino-1H-indazol-4-yl)phenyl group. It is a potent, selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases. | linifanib |
| abt-199 | A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. | venetoclax |
| abt-737 | A biphenyl that is 4-chloro-1,1'-biphenyl substituted by a (4-{4-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)carbamoyl]phenyl}piperazin-1-yl)methyl group at position 2'. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. | ABT-737 |
| acadesine | A 1-ribosylimidazolecarboxamide in which the carboxamide group is situated at position 4 of the imidazole ring, which is further substituted at position 5 by an amino group. A purine nucleoside analogue and activator of AMP-activated protein kinase, it is is used for the treatment of acute lymphoblastic leukemia and is reported to have cardioprotective effects. | acadesine |
| acarbose | A chondramide that is chondramide A in which the hydrogen at position 2 of the indole moiety has been replaced by a chlorine. It is produced by strains of the myxobacterium, Chondromyces crocatus. | chondramide B |
| acetopyrrothine | A dithiolopyrrolone antibiotic that is 4,5-dihydro[1,2]dithiolo[4,3-b]pyrrole in which the hydrogens at positions 4,5 and 6 have been replaced by methyl, oxo and acetamido groups, respectively. It is a potent inhibitor of RNA polymerases, inhibits the angiogenesis of human umbilical vein endothelial cells, and also inhibits JAMM metalloproteases. | thiolutin |
| acetyl aleuritolic acid | A pentacyclic triterpenoid isolated from the leaves of Garcia parviflora. | acetyl aleuritolic acid |
| acivicin | An L-alpha-amino acid that is L-alanine in which the methyl group is replaced by a (5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl group. A glutamine analogue antimetabolite, it interferes with glutamate metabolism and several glutamate-dependent synthetic enzymes. It is obtained as a fermentation product of Streptomyces sviceus bacteria. | acivicin |
| aclacinomycin | An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage. | aclacinomycin T zwitterion; aclacinomycin T |
| aclacinomycin | A zwitterion obtained by transfer of a proton from the 5-hydroxy to the tertiary amino group of aclacinomycin T. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). | aclacinomycin T zwitterion; aclacinomycin T |
| aclarubicin | An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity. | aclacinomycin A zwitterion; aclacinomycin A |
| aclarubicin | A zwitterion obtained by transfer of a proton from the 5-hydroxy to the tertiary amino group of aclacinomycin A. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). | aclacinomycin A zwitterion; aclacinomycin A |
| acp-196 | A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. | acalabrutinib |
| acronine | An alkaloid antineoplastic agent isolated from Acronychia baueri. | acronycine |
| actinodaphine | An organic heteropentacyclic compound 6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline bering additional hydroxy and methoxy substituents at positions 10 and 11 respectively. | actinodaphnine |
| adenosine-5'-(n-ethylcarboxamide) | A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group. | N-ethyl-5'-carboxamidoadenosine |
| adonixanthin | A carotenone that consists of beta,beta-caroten-4-one bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'R diastereomer). | adonixanthin |
| aee 788 | A 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine which adopts an R-configuration. It is a potent inhibitor of human EGFR, VEGFR and HER2 receptor tyrosine kinases and exhibits anticancer and antiangiogenic activity. | AEE788 |
| afimoxifene | A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. | afimoxifene |
| agathisflavone | A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-6 and C-8 of the two chromene rings. | agathisflavone |
| ageladine a | An imidazopyridine that is 1H-imidazo[4,5-c]pyridin-2-amine substituted by a 4,5-dibromo-1H-pyrrol-2-yl group at position 4. It is an alkaloid isolated from a marine sponge Agelas nakamurai and acts as an inhibitor of the matrix metalloproteinases, the key enzymes involved in tumour growth, migration, angiogenesis, invasion and metastasis. | ageladine A |
| aklavinone | | aklavinone |
| alantolactone | A sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3. | alantolactone |
| albicanol | A drimane-type sesquiterpenoid orginally isolated from the liverwort Diplophyllum albicans. It exhibits fish antifeedant, antifungal and antineoplastic activities. | (+)-albicanol |
| alectinib | An organic heterotetracyclic compound that is 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one carrying additional cyano, 4-(morpholin-4-yl)piperidin-1-yl and ethyl substituents at positions 3, 8 and 9 respectively. Used (as the hydrochloride salt) for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer. | alectinib |
| alfuzosin | | alfuzosin |
| alitretinoin | A retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry. | 9-cis-retinoic acid |
| allyl isothiocyanate | An isothiocyanate with the formula CH2=CHCH2N=C=S. A colorless oil with boiling point 152degreeC, it is responsible for the pungent taste of mustard, horseradish, and wasabi. | allyl isothiocyanate |
| aloe emodin | A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe. | Aloe emodin |
| alpha-glutamyltryptophan | A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. | Glu-Trp |
| alpha-peltatin | An organic heterotetracyclic compound that is 4'-demethylpodophyllotoxin which is substituted by a hydroxy group at position 10 but which is lacking the hydroxy group at position 9. It is found as a glucoside in the rhizomes of Podophyllum peltatum. | alpha-peltatin |
| alpha-solanine | A glycoalkaloid poison found in species of the nightshade family (Solanaceae), such as the potato (Solanum tuberosum). It is a trisccharide derivative of solanidine [(22beta)-solanid-5-en-3beta-ol]. | solanine |
| alsterpaullone | An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole. | alsterpaullone |
| alvocidib | A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. | alvocidib |
| am 251 | A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor. | AM-251 |
| am 580 | An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist. | 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid |
| AMG-208 | A member of the class of quinolines that is 7-methoxyquinoline substituted at position 4 by a (6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy group. AMG exhibits antitumour activity, particularly in prostate cancer. | AMG-208 |
| aminoglutethimide | A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position. | aminoglutethimide |
| aminolevulinic acid | The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 5-aminolevulinic acid; 5-ammoniolevulinate |
| aminolevulinic acid hydrochloride | A hydrochloride that is the monohydrochloride of 5-aminolevulinic acid. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 5-aminolevulinic acid hydrochloride |
| aminopropionitrile | An aminopropionitrile carrying an amino group at the beta-position. | beta-aminopropionitrile |
| ampelopsin | An optically active form of dihydromyricetin having (2R,3R)-configuration. | (+)-dihydromyricetin |
| amrubicin | A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol. | amrubicin |
| amrubicinol | A diastereoisomeric mixture resulting from the formal reduction of the acetyl group at position 9 of amrubicin to the corresponding 1-hydroxyethyl group. The active metabolite of amrubicin in lung cancer patients. | amrubicinol |
| amsacrine | A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity. | amsacrine |
| amygdalin | An amygdalin in which the stereocentre on the cyanohydrin function has R-configuration. | (R)-amygdalin |
| anastrozole | A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. | anastrozole |
| ancitabine | An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action. | ancitabine |
| andrographolide | A labdane diterpenoid isolated from the leaves and roots of Andrographis paniculata that exhibits anti-HIV, anti-inflammatory and antineoplastic properties. | andrographolide |
| anisomycin | An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. | (-)-anisomycin |
| anonaine | An aporphine alkaloid that exhibits anti-cancer, trypanocidal and antiplasmodial activites. | (-)-annonaine |
| anthricin | A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 3,4,5-trimethoxyphenyl group. | deoxypodophyllotoxin |
| antofine | An organic heteropentacyclic compound that is (13aR)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline substituted at positions 2, 3 and 6 by methoxy groups. It is an alkaloid produced by relatives of the milkweed family and exhibits antiviral, anti-inflammatory, antiadipogenic and antitumorigenic activities. | (-)-antofine |
| antroquinonol d | An enone that is cyclohex-2-en-1-one substituted by a hydroxy group at position 4, methoxy groups at positions 2 and 3, a methyl group at position 6 and a (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl group at position 5 (the 4R,5R,6R stereoisomer). It is isolated from the solid-state fermented mycelium of the fungus Antrodia camphorata and has been found to exhibit potent cytotoxicity against a number of human cancer cell lines. However, a synthesis-enabled biological re-examination published in 2016, revealed minimal in vitro and in vivo antitumour activity in preclinical models. | antroquinonol |
| aphidicolin | A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication. | aphidicolin |
| apigenin | A trihydroxyflavone that is flavone substituted by hydroxy groups at positions 4', 5 and 7. It induces autophagy in leukaemia cells. | apigenin |
| apratoxin a | An aprotoxin having the common aprotoxin cyclodepsipeptide skeleton where the isoleucyl residue carries an N-methyl substituent and the side-chain adjacent to the lactone is tert-butyl. | apratoxin A |
| arglabin | An organic heterotetracyclic compound and guaianolide sesquiterpene lactone that is acrylic acid which is substituted at position 2 by a 4-hydroxy-3,8-dimethyl-1,3a,4,5,6,7-hexahydroazulen-5-yl group in which the double bond in the 7-membered ring has been epoxidised and in which the hydroxy group and the carboxy group have undergone formal condensation to give the corresponding gamma-lactone. It is found in Artemisia glabella. Arglabin-DMA HCl, the hydrochloride salt of the adduct resulting from the conjugate addition of dimethylamine to the ene-lactone moiety, has been successfully used in Khazakhstan for the treatment of breast, colon, ovarian and lung cancers. | arglabin |
| aromasil | A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. | exemestane |
| ARS-1620 | A qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. | ARS-1620 |
| arsenic trioxide | An arsenic oxide in which arsenic and oxygen atoms are present in the ratio 2:3. | diarsenic trioxide |
| artesunate | An artemisinin derivative that is the hemisuccinate ester of the lactol resulting from the reduction of the lactone carbonyl group of artemisinin. It is used, generally as the sodium salt, for the treatment of malaria. | artesunate |
| artocarpin lectin | A trihydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 2', and 4', a methoxy group at position 7, a prenyl group at position 3 and a (1E)-3-methylbut-1-enyl group at position 6. Isolated from Artocarpus heterophyllus and Artocarpus integrifolia, it exhibits antineoplastic activity. | artocarpin |
| as 1842856 | A quinolone that is 4-quinolone substituted at positions 1, 3, 5, 6 and 7 by ethyl, carboxy, amino, fluorine, and cyclohexylamino groups, respectively. It can directly bind to and block the transcription activity of the active forkhead box protein O1 (Foxo1), but not the Ser256-phosphorylated form. It induces cell death and growth arrest in Burkitt lymphoma cell lines at low concentrations. | AS1842856 |
| ascochlorin | A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (1E,3E)-3-methyl-1-[(1R,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]penta-1,3-dien-5-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by several fungi including Ascochyta viciae . It exhibits anticancer, antifungal and antiprotozoal activities. | ascochlorin |
| ascofuranone | A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis. | ascofuranone |
| asp3026 | A member of the class of diamino-1,3,5-triazines that is 1,3,5-triazine-2,4-diamine in which the amino groups at positions 2 and 4 are respectively carrying 2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl and 2-(propan-2-ylsulfonyl)phenyl substituents. It is a potent inhibitor of anaplastic lymphoma kinase (ALK), Ack and ROS1 activity (IC50 values are 3.5, 5.8 and 8.9 nM respectively) and exhibits anti-cancer properties. | ASP-3026 |
| asperfuranone | A member of the class of 2-benzofurans that is 6,7-dihydro-2-benzofuran-4(5H)-one that is substituted at positions 5 and 6 by hydroxy groups, at position 5 by a methyl group and at position 1 by a (2E,4E,6S)-4,6-dimethylocta-2,4-dienoyl group (the 5S,6R-diastereoisomer). A polyketide that was first obtained from the fungus Aspergillus nidulans by using a genomic mining approach. | asperfuranone |
| aspergillide a | A macrolide that is 4,15-dioxabicyclo[9.3.1]pentadec-9-en-3-one substituted by a hydroxy group at position 14 and a methyl group at position 5 (the 1R,5S,9E,11R,14S stereoisomer). It is isolated from the marine-derived fungus Aspergillus ostianus and exhibits cytotoxic activity against mouse lymphocytic leukemia cells (L1210). | aspergillide A |
| aspergillide b | A macrolide that is 4,15-dioxabicyclo[9.3.1]pentadec-9-en-3-one substituted by a hydroxy group at position 14 and a methyl group at position 5 (the 1S,5S,9E,11R,14S stereoisomer). It is isolated from the marine-derived fungus Aspergillus ostianus and exhibits cytotoxic activity against mouse lymphocytic leukemia cells (L1210). | aspergillide B |
| asperphenamate | A carboxylic ester resulting from the formal condensation of the carboxy group of N-benzoyl-L-phenylalanine with the hydroxy group of N-benzoyl-L-phenylalaninol. A metabolite found in several Pencillium and Aspergillus species, as well as in plants as a product of endophytic fungi. | asperphenamate |
| astringin | A stilbenoid that is piceatannol substituted at position 3 by a beta-D-glucosyl residue. | trans-astringin |
| asukamycin | A polyketide that is a member of the manumycin family of antibiotics and exhibits strong antibacterial, antifungal, and antineoplastic activities. Isolated from from the actinomycete bacterium Streptomyces nodosus subsp. asukaensis. | asukamycin |
| at 13387 | A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor. | onalespib |
| at 7519 | A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine. | 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide |
| at 7867 | A member of the class of piperidines carrying two aryl substituents (4-chlorophenyl and 4-(pyrazol-4-yl)phenyl) at position 4. | AT7867 |
| atromentin | A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxycyclohexa-2,5-diene-1,4-dione which is substituted by a 4-hydroxyphenyl group at positions 3 and 6. It is a mushroom pigment isolated from several fungi species and acts as a smooth muscle stimulant, and exhibits anticoagulant, antibacterial and antineoplastic properties. | atromentin |
| aurapten | A member of the class of coumarins that is umbelliferone in which the phenolic hydrogen has been replaced by a geranyl group. Ii is isolated from several edible fruits and vegetables and exhibits a variety of therapeutic properties. | auraptene |
| aureothin | A C-nitro compound that is (3Z)-3-[(2E)-2-methyl-3-(4-nitrophenyl)prop-2-en-1-ylidene]tetrahydrofuran which is substituted by a 6-methoxy-3,5-dimethyl-4-oxo-4H-pyran-2-yl group at position 5. It is isolated from the soil bacterium, Streptomyces thioluteus and exhibits antitumor, antifungal, and insecticidal activities. | aureothin |
| avenanthramide b | A monohydroxybenzoic acid resulting from the formal condensation of the carboxy group of ferulic acid with the amino group of 2-amino-5-hydroxybenzoic acid. It is an oat phytoalexin produced in response to pathogen attack and elicitation. | avenanthramide B |
| axitinib | An indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic treatment. | axitinib |
| ay 25545 | A C-glycosylated naphthoisochromene derivative obtained from Streptomyces ravidus; exhibits antibiotic and anticancer properties. | ravidomycin |
| azacitidine | An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. | 5-azacytidine |
| azadirone | A tetracyclic triterpenoid that is 4,4,8-trimethylandrosta-1,14-diene substituted by an oxo group at position 3, an acetoxy group at position 7 and a furan-3-yl group at position 17. Isolated from Azadirachta indica, it exhibits antiplasmodial and antineoplastic activities. | azadirone |
| azaguanine | A triazolopyrimidine that consists of 3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidine bearing amino and oxo substituents at positions 5 and 7 respectively. | 8-azaguanine |
| azaserine | A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species. | azaserine |
| azathioprine | A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. | azathioprine |
| azauridine | | 6-azauridine |
| azd 1152 | A dihydrogen phosphate prodrug of a pyrazoloquinazoline aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide(HQPA) and is converted rapidly to the active AZD1152-HQPA in plasma. | AZT-1152 |
| azd 1152-hqpa | A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether. | AZD-1152 |
| azd 6244 | A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor. | selumetinib |
| azd2858 | A member of the class of pyrazines that is pyrazine substituted by (pyridin-3-yl)aminocarbonyl, amino, and 4-(4-methylpiperazine-1-sulfonyl)phenyl groups at positions 2, 3 and 6, respectively. It is a potent inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.9 and 4.9 nM, respectively) and increases bone mass (via Wnt activation) in rats. | AZD2858 |
| AZD3463 | A member of the class of indoles that is 1H-indole substituted by a 2-[4-(4-aminopiperidin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl group at position 3. It is an orally bioavailable dual inhibitor of ALK and IGF1R with Ki value of 0.75 nM for ALK. | AZD3463 |
| azelaic acid | An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups. | nonanedioic acid |
| baicalein | A trihydroxyflavone with the hydroxy groups at positions C-5, -6 and -7. | baicalein |
| baicalin | The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. It is an active ingredient of Chinese herbal medicine Scutellaria baicalensis. | baicalin |
| baohuoside i | A glycosyloxyflavone that is 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone in which the hydroxy group at position 3 has been converted into its alpha-L-rhamnopyranoside. | icariside II |
| bassianolide | A cyclodepsipeptide consisting of a cyclic tetramer of the depsipeptide D-Hiv-N-methyl-L-leucine (where D-Hiv = D-alpha-hydroxyisovaleric acid). Found in the fungal species Beauveria bassiana and Verticillium lecanii, it has insecticidal properties and is used as a commercial biopesticide to control of insects of agricultural, veterinary and medical significance. For elucidation of the structure, see Suzuki et al., Tetrahedron Lett. 1977 v25, 2167-2170. | bassianolide |
| batimastat | A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. | batimastat |
| bay 11-7085 | A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB. | BAY11-7085 |
| BDA-366 | A member of the class of anthraquinone that is 1,4-diamino-9,10-anthraquinone in which the two amino groups are carrying 3-(diethylamino)-2-hydroxypropyl and (oxiran-2-yl)methyl substituents. It exhibits anti-cancer properties. | BDA-366 |
| beauvericin | A trimeric cyclodepsipeptide composed from alternating methylphenylalanyl and hydroxyvaleryl residues. | beauvericin |
| belinostat | A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. | belinostat |
| berberine | | berberine |
| berkeleydione | A meroterpenoid found in Penicillium rubrum. It has been shown to exhibit inhibitory activity against caspase-1. | berkeleydione |
| beta-aminopropionitrile fumarate (2:1) | A fumarate salt prepared from beta-aminopropionitrile by reaction of one molecule of fumaric acid for every two molecules of beta-aminopropionitrile. | beta-aminopropionitrile hemifumarate |
| beta-elemene | The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration. | (-)-beta-elemene |
| beta-lapachone | A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. | beta-lapachone |
| beta-peltatin | An organic heterotetracyclic compound that is alpha-peltatin in which the phenolic hydroxy group of the 4-hydroxy-3,5-dimethoxyphenyl substitutent had been converted into the corresponding methyl ether. | beta-peltatin |
| beta-thujaplicin | A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities. | beta-thujaplicin |
| betulin | A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents. | betulin |
| betulinic acid | A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-carboxy substituents. It is found in the bark and other plant parts of several species of plants including Syzygium claviflorum. It exhibits anti-HIV, antimalarial, antineoplastic and anti-inflammatory properties. | betulinic acid |
| bexarotene | | bexarotene |
| bgt226 | An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor. | BGT226 free base |
| bibw 2992 | A quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a 4-dimethylamino-trans-but-2-enamido group at the 6-position, and an (S)-tetrahydrofuran-3-yloxy group at the 7-position. Used (as its dimaleate salt) for the first-line treatment of patients with metastatic non-small cell lung cancer. | afatinib |
| bielschowskysin | A diterpenoid that is isolated from Pseudopterogorgia kallos and exhibits antimalarial and anticancer activity. | bielschowskysin |
| bigelovin | A sesquiterpene lactone that is 3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione substituted by methyl groups at positions 4a and 8, a methylidene group at position 3 and an acetoxy group at position 4. Isolated from Inula hupehensis, it exhibits antineoplastic activity. | bigelovin |
| binimetinib | A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. | binimetinib |
| biochanin a | A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at position 5 and a methoxy group at position 4'. A phytoestrogen, it has putative benefits in dietary cancer prophylaxis. | biochanin A |
| bisantrene | A hydrazone resulting from the formal condensation of both of the aldehyde groups of anthracene-9,10-dicarbaldehyde with 2-hydrazinyl-4,5-dihydro-1H-imidazole. | bisantrene |
| bl1521 | An enamide resulting from the formal condensation of the carboxy group of (2E,4E,6E)-7-phenylhepta-2,4,6-trienoic acid with the amino group of hydroxylamine. It is an inhibitor of histone deacetylase (HDAC) which exhibits anticancer properties. | CG-1521 |
| bleomycin | | bleomycin A2 |
| bml 210 | A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and 1,2-diaminobenzene. | BML-210 |
| bms 214662 | A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors. | BMS-214662 |
| bms 387032 | A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties. | N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide |
| bms 754807 | A pyrrolotriazine that is pyrrolo[2,1-f][1,2,4]triazine which is substituted at position 2 by the pyrrolidine nitrogen of (2S)-N-(6-fluoropyridin-3-yl)-2-methylprolinamide, and at position 4 by a (5-cyclopropyl-1H-pyrazol-3-yl)amino group. It is a potent, reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases. | BMS-754807 |
| bmy 25067 | An organic disulfide that is mitomycin C in which the amino group at position 7 is replaced by a {2-[(4-nitrophenyl)disulfanyl]ethyl}amino group. It is a derivative of mitomycin C with activity against a range of tumour cell lines and xenografts. | BMY-25067 |
| borrelidin | A macrolide that is isolated from several Streptomyces species and displays antibiotic, antineoplastic and antimalarial properties. | borrelidin |
| bortezomib | L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. | bortezomib |
| bosutinib | An aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. | bosutinib |
| brasilicardin a | A diterpenoid antibiotic isolated from the culture broth of Nocardia brasiliensis IFM0406. It exhibits antitumour and strong immunosuppressive activity. | brasilicardin A |
| brazilin | A organic heterotetracyclic compound that is a red pigment obtained from the wood of Caesalpinia echinata (Brazil-wood) or Caesalpinia sappan (sappan-wood). | brazilin |
| brequinar | A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties. | brequinar |
| brequinar sodium | An organic sodium salt of brequinar. | brequinar sodium |
| brivanib | A secondary alcohol resulting from the hydrolysis of the carboxylic ester group of brivanib alaninate. It is a dual VEGFR-2/FGFR-1 kinase inhibitor whose alanine prodrug, brivanib alaninate is currently under development as an oral agent for the treatment of cancer. | (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol; brivanib |
| bromodeoxyuridine | A pyrimidine 2'-deoxyribonucleoside compound having 5-bromouracil as the nucleobase. | 5-bromo-2'-deoxyuridine |
| bromophycolide a | A diterpenoid that is a macrolide isolated from the Fijian red alga Callophycus serratus. It has been found to exhibit moderate cytotoxicity against several human tumour cell lines via specific apotopic cell death. It also displays anti-HIV, antibacterial, antifungal and antimalarial activity. | bromophycolide A |
| bromopyruvate | A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug | 3-bromo-2-oxopropanoic acid; 3-bromopyruvic acid |
| bryostatin 1 | A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins. | bryostatin 1 |
| bryostatin 2 | A member of the class of bryostatins that is bryostatin 1 in which the acetoxy group has been replaced by a hydroxy group. | bryostatin 2 |
| bufalin | A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo. | bufalin |
| buformin | A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect. | buformin |
| buparlisib | An aminopyridine that is 4-(trifluoromethyl)pyridin-2-amine substituted at position 5 by a 2,6-di(morpholin-4-yl)pyrimidin-4-y group. A selective PI3K inhibitor with anti-tumour properties. | BKM120 |
| busulfan | A methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant. | busulfan |
| butein | A chalcone that is (E)-chalcone bearing four additional hydroxy substituents at positions 2', 3, 4 and 4'. | butein |
| cabazitaxel | A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly. | cabazitaxel |
| cabergoline | An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. | cabergoline |
| cabozantinib | A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. | cabozantinib |
| cafestol | An organic heteropentacyclic compound and furan diterpenoid with formula C20H28O3 obtained from the unsaponifiable fraction of coffee oil (a lipid fraction obtained from coffee beans by organic solvent extraction). | cafestol |
| caffeic acid phenethyl ester | An alkyl caffeate ester in which 2-phenylethyl is the alkyl component. | phenethyl caffeate |
| calcitriol | A hydroxycalciol that is calcidiol in which the pro-S hydrogen of calcidiol is replaced by a hydroxy group. It is the active form of vitamin D3, produced fom calciol via hydoxylation in the liver to form calcidiol, which is subsequently oxidised in the kidney to give calcitriol. | calcitriol |
| calicheamicin gamma(1)i | A calcheamicin in which contains 3-O-methyl-alpha-L-rhamnosyl, 2,6-dideoxy-4-thio-beta-D-ribo-hexopyranosyl, and 4-amino-4,6-dideoxy-2-O-[2,4-dideoxy-4-(ethylamino)-3-O-methyl-alpha-L-threo-pentopyranosyl]-alpha-L-idopyranose units and in which the aromatic ring contains an iodo substituent. | calicheamicin gamma1(I) |
| camostat | A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients. | camostat |
| camostat mesylate | A methanesulfonate (mesylate) salt prepared from equimolar amounts of camostat and methanesulfonic acid. It is a serine protease inhibitor approved and marketed in Japan in 1985 for the alleviation of acute symptoms associated with chronic pancreatitis. In 1994, it was approved for the treatment of postoperative reflux esophagitis. | camostat mesylate |
| camptothecin | A pyranoindolizinoquinoline that is pyrano[3',4':6,7]indolizino[1,2-b]quinoline which is substituted by oxo groups at positions 3 and 14, and by an ethyl group and a hydroxy group at position 4 (the S enantiomer). | camptothecin |
| can 508 | A member of the class of pyrazoles that is 1H-pyrazole substituted by amino, (4-hydroxyphenyl)diazenyl, and amino groups at positions 3, 4 and 5, respectively. It is a CDK9 inhibitor (IC50 = 0.35 muM) with 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. | CAN-508 |
| canaline | A non-proteinogenic L-alpha-amino acid that is L-homoserine in which the hydroxy group at position 4 is substituted by an aminooxy group. It has been isolated from legumes and plays an essential role in lugume chemical defense against insects. | L-canaline zwitterion; L-canaline |
| canertinib | A quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a propenamido group at the 6-position, and a 3-morpholinopropoxy group at the 7-position. | canertinib |
| capecitabine | A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers. | capecitabine |
| capilliposide b | A triterpenoid saponin that consists of anagalligenin A substituted by a caproyl group at position 22 and a beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->4)-[beta-D-glucopyranosyl-(1->2)]-alpha-L-arabinopyranosyl moiety at position 3 via a glycosidic linkage. It is isolated from the whole plants of Lysimachia capillipes and has been shown to exhibit potent cytotoxicity against human A-2780 cells. | capilliposide B |
| carfilzomib | A synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma | carfilzomib |
| carmustine | A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. | carmustine |
| carnosine | A dipeptide that is the N-(beta-alanyl) derivative of L-histidine. | carnosine zwitterion; carnosine |
| carubicin | A toxic anthracycline antibiotic that is produced by Actinomadura carminata and also has potent antineoplastic activity. | carminomycin |
| cblc137 | A member of the class of carbazoles that is 9H-carbazole which is substituted by acetyl groups at positions 3 and 6, and by a 2-isopropylethyl group on the nitrogen atom (position 9). It is a modulator of histone chaperone FACT (FAcilitates Chromatin Transcription) - interaction of CBL0137 with the FACT complex results in simultaneous NF-kappa beta suppression, Heat Shock Transcription Factor 1 (HSF1) suppression and p53 activation - and shows antitumour effects in animal models of various cancers. | CBL0137 |
| cct018159 | A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively. | CCT-018159 |
| CCT251545 | A chloropyridine that is 3-chloropyridine substituted by a 1-oxo-2,8-diazaspiro[4.5]decan-8-yl group and a 4-(1-methyl-1H-pyrazol-4-yl)phenyl group at positions 4 and 5, respectively. It is an orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM) and a potent and selective chemical probe for cyclin-dependent kinases CDK8 and CDK19. | CCT251545 |
| celastrol | A pentacyclic triterpenoid that is 24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid bearing an oxo substituent at position 2, a hydroxy substituent at position 3 and two methyl groups at positions 9 and 13. An antioxidant and anti-inflammatory agent. Potently inhibits lipid peroxidation in mitochondria and inhibits TNF-alpha-induced NFkappaB activation. Also shown to inhibit topoisomerase II activity in vitro (IC50 = 7.41 muM). | celastrol |
| cembra-2,7,11-triene-4,6-diol | A cembrane diterpenoid obtained from tobacco and shown to have antitumour-promoting activity. | cembra-2,7,11-triene-4,6-diol |
| centaureidin | A trihydroxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii and Athroisma proteiforme. | centaureidin |
| cerberin | A cardenolide glycoside that is the 2'-acetyl derivative of neriifolin. | cerberin |
| ceritinib | A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. | ceritinib |
| cerulomycin | A pyridine alkaloid that is 2,2'-bipyridine substituted by a methoxy group at position 4 and a (E)-(hydroxyimino)methyl group at position 6. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity. | caerulomycin A |
| cetrorelix | A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast. | cetrorelix |
| cgp 42112a | A hexapeptide consisting of L-tyrosine, L-lysine, L-histidine, L-proline and L-isoleucine amino acid residues coupled in sequence and in which the amino group of the L-tyrosyl residue is substituted by a (pyridin-3-ylcarbonyl)nitrilo group and in which the L-lysyl side chain amino group is substituted by a {N(2)-[(benzyloxy)carbonyl]-L-arginyl}nitrilo group. It is a potent angiotensin II receptor type 2 (AT2 receptor) agonist. | CGP-42112A |
| cgs 15943 | A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors. | 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine; CGS 15943 |
| chelerythrine | A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae. | chelerythrine |
| chir 98014 | A member of the class of aminopyrimidines that is pyrimidine substituted by {2-[(6-amino-5-nitropyridin-2-yl)amino]ethyl}amino, 2,4-dichlorophenyl, and 1H-imidazol-1-yl groups at positions 2, 4 and 5, respectively. It is a potent ATP-competitive inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.65 and 0.58 nM, respectively). | CHIR-98014 |
| chlorambucil | A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. | chlorambucil |
| chlorotrianisene | | chlorotrianisene |
| chondramide a | A chondramide that is chondramide C in which the pro-S hydrogen at position 2 of the beta-tyrosine residue is replaced by a methoxy group. It is produced by strains of the myxobacterium, Chondromyces crocatus. | chondramide A |
| chondramide c | A chondramide formally obtained from N-[(2S,4E,6R,7R)-7-hydroxy-2,4,6-trimethyloct-4-enoyl]-L-alanyl-Nalpha-methyl-D-tryptophanyl-beta-R-beta-tyrosine by intramolecular condensation of the alcoholic hydroxy group with the carboxy group of the beta-tyrosine residue. It is produced by strains of the myxobacterium, Chondromyces crocatus. | chondramide C |
| chondramide d | A chondramide that is chondramide C in which the hydrogen at position 2 of the indole moiety is replaced by a chlorine. It is produced by strains of the myxobacterium, Chondromyces crocatus. | chondramide D |
| chrysin | A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7. | chrysin |
| chrysoeriol | The 3'-O-methyl derivative of luteolin. | 4',5,7-trihydroxy-3'-methoxyflavone |
| chrysosplenol c | A trimethoxyflavone that is the 3,7,3'-trimethyl ether derivative of quercetagetin. | chrysosplenol C |
| ci 994 | A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers. | tacedinaline |
| cidofovir anhydrous | Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. | cidofovir anhydrous |
| cigb-300 | A synthetic 25-membered heterodetic cyclic peptide consisting of a 14-membered linear component attached to an 11-membered cyclic portion. A CK2 inhibitor with potential antineoplastic activity. | CIGB-300 |
| ciglitazone | An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist. | ciglitazone |
| cirsilineol | A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 3' and hydroxy groups at positions 5 and 4' respectively. | cirsilineol |
| cisplatin | A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups). | cisplatin; transplatin |
| cl 387785 | A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group. | N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide |
| cladribine | 2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia. | cladribine |
| clioquinol | A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease. | 5-chloro-7-iodoquinolin-8-ol |
| clodronic acid | An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases. | clodronic acid |
| clofarabine | A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. | clofarabine |
| clofibric acid | A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate. | clofibric acid |
| cnf 2024 | A member of the class of 2-aminopurines that is 2-aminopurine which is substituted by a chlorine at position 6 and by a (4-methoxy-3,5-dimethylpyridin-2-yl)methyl group at position 9. | BIIB021 |
| columbianadin | An alpha,beta-unsaturated carboxylic ester obtained by formal condensation of the carboxy group of angelic acid with the hydroxy group of 2-[(8S)-2-oxo-8,9-dihydro-2H-furo[2,3-h][1]benzopyran-8-yl]propan-2-ol. | columbianadin |
| coronardine | A monoterpenoid indole alkaloid with formula C21H26N2O2. It is isolated from the flowering plant genus, Tabernaemontana. | (-)-coronaridine |
| corynoline | A benzophenanthridine alkaloid that is chelidonine substituted by a methyl group at position 13. Isolated from the aerial parts of Corydalis incisa, it acts as an acetylcholinesterase inhibitor and also exhibits antineoplastic and hepatoprotective activity. | corynoline |
| costunolide | A germacranolide with anthelminthic, antiparasitic and antiviral activities. | costunolide |
| coumermycin | A hydroxycoumarin antibiotic that is obtained from Streptomyces rishiriensis and exhibits potent antibacterial and anticancer activity. | coumermycin A1 |
| cp 724714 | A 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide in which the double bond adopts a trans-configuration. It is a potent inhibitor of HER2/ErbB2 (IC50 = 10 nM) and exhibits anti-cancer activity. | CP-724714 |
| crenolanib | A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a 8-(4-aminopiperidin-1-yl)quinolin-2-yl group at position 1 and by a (3-methyloxetan-3-yl)methoxy group at position 5. It is an inhibitor of type III tyrosine kinases, PDGFRalpha/beta and FLT3 (IC50 of 11, 3.2, and 4 nM). Currently under clinical development for the treatment of acute myeloid leukemia. | crenolanib |
| crizotinib | A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | crizotinib |
| cryptolepine | An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group. | cryptolepine |
| cryptopleurine | An organic heteropentacyclic compound that is (14aR)-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline substituted at positions 2, 3 and 6 by methoxy groups. | cryptopleurine |
| cucurbitacin i | A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22. | cucurbitacin I |
| cudraflavone c | A tetrahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 7, 2' and 4' and prenyl groups at positions 3 and 6. Isolated from Morus nigra, it exhibits antibacterial and cytotoxic activities. | cudraflavone C |
| curcumin | A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. | curcumin |
| cx 5461 | An organic heterotetracyclic compound that is 5-oxo-5H-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxylic acid substituted by a 4-methyl-1,4-diazepan-1-yl group at position 2 and in which the carboxy group at position 6 is substituted by a [(5-methylpyrazin-2-yl)methyl]nitrilo group. An inhibitor of ribosomal RNA (rRNA) synthesis which specifically inhibits RNA polymerase I-driven transcription of rRNA in several cancer cell lines. It is currently in phase I/II clinical trials for advanced hematologic malignancies and triple-negative breast cancer with BRCA1/2 mutation. | CX-5461 |
| cyc 682 | A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML). | sapacitabine |
| cyclobenzaprine | A 9,11,13-octadecatrienoic acid having its double bonds in cis, trans and cis configurations, respectively. It has been isolated from pomegranate (Punica granatum). | (9Z,11E,13Z)-octadecatrienoic acid |
| cyclophosphamide | The monohydrate of cyclophosphamide. | cyclophosphamide hydrate |
| cystothiazole a | An organonitrogen heterocyclic antibiotic that is 2,4'-bi-1,3-thiazole substituted by an isopropyl group at position 2' and a 3,5,7-trimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl group at position 4 (the 2E,4R,5S,6E stereoisomer). It is isolated from the culture broth of myxobacterium, Cystobacter fuscus, and exhibits antifungal and cytotoxic activity. | cystothiazole A |
| cytarabine | A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties. | cytarabine |
| cytotrienin a | A 21-membered macrocyclic lactam which contains three conjugated double bonds as part of the ring system. It acts as an apoptosis inducer in human leukemia HL-60 cells and is isolated from Streptomyces sp. | cytotrienin A |
| dabrafenib | An organofluorine compound and antineoplastic agent, used as its mesylate salt in treatment of metastatic melanoma. | dabrafenib |
| dacarbazine | A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. | dacarbazine |
| dactolisib | An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. | dactolisib |
| daidzein | A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by an additional hydroxy group at position 4'. | daidzein |
| daphnoretin | A member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 6 and a (2-oxo-2H-chromen-7-yl)oxy group at position 3. | daphnoretin |
| dasatinib | An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). | dasatinib (anhydrous) |
| daunorubicin | A natural product found in Actinomadura roseola. | daunorubicin |
| decursinol | An organic heterotricyclic compound that is 7,8-dihydro-2H,6H-pyrano[3,2-g]chromen-2-one substituted by a beta-hydroxy group at position 7 and two methyl groups at position 8. It is isolated from the roots of Angelica gigas and has been found to possess significant inhibitory activity against acetylcholinesterase enzyme (EC 3.1.1.7). | decursinol |
| deferrioxamine e | A cyclic hydroxamic acid siderophore that is produced by several bacterial species and exhibits antitumour activity. | desferrioxamine E |
| deguelin | A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers. | deguelin |
| dehydrocostus lactone | An organic heterotricyclic compound and guaianolide sesquiterpene lactone that is acrylic acid which is substituted at position 2 by a 4-hydroxy-3,8-bis(methylene)decahydoazulen-5-yl group and in which the hydroxy group and the carboxy group have undergone formal condensation to afford the corresponding gamma-lactone. | dehydrocostus lactone |
| delanzomib | A C-terminal boronic acid peptide inhibitor which induces apoptosis in multiple myeloma, hematological and solid tumor cell lines. | delanzomib |
| delphinidin | An anthocyanidin cation consisting of benzopyrylium with hydroxy substituents at the 3-, 5- and 7-positions and a 3,4,5-trihydroxyphenyl group at the 2-position. It is a plant pigment responsible for the colours of the plants of the genera Viola and Delphinium. | delphinidin |
| demecolcine | A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic. | (-)-demecolcine |
| demethoxycurcumin | A beta-diketone that is curcumin in which one of the methoxy groups is replaced by hydrogen. It is found in Curcuma zedoaria and Etlingera elatior. | demethoxycurcumin |
| dequalinium | A quinolinium ion comprising decane in which one methyl hydrogen at each end of the molecule has been replaced by a 4-amino-2-methylquinolin-1-yl group. | dequalinium |
| dequalinium chloride | An organic chloride salt that is the dichloride salt of dequalinium. | dequalinium chloride |
| devazepide | An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders. | devazepide |
| dexmedetomidine | A trimethoxyflavone that is the 3,6,7-trimethyl ether derivative of quercetagetin. | 3',4',5-trihydroxy-3,6,7-trimethoxyflavone |
| dexrazoxane | | (+)-dexrazoxane |
| diallyl disulfide | An organic disulfide where the organic group specified is allyl. It has been isolated from garlic and other species of the genus Allium. | diallyl disulfide |
| diallyl trisulfide | An organic trisulfide that is trisulfane in which both of the hydrogens are replaced by allyl groups. A component of the essential oil of garlic and a major component of the traditional Chinese medicine allitridium, it exhibits antifungal, antitumour and antioxidant activity | diallyl trisulfide |
| diaziquone | A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups. | diaziquone |
| diazomethane | The simplest diazo compound, in which a diazo group is attached to a methylene group. | diazomethane |
| diazooxonorleucine | A non-proteinogenic L-alpha-amino acid that is L-norleucine which is substituted at position 5 by an oxo group and at position 6 by a diazo group. It is as inhibitor of various glutamine-utilising enzymes. | 6-diazo-5-oxo-L-norleucine zwitterion; 6-diazo-5-oxo-L-norleucine |
| dibenzoylmethane | A beta-diketone that is acetylacetone (acac) in which both methyl groups have been replaced by phenyl groups. It is a minor constituent of the root extract of licorice (Glycyrrhiza glabra) and exhibits antimutagenic and anticancer effects. | dibenzoylmethane |
| diethylstilbestrol | An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups. | diethylstilbestrol |
| diflomotecan | An organic heteropentacyclic compound that is (5R)-8-[(6,7-difluoroquinolin-3-yl)methyl]-5-ethyl-5-hydroxy-1,4,5,8-tetrahydrooxepino[3,4-c]pyridine-3,9-dione in which position 7 of the oxepinopyridine moiety is joined to position 3 of the difluoroquinoine ring by a single bond. An E-ring modified camptothecin analogue that has greater lactone stability in plasma compared with other topoisomerase I inhibitors. | diflomotecan |
| dioscin | A spirostanyl glycoside that consists of the trisaccharide alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc attached to position 3 of diosgenin via a glycosidic linkage. | dioscin |
| diosgenin | A sapogenin that is spirostan which is substituted by a hydroxy group at the 3beta position, contains a double bond at the 5-6 position, and has R- configuration at position 25. A natural product found in Dioscorea (wild yam) species, it is used as the starting point for the commercial synthesis of a number of steroids, including cortisone, pregnenolone and progesterone. | diosgenin |
| diosmetin | A monomethoxyflavone that is the 4'-methyl ether derivative of luteolin. It is a natural product isolated from citrus fruits which exhibits a range of pharmacological activities. | diosmetin |
| disulfiram | An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties. | disulfiram |
| DMH1 | A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine bearing quinolin-4-yl and 4-isopropyloxyphenyl substituents at positions 3 and 6 respectively. | DMH1 |
| docetaxel | The trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. | docetaxel trihydrate |
| docetaxel anhydrous | A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. | docetaxel anhydrous |
| docosahexaenoate | A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19. | all-cis-docosa-4,7,10,13,16,19-hexaenoic acid |
| dolastatin 10 | A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization. | dolastatin 10 |
| doxazosin | A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. | doxazosin |
| doxifluridine | A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase. | doxifluridine |
| dromostanolone | | metholone |
| dromostanolone propionate | | dromostanolone propionate |
| dw a 2114r | | miboplatin |
| ebc-46 | A diterpenoid natural product isolated from the kernels of the Australian blushwood tree (Fontainea picrosperma). It is approved as a veterinary pharmaceutical for the treatment of non-metastatic and non-resectable canine mast cell tumours. | tigilanol tiglate |
| ebselen | A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase. | ebselen |
| ecteinascidin 743 | A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. | trabectedin |
| EG00229 | A member of the class of thiophenes that is thiophene substituted by a carbonyl-L-arginine and (2,1,3-benzothiadiazole-4-sulfonyl)amino groups at positions 2 and 3. It is an inhibitor of the neuropilin-1 and VEGF-A interaction and a potential anti-cancer agent. | EG00229 |
| eicosapentaenoic acid | An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17. | all-cis-5,8,11,14,17-icosapentaenoic acid |
| elesclomol | A carbohydrazide obtained by formal condensation of the carboxy groups of malonic acid with the hydrino groups of two molar equivalents of N-methylbenzenecarbothiohydrazide | elesclomol |
| elisidepsin | A synthetic cyclodepsipeptide derived from a marine metabolite that exhibits antineoplastic properties. | elisidepsin |
| ellipticine | A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11. | ellipticine |
| embelin | A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease. | embelin |
| emetine | A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties. | emetine |
| emetine dihydrochloride | The dihydrochloride salt of emetine. | emetine dihydrochloride |
| emodin | A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs. | emodin |
| enasidenib | A 1,3,5-triazine which is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has been approved for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML). | enasidenib |
| englerin a | A guaiane sesquiterpenoid that is isolated from the bark of Phyllanthus engleri, a plant native to Tanzania and Zimbabwe. It acts as a potent and specific inhibitor of renal cancer cell growth. | englerin A |
| enkephalin, methionine | A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-methionine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide with antitumor, analgesic, and immune-boosting properties. | Met-enkephalin zwitterion; Met-enkephalin |
| enrofloxacin | A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets. | enrofloxacin |
| entinostat | A member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibitor of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3). | entinostat |
| entrectinib | A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours. | entrectinib |
| epigallocatechin gallate | A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. | (-)-epigallocatechin 3-gallate |
| epirubicin | An anthracycline that is the 4'-epi-isomer of doxorubicin. | 4'-epidoxorubicin |
| episilvestrol | An organic heterotricyclic compound that is a 5'''-epimer of silvestrol. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. | epi-silvestrol |
| epothilone a | An epithilone that is epothilone C in which the double bond in the macrocyclic lactone ring has been oxidised to the corresponding epoxide (the 13R,14S diastereoisomer). | epothilone A |
| epothilone b | An epithilone that is epithilone D in which the double bond in the macrocyclic ring has been oxidised to the corresponding epoxide (the S,S stereoisomer). | epothilone B |
| er-086526 | A fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage | eribulin |
| erastin | A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer. | erastin |
| ergolide | A sesquiterpene lactone that is decahydroazuleno[6,5-b]furan-2,5-dione substituted by methyl groups at positions 4a and 8, a methylidene group at position 3 and an acetyloxy group at position 4. It has been isolated from the aerial parts of Inula hupehensis. | ergolide |
| ergosterol-5,8-peroxide | An ergostanoid that is ergosta-6,22-dien-3-ol with a peroxy group between positions 5 and 8 (the 3beta,5alpha,8alpha,22E stereoisomer). Isolated from Ganoderma lucidum and Cordyceps sinensis, it exhibits antimycobacterial, trypanocidal and antineoplastic activities. | ergosterol peroxide |
| erlotinib | A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions. | erlotinib |
| erlotinib hydrochloride | The hydrochloride salt of erlotinib. | erlotinib hydrochloride |
| ermanin | A dimethoxyflavone that is kaempferol in which the hydroxy groups at position 3 and 4' have been replaced by methoxy groups. It is a component of bee glue and isolated from several plant species including Tanacetum microphyllum. | 3,4'-dimethylkaempferol |
| es-285 | A bioactive sphingoid, sphinganine, in which the terminal hydroxy group has been replaced by a hydrogen. | 1-deoxysphinganine |
| esculeoside a | A steroid saponin that is spirosolane-3,23,27-triol in which the hydroxy group at position 23 is acetylated and the hydroxy groups at positions 3 and 27 are glycosylated by lycotetraosyl and a beta-D-glucopyranosyl moieties respectively. Isolated from the fruits of Lycopersicon esculentum, it exhibits cytotoxic activity. | esculeoside A |
| estramustine | A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. | estramustine |
| estrone | A 17-oxo steroid that is estra-1,3,5(10)-triene substituted by an hydroxy group at position 3 and an oxo group at position 17. | estrone |
| etanidazole | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells. | etanidazole |
| ethinylestradiol-3-sulfate | A steroid sulfate that is 17alpha-ethynylestradiol in which the phenolic hydrogen at position 3 has been replaced by a sulfo group. | 17alpha-ethynylestradiol 3-sulfate |
| ethyl caffeate | An ethyl ester resulting from the formal condensation of the carboxy group of trans-caffeic acid with ethanol. | Caffeic acid ethyl ester; ethyl trans-caffeate |
| ethyl methanesulfonate | A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with ethanol. | ethyl methanesulfonate |
| etidronate | A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces. | etidronic acid |
| etidronate disodium | An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions. | etidronate disodium |
| etoposide | | etoposide |
| eugeniin | An ellagitannin isolated from the dried flower buds of Eugenia caryophyllata. It exhibits alpha-glucosidase inhibitory activity and antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1. | eugeniin |
| eupatilin | A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities. | eupatilin |
| eupatolide | A germacranolide with formula C15H20O3, isolated from several Inula species. It exhibits anti-cancer properties. | eupatolide |
| eupatorin | A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups. | eupatorin |
| eurycomanone | A quassinoid isolated from Eurycoma longifolia and has been shown to exhibit antineoplastic and antimalarial activties. | eurycomanone |
| everolimus | A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. | everolimus |
| fangchinoline | A bisbenzylisoquinoline alkaloid that is (1beta)- berbaman which has been substituted by methyl groups at the 2 and 2' positions, by methoxy groups at the 6, 6', and 12 positions, and by a hydroxy group at position 7. Isolated from Stephania tetrandra, it has been found to possess neuroprotective and anti-tumour activity. | fangchinoline |
| fazarabine | An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-arabinofuranosyl residue via an N-glycosidic linkage. A synthetic analogue of cytosine arabinoside and 5-azacytidine that incorporates structural features of both compounds, it shows good activity against a variety of transplanted tumors. | fazarabine |
| fenretinide | A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids. | 4-hydroxyphenyl retinamide |
| ferruginol | An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12. | ferruginol |
| fingolimod | An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate. | fingolimod |
| firocoxib | An enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs. | firocoxib |
| flavokawain b | A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities. | flavokawain B |
| floxuridine | A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | floxuridine |
| fludarabine phosphate | A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. | fludarabine phosphate |
| fluorouracil | A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth. | 5-fluorouracil |
| fluoxymesterone | | fluoxymesterone |
| flutamide | | flutamide |
| forapin | A 26-membered polypeptide consisting of Gly, Ile, Gly, Ala, Val, Leu, Lys, Val, Leu, Thr, Thr, Gly, Leu, Pro, Ala, Leu, Ile, Ser, Trp, Ile, Lys, Arg, Lys, Arg, Gln and Gln-NH2 residues joined in sequence. It is the principal active component of bee venom. | melittin |
| formestane | A 17-oxo steroid that is androst-4-ene-3,17-dione in which the hydrogen at position 4 is replaced by a hydroxy group. Formestane was the first selective, type I steroidal aromatase inhibitor, suppressing oestrogen production from anabolic steroids or prohormones. It was formerly used in the treatment of oestrogen-receptor positive breast cancer in post-meopausal women. As it has poor oral bioavailability, it had to be administered by (fortnightly) intramuscular injection. It fell out of use with the subsequent development of cheaper, orally active aromatase inhibitors. Formestane is listed by the World Anti-Doping Agency as a substance prohibited from use by athletes. | formestane |
| formycin | | formycin A |
| fostriecin | A structurally unique, naturally-occurring phosphate monoester isolated from the soil bacterium Streptomyces pulveraceus. It inhibits DNA topoisomerase II as well as several protein phosphatase including PP2A and PPA4, and exhibits potent antitumor activity against several cancer cell lines. | fostriecin |
| fr 148083 | A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB. | 5Z-7-oxozeaenol |
| fr 901464 | A spiro-epoxide with potent anticancer activity that lowers the mRNA levels of oncogenes and tumour supressor genes. It is isolated from Pseudomonas sp. no.2663. | FR901464 |
| fty 720p | A primary amino compound that is fingolimod in which one on the hydroxy groups has been converted into its dihydrogen phosphate derivative. It is the active metabolite of fingolimod. | fingolimod phosphate |
| fulvestrant | A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer. | fulvestrant |
| gallic acid | A trihydroxybenzoic acid in which the hydroxy groups are at positions 3, 4, and 5. | gallic acid |
| gamma-mangostin | A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity. | gamma-mangostin |
| gamma-tocotrienol | A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 7 and 8 and a farnesyl chain at position 2. A vitamin E family member that has potent anti-cancer properties against a wide-range of cancers. | gamma-tocotrienol |
| gant 61 | An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor. | 2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline; GANT61 |
| gartanin | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 5 and 8 and prenyl groups at positions 2 and 4. | gartanin |
| gastrin 17 | One of the primary forms of gastrin that is a 17-membered peptide consisting of Glp, Gly, Pro, Trp, Leu, Glu, Glu, Glu, Glu, Glu, Ala, Tyr, Gly, Trp, Met, Asp and Phe-NH2 residues joined in sequence. | gastrin-17 |
| gdc 0449 | A benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma. | vismodegib |
| GDC-0623 | A member of the class of imidazopyridines that is imidazo[1,5-a]pyridine substituted by (2-fluoro-4-iodophenyl)amino and (2-hydroxyethoxy)aminoacyl groups at positions 5 and 6. It is a potent ATP non-competitive inhibitor of MEK1 (Ki = 0.13nM) and also has efficacy against both mutant BRAF and mutant KRAS. It is in clinical development for treatment of patients with locally advanced or metastatic solid tumors. | GDC-0623 |
| GDC-0879 | A member of the class of pyrazoles that is 1-(2-hydroxyethyl)pyrazole carrying additional 4-pyridyl and 1-(hydroxyimino)indan-5-yl substituents at positions 3 and 4 respectively. | GDC-0879 |
| gdc-0973 | A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. | cobimetinib |
| gedunin | A pentacyclic triterpenoid natural product found particularly in Azadirachta indica and Cedrela odorata. | gedunin |
| gefitinib | A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer. | gefitinib |
| geldanamycin | An ansamycin consisting of a 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It shows antimicrobial activity against many Gram-positive and some Gram-negative bacteria. | geldanamycin |
| gemcitabine | A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. | gemcitabine |
| gemcitabine hydrochloride | A 2'-deoxycytidine hydrochloriode having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine hydrochloride is used in the treatment of various carcinomas, including non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. | gemcitabine hydrochloride |
| genistein | A 7-hydroxyisoflavone with additional hydroxy groups at positions 5 and 4'. It is a phytoestrogenic isoflavone with antioxidant properties. | genistein |
| germacrone | A germacrane sesquiterpenoid that has formula C15H22O. It is a natural product found in traditional medicinal plants of the family Zingiberaceae. The compound exhibits a range of pharmacological activities including anti-inflammatory, anticancer, antiviral, anti-androgenic, antioxidant, antimicrobial, antifungal, neuroprotective and insecticidal activities. | (E,E)-germacrone |
| gilteritinib | A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. | gilteritinib |
| gingerol | A beta-hydroxy ketone that is 5-hydroxydecan-3-one substituted by a 4-hydroxy-3-methoxyphenyl moiety at position 1; believed to inhibit adipogenesis. It is a constituent of fresh ginger. | gingerol |
| ginkgetin | A biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2. | ginkgetin |
| ginsenoside f2 | A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranosides, and in which a double bond has been introduced at the 24-25 position. | ginsenoside F2 |
| ginsenoside m1 | A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. | ginsenoside C-K |
| ginsenoside re | A ginsenoside found in Panax ginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. | ginsenoside Re |
| ginsenoside rf | A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 6 has been converted to the corresponding beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. | ginsenoside Rf |
| ginsenoside rg3 | A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. | (20S)-ginsenoside Rg3 |
| ginsenoside rh2 | A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position. | (20S)-ginsenoside Rh2 |
| glasdegib | A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy. | glasdegib |
| glaucarubinone | A quassinoid with formula C25H34O10. It is a natural product isolated from several plant species and exhibits anti-cancer and anti-malarial properties. | glaucarubinone |
| glaucine | An aporphine alkaloid that is (S)-1,2,9,10-tetrahydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline in which the four phenolic hydrogens have been replaced by methyl groups. | (S)-glaucine |
| glucaric acid | The D-enantiomer of glucaric acid. | D-glucaric acid |
| glyceryl behenate | A fatty acid ester resulting from the formal condensation of the hydroxy group at position-1 of glycerol with the carboxy group of docosanoic acid. | 1-behenoylglycerol |
| grassypeptolide | A 31-membered macrocyclic cyclodepsipeptide isolated from the cyanobacterium Lyngbya confervoides and has been shown to exhibit antineoplastic activity. | grassypeptolide |
| gsk 2126458 | A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors. | omipalisib |
| GSK1059615 | A thiazolidinone that is the 5-{[4-(pyridin-4-yl)quinolin-6-yl]methylene} derivative of 1,3-thiazolidine-2,4-dione. A PI3K inhibitor | GSK1059615 |
| gsk2656157 | A pyrrolopyrimidine that is 7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine which has been substituted at position 5 by a 4-fluoro-2,3-dihydro-1H-indol-5-yl group, the nitrogen of which has been acylated by a (6-methylpyridin-2-yl)acetyl group. An orally bioavailable PERK inhibitor. | GSK2656157 |
| gsk2879552 | A member of the class of piperidines that is piperidine substituted by (4-carboxyphenyl)methyl and {[(1R,2S)-2-phenylcyclopropyl]amino}methyl groups at positions 1 and 4, respectively. It is a potent and irreversible inhibitor of lysine specific demethylase 1 (LSD1, also known as KDM1A). It was under clinical investigation for the treatment of acute myeloid leukaemia and small cell lung carcinoma. | GSK2879552 |
| gsk343 | A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). | GSK343 |
| gsk690693 | A member of the class of imidazopyridines that is 4-(1-ethylimidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol carrying additional 2-(4-amino-1,2,5-oxadiazol-3-yl and [(3S)-piperidin-3-yl]methoxy substituents at positions 4 and 7 respectively. | GSK690693 |
| guanazole | An aromatic amine that is 1,2,4-triazole substituted at positions 3 and 5 by amino groups. | guanazole |
| hadacidin | A monocarboxylic acid that is N-hydroxyglycine in which the hydrogen attached to the nitrogen is replaced by a formyl group. It was originally isolated from cultures of Penicillium frequentans. | hadacidin |
| hc toxin | A homodetic cyclic tetrapeptide made up from L-alanyl, D-alanyl, L-prolyl and 2-amino-8-oxo-9,10-epoxydecanoyl residues. | HC toxin |
| helenalin | A sesquiterpene lactone that is 3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione substituted by a hydroxy group at position 4, methyl groups at positions 4a and 8 and a methylidene group at position 3 (the 3aS,4S,4aR,7aR,8R,9aR stereoisomer). | helenalin |
| helioxanthin | A furonaphthodioxole that is furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7(9H)-one substituted by a 1,3-benzodioxol-5-yl group at posiiton 10. It is a inhibitor of HBV, HCV and HSV-1 viruses. | helioxanthin |
| helveticoside | A cardenolide glycoside that consists of strophanthidin having a digitoxosyl group attached at position 3. | helveticoside |
| herbacetin | A pentahydroxyflavone that is kaempferol substituted by a hydroxy group at position 8. It is a natural flavonoid from flaxseed which exerts antioxidant, anti-inflammatory and anticancer activities. | herbacetin |
| hesperetin | A trihydroxyflavanone having the three hydroxy gropus located at the 3'-, 5- and 7-positions and an additional methoxy substituent at the 4'-position. | hesperetin |
| hg-9-91-01 | A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer. | HG-9-91-01 |
| hinokiflavone | A biflavonoid that is apigenin substituted by a 4-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)phenoxy group at position 6. A diflavonyl ether, it is isolated from Rhus succedanea and has been found to possess significant cytotoxic potential. | hinokiflavone |
| hippeastrine | An indole alkaloid isolated from the Amaryllidaceae family and has been shown to exhibit cytotoxic activity. | hippeastrine |
| hispidulin | A monomethoxyflavone that is scutellarein methylated at position 6. | hispidulin |
| histrelin | An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. | histrelin |
| hki 272 | A quinoline compound having a cyano group at the 3-position, a 3-chloro-4-(2-pyridylmethoxy)anilino group at the 4-position, a 4-dimethylamino-trans-but-2-enoylamido group at the 6-position, and an ethoxy group at the 7-position. | neratinib |
| hmr 1275 | A hydrochloride salt resulting from the formal reaction of equimolar amounts of alvocidib and hydrogen chloride. A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. | alvocidib hydrochloride |
| holomycin | A dithiolopyrrolone antibiotic that is 4,5-dihydro[1,2]dithiolo[4,3-b]pyrrole in which the hydrogens at positions 5 and 6 have been replaced by oxo and acetamido groups, respectively. It is an inhibitor of DNA-dependent RNA polymerase, and exhibits antibacterial and antitumour properties. | holomycin |
| homocamptothecin | An organic heteropentacyclic compound that is (5R)-5-ethyl-5-hydroxy-8-(quinolin-3-ylmethyl)-1,4,5,8-tetrahydrooxepino[3,4-c]pyridine-3,9-dione in which position 7 of the oxepinopyridine group has been joined to position 2 of the quinoline ring by a single bond. A semisynthetic analogue of camptothecin, it is an inhibitor of topoisomerase I. | (R)-homocamptothecin |
| homoharringtonine | A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. | omacetaxine mepesuccinate |
| homoorientin | A flavone C-glycoside consisting of luteolin having a beta-D-glucosyl residue at the 6-position. | isoorientin |
| hydrazinocurcumin | A pyrazole obtained by cyclocodensation of the two carbonyl groups of curcumin with hydrazine. | hydrazinocurcumin |
| hydroxyguanidine | A member of the class of guanidines that is guanidine in which one of the hydrogens attached to the nitrogen at position 1 is substituted by a hydroxy group. | N-hydroxyguanidine |
| hydroxyurea | A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease. | hydroxyurea |
| hymecromone | A hydroxycoumarin that is umbelliferone substituted by a methyl group at position 4. | 4-methylumbelliferone |
| hypothemycin | A macrolide that is isolated from the cultured broth of Hypomyces subiculosus and shows antifungal activity and inhibits the growth of some human cancer cells. | hypothemycin |
| i-677 | An L-alpha-amino acid that is L-serine in which the hydroxy group at position 3 is converted to the corresponding 2-aminoethyl ether. An antimetabolic antibiotic obtained from Streptomyces reseoviridofuscus. | O-(2-aminoethyl)-L-serine |
| ici 164384 | A 3-hydroxy steroid that is 17beta-estradiol substituted by a 11-[butyl(methyl)amino]-11-oxoundecyl group at position 7R. It is a steroidal antioestrogen that inhibits the cell proliferation of breast-carcinoma cell lines. | ICI-164384 |
| idelalisib | A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia. | idelalisib |
| iejimalide b | A macrolide that is isolated from the marine tunicate Eudistoma cf. rigida and exhibits potent in vitro cytotoxic activity. | lejimalide B |
| ifosfamide | The simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer. | ifosfamide |
| iFSP1 | A member of the class of pyridobenzimidazoles that is pyrido[1,2-a]benzimidazole substituted by amino, cyano, 4-methylphenyl, and cyano groups at positions 1, 2, 3 and 4, respectively. It is a potent inhibitor of ferroptosis suppressor protein 1 (FSP1) with EC50 of 103 nM. It induces ferroptosis in GPX4 knockout cells that overexpress FSP1. | iFSP1 |
| ilomastat | An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | ilomastat |
| imatinib | A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. | imatinib |
| imatinib mesylate | A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. | imatinib methanesulfonate |
| imiquimod | An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. | imiquimod |
| incb-018424 | A pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. | ruxolitinib |
| indole-3-carbinol | An indolyl alcohol carrying a hydroxymethyl group at position 3. It is a constituent of the cruciferous vegetables and had anticancer activity. | indole-3-methanol |
| INDY | A member of the class of benzothiazoles that is 2,3-dihydro-1,3-benzothiazole substituted by 2-oxopropylidene, ethyl, and hydroxy groups at positions 2, 3 and 5, respectively. It is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B (IC50 of 0.24 muM and 0.23 muM, respectively). | INDY |
| irilone | A hydroxyisoflavone that is 6,7-methylenedioxyisoflavone substituted by hydroxy groups at positions 5 and 4'. | irilone |
| irinotecan | A member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. | irinotecan |
| irinotecan hydrochloride | A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. | irinotecan hydrochloride (anhydrous) |
| isoginkgetin | A biflavonoid resulting from the formal oxidative dimerisation between position 8 of one molecule of 5,7-dihydroxy-4'-methoxyflavone and the 3' position of another. Found in the leaves of Ginkgo biloba, it is a potent inhibitor of matrix metalloproteinase 9 (MMP-9). | isoginkgetin |
| isoliquiritigenin | A member of the class of chalcones that is trans-chalcone hydroxylated at C-2', -4 and -4'. | isoliquiritigenin |
| isopentenyladenosine | A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group. | N(6)-(Delta(2)-isopentenyl)adenosine |
| isotretinoin | A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases. | isotretinoin |
| ivosidenib | A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. | ivosidenib |
| ixabepilone | A macrocycle that is a lactam analogue of epothilone B. Binds directly to beta-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. | ixabepilone |
| ixazomib | A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. | ixazomib |
| jaceosidin | A trihydroxyflavone that is flavone with hydroxy groups at positions 5, 7 and 4' and methoxy groups at positions 3' and 6. Isolated from Salvia tomentosa and Artemisia asiatica, it exhibits anti-allergic, anti-inflammatory and apoptosis inducing activties. | jaceosidin |
| jadomycin b | A jadomycin that is jadomycin A in which the phenolic hydroxy group at position 12 has been converted to the corresponding 2,6-dideoxy-alpha-L-ribo-hexopyranoside, isolated from Streptomyces venezuelae. It exists as a diastereoisomeric mixture consisting of both 3aS and 3aR isomers. | jadomycin B |
| jaspamide b | A cyclodepsipeptide isolated from Jaspis splendens. A derivative of jaspamide, it exhibits anti-tumour activity. | jaspamide B |
| jasplakinolide | A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer. | jaspamide |
| jq1 compound | A member of the class of thienotriazolodiazepines that is the tert-butyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. An inhibitor of bromodomain-containing protein 4 that exhibits anti-cancer and cardioprotective properties. | JQ1 |
| jte 013 | A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM). | JTE-013 |
| jte 607 | The dihydrochloride salt of JTE-607. It is a cytokine inhibitor which suppresses the production of proinflammatory cytokines such as interleukin (IL-1beta), IL-6, IL-8, granulocyte macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor (TNF-alpha). It acts as a pro-drug which is cleaved by carboxylesterase 1 (CES1) to its active free acid form, which then binds to cleavage and polyadenylation specificity factor 3 (CPSF3). | JTE-607 dihydrochloride |
| jwh-133 | A dibenzopyran that is Delta(9)-tetrahydrocannabinol which is lacking the hydroxy group and in which the pentyl group at position 3 has been replaced by a 1,1-dimethylbutyl group. A potent and highly selective CB2 receptor agonist. | JWH-133 |
| kahweol | A diterpenoid with formula C20H26O3, isolated from the beans of Coffea arabica. It exhibits antioxidant, anti-inflammatory, anti-angiogenesis and anti-proliferative properties. | kahweol |
| kaurenoic acid | An ent-kaurane diterpenoid that is ent-kauran-19-oic acid in which a double bond is present at position 16(17); exhibits anticancer and anti-HIV 1 activity. | ent-kaur-16-en-19-oic acid |
| kerriamycin b | | urdamycin A |
| ki11502 | A member of the class of quinolines that acts as a receptor tyrosine kinase inhibitor and apoptosis inducer with potential for use in treatment of leukemia and colorectal cancer. | Ki11502 |
| knipholone | An anthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 4 and 6, a methyl group at position 2 and a 3-acetyl-2,6-dihydroxy-4-methoxyphenyl group at position 1. It exhibits antioxidant, cytotoxic and antiplasmodial activities. | knipholone |
| krn 7000 | A glycophytoceramide having an alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. | 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine |
| ku 0063794 | A member of the class of pyridopyrimidines that is an mTOR inhibitor and shows anti-tumour properties. | Ku-0063794 |
| l 663536 | A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase. | 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid |
| l 744832 | A secondary carboxamide resulting from the formal condensation of the carboxy group of 2-{[(2S,3S)-2-{[(2R)-2-amino-3-sulfanylpropyl]amino}-3-methylpentyl]oxy}-3-phenylpropanoic acid with the amino group of propan-2-yl (2S)-2-amino-4-(methylsulfonyl)butanoate. It is a farnesyltransferase inhibitor that exhibits anticancer properties. | L-744,832 |
| l 778,123 | The hydrochloride salt of L-778,123. It is a dual inhibitor of FPTase and GGPTase-I (IC50 of 2nM and 98nm, respectively) and exhibits anti-cancer properties. | L-778,123 hydrochloride |
| l 778,123 | A member of the class of imidazoles that is 1H-imidazole substituted by (4-cyanophenyl)methyl and [4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl groups at positions 1 and 5, respectively. It is a dual inhibitor of FPTase and GGPTase-I. | L-778,123 (free base) |
| lanperisone | A 2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-one in which the methyl group at position 2 adopts R-configuration. It is a muscle relaxant and induces ferroptosis in cancer cells. | lanperisone |
| lapatinib | | lapatinib |
| lasofoxifene | A member of the class of tetralins that is 5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogens at positions 5 and 6 are replaced by 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl and phenyl groups, respectively (the 5R,6S-stereoisomer). It is a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis in post-menopausal women. | lasofoxifene |
| laulimalide | A macrolide with formula C30H42O7 that is isolated from the marine sponges, Cacospongia mycofijiensis and Hyattella sp. | laulimalide |
| lcl161 | | LCL161 |
| ldc4297 | A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity. | LDC4297 |
| lde225 | A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. | sonidegib |
| leachianone a | A trihydroxyflavanone that is (2S)-flavanone substituted by a lavandulyl group at position 8, hydroxy groups at positions 5, 7 and 4' and a methoxy group at position 2'. Isolated from the roots of Sophora flavescens and Sophora leachiana, it exhibits antineoplastic and antimalarial activity. | leachianone A |
| leflunomide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. | leflunomide |
| lenalidomide | A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. | lenalidomide |
| lenvatinib | A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. | lenvatinib |
| lespenefril | A glycosyloxyflavone that is kaempferol attached to alpha-L-rhamnopyranosyl residues at positions 3 and 7 respectively via glycosidic linkages. It has been isolated from the aerial parts of Vicia faba and Lotus edulis. | kaempferol 3,7-di-O-alpha-L-rhamnoside |
| letrozole | | letrozole |
| leuprolide | An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. | leuprolide |
| leuprolide acetate | An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. | leuprolide acetate |
| levoleucovorin | The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid. | (6S)-5-formyltetrahydrofolic acid |
| lfm a13 | An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties. | LFM-A13 |
| ligstroside | A secoiridoid glycoside that is the methyl ester of 3,4-dihydro-2H-pyran-5-carboxylic acid which is substituted at positions 2, 3, and 4 by hydroxy, ethylidene, and carboxymethyl groups, respectively and in which the anomeric hydroxy group at position 2 has been converted into its beta-D-glucoside and the carboxylic acid moiety of the carboxymethyl substituent has been converted to the corresponding 4-hydroxyphenethyl ester (the 2S,3E,4S stereoisomer). An important phenolic compound present in olive cultivars. | ligstroside |
| liriodenine | An oxoaporphine alkaloid that is 4,5,6,6a-tetradehydronoraporphin-7-one substituted by a methylenedioxy group across positions 1 and 2. It is isolated from Annona glabra and has been shown to exhibit antimicrobial and cytotoxic activities. | liriodenine |
| lomustine | An N-nitrosourea that is urea in which one of the nitrogens is substituted by a 2-chloroethyl group and by a nitroso group, while the other nitrogen is substituted by a cyclohexyl group. An alkylating antineoplastic agent, it is used in the treatment of brain tumours, lung cancer, malignant melanoma and other solid tumours. | lomustine |
| lonafarnib | A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. | lonafarnib |
| lonazolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 3-(4-chlorophenyl)-1-phenylpyrazol-4-yl group. | lonazolac |
| lonidamine | A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively. | lonidamine |
| lovastatin | A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). | lovastatin |
| lrrk2-in1 | A member of the class of pyrimidobenzodiazepines that is 5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a 4-[(4-methylpiperazin-1-yl)piperidine-1-carbonyl]-2-methoxyanilino substituent. It is an inhibitor of the Parkinson's disease kinase LRRK2. | LRRK2-IN-1 |
| lucanthone | A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone. | lucanthone |
| lucidenic acid n | A tetracyclic triterpenoid that is 25,26,27-trinorlanost-8-en-24-oic acid substituted by hydroxy groups at positions 3 and 7 and oxo groups at positions 11 and 15 respectively (the 3beta,5alpha,7beta stereoisomer). Isolated from the fruiting bodies of Ganoderma lucidum, it exhibits cytotoxicity against tumour cells. | lucidenic acid N |
| lucitanib | A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine. | E-3810 free base |
| lupulon | A beta-bitter acid in which the acyl group is specified as 3-methylbutanoyl. | lupulone |
| luteolin | A tetrahydroxyflavone in which the four hydroxy groups are located at positions 3', 4', 5 and 7. It is thought to play an important role in the human body as an antioxidant, a free radical scavenger, an anti-inflammatory agent and an immune system modulator as well as being active against several cancers. | luteolin |
| ly-2157299 | A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma. | LY-2157299 |
| ly2090314 | A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer. | LY-2090314 |
| ly3009120 | A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by methylamino, 5-{[(3,3-dimethylbutyl)carbamoyl]amino}-4-fluoro-2-methylphenyl, and methyl groups at positions 2, 6 and 7, respectively. It is a potent pan RAF inhibitor which inhibits BRAF(V600E), BRAF(WT) and CRAF(WT) (IC50 = 5.8, 9.1 and 15 nM, respectively). It also inhibits RAF homo- and heterodimers and exhibits anti-cancer properties. | LY3009120 |
| lyoniresinol | A lignan that is tetralin substituted by a 4-hydroxy-3,5-dimethoxy group at position 4, hydroxymethyl groups at positions 2 and 3, methoxy groups at positions 5 and 7 and a hydroxy group at position 6. Isolated from Machilus robusta and Sinocalamus affinis, it exhibits antineoplastic activity. | (+)-lyoniresinol |
| ma-1 | A member of the class of pyrimidones that is uracil substituted by chloro and (2-iminopyrrolidin-1-yl)methyl groups at positions 5 and 6 respectively. Used (as the hydrochloride salt) in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. | tipiracil |
| macluraxanthone b | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7, a dimethylallyl group at position 2 and a prenyl group at position 4. Isolated from Maclura tinctoria and Cudrania tricuspidata, it exhibits anti-HIV and antineoplastic activity. | macluraxanthone B |
| manassantin b | A lignan isolated from Saururus cernuus and Saururus chinensis and has been shown to exhibit antineoplastic activity. | manassantin B |
| mangostin | A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. | alpha-mangostin |
| manool | A labdane diterpenoid in which the labdane skeleton has double bonds at positions 8(17) and 14 and carries an R-hydroxy group at position 13. | manool |
| manumycin | A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. | manumycin A |
| manzamine a | An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26). | manzamine A |
| marimastat | A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. | marimastat |
| marineosin a | A macrocycle isolated from a marine sediment-derived actinomycete, Streptomyces sp. It exhibits cytotoxicity against colon tumour cell lines. | marineosin A |
| marineosin b | A macrocycle isolated from a marine sediment-derived actinomycete, Streptomyces sp. A stereoisomer of marineosin A, it exhibits cytotoxicity against colon tumour cell lines. | marineosin B |
| marinopyrrole a | A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities. | (-)-marinopyrrole A |
| marizomib | A salinosporamide in which the core (1R)-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione skeleton is substituted at positions 1, 4, and 5 by (1S)-cyclohex-2-en-1-yl(hydroxy)methyl, 2-chloroethyl, and methyl groups, respectively (the 1R,4R,5S diastereoisomer). A potent proteasome inhibitor, it has attracted interest for potential use in the treatment of various cancers. | salinosporamide A |
| masitinib | A member of the class of benzamides that is the carboxamide resulting from the formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)-1,3-thiazol-2-yl]benzene-1,3-diamine. It is a highly selective oral tyrosine kinase inhibitor. | masitinib |
| maslinic acid | A pentacyclic triterpenoid that is olean-12-ene substituted by hydroxy groups at positions 2 and 3 and a carboxy group at position 28 (the 2alpha,3beta stereoisomer). It is isolated from Olea europaea and Salvia canariensis and exhibits anti-inflammatory, antioxidant and antineoplastic activity. | maslinic acid |
| masoprocol | The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase. | masoprocol |
| maytansine | An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines. | maytansine |
| mcb-613 | A cyclic ketone that is 4-ethylcyclohexanone which is substituted by pyridin-3-ylmethylene groups at positions 2 and 6. It is a potent small molecule stimulator of steroid receptor coactivators (SRCs). MCB-613 increases SRCs' interactions with other coactivators and markedly induces ER stress coupled to the generation of reactive oxygen species. Since cancer cells overexpress SRCs and rely on them for growth, MCB-613 can be used to selectively induce excessive stress in cancer cells. | MCB-613 |
| mdv 3100 | A benzamide obtained by formal condensation of the carboxy group of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluorobenzoic acid with methylamine. Used for the treatment of of metastatic castration-resistant prostate cancer. | enzalutamide |
| mechlorethamine hydrochloride | The hydrochloride salt of mechlorethamine. | mechlorethamine hydrochloride |
| meclofenamate sodium anhydrous | A hydrate that is the monohydrate of the sodium salt of meclofenamic acid. It is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | sodium meclofenamate monohydrate |
| meclofenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | meclofenamic acid |
| medroxyprogesterone acetate | An acetate ester resulting from the formal condensation of the 17alpha-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control. | medroxyprogesterone acetate |
| megestrol | A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17. | megestrol |
| megestrol acetate | A steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. | megestrol acetate |
| melphalan | A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. | melphalan |
| mercaptopurine | A thiol that is the tautomer of mercaptopurine. | 3,7-dihydropurine-6-thione; mercaptopurine; purine-6-thiol |
| mercaptopurine | A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. | 3,7-dihydropurine-6-thione; mercaptopurine; purine-6-thiol |
| methotrexate | | methotrexate |
| methoxsalen | A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. | methoxsalen |
| methoxyacetic acid | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group. | methoxyacetic acid |
| methyl 5-aminolevulinate | The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. | methyl 5-aminolevulinate |
| methyl 5-aminolevulinate hydrochloride | The hydrochloride salt of methyl 5-aminolevulinate. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. | methyl 5-aminolevulinate hydrochloride |
| methylselenic acid | An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group. | methylseleninic acid |
| methyltestosterone | A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position. | methyltestosterone |
| midazolam | An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. | midazolam |
| midazolam hydrochloride | The hydrochloride salt of midazolam. | midazolam hydrochloride |
| midostaurin | An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine. | midostaurin |
| migrastatin | A 14-membered macrolide which is isolated from Streptomyces sp.MK929-43F1 and inhibits cell migration of human esophageal cancer EC17 cells and mouse melanona B16 cells. | migrastatin |
| miltefosine | A phospholipid that is the hexadecyl monoester of phosphocholine. | miltefosine |
| minquartynoic acid | A straight-chain, C18 polyunsaturated fatty acid having four conjugated C#C bonds at positions 9, 11, 13 and 15 as well as an (S)-hydroxy group at position 17. | minquartynoic acid |
| mitoguazone | A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine. | mitoguazone |
| mitomycin | | mitomycin C |
| mitomycin a | A member of the family of mitomycins that exhibits antibiotic and antitumour properties as well as a high level of toxicity. | mitomycin A |
| mitoxantrone | A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. | mitoxantrone |
| mitoxantrone hydrochloride | | mitoxantrone dihydrochloride |
| MK-8353 | A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. | MK-8353 |
| ML-210 | An N-acylpiperazine that is piperazine substituted by 5-methyl-4-nitro-1,2-oxazole-3-carbonyl and bis(4-chlorophenyl)methyl groups at positions 1 and 4, respectively. It is a glutathione peroxidase 4 (GPX4) inhibitor which induces ferroptosis in cancer cells expressing the RAS oncogene. | ML-210 |
| ML240 | A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP). | ML240 |
| MMP-9-IN-1 | A secondary carboxamide resulting from the formal condensation of the carboxy group of [(4-oxo-6-propyl-1,4-dihydropyrimidin-2-yl)sulfanyl]acetic acid with the amino group of 4-(difluoromethoxy)aniline. It is a specific matrix metalloproteinase-9 (MMP-9) inhibitor. | MMP-9-IN-1 |
| mocetinostat | A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). | mocetinostat |
| mogrol | A tetracyclic triterpenoid that is cucurbitadienol in which the side-chain double bond (position 24-25) has undergone formal oxidation to introduce hydroxy groups at positions 24 and 25 (the 24R stereoisomer). It is a biometabolite of mogrosides found in Siraitia grosvenorii. | mogrol |
| monascin | An organic heterotricyclic compound that is 3a,4,8,9a-tetrahydro-2H-furo[3,2-g][2]benzopyran-2,9(3H)-dione that is substituted at positions 3, 6, and 9a by hexanoyl, (1E)-prop-1-en-1-yl and methyl groups, respectively (the 3S,3aR,9aR diastereoisomer). One of the azaphilonoid pigments in extracts of Monascus pilosus-fermented rice (red-mould rice), it is a potent inhibitor of carcinogenesis measured against chemical- or UV-initiated, phorbol-promoted mouse skin tumours. | monascin |
| monascorubrin | | monascorubrin |
| monastrol | A racemate comprising equimolar amounts of R- and S-monastrol. | ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate; monastrol |
| morin | A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5. | morin |
| morusin | An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8. | morusin |
| mucronulatol | A methoxyisoflavan that is (S)-isoflavan substituted by methoxy groups at positions 2' and 4' and hydroxy groups at positions 7 and 3' respectively. | mucronulatol |
| muromonab-cd3 | An organic heteropentacyclic compound that is isolated from the marine sponge Xestospongia exigua. | xestospongin C |
| mycophenolic acid | A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases. | mycophenolic acid |
| myriaporone 3 | A member of the class of oxanes isolated from the Mediterranean bryozoan Myriapora truncata and has been shown to exhibit inhibitory activity against murine leukemia cells. | myriaporone 3 |
| myricanone | A cyclic ketone isolated from the bark of Morella species and has been shown to exhibit cytotoxic activity against cancer cells. | Myricanone |
| myricetin | A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7. It has been isolated from the leaves of Myrica rubra and other plants. | myricetin |
| n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamide | A member of the class of hydroxyindoles that is melatonin in which the hydrogen at position 2 of the indole ring has been replaced by a hydroxy group. A predominant hydroxylated melatonin metabolite in plants. | 2-hydroxymelatonin |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2. | NS-398 |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. | indisulam |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis. | momelotinib |
| n(1)-guanyl-1,7-diaminoheptane | A member of the class of guanidines in which the imino hydrogen of guanidine itself has been replaced by a 7-aminoheptyl group. It is an inhibitor of deoxyhypusine synthase activity (GO:0034038). | 2-(7-aminoheptyl)guanidine |
| n(1), n(12)-diethylspermine | A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group. | N(1),N(12)-diethylspermine |
| N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | A hydroxamic acid that is N-hydroxy-D-valinamide in which the alpha-amino group has been substituted by isopropoxy and [biphenyl]-4-ylsulfonyl groups. A selective matrix metalloproteinase-2 (MMP-2) inhibitor, it is one of the most potent inducers of autophagy. Its physiological roles include angiogenesis, cancer metastasis, embryogenesis, tissue remodeling in development, and wound healing. | N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide |
| naphthazarin | A naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 5 and 8 are replaced by hydroxy groups. | naphthazarin |
| naringin | A disaccharide derivative that is (S)-naringenin substituted by a 2-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. | naringin |
| navitoclax | A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies. | navitoclax |
| nelarabine | A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). | nelarabine |
| nelfinavir | An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. | nelfinavir |
| nelfinavir mesylate | A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties. | nelfinavir mesylate |
| neobavaisoflavone | A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone with an additonal hydroxy group at position 4' and a prenyl group at position 3'. Isolated from seeds of Psoralea corylifolia, it exhibits inhibitory activity against DNA polymerase and platelet aggregation. | neobavaisoflavone |
| neocarzinostatin chromophore | A naphthoate ester obtained by formal condensation of the carboxy group of 2-hydroxy-7-methoxy-5-methyl-1-naphthoic acid with the 5-hydroxy group of (1aS,5R,6R,6aE,9aR)-5-hydroxy-1a-[(4R)-2-oxo-1,3-dioxolan-4-yl]-2,3,8,9-tetradehydro-1a,5,6,9a-tetrahydrocyclopenta[5,6]cyclonona[1,2-b]oxiren-6-yl 2,6-dideoxy-2-(methylamino)-alpha-D-galactopyranoside. The chromophoric part of neocarzinostatin, it is tightly and non-covelently bound to a 113-membered apoprotein, which serves to protect it and release it to the target DNA. | neocarzinostatin chromophore |
| neoglycyrol | A member of the class of coumestans that is coumestan substituted by hydroxy groups at positions 1 and 9, a methoxy group at position 3 and a prenyl group at position 2 respectively. | glycyrol |
| nidulalin a | A member of the class xanthones which consists of a dihydroxanthone skeleton substituted by hydroxy groups at positions 4 and 8, a methyl group at position 6 and a methoxycarbonyl group at position 4a (the 4R,4aS stereoisomer). It is isolated from Emericella nidulans var lata and Penicillium and exhibits potent antitumour activity against both human and murine tumour cell lines. | nidulalin A |
| nigranoic acid | A tetracyclic triterpenoid that is 3,4-secocycloarta-4(28),24-(Z)-diene substituted by carboxy groups at positions 3 and 26. Isolated from Schisandra henryi and Schisandra propinqua, it exhibits cytotoxic and anti-HIV activities. | nigranoic acid |
| nilutamide | | nilutamide |
| nimustine | An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors. | nimustine |
| nimustine | A hydrochloride obtained by combining nimustine with one equivalent of hydrochloric acid. An antineoplastic agent especially effective against malignant brain tumors. | nimustine hydrochloride |
| niraparib | A member of the class of indazoles that is 2H-indazole substituted by 4-(piperidin-3-yl)phenyl and aminocarbonyl groups at positions 2 and 7, respectively. It is a potent PARP1 inhibitor with IC50 of 3.2 nM. | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide |
| niraparib | A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. | niraparib |
| nitrogenase stabilizing-protective protein, bacteria | A N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide that is the (R)-enantiomer of bicalutamide. | (R)-bicalutamide |
| nnc 55-0396 | The dihydrochloride salt of NNC 55-0396. It is a stable analogue of mibefradil and a highly selective T-type calcium channel blocker. | NNC 55-0396 dihydrochloride |
| NNC 55-0396 (free base) | | NNC 55-0396 (free base) |
| nobiletin | A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively. | nobiletin |
| nocodazole | A member of the class of benzimidazoles that is benzimidalole which is substituted at position 2 by a (methoxycarbonyl)amino group and at position 5 by a 2-thienoyl group. It is an antineoplastic agent that exerts its effect by depolymerising microtubules. | nocodazole |
| norathyriol | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7. Isolated from Garcinia mangostana and Maclura pomifera, it exhibits inhibitory activity against protein kinase C. | norathyriol |
| nortriptyline | An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. | nortriptyline |
| noscapine | A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects. | (-)-noscapine |
| npi 2358 | A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer. | plinabulin |
| nsc 224070 | A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which the hydrogens at positions 2 and 5 have been replaced by aziridin-1-yl groups while the hydrogens at positions 3 and 6 have been replaced by (2-hydroxyethyl)amino groups. | 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinylbenzoquinone |
| nsc 716970 | An indolecarboxamide obtained by the formal condensation of the carboxy group of 5,6,7-trimethoxyindole-2-carboxylic acid with the 2-amino group of 1-(2-chloroethyl)-2,4-diaminonaphthalene. | AS-I-145 |
| nsc-145,668 | A hydrochloride salt resulting from the reaction of equimolar amounts of ancitabine and hydrogen chloride. | ancitabine hydrochloride |
| o-(chloroacetylcarbamoyl)fumagillol | A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative. | O-(chloroacetylcarbamoyl)fumagillol |
| obolactone | A pyranone isolated from the trunk barks of Cryptocarya obovata and has been shown to exhibit cytotoxicity against the KB cell line. | obolactone |
| olaparib | A member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. | olaparib |
| oleuropein | A secoiridoid glycoside that is the methyl ester of 3,4-dihydro-2H-pyran-5-carboxylic acid which is substituted at positions 2, 3, and 4 by hydroxy, ethylidene, and carboxymethyl groups, respectively and in which the anomeric hydroxy group at position 2 has been converted into its beta-D-glucoside and the carboxylic acid moiety of the carboxymethyl substituent has been converted to the corresponding 3,4-dihydroxyphenethyl ester (the 2S,3E,4S stereoisomer). The most important phenolic compound present in olive cultivars. | oleuropein |
| oligomycin a | An oligomycin with formula C45H74011. An inhibitor of mitochondrial F1FO ATP synthase that induces apoptosis in a variety of cell types and exhibits antifungal, antitumour, and nematicidal activities, but its clinical application has been limited by poor solubility in water and other biocompatible solvents. | oligomycin A |
| oltipraz | A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively. | oltipraz |
| on 01910 | An N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties. | rigosertib |
| oncrasin-1 | A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations. | oncrasin-1 |
| orantinib | An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1. | orantinib |
| oridonin | An organic heteropentacyclic compound and ent-kaurane diterpenoid with formula C20H28O6 isolated from the leaves of the medicinal herb Rabdosia rubescens. | oridonin |
| osimertinib | A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer. | osimertinib |
| ospemifene | An organochlorine compound that is a selective estrogen receptor modulator; used for treatment of dyspareunia. | ospemifene |
| ossamycin | A macrolide antibiotic that was originally isolated from the culture broths of Streptomyces hygroscopicus var. ossamyceticus. | ossamycin |
| osu 03012 | A member of the class of pyrazoles that is N-[4-(pyrazol-1-yl)phenyl]glycinamide in which the pyrazole ring is substituted at positions 3 and 5 by trifluoromethyl and phenanthrene-2-yl groups respectively. | OSU-03012 |
| oxophenylarsine | An arsine oxide derived from phenylarsine. | phenylarsine oxide |
| oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
| paclitaxel | A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark. | paclitaxel |
| palbociclib | A member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combination with letrozole for the treatment of metastatic breast cancer. | palbociclib |
| pannarin | A member of the class of depsidones that is 11H-dibenzo[b,e][1,4]dioxepine substituted by methyl groups at positions 1,6 and 9, chloro group at position 2, hydroxy group at position 3, formyl group at position 4, methoxy group at position 8 and an oxo group at position 11. It is a lichen metabolite isolated from several Psoroma species. | pannarin |
| panobinostat | A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. | panobinostat |
| papuamide b | A cyclodepsipeptide that is isolated from Papua New Guinea collections of the marine sponges Theonella mirabilis and Theonella swinhoei. It exhbits anti-HIV-1 activity and cytotoxicity against some human cancer cell lines. | papuamide B |
| pasireotide | A six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease. | pasireotide |
| pateamine a | A marine macrodiolide that is isolated from the sponge Mycale hentscheli and exhibits anticancer and antiviral properties | pateamine |
| pazopanib | A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. | pazopanib |
| PB28 | A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities. | PB28 |
| pci 32765 | A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. | ibrutinib |
| pd 0325901 | A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer). | PD 0325901 |
| pd 158780 | A pyridopyrimidine that is pyrido[3,4-d]pyrimidine-4,6-diamine in which the amino groups at positions 4 and 6 are substituted by a m-bromophenyl group and a methyl group, respectively. It is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity [IC50 values of 0.008, 49 and 52 nM for EGFR, ErbB2 (HER2) and Erb4 (HER4)]. It does not inhibit FGF or PDGF-mediated tyrosine phosphorylation. Induces G1 cell cycle arrest in MCF10A cells and is antiproliferative in A431 human epidermal carcinoma cells. | PD158780 |
| pd 166866 | A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by an amino group at position 2, 3,5-dimethoxyphenyl group at position 6, and by a (tert-butylcarbamoyl)nitrilo group at position 7. It is a selective ATP competitive inhibitor of the human fibroblast growth factor-1 receptor (FGFR1) tyrosine kinase with an IC50 of 52.4 nM. | PD-166866 |
| pd 173074 | A member of the class of ureas that is 1-tert-butylurea in which one of the hydrogens attached to N(3) is substituted by a pyrido[2,3-d]pyrimidin-7-yl group, which is itself substituted at positions 2 and 6 by a 4-(diethylamino)butyl]amino group and a 3,5-dimethoxyphenyl group, respectively. It is a FGF/VEGF receptor tyrosine kinase inhibitor. | PD173074 |
| pectolinarin | A disaccharide derivative that consists of pectolinarigenin substituted by a 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. | pectolinarin |
| pederin | A polyketide and carboxamide produced by a (Pseudomonas) bacterial endosymbiont of certain rove beetles (genus Paederus). Pederin is the agent responsible for the vesicant effects (linear or Paederus dermatitis) when the beetle is crushed against the skin. It is a powerful inhibitor of protein biosynthesis and mitosis and a potent antitumour agent. | pederin |
| pelabresib | An organic heterotricyclic compound that is 4H-[1,2]oxazolo[5,4-d][2]benzazepine substituted by methyl, 2-amino-2-oxoethyl, and 4-chlorophenyl groups at positions 1, 4S and 6, respectively. It is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins and exhibits antineoplastic activity. | pelabresib |
| pemetrexed | An N-acylglutamic acid in which the N-acyl group is specified as 4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). | pemetrexed |
| pentostatin | A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. | pentostatin |
| peonidin | An anthocyanidin cation that is flavylium bearing four hydroxy substituents at positions 3, 4', 5 and 7 as well as a methoxy substituent at position 3'. | peonidin |
| perfosfamide | A phosphorodiamide that is the active metabolite of the nitrogen mustard cyclophosphamide. It has potent antineoplastic and immunosuppressive properties. | 4-hydroperoxycyclophosphamide |
| perillic acid | | perillic acid |
| pevonedistat | A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. | pevonedistat; sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester |
| pexidartinib | A pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). | pexidartinib |
| pf 00299804 | A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group. | dacomitinib |
| pf-06463922 | A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. | lorlatinib |
| pha 665752 | A member of the class of indolones that is 1,3-dihydro-2H-indol-2-one which is substituted by a (2,6-dichlorobenzyl)sulfonyl group at position 5 and by a (1H-pyrrol-2-yl)methylidene group at position 2, the pyrrole ring of which is substituted by methyl groups at positions 3 and 5, and by a [2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl group at position 4 (the Z,R isomer). | PHA-665752 |
| phenethyl isothiocyanate | An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties. | phenethyl isothiocyanate |
| phenformin | A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis. | phenformin |
| phleomycin d1 | A glycopeptide originally isolated from the bacterium Streptomyces verticillus which contains a (4'R)-4',5'-dihydro-2,4'-bi-1,3-thiazole-2',4-diyl moiety with a a 4-guanidylbutylaminocarbonyl group attached to the 4-position of the terminal thiazole ring. Like all phleomycins, phleomycin D1 can form complexes with redox-active metals such as Co, Cu, and Fe. | phleomycin D1 |
| phloretin | A member of the class of dihydrochalcones that is dihydrochalcone substituted by hydroxy groups at positions 4, 2', 4' and 6'. | phloretin |
| physalin b | A physalin with antimalarial, antitumour and antimicrobial activities isolated from Physalis angulata. | physalin B |
| physalin d | A physalin with antimalarial and antimycobacterial activities isolated from Physalis angulata. | physalin D |
| physalin f | A physalin with antimalarial and antitumour activities isolated from Physalis angulata. | physalin F |
| physcione | A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources. | physcion |
| pi103 | An organic heterotricyclic compound that is pyrido[3',2':4,5]furo[3,2-d]pyrimidine substituted at positions 2 and 4 by 3-hydroxyphenyl and morpholin-4-yl groups respectively. A dual-kinase inhibitor with anti-cancer properties. | PI-103 |
| picropodophyllin | An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents. | picropodophyllotoxin |
| pinocembrin | A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea. | pinocembrin |
| pipobroman | An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug. | pipobroman |
| pj-34 | A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | PJ34 |
| pk 11195 | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine | PK-11195 |
| plaunotol | A diterpenoid that is geranylgeraniol carrying an additional hydroxy substituent at position 18. | plaunotol |
| plerixafor | An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. | plerixafor |
| plitidepsin | A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans. | plitidepsin |
| plumbagin | A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively. | plumbagin |
| plx 4720 | A pyrrolopyridine that is vemurafenib in which the p-chlorophenyl group has been replaced by chlorine. It is a potent and selective inhibitor of the Raf kinase B-Raf(V600E). | PLX-4720 |
| plx4032 | A pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases. | vemurafenib |
| podophyllotoxin | An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing a 3,4,5-trimethoxyphenyl substituent. It is found in the roots and rhizomes of Podophyllum species and is used for the topical treatment of genital warts. | podophyllotoxin |
| pomalidomide | An aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. | pomalidomide |
| ponatinib | A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). | ponatinib |
| poziotinib | A member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, [1-(prop-2-enoyl)piperidin-4-yl]oxy, and methoxy groups at positions 4, 6, and 7, respectively. It is a potent and irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. | poziotinib |
| PP121 | A pyrazolopyrimidine that is 1H-pyrazolo[3,4-d]pyrimidine which is substituted by a cyclopentyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, and amino groups at positions 1, 3 and 4, respectively. It is a dual inhibitor of tyrosine and phosphoinositide kinases and exhibits anti-cancer properties. | PP121 |
| pp242 | A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | torkinib |
| pracinostat | A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours. | pracinostat |
| prednisolone | A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone. | prednisolone |
| prednisolone phosphate | A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases. | prednisolone phosphate |
| prednisone | A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. | prednisone |
| prinomastat | A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14. | prinomastat |
| procarbazine | A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. | procarbazine |
| procarbazine hydrochloride | A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. | procarbazine hydrochloride |
| promegestone | A progestin consisting of 17beta-propionylestra-4,9-dien-3-one substituted at position 17 by a methyl group. | promegestone |
| protocatechuic acid | A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 4. | 3,4-dihydroxybenzoic acid |
| psorospermin | An organic heterotetracyclic compound that is 1,2-dihydro-6H-furo[2,3-c]xanthene substituted by a hydroxy group at position 10, a methoxy group at position 5 nad a 2-methyloxiran-2-yl group at position 2. | psorospermin |
| pterostilbene | A stilbenol that consists of trans-stilbene bearing a hydroxy group at position 4 as well as two methoxy substituents at positions 3' and 5'. | pterostilbene |
| ptk 787 | A succinate salt obtained by combining vatalanib with one molar equivalent of succinic acid. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit. | vatalanib succinate |
| puromycin | An aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium, that causes premature chain termination during translation taking place in the ribosome. | puromycin |
| pyrazofurin | A C-glycosyl compound that is 4-hydroxy-1H-pyrazole-5-carboxamide in which the hydrogen at position 3 has been replaced by a beta-D-ribofuranosyl group. | pirazofurin |
| pyrazolanthrone | A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase. | anthra[1,9-cd]pyrazol-6(2H)-one |
| pyrrolidine dithiocarbamate | A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine. | pyrrolidine dithiocarbamate |
| pyrvinium | A quinolinium ion that is 1-methylquinolinium substituted by dimethylamino group at position 6 and a (E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl at position 2. It is a anthelminthic drug active against pinworms. The salts of pyrvinium can also be used as anticancer agents. | pyrvinium |
| quercetin | A pentahydroxyflavone having the five hydroxy groups placed at the 3-, 3'-, 4'-, 5- and 7-positions. It is one of the most abundant flavonoids in edible vegetables, fruit and wine. | quercetin |
| quercetin 3-o-glucopyranoside | A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells | quercetin 3-O-beta-D-glucopyranoside |
| quizartinib | A member of the class of phenylureas that is urea in which one of the amino groups has been substituted by a 5-tert-butyl-1,2-oxazol-3-yl group while the other has been substituted by a phenyl group substituted at the para- position by an imidazo[2,1-b][1,3]benzothiazol-2-yl group that, in turn, is substituted at position 7 by a 2-(morpholin-4-yl)ethoxy group. | quizartinib |
| regorafenib | A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. | regorafenib |
| respirantin | A cyclodepsipeptide isolated from Streptomyces and Kitasatospora and has been shown to exhibit antimicrobial and antineoplastic activity. | respirantin |
| reumycin | A pyrimidotriazine that is 6-methyl-5,6,7,8-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 6. | reumycin |
| rhamnazin | A dimethoxyflavone that is quercetin in which the hydroxy groups at the 3' and 7 positions have been replaced by methoxy groups. | rhamnacene |
| rhapontin | A rhaponticin in which the double bond adopts a trans-configuration. It possesses a range of pharmacological activities including antitumour, antiinflammatory, antilipemic and neuroprotective activities. | trans-rhaponticin |
| rhizoxin | An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity. | rhizoxin |
| rhosin | A D-tryptophan derivative obtained by formal condensation of the carboxy group of D-tryptophan with the amino group of (quinoxalin-6-yl)methylidenehydrazide. It directly targets the Rho GEF binding domain, thereby preventing Rho from interacting with its GEFs | rhosin |
| rifampin | A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei). | rifampicin zwitterion; rifampicin |
| ro 48-8071 | An aromatic ketone that is 2-fluoro-4'-bromobenzophenone in which the hydrogen at position 4 (meta to the fluoro group) is replaced by a 6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy group. An inhibitor of lanosterol synthase. | Ro 48-8071 |
| ro 5-3335 | A 1,4-benzodiazepinone that is nordazepam in which the phenyl substituent has been replaced by a 1H-pyrrol-2-yl group. It inhibits gene expression in HIV-1 at the transcriptional level through interference with Tat-mediated transactivation. | Ro 5-3335 |
| ro5126766 | A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3. | CH5126766 |
| robustaflavone | A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-3 of the hydroxyphenyl ring and C-6 of the chromene ring. Isolated from Thuja orientalis and Rhus succedanea it exhibits antioxidant, cytotoxic and anti-hepatitis B activity. | robustaflavone |
| rocaglamide | An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity. | rocaglamide |
| romidepsin | A cyclodepsipeptide consisting of the cyclic disulfide of (2Z)-2-aminobut-2-enoyl, L-valyl, (3S,4E)-3-hydroxy-7-sulfanylhept-4-enoyl, D-valyl and D-cysteinyl residues coupled in sequence and cyclised head-to tail. | romidepsin |
| rotenone | A member of the class of rotenones that consists of 1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one substituted at position 2 by a prop-1-en-2-yl group and at positions 8 and 9 by methoxy groups (the 2R,6aS,12aS-isomer). A non-systemic insecticide, it is the principal insecticidal constituent of derris (the dried rhizome and root of Derris elliptica). | rotenone |
| rottlerin | A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. | rottlerin |
| rtki cpd | A member of the class of quinazolines that is quinazoline substituted by methoxy groups at positions 6 and 7 and a (3-chlorophenyl)nitrilo group at position 4. It acts as an epidermal growth factor receptor antagonist. | tyrphostin AG 1478 |
| ru 58668 | A 17beta-hydroxy steroid that is 17beta-estradiol in the the hydrogen at the 11beta position has been replaced by a p-({5-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]pentyl}oxy)phenyl group. RU 58668 is a pure anti-estrogen that downregulates estrogen receptor expression (IC50 = 0.04 nM). | RU 58668 |
| rubimaillin | A benzochromene that is 2H-benzo[h]chromene which is substituted by two methyl groups at position 2, a methoxycarbonyl group at position 5, and a hydroxy group at position 6. Found in the Chinese medical plant Rubia cordifola, It has an anti-cancer effect by inhibition of TNF-alpha-induced NF-kappaB activation. It is also a dual inhibitor of acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), but is more selective for the ACAT2 isozyme. | rubimaillin |
| rubitecan | A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. | rubitecan |
| rubraxanthone | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 3, 6 and 8, a geranyl group at position 1 and a methoxy group at position 2. Isolated from Mesua and Garcinia dioica, it exhibits antibacterial and cytotoxic activities. | rubraxanthone |
| rucaparib | A member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. | rucaparib |
| rx-3117 | A triol that is (1S,2R)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol which is substituted by a 4-amino-2-oxopyrimidin-1(2H)-yl group at position 5. It is a cytidine analog which exhibits anticancer activity in several cancers, including gemcitabine-resistant tumours. | roducitabine |
| s 1033 | | nilotinib |
| s-allylcysteine | An S-hydrocarbyl-L-cysteine that is L-cysteine in which the hydrogen attached to the sulphur is replaced by a prop-2-enyl group. It commonly occurs in garlic and has been found to exhibit antineoplastic activity. | S-allylcysteine zwitterion; S-allylcysteine |
| saintopin | A member of the class of tetracenequinones that is tetracene-5,12-dione in which the hydrogens at positions 1, 3, 8, 10, and 11 have been replaced by hydroxy groups. Isolated from Paecilomyces. | saintopin |
| salicylsalicylic acid | A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. | salsalate |
| salvianolic acid B | A member of the class of 1-benzofurans that is an antioxidant and free radical scavenging compound extracted from S. miltiorrhiza | salvianolic acid B |
| salvigenin | A trimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4', 6, and 7 are replaced by methoxy groups. | salvigenin |
| salvileucalin b | A diterpenoid with a rearranged neo-clerodane skeleton isolated from Salvia leucantha and has been shown exhibit antineoplastic activity. | salvileucalin B |
| salvin | An abietane diterpenoid that is abieta-8,11,13-triene substituted by hydroxy groups at positions 11 and 12 and a carboxy group at position 20. It is isolated from rosemary (Rosmarinus officinalis) and common sage (Salvia officinalis) and exhibits anti-angiogenic, antineoplastic, antioxidant and anti-HIV activity. | carnosic acid |
| saracatinib | A member of the class of quinazolines that is quinazoline substituted by (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy and 2-(4-methylpiperazin-1-yl)ethoxy groups at positions 4, 5 and 7, respectively. It is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). Saracatinib was originally developed by AstraZeneca for the treatment of cancer but in 2019 it was granted orphan drug designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. | saracatinib |
| sc 560 | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1. | SC560 |
| sc 58125 | A member of the class of pyrazoles that is 1H-pyrazole substituted by a 4-fluorophenyl group at position 5, a 4-(methylsulfonyl)phenyl group at position 1 and a trifluoromethyl group at position 3. A selective cyclooxygenase 2 inhibitor, it exhibits anticancer property. | SC-58125 |
| sch 51344 | A pyrazoloquinoline that is 6-methoxy-3-methyl-1H-pyrazolo[3,4-b]quinoline bearing an additional 2-[(2-hydroxyethoxy)ethyl]amino substituent at position 4 | SCH51344 |
| sch772984 | A member of the class of indazoles that is 1H-indazole substituted by pyridin-4-yl and {[(3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)pyrrolidin-3-yl]carbonyl}amino groups at positions 3 and 5, respectively. It is a potent inhibitor of mitogen-activated protein kinases ERK1 and ERK2 (IC50 = 4 and 1 nM, respectively) that exhibits anti-cancer properties. | SCH772984 |
| schweinfurthin g | A stilbenoid that is the 3-deoxy derivative of vedelianin. Isolated from Macaranga alnifolia, it exhibits cytotoxic activity. | schweinfurthin G |
| scio-469 | An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties. | talmapimod |
| scutellarin | The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein. | scutellarin |
| selenomethylselenocysteine | An alpha-amino acid compound having methylselanylmethyl as the side-chain. | Se-methylselenocysteine |
| selenomethylselenocysteine | An L-alpha-amino acid compound having methylselanylmethyl as the side-chain. | Se-methyl-L-selenocysteine zwitterion; Se-methyl-L-selenocysteine |
| semaxinib | An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group. | semaxanib |
| semustine | An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group. | semustine |
| sesamin | A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity. | (+)-sesamin |
| sibiromycin | An aminoglycoside antibiotic produced by Streptosporangium sibiricum that also exhibits antitumour properties. | sibiromycin |
| silvestrol | An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. | silvestrol |
| silybin | A flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities. | silibinin |
| simalikalactone D | A quassinoid isolated from Quassia amara and Quassia africana. It has been shown to exhibit antimalarial, cytotoxic and antiviral activities. | simalikalactone D |
| sirolimus | A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. | sirolimus |
| sm 164 | A potent cell-permeable and bivalent Smac mimetic which binds to XIAP, cIAP-1 and cIAP-2 proteins (Ki = 0.56 nM, 0.31 nM and 1.1 nM, respectively). It induces apoptosis and tumor regression in cancer xenograft models. | SM-164 |
| sn 38 | A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself. | SN-38 |
| soblidotin | A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity. | soblidotin |
| sodium arsenite | An inoganic sodium salt with formula with formula NaAsO2. | sodium arsenite |
| sophoraflavanone a | A trihydroxyflavanone that is (S)-naringenin substituted by a geranyl group at position 8. Isolated from Macaranga bicolor, it exhibits antibacterial and antineoplastic activities. | sophoraflavanone A |
| sorafenib | A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group. | sorafenib |
| sotorasib | A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. | sotorasib |
| spiculoic acid a | A carbobicyclic compound that is 2,3,3a,4,5,7a-hexahydro-1H-indene substituted by ethyl groups at positions 3, 4, 5 and 7, a methyl group at position 1, an oxo group at position 2, a 2-phenylethenyl group at position 5 and a carboxy group at position 4 (the 1R,3R,3aS,4S,5R,7aS stereoisomer). Isolated from Plakortis angulospiculatus, it exhibits cytotoxicity against human breast cancer MCF-7 cells. | spiculoic acid A |
| spiraeoside | A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 4'. | quercetin 4'-O-beta-D-glucopyranoside |
| spiruchostatin b | A spiruchostatin with molecular formula C21H33N3O6S2 originally isolated from a Pseudomonas culture broth. | spiruchostatin B |
| sr 11302 | A retinoid that is all-trans-retinoic acid in which the methyl group at position 9 is replaced by a 4-methylphenyl group. It is an inhibitor of activator protein-1 which exhibits antitumour effects in vivo. | SR11302 |
| sr9243 | A sulfonamide resulting from the formal condensation of the sulfonic acid group of mesitylene-2-sulphonic acid with the amino group of 2-(m-bromophenyl)ethylamine in which the nitrogen is substituted by a 4-[m-(methylsulfonyl)phenyl]benzyl group. | SR9243 |
| ssr128129e | An organic sodium salt having 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate as the counterion. | sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate |
| stattic | A member of the class of 1-benzothiophenes that is 1-benzothiophene-1,1-dioxide substituted at position 6 by a nitro group. Used as a radiosensitising agent for esophageal squamous cell carcinoma. | stattic |
| steviol | An ent-kaurane diterpenoid that is 5beta,8alpha,9beta,10alpha-kaur-16-en-18-oic acid in which the hydrogen at position 13 has been replaced by a hydroxy group. | steviol |
| stevioside | A diterpene glycoside that is rubusoside in which the hydroxy group at position 2 of the allylic beta-D-glucoside has been converted to the corresponding beta-D-glucoside. It is a natural herbal sweetener that is 250-300 times sweeter than sucrose (though with a bitter aftertaste), extracted from the Stevia rebaudiana plant native to South America. | stevioside |
| streptonigrin | Complex cytotoxic antibiotic obtained from Streptomyces flocculus or S. rufochronmogenus. It is used in advanced carcinoma and causes leukopenia. | streptonigrin |
| streptozocin | An N-nitrosourea that is an antibiotic produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. | streptozocin |
| su 11248 | | sunitinib |
| SU6656 | A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase. | SU6656 |
| sugiol | An abietane diterpenoid that is ferruginol in which the methylene group para to the phenolic hydroxy group has been substituted by an oxo group. | sugiol |
| sulforaphane | An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen. | sulforaphane |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| sulindac sulfide | An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity. | sulindac sulfide |
| suramin | A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years. | suramin |
| suramin sodium | An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness. | suramin sodium |
| surfactin A | A cyclodepsipeptide that is N-[(3R)-3-hydroxy-11-methyldodecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group. | surfactin A |
| surfactin c | A cyclodepsipeptide that is N-[(3R)-3-hydroxy-13-methyltetradecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group. | surfactin C |
| swainsonine | An indolizidine alkaloid isolated from the plant Swainsona canescens with three hydroxy substituents at positions 1, 2 and 8. | swainsonine |
| SYC-435 | A cyclic hydroxamic acid that is 1-hydroxypyridin-2(1H)-one in which the hydrogens at positions 4 and 6 are substituted by methyl and benzyl groups, respectively. It is a potent inhibitor of mutant isocitrate dehydrogenase 1 (Ki values of 190 nM against R132H mutant and 120 nM against R132C mutant). | SYC-435 |
| syringaresinol | The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol. | (+)-syringaresinol |
| tabersonine | A monoterpenoid indole alkaloid with cytotoxic activity. | tabersonine |
| taiwanin c | A furonaphthodioxole that is furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one substituted by a 1,3-benzodioxol-5-yl group at position 5. It is a naturally occurring lignan extracted from Taiwania cryptomerioides and found to be a potential inhibitor of COX2 expression. | taiwanin C |
| TAK-580 | A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults. | TAK-580 |
| tak-632 | A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively. | TAK-632 |
| tamibarotene | A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. | tamibarotene |
| tamoxifen | | tamoxifen |
| tamsulosin | A 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide that has (R)-configuration. A specific alpha1 adrenoceptor antagonist used (generally as its hydrochloride salt, tamsulosin hydrochloride) in the treatment of prostatic hyperplasia, chronic prostatitis, urinary retention, and help with the passage of kidney stones. | tamsulosin |
| tamsulosin hydrochloride | A hydrochloride resulting from the reaction of equimolar amounts of tamulosin and hydrogen chloride. | tamsulosin hydrochloride |
| tandutinib | An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT. | tandutinib |
| tanespimycin | A 19-membered macrocyle that is geldanamycin in which the methoxy substituent attached to the benzoquinone moiety has been replaced by an allylamino group. It is a potent inhibitor of heat shock protein 90 (Hsp90). A less toxic analogue than geldanamycin, it induces apoptosis and displays antitumour effects. | tanespimycin |
| tangeretin | A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8. | tangeretin |
| tectochrysin | A monohydroxyflavone that is flavone substituted by a hydroxy group at position 4 and a methoxy group at position 7 respectively. | tectochrysin |
| temozolomide | An imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma. | temozolomide |
| tempol | A member of the class of aminoxyls that is TEMPO carrying a hydroxy substituent at position 4. It is a radical scavenger which exhibits anti-inflammatory and analgesic properties. | 4-hydroxy-TEMPO |
| teniposide | A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding. | teniposide |
| tenovin-6 | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide. | tenovin-6 |
| tephrosin | A member of the class of rotenones that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted with geminal methyl groups at position 3, hydroxy group at position 7a and methoxy groups at positions 9 and 10 (the 7aR,13aR stereoisomer). It is isolated from the leaves and twigs of Antheroporum pierrei and exhibits antineoplastic and pesticidal activities. | tephrosin |
| terazosin | | terazosin |
| terreic acid | | terreic acid |
| tetradecanoylphorbol acetate | A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types. | phorbol 13-acetate 12-myristate |
| tetramethylpyrazine | A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii). | tetramethylpyrazine |
| tetrazolium violet | An organic chloride salt having tetrazolium violet(1+) as the counterion. | tetrazolium violet |
| tg101209 | A member of the class of pyrimidines that is 5-methylpyrimidine-2,4-diamine in which the amino group at position 2 is substituted by a p-(4-methylpiperazin-1-yl)phenyl group, while that at position 4 is substituted by a m-(tert-butylsulfamoyl)phenyl group. A Janus kinase 2 (JAK2) inhibitor. | TG101209 |
| thermozymocidin | An amino acid-based antibiotic derived from certain thermophilic fungi; acts as a potent inhibitor of serine palmitoyltransferase, the first step in sphingosine biosynthesis. Myriocin also possesses immunosuppressant activity. | myriocin |
| thioguanine anhydrous | A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. | tioguanine |
| thiopental sodium | A pyrimidine compound having a 2-methoxy-4-(4-methylpiperazin-1-yl)anilino group at the 2-position, a 3-(acryloylamino)phenoxy group at the 4-position, and a chloro substituent at the 5-position. | WZ4002 |
| thymoquinone | A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity. | thymoquinone |
| THZ531 | A member of the class of indoles that is 5-chloro-4-(1H-indol-3-yl)-N-[(3R)-piperidin-3-yl]pyrimidin-2-amine in which the piperidine NH group is substituted by a 4-{[(2E)-4-(dimethylamino)but-2-enoyl]amino}benzoyl group. It is a first-in-class CDK12 and CDK13 covalent kinase inhibitor with IC50 of 158 nM and 69 nM, respectively. | THZ531 |
| tiazofurin | A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase). | tiazofurine |
| tilorone | A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug. | tilorone |
| tipifarnib | A quinolone that is 1-methylquinolin-2-one which carries a 3-chlorophenyl and an amino(4-chlorophenyl)(1-methyl-imidazol-5-yl)methyl groups at the 4 and 6 positions, respectively (the R-isomer). | tipifarnib |
| tirapazamine | A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4. | tirapazamine |
| tln 4601 | | diazepinomicin |
| tmc-95a | A 17-membered macrocyclic lactam that incorporates a phenol and a substituted indole moiety. It includes a R-hydroxy group at position 11 and a (3-methyl-2-oxopentanoyl)amino group at position at position 18 with a S-methyl group. It acts as a proteasome inhibitor and is obtained from Apiospora montagnei Sacc. TC 1093, isolated from a soil sample. | TMC-95A |
| tmc-95b | A 17-membered macrocyclic lactam that incorporates a phenol and a substituted indole moiety. A stereoisomer of TMC-95A, it has a [(3R)-3-methyl-2-oxopentanoyl]amino group at position 18. It acts as a proteasome inhibitor and is isolated from Apiospora montagnei Sacc. TC 1093, isolated from a soil sample. | TMC-95B |
| tocotrienol, beta | A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 5 and 8 and a farnesyl chain at position 2. It has been isolated from various cultivars of wheat. | beta-tocotrienol |
| tocotrienol, delta | A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2 and 8 and a farnesyl chain at position 2. | delta-tocotrienol |
| top 53 | A furonaphthodioxole that is 4'-demethyldeoxypodophyllotoxin which is substituted at position 4 of the C-ring by a 2-{[2-(dimethylamino)ethyl](methyl)amino}ethyl group. While structurally related to etoposide, TOP-53 is significantly more toxic to non-small cell lung cancer cells, more active at generating chromosomal breaks, and displays improved cellular uptake and pharmacokinetics in animal lung tissues. | TOP-53 |
| topopyrone c | A naphthochromene that is 4H-naphtho[2,3-h]chromene-4,7,12-trione substituted by hydroxy groups at positions 5, 9 and 11 and a methyl group at position 2. It is isolated from fungal strains Phoma and Penicillium and acts as an inhibitor of the enzyme topoisomerase I. | topopyrone C |
| topotecan | A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks. | topotecan |
| toremifene | | toremifene |
| torin 1 | A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | torin 1 |
| torin 2 | A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | torin 2 |
| toxoflavin | A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7. | toxoflavin |
| toyocamycin | An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group. | toyocamycin |
| trametinib | A pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. | trametinib |
| tranilast | An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group. | tranilast |
| trapoxin a | A homodetic cyclic tetrapeptide constructed from L-phenylalanyl (x2), D-pipecolinyl and L-2-amino-8-oxo-9,10-epoxydecanoyl residues. | trapoxin A |
| tretinoin | A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. | all-trans-retinoic acid |
| triaziquone | A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups. | triaziquone |
| tributyrin | A triglyceride obtained by formal acylation of the three hydroxy groups of glycerol by butyric acid. | tributyrin |
| tricetin | Flavone hydroxylated at positions 3', 4', 5, 5' and 7. | tricetin |
| trifluridine | A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. | trifluridine |
| trilobacin | A polyketide isolated from the bark of Asimina triloba. It has been shown to exhibit cytotoxicity in the NCI human tumor cell line screen. | trilobacin |
| trilostane | An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions. | trilostane |
| triptonide | A diterpene triepoxide that is triptobenzene K in which the acylhydroquinone moiety has undergone oxidation to the corresponding triepoxyketone derivative. It has been isolated from the roots of Tripterygium wilfordii. | triptonide |
| troglitazone | | troglitazone |
| tubercidin | An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus. | tubercidin |
| tubocapsanolide a | A withanolide that is 5beta,6beta:16alpha,17alpha-diepoxywitha-2,24-dienolide substituted by a hydroxy group at position 4 and an oxo group at position 1. Isolated from Tubocapsicum anomalum, it exhibits cytotoxic activity. | tubocapsanolide A |
| u 0126 | An aryl sulfide that is (2Z,3Z)-bis[amino(sulfanyl)methylidene]butanedinitrile in which the sulfanyl hydrogens are replaced by 2-aminophenyl groups. An inhibitor of mitogen-activated protein kinase that also exhibits anti-cancer properties. | U0126 |
| undecylprodigiosin | A member of the class of tripyrroles that is 1H-pyrrole substituted by (4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl and undecyl groups at positions 2 and 5, respectively. It is a pigment produced by Stveptomyces coelicolor. | undecylprodigiosin |
| uvaretin | A member of the class of dihydrochalcones that is 1,3-diphenylpropan-1-one in which the phenyl group that is bonded to the carbonyl group is substituted by hydroxy groups at positions 2 and 4, an o-hydroxybenzyl group at position 3, and a methoxy group at position 6. A cytotoxic natural product found particularly in Uvaria acuminata and Uvaria chamae. | uvaretin |
| vadimezan | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group. | vadimezan |
| vatalanib | A member of the class of phthalazines that is phthalazine in which the hydrogens at positions 1 and 4have been replaced by a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit. | vatalanib |
| vedelianin | A stilbenoid derivative isolated from Macaranga alnifolia and Macaranga alnifolia and has been shown to exhibit cytotoxic activity. | vedelianin |
| ver 52296 | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine. | luminespib |
| vidarabine | A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. | adenine arabinoside |
| vincaleukoblastine | | vincaleukoblastine |
| vincristine | A vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. | vincristine |
| vincristine sulfate | An organic sulfate salt containing equimolar amounts of vincristine(2+) and sulfate. Used for the treatment of a variety of cancers. | vincristine sulfate |
| vindesine | | vindesine |
| vinflunine | An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group. | vinflunine |
| vinorelbine | A vinca alkaloid with a norvinblastine skeleton. | vinorelbine |
| vitamin k 3 | A member of the class of 1,4-naphthoquinones that is 1,4-naphthoquinone which is substituted at position 2 by a methyl group. It is used as a nutritional supplement and for the treatment of hypoprothrombinemia. | menadione |
| vitexin | An apigenin flavone glycoside, which is found in the passion flower, bamboo leaves and pearl millet | vitexin |
| voacamine | A monoterpenoid indole alkaloid with formula C22H28N2O3, isolated from several plant species. | (-)-voacangine |
| vorinostat | A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). | vorinostat |
| wedelolactone | A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3. | wedelolactone |
| withaferin a | A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity. | withaferin A |
| withanolide d | A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 22 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Tubocapsicum anomalum and Withania somnifera, it exhibits cytotoxic activity. | withanolide D |
| wogonin | A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8. | wogonin |
| wortmannin | | wortmannin |
| xanthohumol | A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells. | xanthohumol |
| xanthomicrol | A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 8 and hydroxy groups at positions 5 and 4'. | xanthomicrol |
| xl147 | A sulfonamide that is the N-4-toluenesulfonyl (N-tosyl) derivative of N-(2,1,3-benzothiadiazol-5-yl)quinoxaline-2,3-diamine. A selective PI3K inhibitor used in cancer treatment. | XL147 |
| XL413 | A benzofuropyrimidine that is 3,4-dihydro[1]benzofuro[3,2-d]pyrimidine substituted by (2S)-pyrrolidin-2-yl, oxo and chloro groups at positions 2, 4, and 8, respectively. It is a potent ATP competitive inhibitor of Cdc7 kinase (IC50 = 3.4 nM) and exhibits anticancer properties. | XL413 |
| xl765 | A sulfonamide obtained by formal condensation of the sulfonic acid group of 4-[(3-methoxy-4-methylbenzoyl)amino]benzenesulfonic acid with the primary aromatic amino group of N-(3,5-dimethoxyphenyl)quinoxaline-2,3-diamine. A dual PI3K/mTOR inhibitor used in cancer treatment. | XL765 |
| yakuchinone-a | A ketone that is heptan-3-one substituted by a 4-hydroxy-3-methoxyphenyl group at position 1 and a phenyl group at position 7. Isolated from in Alpinia oxyphylla, it exhibits antineoplastic and inhibitory activities against COX-1, COX-2 and NO synthase. | 1-(4'-hydroxy-3'-methoxyphenyl)-7-phenyl-3-heptanone |
| ym 155 | An organic bromide salt consisting of sepantronium cations and bromide anions. It has been found to selectively inhibit survivin (BIRC5) gene promoter activity and to down-regulate survivin in vitro, so leading to induction of apoptosis. | sepantronium bromide |
| ym 216391 | An azamacrocycle with formula C34H32N8O7S isolated from the cultured mycelium of Streptomyces nobilis. It exhibits potent cytotoxic activity against human cancer cell lines. | YM-216391 |
| zd 6474 | A quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. | vandetanib |
| zm 447439 | A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively. | ZM447439 |
| zstk474 | A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase. | ZSTK-474 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial | Homo sapiens (human) | IC50 | 8.1000 | 2 | 2 |
| [tau protein] kinase | Oryctolagus cuniculus (rabbit) | IC50 | 2.0000 | 1 | 1 |
| [Tau protein] kinase | Sus scrofa (pig) | IC50 | 0.3600 | 1 | 1 |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | IC50 | 6.2318 | 2 | 8 |
| 1-deoxy-D-xylulose 5-phosphate reductoisomerase | Escherichia coli K-12 | IC50 | 2.2500 | 1 | 4 |
| 1,25-dihydroxyvitamin D-3 receptor | Sus scrofa domesticus (domestic pig) | IC50 | 1.0400 | 1 | 1 |
| 10 kDa chaperonin | Escherichia coli | IC50 | 25.6410 | 4 | 20 |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | IC50 | 27.0300 | 2 | 10 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Homo sapiens (human) | IC50 | 2.7000 | 1 | 1 |
| 17-beta-hydroxysteroid dehydrogenase type 1 | Homo sapiens (human) | IC50 | 0.9771 | 7 | 8 |
| 17-beta-hydroxysteroid dehydrogenase type 1 | Homo sapiens (human) | Ki | 4.7515 | 2 | 2 |
| 17-beta-hydroxysteroid dehydrogenase type 2 | Homo sapiens (human) | IC50 | 9.5475 | 2 | 12 |
| 2-5A-dependent ribonuclease | Homo sapiens (human) | IC50 | 227.0000 | 1 | 2 |
| 2-oxoglutarate receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0320 | 1 | 2 |
| 26S proteasome complex subunit SEM1 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 1 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 11 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 12 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 13 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 14 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 2 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 3 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 4 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 6 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 7 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome non-ATPase regulatory subunit 8 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 10B | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 4 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 6A | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 6B | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 7 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 26S proteasome regulatory subunit 8 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Homo sapiens (human) | IC50 | 0.0120 | 1 | 1 |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Homo sapiens (human) | Ki | 0.0050 | 1 | 1 |
| 3-dehydroquinate synthase | Escherichia coli K-12 | Ki | 54.5000 | 2 | 2 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | IC50 | 4.5553 | 10 | 11 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | IC50 | 0.0529 | 9 | 10 |
| 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ | Yersinia pseudotuberculosis YPIII | IC50 | 21.6500 | 1 | 4 |
| 3-oxoacyl-[acyl-carrier-protein] reductase | Plasmodium falciparum 3D7 | IC50 | 0.3200 | 1 | 1 |
| 3-oxoacyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 5.3000 | 1 | 7 |
| 3-oxoacyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 1.3000 | 2 | 2 |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | IC50 | 16.4800 | 5 | 5 |
| 30S ribosomal protein S1 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S10 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S11 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S12 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S13 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S14 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S15 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S16 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S17 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S18 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S19 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S2 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S20 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S21 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S3 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S4 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S5 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S6 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S7 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S8 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 30S ribosomal protein S9 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) | IC50 | 12,800.0000 | 1 | 1 |
| 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 | Homo sapiens (human) | IC50 | 45.4114 | 1 | 14 |
| 4-hydroxyphenylpyruvate dioxygenase | Arabidopsis thaliana (thale cress) | IC50 | 73.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 7.4362 | 6 | 8 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 25.3382 | 4 | 4 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 2.7044 | 2 | 4 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 11.0790 | 4 | 5 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 4.0085 | 1 | 2 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 20.0850 | 2 | 2 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 20.0850 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 4.4004 | 1 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 14.5985 | 6 | 6 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 2.2420 | 5 | 9 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 1.9520 | 2 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 6.5566 | 1 | 12 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 3.3500 | 4 | 15 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 11.7185 | 1 | 6 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.0664 | 3 | 3 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 4.6962 | 3 | 8 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 11.7185 | 1 | 6 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 6.1375 | 1 | 6 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 3.2960 | 1 | 1 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 8.4683 | 1 | 6 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 3.5184 | 3 | 10 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 14.3500 | 1 | 4 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 240.8500 | 1 | 4 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 2.3993 | 3 | 3 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-lipoxygenase | Bos taurus (cattle) | IC50 | 3.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Homo sapiens (human) | IC50 | 0.1580 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Homo sapiens (human) | IC50 | 0.0617 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0500 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | IC50 | 0.1079 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | IC50 | 0.1079 | 1 | 1 |
| 5'-nucleotidase | Homo sapiens (human) | IC50 | 15.7850 | 2 | 4 |
| 5'-nucleotidase | Mus musculus (house mouse) | IC50 | 73.0367 | 2 | 3 |
| 5'-nucleotidase | Rattus norvegicus (Norway rat) | Ki | 0.0453 | 1 | 1 |
| 50S ribosomal protein L1 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L10 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L11 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L13 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L14 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L15 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L16 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L17 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L18 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L19 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L2 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L20 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L21 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L22 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L23 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L24 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L25 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L27 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L28 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L29 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L3 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L30 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L31 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L32 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L33 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L34 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L35 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L36 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L4 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L5 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L6 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | IC50 | 0.9000 | 1 | 1 |
| 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | Homo sapiens (human) | IC50 | 49.3000 | 3 | 3 |
| 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | Homo sapiens (human) | Ki | 25.1000 | 1 | 1 |
| 6-phosphogluconate dehydrogenase, decarboxylating | Homo sapiens (human) | IC50 | 1.0850 | 1 | 2 |
| 6-phosphogluconate dehydrogenase, decarboxylating | Homo sapiens (human) | Ki | 136.7000 | 1 | 1 |
| 60 kDa chaperonin | Escherichia coli K-12 | IC50 | 250.0000 | 1 | 9 |
| 60 kDa chaperonin | Escherichia coli | IC50 | 25.6410 | 4 | 20 |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | IC50 | 27.0300 | 2 | 10 |
| 7-dehydrocholesterol reductase | Homo sapiens (human) | IC50 | 0.0120 | 1 | 1 |
| 7,8-dihydro-8-oxoguanine triphosphatase | Homo sapiens (human) | IC50 | 14.9081 | 5 | 7 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 | 12.6709 | 42 | 66 |
| 72 kDa type IV collagenase | Homo sapiens (human) | Ki | 0.0003 | 8 | 8 |
| 90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | IC50 | 17.3710 | 2 | 3 |
| A disintegrin and metalloproteinase with thrombospondin motifs 4 | Homo sapiens (human) | IC50 | 5.2400 | 2 | 2 |
| A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) | IC50 | 5.2500 | 2 | 2 |
| Accessory gene regulator protein A | Staphylococcus aureus | IC50 | 17.1000 | 1 | 1 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 67.6380 | 11 | 11 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 179.4801 | 14 | 19 |
| Acetylcholinesterase | Mus musculus (house mouse) | IC50 | 0.0210 | 1 | 1 |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | IC50 | 200.0000 | 2 | 3 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | Ki | 100.0000 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 63.0455 | 4 | 11 |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | Ki | 0.0264 | 1 | 1 |
| Actin | Saccharomyces cerevisiae S288C | IC50 | 13.9000 | 1 | 4 |
| Actin-related protein 3 | Homo sapiens (human) | IC50 | 0.0530 | 1 | 1 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | IC50 | 0.0231 | 4 | 4 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | Ki | 0.0135 | 2 | 2 |
| Activin receptor type-1 | Homo sapiens (human) | IC50 | 0.1053 | 3 | 3 |
| Activin receptor type-1B | Homo sapiens (human) | IC50 | 4.9105 | 2 | 2 |
| Acyl carrier protein, mitochondrial | Bos taurus (cattle) | IC50 | 0.0051 | 1 | 1 |
| Acyl carrier protein, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| Acyl-CoA desaturase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0013 | 1 | 1 |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | IC50 | 16.8000 | 1 | 1 |
| ADAM10 | Homo sapiens (human) | IC50 | 0.0482 | 2 | 2 |
| Adenomatous polyposis coli protein | Homo sapiens (human) | Ki | 118.0000 | 2 | 2 |
| Adenosine deaminase | Homo sapiens (human) | Ki | 0.0001 | 8 | 8 |
| Adenosine deaminase | Bos taurus (cattle) | Ki | 0.0000 | 2 | 3 |
| Adenosine deaminase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 0.0041 | 2 | 2 |
| Adenosine kinase | Homo sapiens (human) | IC50 | 1,292,888.1240 | 4 | 5 |
| Adenosine receptor A1 | Gallus gallus (chicken) | IC50 | 0.0170 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | IC50 | 17.6540 | 3 | 7 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 248,937.6701 | 11 | 13 |
| Adenosine receptor A1 | Bos taurus (cattle) | Ki | 0.0140 | 3 | 3 |
| Adenosine receptor A1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0100 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 1.9547 | 39 | 48 |
| Adenosine receptor A1 | Mus musculus (house mouse) | Ki | 0.0004 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 1.4623 | 28 | 38 |
| Adenosine receptor A2a | Homo sapiens (human) | IC50 | 3.2521 | 12 | 16 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 170,315.4500 | 9 | 19 |
| Adenosine receptor A2a | Homo sapiens (human) | Ki | 0.6392 | 62 | 85 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 2.0957 | 22 | 30 |
| Adenosine receptor A2b | Homo sapiens (human) | IC50 | 0.5102 | 3 | 3 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | IC50 | 231,138.5824 | 4 | 14 |
| Adenosine receptor A2b | Homo sapiens (human) | Ki | 0.5371 | 13 | 18 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Ki | 0.2480 | 7 | 11 |
| Adenosine receptor A3 | Homo sapiens (human) | IC50 | 5.1469 | 17 | 26 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | IC50 | 1,617,970.0303 | 2 | 2 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 2.7137 | 64 | 83 |
| Adenosine receptor A3 | Mus musculus (house mouse) | Ki | 0.0141 | 1 | 1 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | Ki | 26.0109 | 7 | 8 |
| Adenosylhomocysteinase | Mus musculus (house mouse) | Ki | 30.0000 | 1 | 1 |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | Ki | 0.0350 | 1 | 2 |
| Adenylosuccinate synthetase isozyme 2 | Homo sapiens (human) | IC50 | 3.5000 | 1 | 1 |
| ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | Homo sapiens (human) | IC50 | 34.4000 | 1 | 6 |
| Aflatoxin B1 aldehyde reductase member 3 | Rattus norvegicus (Norway rat) | Ki | 0.1100 | 1 | 1 |
| Albumin | Homo sapiens (human) | IC50 | 0.1072 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 26,302,700,000.0000 | 1 | 1 |
| Alcohol dehydrogenase E chain | Equus caballus (horse) | Ki | 10,000.0000 | 1 | 1 |
| Alcohol dehydrogenase S chain | Equus caballus (horse) | Ki | 10,000.0000 | 1 | 1 |
| Aldehyde dehydrogenase, mitochondrial | Homo sapiens (human) | IC50 | 7.1000 | 3 | 4 |
| Aldehyde oxidase | Homo sapiens (human) | IC50 | 1.0500 | 1 | 4 |
| Aldehyde oxidase 1 | Macaca fascicularis (crab-eating macaque) | IC50 | 0.1100 | 1 | 1 |
| Aldehyde oxidase 1 | Mus musculus (house mouse) | IC50 | 0.1500 | 1 | 1 |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | IC50 | 2.0000 | 1 | 1 |
| Aldehyde oxidase 1 | Cavia porcellus (domestic guinea pig) | Ki | 7.2300 | 1 | 1 |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | Ki | 0.0600 | 1 | 1 |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | IC50 | 3.2950 | 1 | 2 |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | Ki | 3.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member A1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member A1 | Rattus norvegicus (Norway rat) | IC50 | 2.3200 | 1 | 1 |
| Aldo-keto reductase family 1 member A1 | Sus scrofa (pig) | IC50 | 38.4000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 11.9086 | 6 | 9 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 59.1091 | 14 | 29 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 13.7856 | 10 | 24 |
| Aldo-keto reductase family 1 member B1 | Sus scrofa (pig) | IC50 | 52.3667 | 1 | 3 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | Ki | 2.1130 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 10.7870 | 1 | 10 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 19.5725 | 7 | 12 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | Ki | 3.0230 | 2 | 2 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 8.5167 | 6 | 6 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 9.1473 | 7 | 7 |
| Aldo-keto reductase family 1 member C21 | Mus musculus (house mouse) | IC50 | 9.6000 | 1 | 2 |
| Aldo-keto reductase family 1 member C21 | Mus musculus (house mouse) | Ki | 11.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 3.3813 | 11 | 11 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 14.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 52.6375 | 4 | 4 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | GI50 | 0.2130 | 7 | 7 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | IC50 | 6.8749 | 195 | 269 |
| ALK tyrosine kinase receptor | Mus musculus (house mouse) | IC50 | 0.0800 | 1 | 1 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | Ki | 0.2345 | 11 | 16 |
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 | 100.0000 | 1 | 3 |
| alkaline phosphatase, intestinal | Homo sapiens (human) | IC50 | 53.5525 | 2 | 4 |
| alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | IC50 | 61.8000 | 1 | 4 |
| Alpha-(1,3)-fucosyltransferase 7 | Homo sapiens (human) | IC50 | 45.4114 | 1 | 14 |
| Alpha-1,2-mannosidase | Bacteroides thetaiotaomicron VPI-5482 | Ki | 9.5000 | 2 | 6 |
| alpha-1,2-Mannosidase | Glycine max (soybean) | IC50 | 0.4000 | 1 | 1 |
| Alpha-1,2-mannosidase family protein | Bacteroides thetaiotaomicron VPI-5482 | Ki | 9.5000 | 2 | 4 |
| Alpha-1,2-mannosidase, putative | Bacteroides thetaiotaomicron VPI-5482 | Ki | 9.5000 | 2 | 6 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.0076 | 4 | 4 |
| Alpha-1A adrenergic receptor | Mus musculus (house mouse) | IC50 | 0.0018 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 6.3853 | 6 | 15 |
| Alpha-1A adrenergic receptor | Bos taurus (cattle) | Ki | 1.4269 | 4 | 14 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0315 | 21 | 36 |
| Alpha-1A adrenergic receptor | Oryctolagus cuniculus (rabbit) | Ki | 0.0114 | 1 | 5 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.2251 | 9 | 27 |
| Alpha-1A adrenergic receptor | Sus scrofa (pig) | IC50 | 0.1800 | 1 | 2 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0092 | 4 | 4 |
| Alpha-1B adrenergic receptor | Mus musculus (house mouse) | IC50 | 0.0018 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 10.9736 | 6 | 16 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.0261 | 19 | 31 |
| Alpha-1B adrenergic receptor | Mesocricetus auratus (golden hamster) | Ki | 0.0004 | 1 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.4031 | 8 | 25 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 1.8752 | 5 | 10 |
| Alpha-1D adrenergic receptor | Mus musculus (house mouse) | IC50 | 0.0018 | 1 | 1 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 9.3667 | 3 | 3 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.2742 | 20 | 36 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.8457 | 7 | 26 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 6.3253 | 2 | 9 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1499 | 4 | 5 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 1.8730 | 7 | 16 |
| Alpha-2A adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0069 | 1 | 2 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0044 | 2 | 5 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 4.8533 | 2 | 8 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1499 | 4 | 5 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 2.7110 | 5 | 12 |
| Alpha-2B adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0069 | 1 | 2 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0146 | 4 | 8 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 4.1248 | 2 | 6 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1499 | 4 | 5 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.4206 | 7 | 12 |
| Alpha-2C adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0069 | 1 | 2 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0044 | 2 | 5 |
| Alpha-amylase 1A | Homo sapiens (human) | IC50 | 192.7938 | 4 | 8 |
| Alpha-amylase 1A | Homo sapiens (human) | Ki | 2.6000 | 1 | 1 |
| Alpha-glucosidase MAL12 | Saccharomyces cerevisiae S288C | IC50 | 192.5500 | 2 | 2 |
| Alpha-glucosidase MAL32 | Saccharomyces cerevisiae S288C | IC50 | 61.0000 | 1 | 2 |
| Alpha-mannosidase | Canavalia ensiformis (jack bean) | IC50 | 49.0000 | 1 | 1 |
| Alpha-mannosidase 2 | Drosophila melanogaster (fruit fly) | Ki | 0.0030 | 1 | 1 |
| Alpha-mannosidase 2C1 | Rattus norvegicus (Norway rat) | IC50 | 1.7500 | 1 | 1 |
| Alpha-synuclein | Homo sapiens (human) | IC50 | 35.3980 | 6 | 15 |
| Alternative oxidase, mitochondrial | Trypanosoma brucei brucei | IC50 | 0.0020 | 1 | 1 |
| Alternative oxidase, mitochondrial | Trypanosoma brucei brucei | Ki | 0.0001 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 19.7161 | 22 | 43 |
| Amine oxidase [flavin-containing] A | Mus musculus (house mouse) | IC50 | 0.0000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | Ki | 9.3575 | 4 | 4 |
| Amine oxidase [flavin-containing] A | Bos taurus (cattle) | IC50 | 47.5050 | 2 | 2 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 | 14.2405 | 4 | 5 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | Ki | 4.8000 | 1 | 1 |
| Amine oxidase [flavin-containing] B | Bos taurus (cattle) | IC50 | 57.5000 | 2 | 2 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | IC50 | 26.5685 | 19 | 31 |
| Amine oxidase [flavin-containing] B | Mus musculus (house mouse) | IC50 | 0.3000 | 2 | 2 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 | 6.9729 | 3 | 7 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | Ki | 10.4667 | 3 | 3 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | Ki | 10.9000 | 1 | 1 |
| Aminopeptidase N | Homo sapiens (human) | IC50 | 28.2500 | 2 | 2 |
| Aminopeptidase N | Sus scrofa (pig) | IC50 | 69.2517 | 4 | 6 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 18.3366 | 48 | 66 |
| Androgen receptor | Homo sapiens (human) | GI50 | 0.7367 | 3 | 3 |
| Androgen receptor | Homo sapiens (human) | IC50 | 53.4226 | 52 | 61 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 | 13.8599 | 7 | 24 |
| Androgen receptor | Homo sapiens (human) | Ki | 1.0951 | 22 | 24 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 4.1131 | 11 | 21 |
| Angiopoietin-1 receptor | Homo sapiens (human) | IC50 | 1.0790 | 22 | 29 |
| Angiopoietin-1 receptor | Mus musculus (house mouse) | IC50 | 0.4480 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 101,159.7497 | 4 | 10 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 1.8481 | 1 | 3 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 | 4,115.4000 | 2 | 2 |
| Angiotensin-converting enzyme | Homo sapiens (human) | Ki | 482.6000 | 2 | 2 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | IC50 | 7.5050 | 2 | 4 |
| Anthrax toxin receptor 2 | Homo sapiens (human) | IC50 | 200.1512 | 2 | 6 |
| AP2-associated protein kinase 1 | Homo sapiens (human) | IC50 | 0.0981 | 3 | 4 |
| apelin receptor | Homo sapiens (human) | IC50 | 11.9650 | 1 | 2 |
| Apoptosis regulator BAX | Homo sapiens (human) | IC50 | 0.0230 | 1 | 1 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | GI50 | 78.5000 | 1 | 2 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | IC50 | 0.5407 | 19 | 26 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Ki | 0.0257 | 38 | 45 |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 | 57.7000 | 2 | 2 |
| Arachidonate 5-lipoxygenase | Sus scrofa (pig) | IC50 | 2,500.0000 | 1 | 1 |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | IC50 | 0.0250 | 13 | 13 |
| Arginase | Leishmania amazonensis | IC50 | 5.4500 | 1 | 4 |
| Arginase | Leishmania amazonensis | Ki | 1.2000 | 1 | 1 |
| Arginase-1 | Bos taurus (cattle) | IC50 | 47.0000 | 1 | 1 |
| Arginase-1 | Homo sapiens (human) | IC50 | 622.5000 | 2 | 2 |
| Arginase-1 | Bos taurus (cattle) | Ki | 136.0000 | 3 | 3 |
| Aromatase | Homo sapiens (human) | IC50 | 230,835,105.1714 | 111 | 159 |
| Aromatase | Rattus norvegicus (Norway rat) | IC50 | 20.1000 | 2 | 2 |
| Aromatase | Homo sapiens (human) | Ki | 12.3298 | 22 | 32 |
| Aromatic-L-amino-acid decarboxylase | Homo sapiens (human) | IC50 | 1,280.0000 | 1 | 1 |
| Arrestin, beta 1 | Homo sapiens (human) | IC50 | 1.5240 | 1 | 1 |
| Arylacetamide deacetylase | Homo sapiens (human) | Ki | 300.0000 | 1 | 1 |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | IC50 | 5.3543 | 4 | 28 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 127.1532 | 1 | 77 |
| ATP-binding cassette sub-family C member 3 | Rattus norvegicus (Norway rat) | Ki | 90.0000 | 1 | 1 |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | IC50 | 1.2850 | 1 | 1 |
| ATP-dependent 6-phosphofructokinase | Trypanosoma brucei brucei | IC50 | 3.0000 | 1 | 1 |
| ATP-dependent Clp protease proteolytic subunit | Staphylococcus aureus subsp. aureus NCTC 8325 | IC50 | 5.3000 | 1 | 2 |
| ATP-dependent molecular chaperone HSC82 | Saccharomyces cerevisiae S288C | IC50 | 9.5500 | 1 | 2 |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | IC50 | 9.1222 | 4 | 9 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 30.9495 | 39 | 54 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | IC50 | 55.6846 | 5 | 13 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 228.4333 | 3 | 6 |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | IC50 | 1.2850 | 1 | 1 |
| Aurora kinase A | Homo sapiens (human) | IC50 | 8.0836 | 30 | 54 |
| Aurora kinase A | Mus musculus (house mouse) | IC50 | 0.0390 | 1 | 1 |
| Aurora kinase A | Homo sapiens (human) | Ki | 1.0422 | 4 | 4 |
| Aurora kinase A-interacting protein | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Aurora kinase B | Homo sapiens (human) | IC50 | 9.6330 | 32 | 53 |
| Aurora kinase B | Homo sapiens (human) | Ki | 0.0008 | 3 | 3 |
| Aurora kinase B-A | Xenopus laevis (African clawed frog) | IC50 | 0.0450 | 1 | 1 |
| Aurora kinase C | Homo sapiens (human) | IC50 | 23.3501 | 4 | 13 |
| Aurora kinase C | Homo sapiens (human) | Ki | 0.0170 | 1 | 1 |
| Autoinducer 2-binding periplasmic protein LuxP | Vibrio harveyi | IC50 | 50.0000 | 1 | 1 |
| B-cell CLL/lymphoma 9 protein | Homo sapiens (human) | IC50 | 5.2130 | 1 | 1 |
| B-cell CLL/lymphoma 9 protein | Homo sapiens (human) | Ki | 4.8780 | 3 | 3 |
| B2 bradykinin receptor | Cavia porcellus (domestic guinea pig) | IC50 | 3.0667 | 2 | 3 |
| B2 bradykinin receptor | Homo sapiens (human) | IC50 | 20.3560 | 1 | 1 |
| B2 bradykinin receptor | Homo sapiens (human) | Ki | 12.0480 | 1 | 1 |
| Baculoviral IAP repeat-containing protein 2 | Homo sapiens (human) | IC50 | 0.3902 | 13 | 13 |
| Baculoviral IAP repeat-containing protein 2 | Homo sapiens (human) | Ki | 0.0010 | 3 | 3 |
| Baculoviral IAP repeat-containing protein 3 | Homo sapiens (human) | IC50 | 0.0134 | 6 | 6 |
| Baculoviral IAP repeat-containing protein 3 | Homo sapiens (human) | Ki | 0.0020 | 2 | 2 |
| Baculoviral IAP repeat-containing protein 7 | Homo sapiens (human) | IC50 | 0.0120 | 2 | 2 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | IC50 | 16.6890 | 3 | 3 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | Ki | 0.0010 | 1 | 1 |
| Bcl-2-binding component 3, isoforms 1/2 | Homo sapiens (human) | IC50 | 0.0003 | 1 | 1 |
| Bcl-2-like protein 1 | Homo sapiens (human) | GI50 | 96.5000 | 1 | 2 |
| Bcl-2-like protein 1 | Homo sapiens (human) | IC50 | 8.3061 | 31 | 42 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Ki | 0.0605 | 48 | 52 |
| Bcl-2-like protein 10 | Homo sapiens (human) | IC50 | 0.3600 | 1 | 1 |
| Bcl-2-like protein 10 | Homo sapiens (human) | Ki | 0.0010 | 1 | 1 |
| Bcl-2-like protein 11 | Homo sapiens (human) | IC50 | 10.7506 | 5 | 10 |
| Bcl-2-like protein 2 | Homo sapiens (human) | IC50 | 1.4001 | 6 | 9 |
| Bcl-2-like protein 2 | Homo sapiens (human) | Ki | 0.1280 | 8 | 8 |
| Bcl-2-related protein A1 | Homo sapiens (human) | IC50 | 0.9589 | 2 | 5 |
| bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 | 73.3333 | 3 | 3 |
| Bcl-2-related protein A1 | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
| Bcl2-associated agonist of cell death | Homo sapiens (human) | Ki | 2.7488 | 5 | 6 |
| BCR/ABL p210 fusion protein | Homo sapiens (human) | GI50 | 0.2700 | 1 | 1 |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | IC50 | 0.1906 | 12 | 12 |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | Ki | 0.0230 | 3 | 3 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 | 33.6823 | 2 | 3 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 19.6885 | 1 | 2 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 11.3695 | 1 | 2 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0018 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 2.7480 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 1.8890 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 19.8847 | 1 | 3 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 14.9157 | 1 | 3 |
| Beta-adrenergic receptor kinase 1 | Bos taurus (cattle) | IC50 | 130.0000 | 1 | 1 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 1.8812 | 4 | 4 |
| Beta-casein | Bos taurus (cattle) | IC50 | 100.0000 | 1 | 3 |
| Beta-casein | Bos taurus (cattle) | Ki | 0.0010 | 1 | 1 |
| Beta-glucuronidase | Rattus norvegicus (Norway rat) | IC50 | 2.8000 | 1 | 1 |
| Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein) | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 6.2530 | 2 | 10 |
| Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein) | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 11.5000 | 1 | 1 |
| Beta-lactamase | Enterobacter cloacae | IC50 | 257.1667 | 3 | 6 |
| Beta-lactamase | Escherichia coli K-12 | IC50 | 41.5000 | 7 | 8 |
| Beta-lactamase TEM | Escherichia coli | IC50 | 55.9000 | 1 | 1 |
| Beta-secretase 1 | Homo sapiens (human) | IC50 | 76.4068 | 17 | 26 |
| Beta-secretase 1 | Homo sapiens (human) | Ki | 17.4283 | 4 | 6 |
| Beta-tubulin | Leishmania donovani | IC50 | 1.0000 | 2 | 2 |
| BH3-interacting domain death agonist | Homo sapiens (human) | IC50 | 4.9361 | 8 | 8 |
| BH3-interacting domain death agonist | Homo sapiens (human) | Ki | 20.8000 | 1 | 1 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | IC50 | 0.0840 | 1 | 1 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | IC50 | 4.8493 | 32 | 54 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | IC50 | 0.1100 | 1 | 1 |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Leishmania major | Ki | 0.0001 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 11.1707 | 9 | 13 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | Ki | 26.1130 | 2 | 2 |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | IC50 | 6.6933 | 2 | 3 |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | Ki | 100.4400 | 1 | 2 |
| bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | IC50 | 85.0300 | 1 | 1 |
| Bile acid receptor | Homo sapiens (human) | IC50 | 6.7300 | 3 | 3 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 166.0874 | 12 | 175 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 369.6667 | 2 | 9 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | Ki | 11.9000 | 1 | 1 |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | IC50 | 0.0050 | 1 | 1 |
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | IC50 | 0.0476 | 1 | 1 |
| Botulinum neurotoxin type A | Clostridium botulinum | IC50 | 15.1667 | 3 | 3 |
| Botulinum neurotoxin type A | Clostridium botulinum | Ki | 14.3000 | 1 | 1 |
| BRCA1-associated RING domain protein 1 | Homo sapiens (human) | IC50 | 3.8900 | 1 | 1 |
| Breakpoint cluster region protein | Homo sapiens (human) | GI50 | 1.4797 | 28 | 91 |
| Breakpoint cluster region protein | Mus musculus (house mouse) | GI50 | 0.0010 | 1 | 1 |
| Breakpoint cluster region protein | Homo sapiens (human) | IC50 | 1.9544 | 52 | 76 |
| Breakpoint cluster region protein | Homo sapiens (human) | Ki | 0.0140 | 1 | 1 |
| Breast cancer type 1 susceptibility protein | Homo sapiens (human) | IC50 | 3.8900 | 1 | 1 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 7.2800 | 34 | 57 |
| Bromodomain testis-specific protein | Homo sapiens (human) | IC50 | 0.1930 | 14 | 14 |
| Bromodomain-containing protein 1 | Homo sapiens (human) | IC50 | 44.5000 | 1 | 1 |
| Bromodomain-containing protein 2 | Homo sapiens (human) | IC50 | 0.0959 | 22 | 22 |
| Bromodomain-containing protein 2 | Homo sapiens (human) | Ki | 0.0128 | 4 | 4 |
| Bromodomain-containing protein 3 | Homo sapiens (human) | IC50 | 0.0573 | 18 | 18 |
| Bromodomain-containing protein 3 | Homo sapiens (human) | Ki | 0.0078 | 4 | 4 |
| Bromodomain-containing protein 4 | Homo sapiens (human) | IC50 | 1.0427 | 131 | 139 |
| Bromodomain-containing protein 4 | Homo sapiens (human) | Ki | 0.0193 | 8 | 8 |
| C-8 sterol isomerase | Saccharomyces cerevisiae S288C | Ki | 1.5000 | 1 | 1 |
| C-C chemokine receptor type 2 | Homo sapiens (human) | IC50 | 1.6613 | 3 | 4 |
| C-C chemokine receptor type 2 | Homo sapiens (human) | Ki | 1.2840 | 1 | 2 |
| C-C chemokine receptor type 4 | Homo sapiens (human) | IC50 | 41.6915 | 4 | 7 |
| C-C chemokine receptor type 4 | Homo sapiens (human) | Ki | 4.3970 | 1 | 1 |
| C-C chemokine receptor type 5 | Homo sapiens (human) | IC50 | 23.6610 | 1 | 1 |
| C-C chemokine receptor type 5 | Homo sapiens (human) | Ki | 18.2840 | 1 | 1 |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 | 35.3780 | 2 | 4 |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | IC50 | 6.0130 | 1 | 1 |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | Ki | 4.2090 | 1 | 1 |
| C-X-C chemokine receptor type 4 | Homo sapiens (human) | IC50 | 0.8234 | 37 | 37 |
| C-X-C chemokine receptor type 4 | Rattus norvegicus (Norway rat) | IC50 | 0.1080 | 1 | 1 |
| C-X-C chemokine receptor type 4 | Homo sapiens (human) | Ki | 6.1137 | 43 | 43 |
| CAAX farnesyltransferase subunit beta | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 0.1335 | 1 | 2 |
| Cadherin-1 | Homo sapiens (human) | Ki | 140.0667 | 3 | 3 |
| Calcium dependent protein kinase | Triticum aestivum (bread wheat) | IC50 | 19.0000 | 1 | 1 |
| Calcium-activated potassium channel subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 0.5600 | 1 | 1 |
| calcium-dependent protein kinase 4 | Plasmodium falciparum 3D7 | IC50 | 0.0210 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Rattus norvegicus (Norway rat) | IC50 | 275.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Rattus norvegicus (Norway rat) | IC50 | 275.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type 1D | Homo sapiens (human) | IC50 | 0.0920 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 | 6.9160 | 5 | 5 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | IC50 | 11.5000 | 2 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | IC50 | 10.0920 | 2 | 2 |
| Calmodulin-1 | Homo sapiens (human) | IC50 | 23.2000 | 1 | 2 |
| cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) | IC50 | 100.0000 | 1 | 3 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | IC50 | 107.3548 | 7 | 13 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | IC50 | 210.0000 | 5 | 5 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | IC50 | 257.5000 | 4 | 4 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit PRKX | Homo sapiens (human) | IC50 | 0.0050 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 1.8700 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 1.8700 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 1.8700 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 4.0567 | 5 | 6 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 122.1012 | 4 | 80 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | Ki | 535.8000 | 1 | 3 |
| Canalicular multispecific organic anion transporter 1 | Rattus norvegicus (Norway rat) | Ki | 257.9875 | 4 | 4 |
| Cannabinoid receptor 1 | Homo sapiens (human) | IC50 | 0.0892 | 7 | 7 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.1248 | 4 | 6 |
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 3.2416 | 21 | 23 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.2276 | 5 | 6 |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | IC50 | 0.0620 | 1 | 1 |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.2000 | 1 | 2 |
| Cannabinoid receptor 2 | Homo sapiens (human) | IC50 | 0.0818 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 1.7632 | 23 | 26 |
| Carbamate kinase | Giardia intestinalis | IC50 | 0.6000 | 1 | 1 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 1.0582 | 3 | 4 |
| Carbonic anhydrase | Dicentrarchus labrax (European seabass) | Ki | 3.6700 | 1 | 2 |
| Carbonic anhydrase | Helicobacter pylori 26695 | Ki | 0.4235 | 2 | 2 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 0.1330 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.3940 | 1 | 1 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.2260 | 1 | 1 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.4230 | 1 | 1 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 0.9630 | 1 | 1 |
| Carbonic anhydrase | Mycobacterium tuberculosis H37Rv | Ki | 0.0150 | 1 | 1 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 0.0940 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.1630 | 2 | 2 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0841 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 83.2901 | 4 | 7 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 22.0150 | 80 | 126 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 11.3436 | 23 | 41 |
| Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 8.4500 | 1 | 1 |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | Ki | 7.7512 | 2 | 4 |
| Carbonic anhydrase 14 | Homo sapiens (human) | Ki | 1.9348 | 6 | 9 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 0.7654 | 5 | 7 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 48.7875 | 7 | 12 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 19.8936 | 91 | 140 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.7170 | 1 | 1 |
| Carbonic anhydrase 3 | Bos taurus (cattle) | Ki | 7.4747 | 2 | 17 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 5.2552 | 4 | 6 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 80.0130 | 3 | 5 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | Ki | 0.0533 | 3 | 3 |
| Carbonic anhydrase 4 | Homo sapiens (human) | Ki | 9.3508 | 9 | 30 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 6.2462 | 7 | 12 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 6.7517 | 5 | 9 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 2.3818 | 10 | 13 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 2.3245 | 8 | 15 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 6.5514 | 50 | 72 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.2730 | 1 | 1 |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | IC50 | 5.7200 | 1 | 3 |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | Ki | 0.9133 | 1 | 3 |
| Carboxylic ester hydrolase | Equus caballus (horse) | IC50 | 1,774.1000 | 1 | 1 |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | IC50 | 200.0000 | 2 | 3 |
| Carboxypeptidase A1 | Bos taurus (cattle) | IC50 | 2.7600 | 1 | 1 |
| Carboxypeptidase B2 | Homo sapiens (human) | IC50 | 1.0810 | 2 | 2 |
| Casein kinase I isoform alpha | Homo sapiens (human) | IC50 | 10.2144 | 2 | 5 |
| Casein kinase I isoform alpha | Sus scrofa (pig) | IC50 | 50.0000 | 1 | 1 |
| Casein kinase I isoform delta | Homo sapiens (human) | IC50 | 5.1200 | 2 | 2 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | IC50 | 2.7450 | 2 | 2 |
| Casein kinase II subunit alpha | Homo sapiens (human) | IC50 | 5.6366 | 17 | 31 |
| Casein kinase II subunit alpha | Homo sapiens (human) | Ki | 4.5033 | 5 | 12 |
| Casein kinase II subunit alpha | Zea mays | Ki | 1.8500 | 1 | 1 |
| Casein kinase II subunit alpha 3 | Homo sapiens (human) | IC50 | 4.0513 | 2 | 8 |
| Casein kinase II subunit alpha 3 | Homo sapiens (human) | Ki | 1.5400 | 1 | 2 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | IC50 | 6.5688 | 13 | 26 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | Ki | 1.5400 | 1 | 2 |
| Casein kinase II subunit beta | Homo sapiens (human) | IC50 | 5.9326 | 16 | 29 |
| Casein kinase II subunit beta | Homo sapiens (human) | Ki | 1.5400 | 1 | 2 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 | 28.1920 | 1 | 2 |
| Caspase-1 | Homo sapiens (human) | IC50 | 3.9482 | 2 | 6 |
| Caspase-3 | Homo sapiens (human) | IC50 | 28.2222 | 9 | 9 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 | 11.4000 | 1 | 1 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 | 11.4000 | 1 | 1 |
| Catechol O-methyltransferase | Rattus norvegicus (Norway rat) | IC50 | 4.7863 | 1 | 1 |
| Catenin beta-1 | Homo sapiens (human) | IC50 | 70.0022 | 6 | 6 |
| Catenin beta-1 | Homo sapiens (human) | Ki | 4.8191 | 7 | 7 |
| Cathepsin B | Homo sapiens (human) | IC50 | 14.2187 | 4 | 5 |
| Cathepsin G | Homo sapiens (human) | IC50 | 22.6240 | 4 | 6 |
| Cathepsin G | Homo sapiens (human) | Ki | 0.6300 | 1 | 1 |
| cathepsin L1 | Homo sapiens (human) | IC50 | 59.6420 | 1 | 1 |
| cathepsin S isoform 1 preproprotein | Homo sapiens (human) | IC50 | 0.1765 | 1 | 1 |
| Cationic trypsin | Bos taurus (cattle) | IC50 | 46.6556 | 2 | 9 |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | IC50 | 2.3600 | 1 | 1 |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | Ki | 0.1010 | 1 | 1 |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | IC50 | 4.4922 | 9 | 10 |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | Ki | 3.9000 | 2 | 2 |
| Cell division cycle 7-related protein kinase | Homo sapiens (human) | IC50 | 2.5654 | 4 | 4 |
| Cellular retinoic acid-binding protein 1 | Gallus gallus (chicken) | IC50 | 2.2283 | 4 | 6 |
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | Ki | 1.9500 | 1 | 2 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 6.5600 | 1 | 2 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Rattus norvegicus (Norway rat) | IC50 | 81.3000 | 1 | 1 |
| cGMP-dependent protein kinase 1 | Homo sapiens (human) | IC50 | 0.0330 | 1 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 16.8000 | 2 | 2 |
| Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase | Helicobacter pylori | Ki | 13.8000 | 1 | 6 |
| Chain A, 5'-methylthioadenosine nucleosidase | Arabidopsis thaliana (thale cress) | Ki | 48.0000 | 1 | 2 |
| Chain A, A disintegrin and metalloproteinase with thrombospondin motifs 5 | Homo sapiens (human) | IC50 | 0.1060 | 1 | 2 |
| Chain A, Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | Ki | 0.0264 | 1 | 1 |
| Chain A, ADENOSINE RECEPTOR A2A | Homo sapiens (human) | Ki | 0.0138 | 1 | 2 |
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | IC50 | 0.0310 | 1 | 1 |
| Chain A, ALPHA-MANNOSIDASE II | Drosophila melanogaster (fruit fly) | IC50 | 0.0200 | 1 | 3 |
| Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | IC50 | 2.4000 | 1 | 1 |
| Chain A, APH(2')-Id | Enterococcus casseliflavus | Ki | 25.1000 | 1 | 1 |
| Chain A, Apoptosis regulator Bcl-X | Homo sapiens (human) | Ki | 0.0005 | 1 | 1 |
| Chain A, ASPARTYLPROTEASE | Human immunodeficiency virus 1 | Ki | 0.0020 | 1 | 1 |
| Chain A, B-Raf proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 0.1600 | 1 | 1 |
| Chain A, Basic fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 | 0.1600 | 1 | 1 |
| Chain A, Casein kinase II subunit alpha | Zea mays | IC50 | 0.7750 | 1 | 6 |
| Chain A, Casein kinase II, alpha chain | Zea mays | Ki | 1.8500 | 1 | 1 |
| Chain A, Catalytic Domain of ADAMTS-5 | Homo sapiens (human) | IC50 | 0.1060 | 1 | 1 |
| Chain A, CES1 protein | Homo sapiens (human) | Ki | 15.2000 | 1 | 1 |
| Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 1.7000 | 1 | 2 |
| Chain A, Cyclin-dependent kinase 9 | Homo sapiens (human) | IC50 | 0.7400 | 1 | 1 |
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | IC50 | 0.7600 | 1 | 1 |
| Chain A, Diaminopimelate decarboxylase | Methanocaldococcus jannaschii | Ki | 89.0000 | 1 | 1 |
| Chain A, Epidermal growth factor receptor | Homo sapiens (human) | Ki | 0.0030 | 1 | 1 |
| Chain A, Estrogen receptor 1 (alpha) | Homo sapiens (human) | IC50 | 0.0090 | 1 | 1 |
| Chain A, Exotoxin A | Pseudomonas aeruginosa | Ki | 0.1400 | 1 | 1 |
| Chain A, Glutathione-requiring prostaglandin D synthase | Homo sapiens (human) | IC50 | 65.0000 | 1 | 1 |
| Chain A, Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | Ki | 19.0100 | 1 | 2 |
| Chain A, Glycogen Synthase Kinase-3 Beta | Homo sapiens (human) | IC50 | 0.0040 | 1 | 2 |
| Chain A, Heat shock protein HSP 90-alpha | Homo sapiens (human) | Ki | 0.0017 | 1 | 1 |
| Chain A, Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 | 0.0090 | 1 | 2 |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | IC50 | 0.9500 | 1 | 2 |
| Chain A, Inosine-5'-Monophosphate Dehydrogenase 2 | Cricetulus griseus (Chinese hamster) | Ki | 0.0060 | 1 | 1 |
| Chain A, Macrophage migration inhibitory factor | Homo sapiens (human) | IC50 | 0.0380 | 1 | 1 |
| Chain A, Mitogen-activated protein kinase 10 | Homo sapiens (human) | IC50 | 0.1500 | 1 | 3 |
| Chain A, MTA/SAH nucleosidase | Escherichia coli | Ki | 10.0000 | 1 | 2 |
| Chain A, Nuclear Receptor ROR-beta | Rattus norvegicus (Norway rat) | Ki | 0.2800 | 1 | 1 |
| Chain A, orotidine 5'-monophosphate decarboxylase | Archaea | Ki | 0.0640 | 1 | 1 |
| Chain A, orotidine 5'-monophosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 0.0640 | 1 | 1 |
| Chain A, orotidine monophosphate decarboxylase | Methanothermobacter thermautotrophicus | Ki | 0.0640 | 1 | 1 |
| Chain A, orotidine monophosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 0.0640 | 1 | 1 |
| Chain A, Pancreatic alpha-amylase | Homo sapiens (human) | Ki | 705.0000 | 1 | 4 |
| Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM | Mus musculus (house mouse) | IC50 | 0.0046 | 1 | 13 |
| Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | IC50 | 0.2620 | 1 | 1 |
| Chain A, PHOSPHOTIDYLINOSITOL 3 KINASE 59F | Drosophila melanogaster (fruit fly) | IC50 | 2.3000 | 1 | 4 |
| Chain A, POLYMERASE PA | Influenza A virus | IC50 | 1.9000 | 1 | 1 |
| Chain A, Polymerase Pa | Influenza A virus (A/California/04/2009(H1N1)) | IC50 | 1.9000 | 1 | 4 |
| Chain A, Probable serine/threonine-protein kinase pknB | Mycobacterium tuberculosis H37Rv | IC50 | 0.8000 | 1 | 1 |
| Chain A, PROTEIN (CRABP-I) | Bos taurus (cattle) | IC50 | 0.1400 | 1 | 1 |
| Chain A, PROTEIN (CRABP-II) | Homo sapiens (human) | IC50 | 0.1400 | 1 | 2 |
| Chain A, Protein (fibroblast Growth Factor (fgf) Receptor 1) | Homo sapiens (human) | Ki | 0.0452 | 1 | 1 |
| Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | IC50 | 1.0000 | 1 | 1 |
| Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta)) | Homo sapiens (human) | IC50 | 4.0000 | 1 | 1 |
| Chain A, Protein farnesyltransferase alpha subunit | Rattus norvegicus (Norway rat) | IC50 | 0.0019 | 1 | 1 |
| Chain A, Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit | Homo sapiens (human) | Ki | 0.0024 | 1 | 2 |
| Chain A, Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit | Rattus norvegicus (Norway rat) | Ki | 0.0024 | 1 | 2 |
| Chain A, PROTEIN KINASE CK2, ALPHA SUBUNIT | Zea mays | IC50 | 1.0000 | 1 | 1 |
| Chain A, Proto-oncogene Serine/threonine Protein Kinase Pim-1 | Homo sapiens (human) | IC50 | 5,000.0000 | 1 | 3 |
| Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1 | Homo sapiens (human) | IC50 | 500.5880 | 1 | 10 |
| Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL | Mus musculus (house mouse) | IC50 | 0.1000 | 1 | 1 |
| Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET | Homo sapiens (human) | IC50 | 0.1700 | 1 | 3 |
| Chain A, Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 | 0.0027 | 1 | 1 |
| Chain A, Purine nucleoside phosphorylase | Escherichia coli | Ki | 120.0000 | 1 | 1 |
| Chain A, Purine nucleoside phosphorylase DeoD-type | Escherichia coli O157:H7 | Ki | 120.0000 | 1 | 1 |
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 | 35.0600 | 1 | 1 |
| Chain A, Serine/threonine-protein Kinase 12-a | Xenopus laevis (African clawed frog) | IC50 | 0.5000 | 1 | 1 |
| Chain A, Thymidylate Synthase | Escherichia coli | Ki | 0.1090 | 1 | 2 |
| Chain A, Thymidylate Synthase | Homo sapiens (human) | Ki | 0.1090 | 1 | 1 |
| Chain A, Tyrosine-protein kinase SYK | Homo sapiens (human) | Ki | 5.0000 | 1 | 1 |
| Chain A, Uracil Phosphoribosyltransferase | Toxoplasma gondii | Ki | 25.0000 | 1 | 1 |
| Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | Homo sapiens (human) | Ki | 0.0005 | 1 | 15 |
| Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase | Helicobacter pylori | Ki | 13.8000 | 1 | 6 |
| Chain B, 5'-methylthioadenosine nucleosidase | Arabidopsis thaliana (thale cress) | Ki | 48.0000 | 1 | 2 |
| Chain B, ASPARTYLPROTEASE | Human immunodeficiency virus 1 | Ki | 0.0020 | 1 | 1 |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 2 |
| Chain B, Diaminopimelate decarboxylase | Methanocaldococcus jannaschii | Ki | 89.0000 | 1 | 1 |
| Chain B, Geranylgeranyl transferase type I beta subunit | Rattus norvegicus (Norway rat) | Ki | 0.0024 | 1 | 2 |
| Chain B, Glycogen Synthase Kinase-3 Beta | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Chain B, MTA/SAH nucleosidase | Escherichia coli | Ki | 10.0000 | 1 | 2 |
| Chain B, orotidine 5'-monophosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 0.0640 | 1 | 1 |
| Chain B, orotidine monophosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 0.0640 | 1 | 1 |
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | IC50 | 0.0013 | 1 | 2 |
| Chain B, Protein farnesyltransferase beta subunit | Homo sapiens (human) | Ki | 0.0024 | 1 | 2 |
| Chain C, Macrophage migration inhibitory factor | Homo sapiens (human) | IC50 | 0.0380 | 1 | 1 |
| Chain H, Proteasome component PUP1 | Saccharomyces cerevisiae (brewer's yeast) | Ki | 0.0006 | 1 | 1 |
| Chain I, Proteasome component PUP3 | Saccharomyces cerevisiae (brewer's yeast) | Ki | 0.0006 | 1 | 1 |
| Chain K, Proteasome component PRE2 | Saccharomyces cerevisiae (brewer's yeast) | Ki | 0.0006 | 1 | 2 |
| Chain L, Proteasome component C5 | Saccharomyces cerevisiae (brewer's yeast) | Ki | 0.0006 | 1 | 2 |
| Chemotaxis protein CheA | Escherichia coli K-12 | IC50 | 111.0000 | 1 | 1 |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | IC50 | 0.2700 | 1 | 1 |
| Cholecystokinin receptor type A | Homo sapiens (human) | IC50 | 2.4464 | 5 | 5 |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | IC50 | 0.0009 | 12 | 12 |
| Cholecystokinin receptor type A | Homo sapiens (human) | Ki | 0.7593 | 3 | 3 |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | Ki | 0.0004 | 2 | 2 |
| Cholesterol side-chain cleavage enzyme, mitochondrial | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| Cholesterol side-chain cleavage enzyme, mitochondrial | Bos taurus (cattle) | IC50 | 29.6667 | 3 | 3 |
| Cholinesterase | Equus caballus (horse) | IC50 | 108.3560 | 8 | 8 |
| Cholinesterase | Homo sapiens (human) | IC50 | 81.6041 | 9 | 9 |
| Cholinesterase | Equus caballus (horse) | Ki | 100.0000 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | Ki | 71.6583 | 2 | 6 |
| Chymase | Homo sapiens (human) | IC50 | 2.3600 | 1 | 2 |
| Chymotrypsin-C | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Chymotrypsin-like elastase family member 1 | Sus scrofa (pig) | IC50 | 28.7500 | 1 | 4 |
| Chymotrypsinogen A | Bos taurus (cattle) | IC50 | 236.5000 | 3 | 6 |
| Chymotrypsinogen A | Bos taurus (cattle) | Ki | 2.4000 | 1 | 1 |
| Chymotrypsinogen B | Homo sapiens (human) | IC50 | 81.6667 | 1 | 3 |
| Chymotrypsinogen B | Homo sapiens (human) | Ki | 0.3200 | 1 | 1 |
| Class A sortase SrtA | Staphylococcus aureus | IC50 | 60.9450 | 4 | 4 |
| CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 | Homo sapiens (human) | IC50 | 45.4114 | 1 | 14 |
| Coagulation factor VII | Homo sapiens (human) | IC50 | 78.0000 | 1 | 1 |
| Coagulation factor X | Homo sapiens (human) | IC50 | 25.0850 | 2 | 2 |
| Coagulation factor X | Homo sapiens (human) | Ki | 0.5700 | 1 | 1 |
| Coagulation factor XI | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Coagulation factor XII | Homo sapiens (human) | Ki | 65.9900 | 1 | 5 |
| Cocaine esterase | Homo sapiens (human) | Ki | 34.1363 | 3 | 3 |
| Coiled-coil domain-containing protein 6 | Homo sapiens (human) | GI50 | 0.0290 | 1 | 1 |
| Coiled-coil domain-containing protein 6 | Homo sapiens (human) | IC50 | 0.2267 | 4 | 5 |
| Collagenase 3 | Homo sapiens (human) | IC50 | 0.8497 | 16 | 22 |
| Collagenase 3 | Homo sapiens (human) | Ki | 0.0006 | 3 | 3 |
| Collagenase ColG | Hathewaya histolytica | IC50 | 24.0000 | 1 | 1 |
| Complex I intermediate-associated protein 30, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Mus musculus (house mouse) | IC50 | 0.3570 | 1 | 1 |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0300 | 1 | 1 |
| Corticosteroid 11-beta-dehydrogenase isozyme 2 | Mus musculus (house mouse) | IC50 | 500.0000 | 1 | 1 |
| Corticosteroid-binding globulin | Homo sapiens (human) | Ki | 5.0155 | 1 | 2 |
| corticotropin releasing factor-binding protein | Homo sapiens (human) | IC50 | 47.1000 | 1 | 1 |
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | IC50 | 0.0040 | 1 | 1 |
| corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | IC50 | 47.1000 | 1 | 1 |
| CPG DNA methylase | Spiroplasma monobiae | Ki | 0.0280 | 1 | 1 |
| CREB-binding protein | Homo sapiens (human) | IC50 | 23.0446 | 10 | 10 |
| Cruzipain | Trypanosoma cruzi | IC50 | 184.9700 | 4 | 10 |
| Cyclic GMP-AMP synthase | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Cyclin homolog | Herpesvirus saimiri (strain 11) | IC50 | 23.4370 | 1 | 20 |
| Cyclin-A1 | Homo sapiens (human) | IC50 | 13.6626 | 7 | 7 |
| Cyclin-A1 | Homo sapiens (human) | Ki | 34.5950 | 1 | 2 |
| Cyclin-A2 | Homo sapiens (human) | IC50 | 7.0757 | 37 | 48 |
| Cyclin-A2 | Homo sapiens (human) | Ki | 18.5585 | 3 | 4 |
| Cyclin-C | Homo sapiens (human) | IC50 | 1.5096 | 4 | 4 |
| Cyclin-C | Homo sapiens (human) | Ki | 0.0090 | 1 | 1 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 | 29.3083 | 71 | 118 |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | IC50 | 18.7728 | 4 | 25 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | Ki | 1.7967 | 5 | 6 |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | IC50 | 2.1337 | 5 | 5 |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | IC50 | 0.2650 | 3 | 3 |
| Cyclin-dependent kinase 14 | Homo sapiens (human) | IC50 | 0.0198 | 1 | 1 |
| Cyclin-dependent kinase 19 | Homo sapiens (human) | IC50 | 0.0602 | 3 | 4 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 | 18.2158 | 103 | 143 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Ki | 8.3614 | 10 | 12 |
| Cyclin-dependent kinase 2-associated protein 2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | IC50 | 125.2700 | 4 | 4 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | IC50 | 6.8288 | 63 | 97 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | Ki | 0.2588 | 4 | 4 |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | IC50 | 12.4215 | 18 | 43 |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | IC50 | 14.7876 | 29 | 55 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | Ki | 0.0270 | 1 | 1 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | IC50 | 9.7412 | 29 | 41 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Ki | 4.2667 | 3 | 3 |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | IC50 | 1.9170 | 13 | 17 |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | Ki | 0.0090 | 1 | 1 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | IC50 | 5.7365 | 51 | 68 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | Ki | 0.1373 | 4 | 6 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | IC50 | 10.4673 | 24 | 53 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| Cyclin-G-associated kinase | Homo sapiens (human) | IC50 | 0.2996 | 3 | 5 |
| Cyclin-H | Homo sapiens (human) | IC50 | 10.9701 | 19 | 25 |
| Cyclin-H | Homo sapiens (human) | Ki | 4.2667 | 3 | 3 |
| Cyclin-K | Homo sapiens (human) | IC50 | 0.5213 | 8 | 8 |
| Cyclin-T1 | Homo sapiens (human) | IC50 | 6.3623 | 35 | 44 |
| Cyclin-T1 | Homo sapiens (human) | Ki | 0.2042 | 3 | 4 |
| Cyclin-Y | Homo sapiens (human) | IC50 | 0.0198 | 1 | 1 |
| Cystathionine beta-synthase | Homo sapiens (human) | IC50 | 17.9500 | 1 | 2 |
| Cystathionine gamma-lyase | Homo sapiens (human) | IC50 | 400.0000 | 1 | 1 |
| Cysteine protease | Trypanosoma brucei rhodesiense | IC50 | 28.8750 | 2 | 2 |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | IC50 | 23.5565 | 1 | 2 |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | Ki | 11.7780 | 1 | 2 |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | IC50 | 15.9000 | 1 | 2 |
| Cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | Ki | 81.0000 | 1 | 1 |
| Cystine/glutamate transporter | Homo sapiens (human) | IC50 | 0.1800 | 3 | 3 |
| Cytidine deaminase | Homo sapiens (human) | Ki | 190.0000 | 1 | 1 |
| Cytochrome c oxidase subunit NDUFA4 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | IC50 | 1.6879 | 7 | 9 |
| Cytochrome P450 11B1, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 2 |
| Cytochrome P450 11B1, mitochondrial | Rattus norvegicus (Norway rat) | Ki | 0.0044 | 1 | 1 |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | IC50 | 0.0012 | 2 | 5 |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | IC50 | 1.6717 | 5 | 6 |
| Cytochrome P450 11B2, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 70.0000 | 2 | 3 |
| Cytochrome P450 1A1 | Homo sapiens (human) | IC50 | 4.1768 | 10 | 18 |
| Cytochrome P450 1A1 | Homo sapiens (human) | Ki | 8.7519 | 6 | 16 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 11.6638 | 30 | 46 |
| Cytochrome P450 1A2 | Homo sapiens (human) | Ki | 3.7740 | 5 | 9 |
| Cytochrome P450 1B1 | Homo sapiens (human) | IC50 | 3.5461 | 11 | 22 |
| Cytochrome P450 1B1 | Homo sapiens (human) | Ki | 2.3511 | 6 | 17 |
| Cytochrome P450 26A1 | Homo sapiens (human) | IC50 | 13.5000 | 1 | 1 |
| Cytochrome P450 26B1 | Homo sapiens (human) | IC50 | 5.9000 | 1 | 1 |
| Cytochrome P450 2A13 | Homo sapiens (human) | Ki | 1.9200 | 1 | 2 |
| Cytochrome P450 2A6 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 2 |
| Cytochrome P450 2A6 | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| Cytochrome P450 2A6 | Homo sapiens (human) | Ki | 1.1625 | 3 | 4 |
| Cytochrome P450 2B6 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 3 |
| Cytochrome P450 2B6 | Homo sapiens (human) | IC50 | 17.2424 | 5 | 5 |
| Cytochrome P450 2B6 | Homo sapiens (human) | Ki | 0.9000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 4 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 14.4601 | 22 | 33 |
| Cytochrome P450 2C19 | Homo sapiens (human) | Ki | 1.6678 | 3 | 3 |
| Cytochrome P450 2C8 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 1 |
| Cytochrome P450 2C8 | Homo sapiens (human) | IC50 | 5.6860 | 11 | 13 |
| Cytochrome P450 2C8 | Homo sapiens (human) | Ki | 24.9534 | 2 | 2 |
| Cytochrome P450 2C9 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 2 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 20.9654 | 28 | 35 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 12.0747 | 3 | 3 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 204.0000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 23.6500 | 1 | 2 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 970.6000 | 1 | 2 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 426.1500 | 1 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 23.6234 | 30 | 38 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 4.1667 | 3 | 3 |
| Cytochrome P450 2E1 | Homo sapiens (human) | IC50 | 0.2370 | 1 | 2 |
| Cytochrome P450 2E1 | Homo sapiens (human) | Ki | 10.4900 | 2 | 2 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | GI50 | 1.8000 | 1 | 5 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 163.8729 | 68 | 88 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 17.6618 | 14 | 17 |
| Cytochrome P450 3A43 | Homo sapiens (human) | IC50 | 0.0140 | 1 | 1 |
| Cytochrome P450 3A5 | Homo sapiens (human) | IC50 | 0.7480 | 3 | 4 |
| Cytochrome P450 3A5 | Homo sapiens (human) | Ki | 19.0850 | 2 | 2 |
| Cytochrome P450 3A7 | Homo sapiens (human) | IC50 | 50.0070 | 2 | 2 |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | GI50 | 0.0090 | 1 | 1 |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | IC50 | 18.0178 | 18 | 20 |
| Cytosol aminopeptidase | Sus scrofa (pig) | IC50 | 41.9500 | 1 | 2 |
| D | Rattus norvegicus (Norway rat) | IC50 | 71.5000 | 1 | 2 |
| D | Rattus norvegicus (Norway rat) | Ki | 2.9000 | 1 | 1 |
| D-amino-acid oxidase | Sus scrofa (pig) | IC50 | 1.0700 | 2 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 10.4895 | 1 | 8 |
| D(1A) dopamine receptor | Sus scrofa (pig) | IC50 | 0.1800 | 1 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 5.2448 | 1 | 8 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 16.7413 | 1 | 3 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 15.6854 | 4 | 5 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 3.3664 | 3 | 5 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 1.4020 | 2 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 6.8825 | 1 | 6 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 18.1000 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 2.0035 | 2 | 7 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 7.1555 | 1 | 2 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 4.2880 | 2 | 3 |
| Death-associated protein kinase 1 | Homo sapiens (human) | IC50 | 89.4500 | 2 | 10 |
| Death-associated protein kinase 3 | Homo sapiens (human) | IC50 | 0.0810 | 1 | 1 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.3750 | 1 | 1 |
| Delta-type opioid receptor | Homo sapiens (human) | IC50 | 17.1254 | 4 | 9 |
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 | 2.6015 | 4 | 6 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0660 | 4 | 4 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 9.4204 | 3 | 7 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 0.0155 | 3 | 3 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0112 | 2 | 2 |
| Deoxyhypusine synthase | Homo sapiens (human) | IC50 | 0.7867 | 3 | 3 |
| Deoxyhypusine synthase | Rattus norvegicus (Norway rat) | IC50 | 0.0300 | 1 | 1 |
| Deoxyhypusine synthase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 0.1000 | 1 | 1 |
| Deoxynucleoside kinase | Drosophila melanogaster (fruit fly) | IC50 | 3,712.6667 | 2 | 3 |
| Deoxyribonuclease-1 | Bos taurus (cattle) | IC50 | 300.0000 | 1 | 1 |
| Deoxyribonuclease-2-alpha | Sus scrofa (pig) | IC50 | 300.0000 | 1 | 1 |
| Diacylglycerol kinase 1 | Drosophila melanogaster (fruit fly) | IC50 | 133.0000 | 1 | 1 |
| Dihydrofolate reductase | Enterococcus faecium | IC50 | 0.0014 | 1 | 1 |
| Dihydrofolate reductase | Escherichia coli K-12 | IC50 | 98.8421 | 25 | 48 |
| Dihydrofolate reductase | Gallus gallus (chicken) | IC50 | 0.0545 | 2 | 2 |
| Dihydrofolate reductase | Homo sapiens (human) | IC50 | 2.4305 | 83 | 113 |
| Dihydrofolate reductase | Lacticaseibacillus casei | IC50 | 20.3740 | 29 | 34 |
| Dihydrofolate reductase | Mus musculus (house mouse) | IC50 | 0.2304 | 12 | 12 |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | IC50 | 0.0174 | 3 | 3 |
| Dihydrofolate reductase | Pneumocystis carinii | IC50 | 15.5555 | 13 | 15 |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | IC50 | 0.2043 | 11 | 12 |
| Dihydrofolate reductase | Escherichia coli K-12 | Ki | 34.5460 | 5 | 5 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 9.0276 | 16 | 16 |
| Dihydrofolate reductase | Lacticaseibacillus casei | Ki | 0.0000 | 1 | 1 |
| Dihydrofolate reductase | Mus musculus (house mouse) | Ki | 0.2347 | 18 | 19 |
| Dihydrofolate reductase | Pneumocystis carinii | Ki | 0.0000 | 1 | 1 |
| Dihydrofolate reductase | Staphylococcus aureus | Ki | 0.0005 | 2 | 2 |
| Dihydrofolate reductase | Bacillus anthracis | IC50 | 0.0136 | 1 | 2 |
| Dihydrofolate reductase | Bos taurus (cattle) | IC50 | 722.1480 | 11 | 11 |
| Dihydroorotate dehydrogenase | Leishmania major | IC50 | 444.2045 | 1 | 10 |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 10.0000 | 1 | 1 |
| Dihydroorotate dehydrogenase | Schistosoma mansoni | IC50 | 20.0000 | 2 | 2 |
| Dihydroorotate dehydrogenase (fumarate) | Saccharomyces cerevisiae S288C | IC50 | 10.0000 | 1 | 1 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 0.9935 | 29 | 31 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | IC50 | 0.0300 | 1 | 1 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 0.1717 | 5 | 6 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | Ki | 0.0120 | 2 | 2 |
| Dipeptidyl peptidase 1 | Homo sapiens (human) | IC50 | 9.9600 | 2 | 5 |
| Dipeptidyl peptidase 3 | Homo sapiens (human) | IC50 | 65.8000 | 1 | 6 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | IC50 | 48.6718 | 4 | 12 |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | IC50 | 27.3333 | 1 | 3 |
| Dipeptidyl peptidase 4 | Sus scrofa (pig) | IC50 | 0.4900 | 1 | 1 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | GI50 | 5.5250 | 2 | 4 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | IC50 | 0.1294 | 10 | 24 |
| Disintegrin and metalloproteinase domain-containing protein 10 | Homo sapiens (human) | IC50 | 0.1356 | 2 | 2 |
| Disintegrin and metalloproteinase domain-containing protein 12 | Homo sapiens (human) | IC50 | 0.0059 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | IC50 | 22.4149 | 9 | 12 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Ki | 0.0024 | 3 | 3 |
| disintegrin and metalloproteinase domain-containing protein 17 isoform 1 preproprotein | Homo sapiens (human) | IC50 | 0.0184 | 2 | 2 |
| Disintegrin and metalloproteinase domain-containing protein 9 | Homo sapiens (human) | IC50 | 0.0286 | 2 | 2 |
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | IC50 | 28.1600 | 4 | 5 |
| DNA (cytosine-5)-methyltransferase 3-like | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| DNA (cytosine-5)-methyltransferase 3A | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| DNA (cytosine-5)-methyltransferase 3A | Mus musculus (house mouse) | IC50 | 7.0000 | 2 | 2 |
| DNA (cytosine-5)-methyltransferase 3B | Mus musculus (house mouse) | IC50 | 100.0000 | 1 | 1 |
| DNA damage-binding protein 1 | Homo sapiens (human) | IC50 | 1.7972 | 3 | 5 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 | 2.6100 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3A isoform a | Homo sapiens (human) | IC50 | 17.5000 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 | 6.6050 | 2 | 2 |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | IC50 | 150.0000 | 3 | 3 |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | IC50 | 125.0000 | 2 | 2 |
| DNA ligase | Tequatrovirus T4 | IC50 | 300.0000 | 1 | 1 |
| DNA polymerase alpha catalytic subunit | Homo sapiens (human) | IC50 | 5.1500 | 6 | 6 |
| DNA polymerase beta | Homo sapiens (human) | IC50 | 55.8875 | 4 | 4 |
| DNA polymerase beta | Rattus norvegicus (Norway rat) | IC50 | 60.7000 | 4 | 4 |
| DNA polymerase catalytic subunit | Human alphaherpesvirus 1 strain 17 | IC50 | 0.5000 | 1 | 1 |
| DNA polymerase catalytic subunit | Human alphaherpesvirus 1 strain KOS | IC50 | 0.4380 | 1 | 1 |
| DNA polymerase catalytic subunit | Human herpesvirus 3 strain Dumas | IC50 | 1.6000 | 1 | 2 |
| DNA polymerase catalytic subunit | Human herpesvirus 5 strain AD169 | IC50 | 0.4435 | 2 | 2 |
| DNA polymerase catalytic subunit | Human herpesvirus 6 (strain Uganda-1102) | IC50 | 0.4000 | 1 | 1 |
| DNA polymerase delta catalytic subunit | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| DNA polymerase lambda | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| DNA polymerase subunit gamma-1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| DNA primase | Mycobacterium tuberculosis CDC1551 | IC50 | 28.1000 | 1 | 3 |
| DNA primase TraC | Escherichia coli | IC50 | 700.0000 | 1 | 1 |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | IC50 | 2.5108 | 5 | 5 |
| DNA topoisomerase | Bos taurus (cattle) | IC50 | 17.0000 | 1 | 1 |
| DNA topoisomerase 1 | Chlorocebus aethiops (grivet) | IC50 | 27.0000 | 1 | 1 |
| DNA topoisomerase 1 | Homo sapiens (human) | IC50 | 74.3036 | 25 | 39 |
| DNA topoisomerase 1 | Mus musculus (house mouse) | IC50 | 49.6000 | 3 | 5 |
| DNA topoisomerase 1 | Rattus norvegicus (Norway rat) | IC50 | 2.8300 | 2 | 2 |
| DNA topoisomerase 1 | Yersinia pestis | IC50 | 250.0000 | 1 | 2 |
| DNA topoisomerase 2 | Drosophila melanogaster (fruit fly) | IC50 | 2.2000 | 1 | 1 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | IC50 | 89.2073 | 33 | 40 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | IC50 | 20.6930 | 9 | 10 |
| DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | IC50 | 2.5280 | 3 | 5 |
| DNA-3-methyladenine glycosylase | Homo sapiens (human) | IC50 | 2.5500 | 2 | 2 |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | IC50 | 9.3664 | 14 | 32 |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | Ki | 0.1200 | 2 | 2 |
| DNA-directed RNA polymerase subunit beta | Escherichia coli O127:H6 str. E2348/69 | IC50 | 511.3333 | 3 | 3 |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | IC50 | 0.0100 | 1 | 1 |
| Dopamine beta-hydroxylase | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Dual serine/threonine and tyrosine protein kinase | Homo sapiens (human) | IC50 | 29.3500 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | IC50 | 3.4387 | 51 | 58 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Mus musculus (house mouse) | IC50 | 0.0042 | 2 | 2 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | IC50 | 3.2707 | 25 | 29 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 4 | Homo sapiens (human) | IC50 | 1.7000 | 2 | 2 |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | IC50 | 0.8000 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | IC50 | 0.8000 | 2 | 2 |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | IC50 | 1.3000 | 1 | 1 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | IC50 | 0.1079 | 1 | 1 |
| Dual specificity protein kinase TTK | Homo sapiens (human) | IC50 | 2.1171 | 6 | 6 |
| Dual specificity protein phosphatase 1 | Mus musculus (house mouse) | IC50 | 16.6850 | 1 | 2 |
| dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 | 1.1700 | 2 | 2 |
| Dual specificity protein phosphatase 5 | Homo sapiens (human) | Ki | 0.0250 | 1 | 1 |
| dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | IC50 | 9.9067 | 2 | 3 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | IC50 | 1.7226 | 8 | 9 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | IC50 | 10.2100 | 3 | 3 |
| E-selectin | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | IC50 | 0.0200 | 1 | 1 |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
| E3 ubiquitin-protein ligase Mdm2 isoform a | Homo sapiens (human) | IC50 | 3.5800 | 1 | 1 |
| E3 ubiquitin-protein ligase XIAP | Homo sapiens (human) | IC50 | 0.7563 | 20 | 20 |
| E3 ubiquitin-protein ligase XIAP | Homo sapiens (human) | Ki | 0.0988 | 5 | 5 |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | IC50 | 0.3576 | 21 | 42 |
| Ectonucleoside triphosphate diphosphohydrolase 1 | Mus musculus (house mouse) | IC50 | 25.6600 | 1 | 2 |
| Ectonucleoside triphosphate diphosphohydrolase 1 | Rattus norvegicus (Norway rat) | Ki | 300.0000 | 2 | 2 |
| Ectonucleoside triphosphate diphosphohydrolase 2 | Rattus norvegicus (Norway rat) | Ki | 65.4000 | 2 | 2 |
| Ectonucleoside triphosphate diphosphohydrolase 3 | Rattus norvegicus (Norway rat) | Ki | 12.7000 | 1 | 1 |
| Ectonucleoside triphosphate diphosphohydrolase 8 | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| eIF-2-alpha kinase GCN2 | Homo sapiens (human) | IC50 | 1.9190 | 2 | 2 |
| Elastase | Pseudomonas aeruginosa PAO1 | IC50 | 427.5000 | 2 | 2 |
| ELAV-like protein 1 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
| ELAV-like protein 3 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 2 |
| Emopamil-binding protein-like | Homo sapiens (human) | Ki | 0.0028 | 1 | 1 |
| Endoplasmin | Canis lupus familiaris (dog) | IC50 | 0.0380 | 2 | 5 |
| Endoplasmin | Homo sapiens (human) | IC50 | 0.0535 | 2 | 2 |
| Endoplasmin | Homo sapiens (human) | Ki | 0.0967 | 2 | 3 |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | IC50 | 9.5450 | 9 | 9 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | IC50 | 0.0300 | 1 | 1 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | IC50 | 59.0000 | 1 | 1 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | IC50 | 17.5000 | 2 | 4 |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | Ki | 7.0500 | 1 | 1 |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 6.5292 | 3 | 12 |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 1.2442 | 4 | 10 |
| Ephrin type-A receptor 1 | Homo sapiens (human) | IC50 | 0.1430 | 1 | 1 |
| Ephrin type-A receptor 2 | Homo sapiens (human) | IC50 | 1.3549 | 6 | 9 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | IC50 | 3.3376 | 2 | 3 |
| Ephrin type-B receptor 4 | Homo sapiens (human) | IC50 | 3.8920 | 10 | 23 |
| Epidermal growth factor receptor | Homo sapiens (human) | GI50 | 0.9350 | 31 | 37 |
| Epidermal growth factor receptor | Mus musculus (house mouse) | GI50 | 2.6000 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 31.8529 | 670 | 1011 |
| Epidermal growth factor receptor | Mus musculus (house mouse) | IC50 | 0.0905 | 2 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | Ki | 0.3910 | 27 | 30 |
| epidermal growth factor receptor isoform a precursor | Homo sapiens (human) | IC50 | 0.0025 | 1 | 2 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | GI50 | 4.2750 | 2 | 4 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | IC50 | 1.9277 | 8 | 17 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| Epoxide hydrolase 1 | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | IC50 | 0.1900 | 1 | 1 |
| Estrogen receptor | Homo sapiens (human) | IC50 | 8.2498 | 115 | 156 |
| Estrogen receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0094 | 2 | 3 |
| Estrogen receptor | Homo sapiens (human) | Ki | 0.6873 | 14 | 24 |
| Estrogen receptor beta | Homo sapiens (human) | IC50 | 2.3283 | 69 | 98 |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | IC50 | 0.0112 | 1 | 2 |
| Estrogen receptor beta | Homo sapiens (human) | Ki | 0.1693 | 11 | 18 |
| estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 | 2.9272 | 1 | 2 |
| Estrogen-related receptor gamma | Homo sapiens (human) | IC50 | 0.0219 | 3 | 4 |
| Eukaryotic elongation factor 2 kinase | Homo sapiens (human) | IC50 | 7.6500 | 2 | 2 |
| Eukaryotic initiation factor 4A-I | Homo sapiens (human) | IC50 | 0.1044 | 4 | 4 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | IC50 | 0.4600 | 1 | 1 |
| Eukaryotic translation initiation factor 2-alpha kinase 3 | Homo sapiens (human) | IC50 | 3.3436 | 3 | 3 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 | 1.1500 | 1 | 1 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 | 1.1500 | 1 | 1 |
| exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 | 101.0373 | 2 | 3 |
| exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 | 101.0373 | 2 | 3 |
| exodeoxyribonuclease V subunit RecD | Escherichia coli str. K-12 substr. MG1655 | IC50 | 101.0373 | 2 | 3 |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Fatty acid synthase | Gallus gallus (chicken) | IC50 | 61.1771 | 5 | 7 |
| Fatty acid synthase | Homo sapiens (human) | IC50 | 27.8200 | 2 | 5 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 13.3000 | 2 | 2 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 26.0738 | 2 | 4 |
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | IC50 | 363.0780 | 1 | 1 |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | IC50 | 0.0800 | 1 | 1 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | IC50 | 1.0341 | 4 | 6 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 | 7.3048 | 79 | 119 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Ki | 5.0280 | 2 | 2 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 | 2.4624 | 23 | 25 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | IC50 | 2.8696 | 29 | 29 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | IC50 | 2.6659 | 24 | 24 |
| Fibroblast growth factor receptor 4 | Mus musculus (house mouse) | IC50 | 0.5610 | 2 | 2 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Fibronectin | Homo sapiens (human) | IC50 | 1.9400 | 1 | 3 |
| Focal adhesion kinase 1 | Homo sapiens (human) | IC50 | 7.2292 | 9 | 16 |
| Focal adhesion kinase 1 | Homo sapiens (human) | Ki | 5.0085 | 2 | 2 |
| Folate receptor alpha | Homo sapiens (human) | IC50 | 0.2936 | 6 | 12 |
| Folate receptor beta | Homo sapiens (human) | IC50 | 0.2185 | 6 | 10 |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | IC50 | 3.2000 | 1 | 1 |
| Folylpolyglutamate synthase, mitochondrial | Mus musculus (house mouse) | Ki | 166.0000 | 1 | 1 |
| Forkhead box protein M1 | Homo sapiens (human) | IC50 | 122.4000 | 1 | 1 |
| Forkhead box protein M1 | Homo sapiens (human) | Ki | 0.0520 | 1 | 1 |
| Forkhead box protein O1 | Homo sapiens (human) | IC50 | 0.0330 | 1 | 1 |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | IC50 | 80.8754 | 12 | 13 |
| Fructose-1,6-bisphosphatase 1 | Sus scrofa (pig) | IC50 | 10.0000 | 1 | 1 |
| Fructose-1,6-bisphosphatase 1 | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Furin | Homo sapiens (human) | IC50 | 0.0180 | 1 | 1 |
| Furin | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
| G protein-coupled receptor kinase 5 | Homo sapiens (human) | IC50 | 0.8300 | 1 | 1 |
| G protein-coupled receptor kinase 6 | Homo sapiens (human) | IC50 | 8.7000 | 1 | 1 |
| G-protein coupled receptor 35 | Homo sapiens (human) | IC50 | 13.1840 | 1 | 5 |
| G-protein coupled receptor 55 | Homo sapiens (human) | IC50 | 2.6423 | 1 | 1 |
| G-protein coupled receptor 84 | Homo sapiens (human) | Ki | 0.0236 | 1 | 1 |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | IC50 | 8.1070 | 46 | 65 |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | Ki | 0.0350 | 2 | 2 |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | IC50 | 0.1680 | 7 | 7 |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | IC50 | 0.1429 | 16 | 16 |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | Ki | 0.0270 | 1 | 1 |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | IC50 | 19.8943 | 37 | 50 |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | Ki | 3.9588 | 4 | 4 |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | IC50 | 36.7621 | 10 | 11 |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | Ki | 6.9200 | 2 | 2 |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | IC50 | 18.7728 | 4 | 25 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | IC50 | 18.4622 | 47 | 74 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | Ki | 3.3967 | 3 | 3 |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | IC50 | 13.7769 | 12 | 18 |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | IC50 | 13.7769 | 12 | 18 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | Ki | 0.2687 | 2 | 12 |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | Ki | 0.0146 | 3 | 15 |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (RF/HAT ISOLATE) | Ki | 0.0285 | 1 | 6 |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (STRAIN UGANDAN / ISOLATE U455) | Ki | 0.0285 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 | 2.5055 | 5 | 6 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 0.6730 | 3 | 4 |
| Gamma-aminobutyric acid receptor subunit rho-1 | Homo sapiens (human) | IC50 | 12.9000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | Ki | 39.7912 | 2 | 8 |
| Gamma-butyrobetaine dioxygenase | Homo sapiens (human) | IC50 | 0.7420 | 5 | 5 |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Gasdermin-D | Homo sapiens (human) | IC50 | 0.4000 | 1 | 1 |
| Gasdermin-D | Mus musculus (house mouse) | IC50 | 0.4000 | 1 | 1 |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | IC50 | 0.1245 | 2 | 2 |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | IC50 | 33.3336 | 3 | 3 |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | Ki | 0.0560 | 3 | 3 |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | Ki | 0.2692 | 1 | 1 |
| GDH/6PGL endoplasmic bifunctional protein | Homo sapiens (human) | IC50 | 18.0000 | 1 | 2 |
| Genome polyprotein | Coxsackievirus B3 (strain Nancy) | IC50 | 1.1000 | 1 | 1 |
| Genome polyprotein | Dengue virus 2 Puerto Rico/PR159-S1/1969 | IC50 | 48.3350 | 2 | 2 |
| Genome polyprotein | Hepatitis C virus (isolate BK) | IC50 | 34.9000 | 1 | 2 |
| Genome polyprotein | | IC50 | 1.1167 | 2 | 3 |
| Genome polyprotein | Human rhinovirus sp. | IC50 | 150.0000 | 1 | 2 |
| Genome polyprotein | Zika virus | IC50 | 52.4600 | 2 | 5 |
| Genome polyprotein | Zika virus | Ki | 0.8000 | 1 | 1 |
| Geranylgeranyl transferase type-1 subunit beta | Bos taurus (cattle) | IC50 | 4.9143 | 5 | 7 |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | IC50 | 20.2632 | 9 | 11 |
| Geranylgeranyl transferase type-1 subunit beta | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Ghrelin O-acyltransferase | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Gli1 | Mus musculus (house mouse) | IC50 | 2.2300 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | IC50 | 3.0895 | 48 | 53 |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0565 | 3 | 3 |
| Glucocorticoid receptor | Homo sapiens (human) | Ki | 0.7813 | 21 | 26 |
| Glucose transporter | Leishmania mexicana | IC50 | 0.1530 | 1 | 2 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | IC50 | 5.1800 | 1 | 1 |
| Glucose-6-phosphate 1-dehydrogenase | Saccharomyces cerevisiae S288C | IC50 | 0.2400 | 1 | 2 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Ki | 22.0924 | 5 | 5 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 57.7333 | 1 | 3 |
| glucose-6-phosphate dehydrogenase | Leuconostoc mesenteroides | IC50 | 25.0000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 46.7860 | 3 | 10 |
| Glutamate dehydrogenase 1, mitochondrial | Bos taurus (cattle) | Ki | 10,000.0000 | 1 | 1 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0140 | 1 | 1 |
| Glutamate receptor 1 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.0140 | 1 | 1 |
| Glutamate receptor 2 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | IC50 | 0.0140 | 1 | 1 |
| Glutamate receptor 3 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 0.0140 | 1 | 1 |
| Glutamate receptor 4 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Ki | 790.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 2.5434 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 92.6000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Glutathione reductase | Saccharomyces cerevisiae S288C | IC50 | 244.9000 | 2 | 2 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | IC50 | 113.0500 | 2 | 2 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | Ki | 14.1000 | 2 | 2 |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | IC50 | 45.7167 | 3 | 3 |
| Glutathione S-transferase P | Homo sapiens (human) | IC50 | 69.0000 | 1 | 1 |
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | IC50 | 5,000.0000 | 1 | 1 |
| Glyceraldehyde-3-phosphate dehydrogenase, glycosomal | Trypanosoma cruzi | IC50 | 142.0000 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 2.2738 | 1 | 6 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 1.0336 | 1 | 6 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 2.2738 | 1 | 6 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 1.0336 | 1 | 6 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 2.2738 | 1 | 6 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 1.0336 | 1 | 6 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | IC50 | 2.2738 | 1 | 6 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | Ki | 1.0336 | 1 | 6 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | IC50 | 4.8000 | 1 | 1 |
| Glycogen phosphorylase, liver form | Rattus norvegicus (Norway rat) | IC50 | 99.0000 | 1 | 1 |
| Glycogen phosphorylase, muscle form | Homo sapiens (human) | IC50 | 0.0012 | 1 | 1 |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | IC50 | 28.1803 | 6 | 14 |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | Ki | 0.1040 | 1 | 1 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | IC50 | 2.7668 | 13 | 17 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | Ki | 0.2310 | 1 | 1 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | IC50 | 8.0737 | 54 | 71 |
| Glycogen synthase kinase-3 beta | Mus musculus (house mouse) | IC50 | 0.0760 | 1 | 1 |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | IC50 | 19.5369 | 3 | 24 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Ki | 0.1270 | 3 | 3 |
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | IC50 | 0.3600 | 1 | 1 |
| Glycoprotein IIb | Oryctolagus cuniculus (rabbit) | IC50 | 0.8500 | 1 | 1 |
| Glycoside hydrolase family 92 | Bacteroides thetaiotaomicron VPI-5482 | Ki | 9.5000 | 2 | 4 |
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | IC50 | 0.0018 | 4 | 5 |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0006 | 3 | 3 |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | Ki | 5,370,320,000,000,000.0000 | 1 | 1 |
| green fluorescent protein, partial | Aequorea victoria | IC50 | 67.5490 | 1 | 2 |
| Growth hormone-releasing hormone receptor | Homo sapiens (human) | IC50 | 0.0001 | 1 | 1 |
| GTPase HRas | Homo sapiens (human) | IC50 | 0.0242 | 3 | 3 |
| GTPase HRas | Homo sapiens (human) | Ki | 0.0016 | 1 | 1 |
| GTPase KRas | Homo sapiens (human) | IC50 | 2.5903 | 14 | 17 |
| GTPase KRas | Homo sapiens (human) | Ki | 48.3000 | 3 | 4 |
| GTPase NRas | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| Guanine deaminase | Homo sapiens (human) | Ki | 1.8800 | 1 | 1 |
| Guanylate cyclase soluble subunit alpha-1 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Guanylate cyclase soluble subunit alpha-2 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Guanylate cyclase soluble subunit beta-1 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Guanylate cyclase soluble subunit beta-2 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| HD2 type histone deacetylase HDA106 | Zea mays | IC50 | 0.2039 | 12 | 13 |
| HD2 type histone deacetylase HDA106 | Zea mays | Ki | 0.1318 | 2 | 2 |
| Heat shock factor protein 1 | Homo sapiens (human) | IC50 | 18.0000 | 2 | 5 |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | IC50 | 0.5507 | 4 | 7 |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | Ki | 0.0390 | 1 | 2 |
| Heat shock protein HSP 90 | Oryctolagus cuniculus (rabbit) | IC50 | 1.1410 | 2 | 2 |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | GI50 | 0.0320 | 1 | 1 |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | IC50 | 12.3881 | 66 | 93 |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | Ki | 0.3057 | 7 | 9 |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | IC50 | 17.3710 | 2 | 3 |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | IC50 | 9.1991 | 47 | 70 |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | Ki | 0.0542 | 6 | 11 |
| Heat-shock protein | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 20.1000 | 1 | 1 |
| Hematopoietic prostaglandin D synthase | Homo sapiens (human) | IC50 | 11.6000 | 2 | 2 |
| Heme oxygenase 1 | Rattus norvegicus (Norway rat) | IC50 | 7.6100 | 3 | 4 |
| Heme oxygenase 2 | Homo sapiens (human) | IC50 | 7.6400 | 1 | 1 |
| Heme oxygenase 2 | Rattus norvegicus (Norway rat) | IC50 | 14.0000 | 2 | 2 |
| Hepatocyte growth factor activator | Homo sapiens (human) | IC50 | 32.0000 | 1 | 1 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 | 3.4435 | 90 | 107 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | Ki | 0.6655 | 4 | 5 |
| hexokinase | Trypanosoma brucei brucei TREU927 | IC50 | 11.6394 | 2 | 2 |
| Hexokinase-2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Hexose transporter 1 | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 0.2080 | 1 | 2 |
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | IC50 | 12.5893 | 1 | 1 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | IC50 | 0.1758 | 19 | 20 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0000 | 1 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0059 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 4.9280 | 2 | 5 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 8.6238 | 1 | 5 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 8.4798 | 1 | 5 |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0010 | 1 | 1 |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | IC50 | 1.3000 | 1 | 2 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.0014 | 1 | 1 |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | IC50 | 0.0014 | 1 | 1 |
| Histidine kinase | Caulobacter vibrioides | IC50 | 17.6500 | 1 | 2 |
| histidine kinase | Streptococcus pneumoniae TIGR4 | IC50 | 216.0000 | 1 | 1 |
| Histone acetyltransferase KAT2B | Homo sapiens (human) | IC50 | 46.2000 | 6 | 6 |
| Histone acetyltransferase KAT5 | Homo sapiens (human) | IC50 | 70.0000 | 2 | 2 |
| Histone acetyltransferase p300 | Homo sapiens (human) | IC50 | 19.5857 | 14 | 14 |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 0.2248 | 3 | 6 |
| Histone deacetylase | Plasmodium falciparum 3D7 | IC50 | 0.1000 | 1 | 1 |
| Histone deacetylase | Rattus norvegicus (Norway rat) | IC50 | 0.7898 | 4 | 10 |
| Histone deacetylase | Zea mays | IC50 | 0.0290 | 2 | 2 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 | 5.3947 | 601 | 837 |
| Histone deacetylase 1 | Mus musculus (house mouse) | IC50 | 0.1120 | 5 | 5 |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.6982 | 5 | 6 |
| Histone deacetylase 1 | Homo sapiens (human) | Ki | 1.8193 | 17 | 34 |
| Histone deacetylase 1 | Mus musculus (house mouse) | Ki | 0.0676 | 1 | 1 |
| Histone deacetylase 11 | Homo sapiens (human) | IC50 | 12.5155 | 224 | 297 |
| Histone deacetylase 11 | Homo sapiens (human) | Ki | 0.6636 | 7 | 10 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 | 7.1755 | 417 | 598 |
| Histone deacetylase 2 | Homo sapiens (human) | Ki | 3.3733 | 16 | 31 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 | 7.5126 | 396 | 585 |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | IC50 | 0.7898 | 4 | 5 |
| Histone deacetylase 3 | Homo sapiens (human) | Ki | 0.3399 | 15 | 30 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 | 17.9658 | 274 | 437 |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | IC50 | 0.7898 | 4 | 5 |
| Histone deacetylase 4 | Homo sapiens (human) | Ki | 4.5833 | 12 | 22 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 | 17.4946 | 234 | 369 |
| Histone deacetylase 5 | Homo sapiens (human) | Ki | 1.2719 | 10 | 20 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 | 9.2324 | 480 | 670 |
| Histone deacetylase 6 | Mus musculus (house mouse) | IC50 | 0.3443 | 5 | 10 |
| Histone deacetylase 6 | Homo sapiens (human) | Ki | 0.3180 | 18 | 35 |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | IC50 | 0.7898 | 4 | 5 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 | 19.6161 | 232 | 368 |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | IC50 | 0.7898 | 4 | 5 |
| Histone deacetylase 7 | Homo sapiens (human) | Ki | 1.1390 | 7 | 16 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 | 9.0260 | 389 | 562 |
| Histone deacetylase 8 | Schistosoma mansoni | IC50 | 5.5530 | 3 | 7 |
| Histone deacetylase 8 | Homo sapiens (human) | Ki | 3.1838 | 16 | 31 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 | 21.1598 | 217 | 316 |
| Histone deacetylase 9 | Homo sapiens (human) | Ki | 0.9805 | 9 | 18 |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | IC50 | 59.5000 | 2 | 2 |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | Ki | 34.1000 | 2 | 3 |
| Histone-arginine methyltransferase CARM1 | Homo sapiens (human) | IC50 | 128.0000 | 1 | 1 |
| Histone-binding protein RBBP4 | Homo sapiens (human) | IC50 | 0.1220 | 2 | 2 |
| Histone-binding protein RBBP4 | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| Histone-binding protein RBBP7 | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Histone-binding protein RBBP7 | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase 2B | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase 2C | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase 2D | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase EHMT1 | Homo sapiens (human) | IC50 | 1.1650 | 1 | 2 |
| Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | IC50 | 24.2000 | 4 | 5 |
| Histone-lysine N-methyltransferase EZH1 | Homo sapiens (human) | IC50 | 0.2400 | 2 | 2 |
| Histone-lysine N-methyltransferase EZH2 | Homo sapiens (human) | IC50 | 1.0255 | 6 | 6 |
| Histone-lysine N-methyltransferase EZH2 | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | IC50 | 25.0333 | 2 | 3 |
| Histone-lysine N-methyltransferase SETMAR | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase SUV39H1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase SUV39H2 | Homo sapiens (human) | IC50 | 123.0000 | 1 | 1 |
| Histone-lysine N-methyltransferase, H3 lysine-79 specific | Homo sapiens (human) | IC50 | 72.0000 | 2 | 2 |
| HLA class II histocompatibility antigen gamma chain | Homo sapiens (human) | IC50 | 0.0021 | 1 | 2 |
| Homeobox protein Nkx-2.5 | Mus musculus (house mouse) | IC50 | 23.0000 | 1 | 2 |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 2 |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 2 |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 2 |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | IC50 | 0.0677 | 2 | 3 |
| hypothetical protein SA1422 | Staphylococcus aureus subsp. aureus N315 | IC50 | 42.9000 | 2 | 2 |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | IC50 | 7.4734 | 20 | 20 |
| Hypoxia-inducible factor 1-alpha inhibitor | Homo sapiens (human) | IC50 | 10.2000 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 | 77.2731 | 13 | 13 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 140.7333 | 1 | 3 |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | Ki | 26.7294 | 12 | 13 |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | IC50 | 17.3000 | 1 | 3 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | IC50 | 12.5301 | 15 | 24 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | Ki | 23.7332 | 18 | 18 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 homolog | Mus musculus (house mouse) | IC50 | 10.1000 | 3 | 3 |
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Homo sapiens (human) | IC50 | 173.3333 | 3 | 3 |
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | IC50 | 90.5867 | 6 | 6 |
| Inosine-5'-monophosphate dehydrogenase | Cryptococcus neoformans var. neoformans JEC21 | IC50 | 0.1200 | 1 | 1 |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | IC50 | 3.3977 | 6 | 6 |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | Ki | 0.0365 | 8 | 8 |
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | IC50 | 1.1421 | 20 | 20 |
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | Ki | 0.0084 | 8 | 8 |
| Inositol hexakisphosphate kinase 2 | Homo sapiens (human) | IC50 | 2.1400 | 1 | 5 |
| Inositol polyphosphate multikinase | Homo sapiens (human) | IC50 | 9.0200 | 1 | 5 |
| Insulin receptor | Homo sapiens (human) | GI50 | 0.6633 | 1 | 3 |
| Insulin receptor | Homo sapiens (human) | IC50 | 15.2632 | 24 | 28 |
| Insulin receptor | Homo sapiens (human) | Ki | 2.6000 | 1 | 1 |
| Insulin receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0200 | 1 | 1 |
| Insulin-degrading enzyme | Homo sapiens (human) | IC50 | 50.0140 | 3 | 4 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | GI50 | 0.6833 | 1 | 3 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 | 125.6666 | 25 | 30 |
| Insulin-like growth factor 1 receptor | Mus musculus (house mouse) | IC50 | 0.0130 | 1 | 1 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Integrase | Human immunodeficiency virus 1 | IC50 | 26.0839 | 19 | 52 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 4.4217 | 2 | 4 |
| Integrin alpha-4 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 | 15.1100 | 1 | 2 |
| Integrin alpha-L | Homo sapiens (human) | IC50 | 2.3767 | 3 | 3 |
| Integrin alpha-V | Homo sapiens (human) | IC50 | 0.0340 | 1 | 1 |
| Integrin beta | Oryctolagus cuniculus (rabbit) | IC50 | 0.8500 | 1 | 1 |
| Integrin beta-1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Integrin beta-2 | Homo sapiens (human) | IC50 | 3.0900 | 2 | 2 |
| Integrin beta-3 | Homo sapiens (human) | IC50 | 10.0847 | 2 | 3 |
| Intercellular adhesion molecule 1 | Homo sapiens (human) | IC50 | 3.7800 | 1 | 1 |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | IC50 | 4.4525 | 2 | 2 |
| Interleukin-1 beta | Homo sapiens (human) | IC50 | 4.4000 | 1 | 1 |
| Interleukin-1 receptor-associated kinase 1 | Homo sapiens (human) | IC50 | 0.3900 | 1 | 1 |
| Interleukin-1 receptor-associated kinase 4 | Homo sapiens (human) | IC50 | 0.5740 | 1 | 1 |
| Interstitial collagenase | Homo sapiens (human) | IC50 | 1.0325 | 33 | 47 |
| Interstitial collagenase | Homo sapiens (human) | Ki | 0.0036 | 8 | 8 |
| intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | IC50 | 8.9350 | 1 | 4 |
| Islet amyloid polypeptide | Homo sapiens (human) | IC50 | 7.8000 | 1 | 1 |
| Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens (human) | IC50 | 23.9619 | 14 | 14 |
| Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens (human) | Ki | 8.8267 | 8 | 9 |
| Isocitrate dehydrogenase [NADP], mitochondrial | Homo sapiens (human) | IC50 | 12.2668 | 10 | 10 |
| Isocitrate lyase 1 | Mycobacterium tuberculosis CDC1551 | IC50 | 17.5000 | 1 | 1 |
| Janus kinase 2 (a protein tyrosine kinase) | Homo sapiens (human) | IC50 | 6.7980 | 1 | 1 |
| Kallikrein-1 | Homo sapiens (human) | IC50 | 34.1000 | 1 | 1 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 107.4090 | 5 | 7 |
| Kappa-type opioid receptor | Homo sapiens (human) | IC50 | 15.5728 | 1 | 4 |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0870 | 3 | 3 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 6.9832 | 2 | 5 |
| kappa-type opioid receptor isoform 1 | Homo sapiens (human) | IC50 | 18.8950 | 2 | 2 |
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Kinesin-1 heavy chain | Homo sapiens (human) | GI50 | 0.0870 | 1 | 1 |
| Kinesin-1 heavy chain | Homo sapiens (human) | IC50 | 0.2000 | 2 | 3 |
| Kinesin-like protein KIF11 | Homo sapiens (human) | IC50 | 6.7902 | 17 | 17 |
| Kinesin-like protein KIFC1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| L-lactate dehydrogenase A chain | Rattus norvegicus (Norway rat) | Ki | 14.3000 | 1 | 1 |
| L-ornithine N(5)-monooxygenase | Aspergillus fumigatus Af293 | IC50 | 11.0000 | 2 | 2 |
| L-selectin | Homo sapiens (human) | IC50 | 27.6000 | 1 | 1 |
| La-related protein 7 | Homo sapiens (human) | Ki | 0.0030 | 1 | 1 |
| Lactoperoxidase | Bos taurus (cattle) | IC50 | 11.9500 | 1 | 2 |
| Lactoylglutathione lyase | Homo sapiens (human) | IC50 | 3.8800 | 4 | 7 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 57.5694 | 4 | 6 |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | IC50 | 115.0000 | 1 | 2 |
| Lanosterol synthase | Homo sapiens (human) | IC50 | 0.0793 | 3 | 3 |
| Large neutral amino acids transporter small subunit 1 | Rattus norvegicus (Norway rat) | Ki | 55.0000 | 1 | 1 |
| large T antigen | Betapolyomavirus macacae | IC50 | 11.8180 | 1 | 5 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 4.4217 | 2 | 4 |
| Lethal factor | Bacillus anthracis | IC50 | 0.0970 | 1 | 1 |
| Leucine-rich repeat serine/threonine-protein kinase 2 | Homo sapiens (human) | IC50 | 5.5235 | 16 | 19 |
| Leucine-rich repeat serine/threonine-protein kinase 2 | Homo sapiens (human) | Ki | 0.0060 | 1 | 1 |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | IC50 | 0.3344 | 3 | 3 |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | Ki | 0.0027 | 1 | 1 |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 | 7.8786 | 2 | 14 |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | IC50 | 3.4700 | 1 | 2 |
| Leukotriene C4 synthase | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| LIM domain kinase 1 | Homo sapiens (human) | IC50 | 4.7832 | 5 | 9 |
| LIM domain kinase 2 | Homo sapiens (human) | IC50 | 5.2593 | 4 | 8 |
| Linoleate 9S-lipoxygenase-4 | Glycine max (soybean) | IC50 | 22.0000 | 1 | 1 |
| Liver carboxylesterase 1 | Homo sapiens (human) | Ki | 51.0243 | 3 | 7 |
| Liver carboxylesterase 1 | Oryctolagus cuniculus (rabbit) | Ki | 55.6500 | 2 | 6 |
| Lon protease homolog, mitochondrial | Homo sapiens (human) | IC50 | 0.1830 | 1 | 1 |
| Low affinity immunoglobulin epsilon Fc receptor | Homo sapiens (human) | IC50 | 0.1000 | 2 | 2 |
| Low molecular weight phosphotyrosine protein phosphatase | Bos taurus (cattle) | IC50 | 10.0000 | 1 | 1 |
| Low molecular weight protein-tyrosine phosphatase A | Mycobacterium tuberculosis H37Rv | IC50 | 4.6500 | 1 | 1 |
| Low-density lipoprotein receptor | Homo sapiens (human) | IC50 | 9.8000 | 1 | 1 |
| Lysine--tRNA ligase | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Lysine-specific demethylase 4A | Homo sapiens (human) | IC50 | 2.5000 | 2 | 2 |
| Lysine-specific demethylase 4B | Homo sapiens (human) | IC50 | 0.7000 | 1 | 2 |
| Lysine-specific demethylase 4C | Homo sapiens (human) | IC50 | 0.6102 | 3 | 4 |
| Lysine-specific demethylase 4E | Homo sapiens (human) | IC50 | 159.5714 | 4 | 7 |
| Lysine-specific demethylase 4E | Homo sapiens (human) | Ki | 3.9400 | 1 | 2 |
| Lysine-specific demethylase 5A | Homo sapiens (human) | IC50 | 3.4200 | 2 | 3 |
| Lysine-specific demethylase 6B | Homo sapiens (human) | IC50 | 0.4000 | 1 | 2 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 | 27.6775 | 24 | 30 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | Ki | 1.1024 | 4 | 4 |
| Lysine-specific histone demethylase 1B | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | IC50 | 128.8000 | 3 | 4 |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | Ki | 4.3500 | 1 | 2 |
| Lysosomal alpha-mannosidase | Homo sapiens (human) | IC50 | 6.6867 | 3 | 3 |
| Lysosomal protective protein | Homo sapiens (human) | IC50 | 19.6000 | 1 | 2 |
| Lysozyme C-1 | Rattus norvegicus (Norway rat) | IC50 | 17.7000 | 1 | 1 |
| Lysyl oxidase homolog 2 | Homo sapiens (human) | IC50 | 0.5354 | 13 | 14 |
| Lysyl oxidase homolog 2 | Mus musculus (house mouse) | IC50 | 0.1280 | 1 | 1 |
| Lysyl oxidase homolog 2 | Rattus norvegicus (Norway rat) | IC50 | 0.1270 | 1 | 1 |
| Lysyl oxidase homolog 3 | Homo sapiens (human) | IC50 | 0.1910 | 2 | 3 |
| Lysyl oxidase homolog 4 | Homo sapiens (human) | IC50 | 50.0295 | 1 | 2 |
| M-phase inducer phosphatase 1 | Homo sapiens (human) | IC50 | 9.4333 | 3 | 6 |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | IC50 | 2.7160 | 3 | 5 |
| M-phase inducer phosphatase 3 | Homo sapiens (human) | IC50 | 18.9000 | 2 | 2 |
| M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 22.8600 | 1 | 1 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 7.3700 | 1 | 1 |
| M18 aspartyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 0.4794 | 1 | 1 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | GI50 | 0.1100 | 1 | 1 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | IC50 | 0.9517 | 33 | 55 |
| Macrophage colony-stimulating factor 1 receptor | Mus musculus (house mouse) | IC50 | 0.2740 | 1 | 2 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| Macrophage metalloelastase | Homo sapiens (human) | IC50 | 9.5772 | 15 | 16 |
| Macrophage migration inhibitory factor | Homo sapiens (human) | IC50 | 3.9126 | 6 | 10 |
| Macrophage migration inhibitory factor | Homo sapiens (human) | Ki | 3.2432 | 5 | 5 |
| Macrophage-expressed gene 1 protein | Homo sapiens (human) | IC50 | 2.9300 | 2 | 4 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | IC50 | 3.4296 | 4 | 7 |
| Macrophage-stimulating protein receptor | Mus musculus (house mouse) | IC50 | 0.0800 | 1 | 1 |
| Malate dehydrogenase | Thermus thermophilus | IC50 | 35.5667 | 1 | 3 |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | IC50 | 6.5017 | 5 | 6 |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | Ki | 6.3667 | 2 | 3 |
| Mannosyl-oligosaccharide alpha-1,2-mannosidase IA | Drosophila melanogaster (fruit fly) | IC50 | 0.0050 | 1 | 1 |
| Mannosyl-oligosaccharide alpha-1,2-mannosidase IA | Drosophila melanogaster (fruit fly) | Ki | 0.0030 | 1 | 1 |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | IC50 | 18.8500 | 4 | 4 |
| MAP kinase-activated protein kinase 3 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | IC50 | 20.9600 | 4 | 5 |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | IC50 | 0.9035 | 2 | 4 |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | IC50 | 0.7102 | 4 | 6 |
| MAP/microtubule affinity-regulating kinase 4 | Homo sapiens (human) | IC50 | 1.7700 | 1 | 1 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | GI50 | 1.7745 | 91 | 180 |
| Mast/stem cell growth factor receptor Kit | Mus musculus (house mouse) | GI50 | 0.1765 | 1 | 2 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 | 6.1758 | 103 | 155 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | Ki | 0.0040 | 1 | 1 |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Matrilysin | Homo sapiens (human) | IC50 | 22.8894 | 12 | 30 |
| Matrilysin | Homo sapiens (human) | Ki | 0.0540 | 1 | 1 |
| Matrix metalloproteinase-14 | Homo sapiens (human) | IC50 | 0.8992 | 18 | 22 |
| Matrix metalloproteinase-15 | Homo sapiens (human) | IC50 | 3.3373 | 3 | 3 |
| Matrix metalloproteinase-16 | Homo sapiens (human) | IC50 | 2.5168 | 4 | 4 |
| Matrix metalloproteinase-17 | Homo sapiens (human) | IC50 | 0.0034 | 1 | 1 |
| Matrix metalloproteinase-20 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Matrix metalloproteinase-24 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Matrix metalloproteinase-25 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Matrix metalloproteinase-26 | Homo sapiens (human) | IC50 | 3.3447 | 3 | 3 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 | 8.7160 | 34 | 43 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | Ki | 0.0048 | 5 | 5 |
| Mcl-1 | Homo sapiens (human) | IC50 | 2.9883 | 1 | 1 |
| Melanocortin receptor 3 | Homo sapiens (human) | IC50 | 19.8560 | 1 | 1 |
| Melanocortin receptor 3 | Homo sapiens (human) | Ki | 17.3290 | 1 | 1 |
| melanocortin receptor 4 | Homo sapiens (human) | IC50 | 54.8937 | 3 | 3 |
| Melanocortin receptor 4 | Homo sapiens (human) | Ki | 29.3080 | 1 | 1 |
| Melanocortin receptor 5 | Homo sapiens (human) | IC50 | 24.0943 | 1 | 3 |
| Melanocortin receptor 5 | Homo sapiens (human) | Ki | 22.6020 | 1 | 3 |
| Melatonin receptor type 1A | Gallus gallus (chicken) | IC50 | 0.0049 | 1 | 1 |
| Melatonin receptor type 1A | Homo sapiens (human) | Ki | 1.9000 | 1 | 1 |
| Melatonin receptor type 1B | Gallus gallus (chicken) | IC50 | 0.0049 | 1 | 1 |
| Melatonin receptor type 1C | Gallus gallus (chicken) | IC50 | 0.0049 | 1 | 1 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | IC50 | 13.4583 | 4 | 12 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | Ki | 6.3351 | 4 | 14 |
| Metabotropic glutamate receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0085 | 2 | 2 |
| Metabotropic glutamate receptor 3 | Rattus norvegicus (Norway rat) | Ki | 10,000.0000 | 1 | 2 |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | IC50 | 1.2000 | 1 | 1 |
| Methionine aminopeptidase 2 | Homo sapiens (human) | IC50 | 0.9604 | 5 | 5 |
| Methionine aminopeptidase 2 | Homo sapiens (human) | Ki | 0.0010 | 2 | 2 |
| microphthalmia-associated transcription factor isoform 9 | Homo sapiens (human) | IC50 | 6.3810 | 3 | 3 |
| Microtubule-associated protein tau | Homo sapiens (human) | IC50 | 32.4375 | 6 | 8 |
| Mineralocorticoid receptor | Homo sapiens (human) | IC50 | 0.4690 | 8 | 8 |
| Mineralocorticoid receptor | Homo sapiens (human) | Ki | 0.0186 | 2 | 2 |
| Misshapen-like kinase 1 | Homo sapiens (human) | IC50 | 0.0220 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 18.5965 | 26 | 32 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | IC50 | 14.9543 | 16 | 42 |
| Mitogen-activated protein kinase 10 | Rattus norvegicus (Norway rat) | IC50 | 6.8000 | 1 | 1 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | IC50 | 12.9227 | 6 | 7 |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | IC50 | 15.0602 | 5 | 6 |
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | IC50 | 15.0602 | 5 | 6 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 22.3307 | 34 | 65 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | IC50 | 3.9772 | 11 | 14 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | IC50 | 6.2453 | 14 | 15 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | IC50 | 1.7791 | 10 | 11 |
| Mitogen-activated protein kinase kinase kinase 1 | Homo sapiens (human) | IC50 | 5.0490 | 2 | 2 |
| Mitogen-activated protein kinase kinase kinase 14 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | IC50 | 5.0234 | 4 | 4 |
| Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (human) | IC50 | 0.0188 | 8 | 9 |
| Mitogen-activated protein kinase kinase kinase 8 | Homo sapiens (human) | IC50 | 9.8567 | 2 | 3 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens (human) | IC50 | 0.0099 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens (human) | IC50 | 0.8745 | 2 | 2 |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | IC50 | 1.5316 | 3 | 10 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens (human) | IC50 | 0.4852 | 2 | 2 |
| MO15-related protein kinase Pfmrk | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 71.8000 | 2 | 5 |
| Monocarboxylate transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 21.0000 | 1 | 2 |
| Monocarboxylate transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 9.5000 | 1 | 2 |
| Monocarboxylate transporter 4 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Monoglyceride lipase | Homo sapiens (human) | IC50 | 0.8095 | 2 | 2 |
| Monoglyceride lipase | Rattus norvegicus (Norway rat) | IC50 | 0.0065 | 1 | 1 |
| MPI protein | Homo sapiens (human) | IC50 | 16.8603 | 2 | 3 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 4.1995 | 3 | 4 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 12.4993 | 2 | 6 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0870 | 3 | 3 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0057 | 4 | 4 |
| Mu-type opioid receptor | Danio rerio (zebrafish) | Ki | 0.6840 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 5.0762 | 2 | 6 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0262 | 3 | 3 |
| Mucin-1 | Homo sapiens (human) | IC50 | 76.0000 | 1 | 1 |
| Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | Homo sapiens (human) | IC50 | 1.5500 | 2 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 42.6585 | 3 | 13 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 14.0512 | 2 | 8 |
| Multidrug resistance associated protein | Homo sapiens (human) | Ki | 1,200.0000 | 1 | 1 |
| Multidrug resistance-associated protein 1 | Rattus norvegicus (Norway rat) | Ki | 0.0597 | 3 | 8 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 | 14.0332 | 7 | 10 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | Ki | 4.3150 | 5 | 8 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 109.5991 | 1 | 77 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.1510 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 4.7077 | 1 | 4 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 0.2045 | 2 | 2 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 5.5955 | 2 | 5 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 7.3665 | 1 | 4 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 3.0526 | 2 | 5 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 9.1310 | 1 | 4 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 5.4479 | 2 | 5 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 4.6672 | 1 | 5 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 1.2060 | 2 | 6 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 1 | 1 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 29.5620 | 1 | 3 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 16.8163 | 2 | 4 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 1 | 1 |
| Myelin transcription factor 1 | Homo sapiens (human) | IC50 | 0.0630 | 1 | 1 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 2.1180 | 4 | 5 |
| Myosin light chain kinase, smooth muscle | Gallus gallus (chicken) | IC50 | 0.2600 | 1 | 1 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | IC50 | 6.2140 | 5 | 5 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | Ki | 1.7000 | 1 | 1 |
| NACHT, LRR and PYD domains-containing protein 3 | Homo sapiens (human) | IC50 | 11.4600 | 4 | 4 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 6.5084 | 5 | 6 |
| NAD | Homo sapiens (human) | IC50 | 5.4667 | 3 | 3 |
| NAD kinase | Homo sapiens (human) | IC50 | 0.9600 | 1 | 1 |
| NAD kinase | Homo sapiens (human) | Ki | 3.2800 | 1 | 1 |
| NAD-dependent protein deacetylase HST2 | Saccharomyces cerevisiae S288C | IC50 | 346.6667 | 1 | 3 |
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | IC50 | 88.9706 | 16 | 18 |
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | IC50 | 21.4400 | 13 | 13 |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| NAD-dependent protein deacetylase sirtuin-3, mitochondrial | Homo sapiens (human) | IC50 | 48.8375 | 4 | 4 |
| NAD-dependent protein deacetylase sirtuin-3, mitochondrial | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| NAD-dependent protein deacetylase sirtuin-7 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | IC50 | 33.4000 | 9 | 11 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] 1 subunit C2 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | Bos taurus (cattle) | IC50 | 0.0051 | 1 | 1 |
| NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 1 | Bos taurus (cattle) | IC50 | 0.0150 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 1 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 2 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 3 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 4 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 4L | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 5 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADH-ubiquinone oxidoreductase chain 6 | Homo sapiens (human) | IC50 | 14.5000 | 2 | 2 |
| NADPH oxidase 4 | Homo sapiens (human) | IC50 | 0.8867 | 1 | 3 |
| NADPH--cytochrome P450 reductase | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| NEDD8 | Homo sapiens (human) | IC50 | 0.0047 | 1 | 1 |
| NEDD8-activating enzyme E1 catalytic subunit | Homo sapiens (human) | IC50 | 0.0033 | 4 | 4 |
| NEDD8-activating enzyme E1 regulatory subunit | Homo sapiens (human) | IC50 | 0.0471 | 4 | 4 |
| NEDD8-conjugating enzyme Ubc12 | Homo sapiens (human) | IC50 | 10.3300 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 | 7.7500 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | IC50 | 229.5000 | 4 | 4 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | Ki | 14.3000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/RI/5+/1957(H2N2)) | IC50 | 11.9000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 | 48.2576 | 4 | 34 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | Ki | 18.5500 | 1 | 4 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 0.6600 | 2 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 0.6600 | 2 | 2 |
| Neuronal proto-oncogene tyrosine-protein kinase Src | Mus musculus (house mouse) | IC50 | 2.2000 | 1 | 1 |
| Neuropilin-1 | Homo sapiens (human) | IC50 | 9.1833 | 6 | 6 |
| Neutrophil collagenase | Homo sapiens (human) | IC50 | 0.8935 | 11 | 12 |
| Neutrophil collagenase | Homo sapiens (human) | Ki | 0.0002 | 2 | 2 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 | 0.3900 | 1 | 1 |
| Neutrophil cytosol factor 1 | Homo sapiens (human) | Ki | 125.0000 | 3 | 3 |
| Neutrophil elastase | Homo sapiens (human) | IC50 | 24.6714 | 9 | 11 |
| Neutrophil elastase | Homo sapiens (human) | Ki | 18.5500 | 2 | 4 |
| NF-kappa-B essential modulator | Homo sapiens (human) | IC50 | 255.0000 | 2 | 2 |
| NF-kappa-B inhibitor alpha | Homo sapiens (human) | IC50 | 27.1000 | 1 | 1 |
| NH(3)-dependent NAD(+) synthetase | Bacillus subtilis subsp. subtilis str. 168 | IC50 | 1.0000 | 1 | 1 |
| Nicastrin | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Nicotinamide phosphoribosyltransferase | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| Nischarin | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 13.7875 | 5 | 8 |
| Nociceptin receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0069 | 1 | 1 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | IC50 | 12.6635 | 13 | 16 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | Ki | 0.0005 | 4 | 4 |
| Non-structural protein 1 | Dengue virus | IC50 | 1.7000 | 1 | 1 |
| nonstructural protein 1 | Influenza A virus (A/California/07/2009(H1N1)) | IC50 | 2.0490 | 1 | 1 |
| NT-3 growth factor receptor | Homo sapiens (human) | IC50 | 0.0100 | 8 | 8 |
| NT-3 growth factor receptor | Homo sapiens (human) | Ki | 0.0460 | 1 | 1 |
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | IC50 | 2.5408 | 4 | 4 |
| Nuclear factor erythroid 2-related factor 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | IC50 | 20.6318 | 6 | 12 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | IC50 | 29.9587 | 10 | 18 |
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | IC50 | 24.3917 | 2 | 6 |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | IC50 | 13.7291 | 2 | 6 |
| Nuclear receptor coactivator 4 | Homo sapiens (human) | IC50 | 0.0100 | 1 | 1 |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | IC50 | 6.4273 | 5 | 5 |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | Ki | 0.0061 | 1 | 2 |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | IC50 | 0.3463 | 48 | 54 |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | Ki | 0.5528 | 5 | 6 |
| nuclear receptor corepressor 2 isoform 2 | Homo sapiens (human) | IC50 | 39.8410 | 1 | 1 |
| Nuclear receptor ROR-alpha | Homo sapiens (human) | IC50 | 0.1995 | 1 | 1 |
| Nuclear receptor ROR-beta | Homo sapiens (human) | IC50 | 12.6224 | 2 | 2 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | IC50 | 0.1995 | 1 | 1 |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | IC50 | 27.0331 | 2 | 9 |
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | IC50 | 14.6000 | 1 | 1 |
| Nuclear receptor subfamily 1 group I member 3 | Homo sapiens (human) | IC50 | 0.3900 | 1 | 1 |
| Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (human) | IC50 | 0.0195 | 2 | 2 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 2.2558 | 1 | 3 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 1.8481 | 1 | 3 |
| Nuclear receptor subfamily 4 group A member 3 | Homo sapiens (human) | IC50 | 0.0780 | 1 | 1 |
| Nucleophosmin | Homo sapiens (human) | IC50 | 22.0427 | 6 | 10 |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | IC50 | 6.4776 | 1 | 2 |
| nucleotide-binding oligomerization domain-containing protein 2 isoform 1 | Homo sapiens (human) | IC50 | 6.2250 | 1 | 1 |
| Olfactory receptor 51E2 | Homo sapiens (human) | IC50 | 0.1600 | 1 | 1 |
| Oligo-1,6-glucosidase IMA1 | Saccharomyces cerevisiae S288C | IC50 | 530.0000 | 1 | 1 |
| Opioid receptor, delta 1b | Danio rerio (zebrafish) | Ki | 0.0450 | 1 | 1 |
| Ornithine decarboxylase | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
| Orotidine 5'-phosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 8.6200 | 3 | 5 |
| Orotidine 5'-phosphate decarboxylase | Saccharomyces cerevisiae S288C | Ki | 0.0640 | 2 | 2 |
| Orotidine 5'-phosphate decarboxylase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 1.0000 | 1 | 1 |
| Oxoeicosanoid receptor 1 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 2 |
| Oxysterols receptor LXR-alpha | Homo sapiens (human) | IC50 | 46.0000 | 3 | 4 |
| Oxysterols receptor LXR-beta | Homo sapiens (human) | IC50 | 48.0000 | 2 | 3 |
| Oxysterols receptor LXR-beta | Homo sapiens (human) | Ki | 45.0000 | 1 | 1 |
| P-selectin | Homo sapiens (human) | IC50 | 19.1000 | 1 | 1 |
| P2X purinoceptor 2 | Rattus norvegicus (Norway rat) | IC50 | 21.9054 | 1 | 2 |
| P2Y purinoceptor 11 | Homo sapiens (human) | Ki | 0.2071 | 2 | 2 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 25.5000 | 1 | 1 |
| P2Y purinoceptor 12 | Homo sapiens (human) | Ki | 15.2800 | 2 | 5 |
| P2Y purinoceptor 2 | Homo sapiens (human) | IC50 | 75.0000 | 2 | 2 |
| P2Y purinoceptor 6 | Homo sapiens (human) | IC50 | 27.0000 | 1 | 1 |
| Pancreatic alpha-amylase | Sus scrofa (pig) | IC50 | 200.0000 | 1 | 2 |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | IC50 | 248.8000 | 5 | 8 |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | IC50 | 0.0042 | 6 | 6 |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | IC50 | 0.0010 | 1 | 1 |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | Ki | 1.3505 | 4 | 4 |
| Peptidyl-prolyl cis-trans isomerase FKBP5 | Homo sapiens (human) | Ki | 0.0030 | 1 | 1 |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | IC50 | 10.4100 | 2 | 2 |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Ki | 0.8200 | 1 | 1 |
| perilipin-1 | Homo sapiens (human) | IC50 | 6.8578 | 1 | 4 |
| perilipin-5 | Homo sapiens (human) | IC50 | 5.6057 | 1 | 4 |
| Peroxiredoxin-like 2A | Homo sapiens (human) | IC50 | 0.9000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 | 1.9051 | 8 | 9 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Ki | 0.7790 | 5 | 6 |
| peroxisome proliferator-activated receptor gamma isoform 2 | Homo sapiens (human) | IC50 | 39.8410 | 1 | 1 |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 | Homo sapiens (human) | IC50 | 121.0411 | 8 | 9 |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | IC50 | 2,071.3392 | 62 | 71 |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | Ki | 0.0002 | 3 | 3 |
| Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | Homo sapiens (human) | IC50 | 13.3000 | 1 | 1 |
| Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 | Homo sapiens (human) | IC50 | 5.5000 | 2 | 2 |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | IC50 | 7.5700 | 4 | 4 |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | IC50 | 6.0866 | 6 | 7 |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha | Homo sapiens (human) | IC50 | 30.1769 | 5 | 7 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta | Homo sapiens (human) | IC50 | 1.0208 | 7 | 13 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | GI50 | 0.0280 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | IC50 | 822.8891 | 147 | 179 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Rattus norvegicus (Norway rat) | IC50 | 0.0612 | 1 | 2 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | Ki | 0.0350 | 4 | 4 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Mus musculus (house mouse) | IC50 | 0.0086 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | GI50 | 0.0280 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | IC50 | 1,315.3923 | 88 | 112 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Rattus norvegicus (Norway rat) | IC50 | 0.2665 | 1 | 2 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | Ki | 0.0003 | 2 | 2 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | GI50 | 0.0280 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | IC50 | 994.9737 | 111 | 148 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | Ki | 0.0000 | 2 | 2 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | GI50 | 0.0280 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | IC50 | 1,263.5118 | 96 | 117 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Mus musculus (house mouse) | IC50 | 1.3020 | 1 | 1 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | Ki | 0.0003 | 2 | 2 |
| Phosphodiesterase | Rattus norvegicus (Norway rat) | IC50 | 275.0000 | 1 | 1 |
| Phosphodiesterase isozyme 4 | Homo sapiens (human) | IC50 | 125.0000 | 1 | 1 |
| phosphoethanolamine/phosphocholine phosphatase isoform 1 | Homo sapiens (human) | IC50 | 0.1110 | 1 | 1 |
| Phosphoglycerate mutase 1 | Homo sapiens (human) | IC50 | 2.5200 | 3 | 4 |
| Phosphoinositide 3-kinase regulatory subunit 5 | Homo sapiens (human) | IC50 | 0.0972 | 4 | 4 |
| Phospholipase A-2-activating protein | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| Phospholipase A2 | Homo sapiens (human) | IC50 | 6.5500 | 2 | 2 |
| phospholipase A2, group III | Homo sapiens (human) | IC50 | 121.7940 | 1 | 1 |
| Phospholipase D1 | Homo sapiens (human) | IC50 | 15.5000 | 2 | 3 |
| Phospholipase D1 | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 1 |
| Phospholipase D2 | Homo sapiens (human) | IC50 | 13.2500 | 1 | 2 |
| phosphomannomutase 2 | Homo sapiens (human) | IC50 | 0.6720 | 1 | 1 |
| Phosphotyrosine protein phosphatase | Mycobacterium tuberculosis | IC50 | 5.2540 | 1 | 2 |
| photoreceptor-specific nuclear receptor | Homo sapiens (human) | IC50 | 20.8810 | 2 | 2 |
| Pirin | Homo sapiens (human) | IC50 | 8.1340 | 1 | 5 |
| Plasma kallikrein | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Plasminogen | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Plasminogen | Rattus norvegicus (Norway rat) | IC50 | 2.6200 | 1 | 1 |
| Plasminogen activator inhibitor 1 | Homo sapiens (human) | IC50 | 3.3455 | 1 | 2 |
| Platelet glycoprotein VI | Homo sapiens (human) | IC50 | 0.6650 | 1 | 2 |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | IC50 | 0.5020 | 2 | 2 |
| Platelet-activating factor receptor | Cavia porcellus (domestic guinea pig) | IC50 | 200.0000 | 1 | 1 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | GI50 | 1.0034 | 6 | 12 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 | 14.7057 | 40 | 42 |
| Platelet-derived growth factor receptor alpha | Rattus norvegicus (Norway rat) | IC50 | 30.2500 | 4 | 4 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| Platelet-derived growth factor receptor alpha | Mus musculus (house mouse) | IC50 | 7.9200 | 10 | 12 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | GI50 | 0.0566 | 3 | 5 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 | 15.4079 | 84 | 130 |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | IC50 | 9.3868 | 16 | 26 |
| Platelet-derived growth factor receptor beta | Rattus norvegicus (Norway rat) | IC50 | 24.2324 | 5 | 5 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | Ki | 0.0090 | 2 | 2 |
| Platelet-derived growth factor subunit A | Homo sapiens (human) | IC50 | 0.6100 | 1 | 1 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | IC50 | 1.0475 | 86 | 128 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | Ki | 0.0016 | 7 | 7 |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | IC50 | 0.1607 | 31 | 48 |
| Poly [ADP-ribose] polymerase 2 | Mus musculus (house mouse) | IC50 | 0.0405 | 1 | 2 |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | Ki | 0.0024 | 2 | 2 |
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | IC50 | 6.8766 | 14 | 28 |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | IC50 | 2.5503 | 9 | 22 |
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 | 51.5750 | 2 | 4 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 | 11.1630 | 218 | 300 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | Ki | 0.6153 | 6 | 9 |
| Polycomb protein EED | Homo sapiens (human) | IC50 | 0.1220 | 2 | 2 |
| Polycomb protein EED | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| Polycomb protein SUZ12 | Homo sapiens (human) | IC50 | 0.1220 | 2 | 2 |
| Polycomb protein SUZ12 | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| Polymerase acidic protein | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 | 5.8600 | 1 | 1 |
| Polypeptide N-acetylgalactosaminyltransferase 2 | Homo sapiens (human) | IC50 | 1.3700 | 1 | 1 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 241.6592 | 11 | 13 |
| Polyphenol oxidase 2 | Agaricus bisporus | Ki | 0.0600 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 8.6038 | 35 | 43 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 32.9193 | 12 | 16 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | Ki | 0.0229 | 3 | 8 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | IC50 | 42.3618 | 5 | 11 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Ki | 1.6000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | IC50 | 34.6331 | 7 | 13 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 9.9962 | 3 | 11 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | Ki | 0.6000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | IC50 | 60.2227 | 4 | 11 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Rattus norvegicus (Norway rat) | IC50 | 0.2600 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 3,256.7494 | 6 | 6 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 181.2724 | 7 | 7 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 2,192.9748 | 55 | 69 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 1.5289 | 3 | 5 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 181.2724 | 7 | 7 |
| Presenilin-1 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Presenilin-2 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | IC50 | 5.0667 | 2 | 3 |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | Ki | 4.3500 | 1 | 2 |
| Procathepsin L | Homo sapiens (human) | IC50 | 5.0095 | 2 | 4 |
| Procathepsin L | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
| procathepsin L isoform 1 preproprotein | Homo sapiens (human) | IC50 | 25.1129 | 2 | 2 |
| Progesterone receptor | Homo sapiens (human) | IC50 | 16.3276 | 14 | 16 |
| Progesterone receptor | Homo sapiens (human) | Ki | 2.5336 | 15 | 15 |
| Programmed cell death 1 ligand 1 | Homo sapiens (human) | IC50 | 50.0050 | 2 | 2 |
| Programmed cell death protein 1 | Homo sapiens (human) | IC50 | 50.0050 | 2 | 2 |
| Programmed cell death protein 4 | Homo sapiens (human) | IC50 | 0.8800 | 1 | 1 |
| Prolyl 4-hydroxylase subunit alpha-1 | Gallus gallus (chicken) | Ki | 21.6667 | 1 | 3 |
| Prolyl endopeptidase | Homo sapiens (human) | IC50 | 60.0500 | 4 | 6 |
| Proprotein convertase subtilisin/kexin type 9 | Homo sapiens (human) | IC50 | 9.8000 | 1 | 1 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Ki | 3.5000 | 1 | 1 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 5.5908 | 32 | 41 |
| Prostaglandin E synthase | Mus musculus (house mouse) | IC50 | 0.0070 | 1 | 1 |
| Prostaglandin E synthase 2 | Homo sapiens (human) | IC50 | 1.6000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 112.9166 | 22 | 40 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 32.6850 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 47.3540 | 32 | 43 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | Ki | 0.0030 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 30.5168 | 5 | 6 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 30.0400 | 4 | 5 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 18.6351 | 57 | 81 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 3.3496 | 11 | 17 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 28.1625 | 7 | 8 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 5.0000 | 1 | 2 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 0.0006 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 30.0400 | 4 | 5 |
| Prostate-specific antigen | Homo sapiens (human) | IC50 | 0.1300 | 1 | 1 |
| Protease | Human immunodeficiency virus 1 | IC50 | 47.0801 | 6 | 6 |
| Protease | Human immunodeficiency virus 1 | Ki | 0.0134 | 21 | 21 |
| Proteasomal ubiquitin receptor ADRM1 | Homo sapiens (human) | IC50 | 0.4285 | 4 | 5 |
| Proteasome subunit alpha type-1 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-2 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-3 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-4 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-5 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-6 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha type-7 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit alpha-type 8 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit beta type-1 | Homo sapiens (human) | IC50 | 1.5159 | 25 | 35 |
| Proteasome subunit beta type-1 | Saccharomyces cerevisiae S288C | IC50 | 1.0000 | 1 | 1 |
| Proteasome subunit beta type-10 | Homo sapiens (human) | IC50 | 0.3161 | 15 | 20 |
| Proteasome subunit beta type-11 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit beta type-2 | Homo sapiens (human) | IC50 | 2.8439 | 27 | 39 |
| Proteasome subunit beta type-2 | Saccharomyces cerevisiae S288C | IC50 | 1.0000 | 1 | 1 |
| Proteasome subunit beta type-3 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit beta type-4 | Homo sapiens (human) | IC50 | 0.1835 | 12 | 14 |
| Proteasome subunit beta type-5 | Homo sapiens (human) | IC50 | 5,846.6228 | 55 | 89 |
| Proteasome subunit beta type-5 | Homo sapiens (human) | Ki | 0.0067 | 3 | 3 |
| Proteasome subunit beta type-6 | Homo sapiens (human) | IC50 | 0.2178 | 13 | 16 |
| Proteasome subunit beta type-7 | Homo sapiens (human) | IC50 | 0.9613 | 13 | 16 |
| Proteasome subunit beta type-8 | Homo sapiens (human) | IC50 | 0.1007 | 21 | 28 |
| Proteasome subunit beta type-8 | Mus musculus (house mouse) | IC50 | 0.0168 | 1 | 1 |
| Proteasome subunit beta type-9 | Homo sapiens (human) | IC50 | 0.3643 | 17 | 22 |
| Protein arginine N-methyltransferase 1 | Homo sapiens (human) | IC50 | 283.6075 | 4 | 4 |
| Protein arginine N-methyltransferase 3 | Homo sapiens (human) | IC50 | 74.0000 | 1 | 1 |
| Protein arginine N-methyltransferase 5 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | IC50 | 7.2078 | 6 | 11 |
| Protein cereblon | Homo sapiens (human) | Ki | 9.2633 | 2 | 3 |
| Protein DBF4 homolog A | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Protein delta homolog 1 | Homo sapiens (human) | Ki | 0.0063 | 1 | 1 |
| Protein disulfide-isomerase | Homo sapiens (human) | Ki | 36.1000 | 1 | 1 |
| Protein E6 | Human papillomavirus 16 | IC50 | 8.2833 | 1 | 3 |
| Protein farnesyltransferase alpha subunit | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 0.1335 | 1 | 2 |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | IC50 | 0.0138 | 6 | 9 |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | IC50 | 12.9474 | 32 | 40 |
| Protein farnesyltransferase subunit beta | Rattus norvegicus (Norway rat) | IC50 | 0.9972 | 3 | 3 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | IC50 | 2.1577 | 11 | 16 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | IC50 | 14.5253 | 41 | 51 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 0.8483 | 5 | 5 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 | 39.1520 | 16 | 25 |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C alpha type | Homo sapiens (human) | Ki | 0.0031 | 3 | 3 |
| Protein kinase C beta type | Homo sapiens (human) | IC50 | 35.9568 | 12 | 13 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | IC50 | 72.2500 | 4 | 4 |
| Protein kinase C beta type | Homo sapiens (human) | Ki | 0.0018 | 1 | 1 |
| Protein kinase C delta type | Homo sapiens (human) | IC50 | 12.5367 | 11 | 11 |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C delta type | Homo sapiens (human) | Ki | 0.0008 | 3 | 3 |
| Protein kinase C epsilon type | Homo sapiens (human) | IC50 | 38.1501 | 9 | 10 |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C epsilon type | Homo sapiens (human) | Ki | 0.0004 | 1 | 1 |
| Protein kinase C eta type | Homo sapiens (human) | IC50 | 15.7502 | 8 | 8 |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C gamma type | Homo sapiens (human) | IC50 | 17.2857 | 7 | 7 |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C gamma type | Homo sapiens (human) | Ki | 0.0049 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | IC50 | 13.5000 | 6 | 6 |
| Protein kinase C theta type | Homo sapiens (human) | IC50 | 21.2224 | 9 | 9 |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| Protein kinase C theta type | Homo sapiens (human) | Ki | 0.0610 | 1 | 1 |
| Protein kinase C zeta type | Homo sapiens (human) | IC50 | 18.7143 | 7 | 7 |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 3 | 3 |
| protein Mdm4 isoform 1 | Homo sapiens (human) | IC50 | 3.5800 | 1 | 1 |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | IC50 | 3.9116 | 2 | 16 |
| Protein mono-ADP-ribosyltransferase PARP12 | Homo sapiens (human) | IC50 | 4.3584 | 1 | 8 |
| Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | IC50 | 7.5248 | 1 | 6 |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | IC50 | 19.1538 | 2 | 10 |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | IC50 | 5.1143 | 1 | 2 |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | IC50 | 0.4784 | 6 | 13 |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | IC50 | 0.5587 | 2 | 8 |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | IC50 | 1.8000 | 1 | 1 |
| Protein Tat | Human immunodeficiency virus type 1 (CLONE 12) | IC50 | 4.0000 | 2 | 2 |
| Protein tyrosine phosphatase type IVA 3 | Homo sapiens (human) | IC50 | 23.0750 | 4 | 4 |
| Protein Wnt-3a | Homo sapiens (human) | IC50 | 0.0070 | 1 | 1 |
| protein Wnt-3a precursor | Mus musculus (house mouse) | IC50 | 50.0000 | 1 | 1 |
| Protein-arginine deiminase type-1 | Homo sapiens (human) | IC50 | 48.3000 | 1 | 1 |
| Protein-arginine deiminase type-2 | Homo sapiens (human) | IC50 | 26.1000 | 1 | 1 |
| Protein-arginine deiminase type-3 | Homo sapiens (human) | IC50 | 0.4300 | 1 | 1 |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | IC50 | 4,101.0000 | 3 | 5 |
| Protein-glutamine gamma-glutamyltransferase 2 | Homo sapiens (human) | IC50 | 8.0000 | 1 | 3 |
| Protein-lysine 6-oxidase | Bos taurus (cattle) | IC50 | 1.9953 | 1 | 1 |
| Protein-lysine 6-oxidase | Homo sapiens (human) | IC50 | 25.3550 | 3 | 4 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | IC50 | 0.0740 | 2 | 2 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | Ki | 0.0140 | 1 | 1 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | IC50 | 30.2953 | 6 | 9 |
| Prothrombin | Homo sapiens (human) | IC50 | 12.3163 | 6 | 6 |
| Prothrombin | Homo sapiens (human) | Ki | 4.8052 | 2 | 7 |
| Prothrombin | Bos taurus (cattle) | IC50 | 19.1933 | 3 | 6 |
| Prothrombin | Bos taurus (cattle) | Ki | 3.9000 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | IC50 | 0.0004 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | Ki | 0.0001 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | GI50 | 0.2669 | 13 | 13 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | IC50 | 1.3032 | 71 | 102 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | Ki | 0.0015 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | IC50 | 0.3845 | 24 | 32 |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | Ki | 0.4988 | 6 | 16 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | GI50 | 0.8568 | 1 | 3 |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | IC50 | 8.1717 | 14 | 25 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 | 8.0142 | 102 | 153 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Ki | 17.1667 | 6 | 6 |
| Proton-coupled folate transporter | Homo sapiens (human) | IC50 | 0.0516 | 5 | 8 |
| Proton-coupled folate transporter | Homo sapiens (human) | Ki | 0.6776 | 7 | 7 |
| Pteridine reductase 1 | Leishmania major | Ki | 0.1095 | 2 | 2 |
| Puromycin-sensitive aminopeptidase | Homo sapiens (human) | IC50 | 6.0750 | 2 | 2 |
| Putative alpha-1,2-mannosidase | Bacteroides thetaiotaomicron VPI-5482 | Ki | 9.5000 | 2 | 26 |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | IC50 | 0.4600 | 1 | 2 |
| Pyruvate kinase PKM | Homo sapiens (human) | IC50 | 38.4975 | 4 | 4 |
| Pyruvate kinase PKM | Homo sapiens (human) | Ki | 3.5300 | 1 | 1 |
| Quinolone resistance protein NorA | Staphylococcus aureus | IC50 | 10.6000 | 1 | 2 |
| Quinone oxidoreductase | Homo sapiens (human) | IC50 | 8.4400 | 1 | 1 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 | 48.8800 | 1 | 3 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 14.6434 | 19 | 21 |
| RAC-alpha serine/threonine-protein kinase | Rattus norvegicus (Norway rat) | IC50 | 6.9700 | 1 | 1 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | Ki | 0.0010 | 2 | 2 |
| RAC-alpha serine/threonine-protein kinase | Mus musculus (house mouse) | IC50 | 0.0220 | 1 | 1 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 8.6742 | 7 | 9 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | Ki | 0.0040 | 2 | 2 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 8.3403 | 4 | 6 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | Ki | 0.0130 | 1 | 1 |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 0.7912 | 44 | 58 |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | Ki | 0.0020 | 4 | 5 |
| Rapamycin-insensitive companion of mTOR | Homo sapiens (human) | IC50 | 0.0280 | 5 | 7 |
| Receptor protein-tyrosine kinase | Homo sapiens (human) | IC50 | 3.6874 | 3 | 14 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 | 1.8298 | 135 | 207 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | Ki | 0.0318 | 3 | 3 |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | GI50 | 0.0040 | 1 | 1 |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | IC50 | 0.8038 | 16 | 24 |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | Ki | 0.0318 | 3 | 3 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | IC50 | 0.5298 | 36 | 54 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | Ki | 0.0318 | 3 | 3 |
| Receptor-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | IC50 | 8.1666 | 7 | 7 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | IC50 | 0.6396 | 6 | 6 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 | 28.1920 | 1 | 2 |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | IC50 | 2.9550 | 4 | 5 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | GI50 | 0.6655 | 13 | 19 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | IC50 | 0.9504 | 130 | 188 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | Ki | 0.0060 | 2 | 2 |
| Receptor-type tyrosine-protein phosphatase epsilon | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Receptor-type tyrosine-protein phosphatase eta | Homo sapiens (human) | IC50 | 33.8750 | 2 | 4 |
| Receptor-type tyrosine-protein phosphatase F | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| Receptor-type tyrosine-protein phosphatase S | Homo sapiens (human) | IC50 | 10.7000 | 1 | 3 |
| Reduced folate transporter | Homo sapiens (human) | IC50 | 0.0611 | 5 | 8 |
| Reduced folate transporter | Homo sapiens (human) | Ki | 3.5000 | 1 | 1 |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | IC50 | 27.9338 | 5 | 5 |
| Regulatory protein RhlR | Pseudomonas aeruginosa PAO1 | IC50 | 945.0000 | 1 | 1 |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | IC50 | 0.0963 | 9 | 13 |
| Renin | Homo sapiens (human) | IC50 | 25.4900 | 2 | 2 |
| Renin | Macaca fascicularis (crab-eating macaque) | IC50 | 0.0670 | 1 | 1 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | IC50 | 66.5440 | 2 | 5 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 12.3950 | 3 | 16 |
| Replicase polyprotein 1ab | Human coronavirus 229E | IC50 | 66.5440 | 2 | 5 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 12.4982 | 37 | 88 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 46.1941 | 10 | 39 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 11.3775 | 1 | 4 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 13.3183 | 3 | 6 |
| REST corepressor 3 | Homo sapiens (human) | Ki | 0.0030 | 1 | 1 |
| Reticulon-4 | Homo sapiens (human) | IC50 | 14.6100 | 1 | 1 |
| Retinal dehydrogenase 1 | Homo sapiens (human) | IC50 | 0.1300 | 1 | 1 |
| Retinoic acid receptor alpha | Homo sapiens (human) | IC50 | 1.1473 | 5 | 8 |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | IC50 | 0.2096 | 3 | 5 |
| Retinoic acid receptor alpha | Homo sapiens (human) | Ki | 0.7361 | 5 | 8 |
| retinoic acid receptor alpha isoform 1 | Homo sapiens (human) | IC50 | 0.0084 | 1 | 1 |
| Retinoic acid receptor beta | Homo sapiens (human) | IC50 | 0.5045 | 4 | 6 |
| Retinoic acid receptor beta | Mus musculus (house mouse) | IC50 | 0.3367 | 2 | 3 |
| Retinoic acid receptor beta | Homo sapiens (human) | Ki | 0.6847 | 5 | 8 |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | IC50 | 0.3360 | 2 | 3 |
| Retinoic acid receptor gamma | Homo sapiens (human) | IC50 | 0.0124 | 3 | 5 |
| Retinoic acid receptor gamma | Homo sapiens (human) | Ki | 0.3784 | 6 | 10 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 14.2655 | 4 | 6 |
| Retinoic acid receptor RXR-alpha | Mus musculus (house mouse) | IC50 | 20.8164 | 3 | 5 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | Ki | 1.0582 | 13 | 18 |
| retinoic acid receptor RXR-alpha isoform a | Homo sapiens (human) | IC50 | 0.0189 | 1 | 1 |
| Retinoic acid receptor RXR-beta | Homo sapiens (human) | IC50 | 0.6707 | 1 | 3 |
| Retinoic acid receptor RXR-beta | Mus musculus (house mouse) | IC50 | 50.0000 | 1 | 2 |
| Retinoic acid receptor RXR-beta | Homo sapiens (human) | Ki | 0.4203 | 6 | 9 |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | IC50 | 0.4513 | 1 | 3 |
| Retinoic acid receptor RXR-gamma | Mus musculus (house mouse) | IC50 | 50.0000 | 2 | 2 |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | Ki | 0.7205 | 6 | 9 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 117.6275 | 7 | 12 |
| Rho guanine nucleotide exchange factor 12 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | IC50 | 0.2285 | 2 | 4 |
| Rho-associated protein kinase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0080 | 1 | 3 |
| Rho-associated protein kinase 2 | Homo sapiens (human) | IC50 | 1.2700 | 1 | 1 |
| Ribonuclease pancreatic | Bos taurus (cattle) | IC50 | 300.0000 | 1 | 1 |
| Ribonucleoside-diphosphate reductase large subunit | Homo sapiens (human) | IC50 | 997.0000 | 1 | 1 |
| Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | IC50 | 4.4879 | 4 | 7 |
| Ribosomal protein S6 kinase alpha-3 | Homo sapiens (human) | IC50 | 10.0920 | 1 | 2 |
| Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | IC50 | 1.9910 | 2 | 4 |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| Ribosomal protein S6 kinase beta-2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | IC50 | 1.1537 | 5 | 7 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | Ki | 0.0390 | 1 | 1 |
| RmtA | Aspergillus nidulans | IC50 | 5.9000 | 1 | 1 |
| RNA polymerase beta subunit (EC 2.7.7.6), partial | Escherichia coli | IC50 | 11.6872 | 1 | 1 |
| RNA-directed RNA polymerase | | IC50 | 29.4000 | 2 | 2 |
| RuvB-like 1 | Homo sapiens (human) | IC50 | 38.0000 | 2 | 2 |
| RuvB-like 2 | Homo sapiens (human) | IC50 | 66.0000 | 1 | 1 |
| S-adenosylmethionine decarboxylase proenzyme | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| S-adenosylmethionine decarboxylase proenzyme | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| SAFB-like transcription modulator | Homo sapiens (human) | IC50 | 0.0013 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Oryctolagus cuniculus (rabbit) | IC50 | 22.8243 | 7 | 7 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Rattus norvegicus (Norway rat) | IC50 | 28.6500 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Oryctolagus cuniculus (rabbit) | Ki | 5.8000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Homo sapiens (human) | IC50 | 27.0000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Homo sapiens (human) | Ki | 53.0000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Mus musculus (house mouse) | IC50 | 27.0000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Rattus norvegicus (Norway rat) | Ki | 5.8000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Homo sapiens (human) | Ki | 8.6000 | 1 | 1 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 20.8143 | 4 | 7 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | Ki | 106.5250 | 2 | 4 |
| Sentrin-specific protease 1 | Homo sapiens (human) | IC50 | 2.7325 | 4 | 4 |
| Sentrin-specific protease 2 | Homo sapiens (human) | IC50 | 6.9000 | 1 | 1 |
| Sentrin-specific protease 6 | Homo sapiens (human) | IC50 | 5.2000 | 1 | 1 |
| sentrin-specific protease 8 | Homo sapiens (human) | IC50 | 1.8500 | 2 | 2 |
| Serine hydrolase RBBP9 | Homo sapiens (human) | IC50 | 7.8000 | 1 | 1 |
| Serine hydroxymethyltransferase, cytosolic | Homo sapiens (human) | Ki | 79.2333 | 3 | 3 |
| Serine hydroxymethyltransferase, mitochondrial | Homo sapiens (human) | IC50 | 2.5704 | 1 | 1 |
| Serine palmitoyltransferase 2 | Homo sapiens (human) | IC50 | 0.0001 | 1 | 1 |
| Serine protease hepsin | Homo sapiens (human) | IC50 | 0.0235 | 2 | 2 |
| Serine protease hepsin | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
| Serine-protein kinase ATM | Homo sapiens (human) | IC50 | 8.8035 | 2 | 2 |
| Serine/threonine-protein kinase 10 | Homo sapiens (human) | IC50 | 0.0520 | 1 | 1 |
| Serine/threonine-protein kinase 24 | Homo sapiens (human) | IC50 | 0.0039 | 1 | 1 |
| Serine/threonine-protein kinase 26 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase 4 | Homo sapiens (human) | IC50 | 0.1910 | 1 | 1 |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | IC50 | 0.2023 | 5 | 11 |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | IC50 | 5.7100 | 2 | 2 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | GI50 | 0.5070 | 2 | 2 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | IC50 | 0.8342 | 136 | 195 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | Ki | 0.0105 | 8 | 10 |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | IC50 | 0.0650 | 4 | 4 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | IC50 | 93.5795 | 6 | 6 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase Chk2 | Homo sapiens (human) | IC50 | 10.0084 | 2 | 2 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | IC50 | 13.0000 | 7 | 7 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | IC50 | 13.5000 | 6 | 6 |
| Serine/threonine-protein kinase LMTK3 | Homo sapiens (human) | IC50 | 3.9070 | 1 | 2 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | IC50 | 2.0701 | 86 | 124 |
| Serine/threonine-protein kinase mTOR | Rattus norvegicus (Norway rat) | IC50 | 0.0450 | 1 | 1 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | Ki | 0.0484 | 3 | 5 |
| Serine/threonine-protein kinase mTOR | Mus musculus (house mouse) | IC50 | 0.2780 | 3 | 3 |
| Serine/threonine-protein kinase N1 | Homo sapiens (human) | IC50 | 5.8000 | 1 | 1 |
| Serine/threonine-protein kinase N2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | IC50 | 6.0013 | 3 | 3 |
| Serine/threonine-protein kinase Nek6 | Homo sapiens (human) | IC50 | 7.1150 | 2 | 2 |
| Serine/threonine-protein kinase NIM1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | IC50 | 8.2500 | 2 | 2 |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | IC50 | 2.7871 | 4 | 4 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | Ki | 0.5000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 5 | Homo sapiens (human) | IC50 | 0.0520 | 1 | 1 |
| Serine/threonine-protein kinase PAK 5 | Homo sapiens (human) | Ki | 0.5000 | 1 | 1 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | IC50 | 0.0060 | 1 | 1 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | Ki | 0.5000 | 1 | 1 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | IC50 | 12.1285 | 14 | 23 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | IC50 | 22.7658 | 15 | 24 |
| Serine/threonine-protein kinase PLK1 | Xenopus laevis (African clawed frog) | IC50 | 21.4000 | 2 | 2 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Ki | 13.2069 | 2 | 21 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | IC50 | 112.9067 | 3 | 3 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | Ki | 13.3672 | 1 | 20 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | IC50 | 62.6084 | 14 | 14 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | Ki | 13.3672 | 1 | 20 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | IC50 | 0.0450 | 3 | 3 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Ki | 11.6242 | 4 | 23 |
| Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | IC50 | 0.0270 | 1 | 1 |
| Serine/threonine-protein kinase SIK1 | Homo sapiens (human) | IC50 | 0.4605 | 2 | 2 |
| Serine/threonine-protein kinase SIK1 | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| Serine/threonine-protein kinase SIK2 | Homo sapiens (human) | IC50 | 118.8213 | 5 | 5 |
| Serine/threonine-protein kinase SIK3 | Homo sapiens (human) | IC50 | 4.8025 | 2 | 2 |
| Serine/threonine-protein kinase STK11 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | IC50 | 0.8062 | 2 | 5 |
| Serine/threonine-protein kinase TNNI3K | Homo sapiens (human) | IC50 | 0.1750 | 2 | 2 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | IC50 | 1.8840 | 1 | 5 |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | IC50 | 30.5730 | 1 | 1 |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 2,352.8750 | 1 | 4 |
| Short transient receptor potential channel 5 | Homo sapiens (human) | IC50 | 9.1250 | 1 | 4 |
| Sialidase | Clostridium perfringens | IC50 | 8.5496 | 6 | 14 |
| Sialidase | Clostridium perfringens | Ki | 2.6280 | 4 | 7 |
| Sialidase-2 | Homo sapiens (human) | IC50 | 366.6667 | 1 | 9 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 667.0000 | 2 | 3 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.0014 | 2 | 2 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | Ki | 0.0136 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | IC50 | 5.0183 | 3 | 4 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.0210 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0073 | 5 | 6 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.0129 | 7 | 7 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 7.1855 | 2 | 2 |
| Signal transducer and activator of transcription 1-alpha/beta | Homo sapiens (human) | IC50 | 9.1000 | 1 | 1 |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | IC50 | 11.2600 | 5 | 5 |
| Signal transducer and activator of transcription 3 | Mus musculus (house mouse) | IC50 | 100.0000 | 1 | 1 |
| Signal transducer and activator of transcription 5A | Homo sapiens (human) | IC50 | 9.4000 | 1 | 1 |
| Signal transducer and activator of transcription 5B | Homo sapiens (human) | IC50 | 10.4000 | 1 | 1 |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | IC50 | 35.7175 | 23 | 48 |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | Ki | 3.2000 | 1 | 2 |
| Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | IC50 | 0.8800 | 3 | 3 |
| Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | Ki | 0.2210 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | IC50 | 0.8800 | 3 | 3 |
| Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | Ki | 0.2210 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 3 | Homo sapiens (human) | IC50 | 1.6500 | 2 | 2 |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | IC50 | 125.6600 | 4 | 4 |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | Ki | 0.1805 | 2 | 2 |
| Smoothened homolog | Homo sapiens (human) | IC50 | 0.0222 | 8 | 8 |
| Smoothened homolog | Mus musculus (house mouse) | IC50 | 0.0627 | 8 | 9 |
| Smoothened homolog | Homo sapiens (human) | Ki | 0.0337 | 2 | 5 |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | IC50 | 1.2000 | 1 | 1 |
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 925.2454 | 14 | 14 |
| Sodium- and chloride-dependent betaine transporter | Mus musculus (house mouse) | IC50 | 170.4120 | 1 | 2 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Mus musculus (house mouse) | IC50 | 389.0225 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 33.3338 | 2 | 3 |
| Sodium- and chloride-dependent GABA transporter 2 | Mus musculus (house mouse) | IC50 | 269.5765 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Mus musculus (house mouse) | IC50 | 250.0945 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 7.7715 | 6 | 8 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0410 | 2 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 6.1078 | 1 | 10 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 4.8521 | 1 | 10 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 10.8747 | 1 | 10 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 9.8069 | 2 | 11 |
| Sodium-dependent phosphate transport protein 2B | Homo sapiens (human) | IC50 | 0.0256 | 1 | 2 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 4.8991 | 2 | 8 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 0.3312 | 6 | 6 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 2.9734 | 1 | 7 |
| Sodium/bile acid cotransporter | Homo sapiens (human) | IC50 | 109.0000 | 1 | 1 |
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | IC50 | 12.4000 | 1 | 1 |
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | Ki | 86.0000 | 1 | 1 |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | IC50 | 18.3000 | 1 | 1 |
| Sodium/hydrogen exchanger 1 | Rattus norvegicus (Norway rat) | Ki | 0.0130 | 2 | 2 |
| Sodium/hydrogen exchanger 3 | Rattus norvegicus (Norway rat) | Ki | 2.4000 | 2 | 2 |
| Sodium/hydrogen exchanger 5 | Homo sapiens (human) | Ki | 0.3700 | 2 | 2 |
| Sodium/hydrogen exchanger 9B2 | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | IC50 | 12,210.0000 | 1 | 1 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| Solute carrier family 15 member 1 | Rattus norvegicus (Norway rat) | Ki | 5,100.0000 | 1 | 2 |
| Solute carrier family 15 member 2 | Homo sapiens (human) | IC50 | 28.0000 | 1 | 1 |
| Solute carrier family 15 member 2 | Rattus norvegicus (Norway rat) | Ki | 148.0000 | 1 | 2 |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | IC50 | 7.2763 | 2 | 3 |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | Ki | 7.0000 | 3 | 3 |
| Solute carrier family 2, facilitated glucose transporter member 2 | Homo sapiens (human) | IC50 | 12.0000 | 2 | 4 |
| Solute carrier family 2, facilitated glucose transporter member 4 | Mus musculus (house mouse) | IC50 | 6.8383 | 2 | 3 |
| Solute carrier family 2, facilitated glucose transporter member 4 | Mus musculus (house mouse) | Ki | 60.0000 | 1 | 1 |
| Solute carrier family 2, facilitated glucose transporter member 4 | Rattus norvegicus (Norway rat) | Ki | 24.7500 | 1 | 2 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 21.8000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 27.5078 | 4 | 9 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 3.7000 | 1 | 1 |
| Solute carrier family 22 member 12 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Solute carrier family 22 member 12 | Rattus norvegicus (Norway rat) | IC50 | 18.0000 | 1 | 1 |
| Solute carrier family 22 member 12 | Homo sapiens (human) | Ki | 5.7400 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 32.1857 | 2 | 7 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 599.7800 | 1 | 2 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | IC50 | 33.8000 | 2 | 5 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 60.0000 | 1 | 1 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 896.1255 | 1 | 2 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 32.0000 | 1 | 1 |
| Solute carrier family 28 member 3 | Homo sapiens (human) | Ki | 32.2800 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 16.9500 | 2 | 2 |
| Solute carrier organic anion transporter family member 1A2 | Homo sapiens (human) | Ki | 51.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 1.4300 | 2 | 2 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 10.8364 | 9 | 11 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 12.4557 | 4 | 7 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 | 18.8400 | 4 | 10 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 9.9533 | 8 | 15 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | IC50 | 23.3500 | 2 | 3 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | Ki | 29.8100 | 2 | 3 |
| Somatostatin receptor type 1 | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
| Somatostatin receptor type 1 | Homo sapiens (human) | Ki | 0.0063 | 1 | 1 |
| Somatostatin receptor type 2 | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
| Somatostatin receptor type 2 | Homo sapiens (human) | Ki | 0.0010 | 1 | 1 |
| Somatostatin receptor type 3 | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
| Somatostatin receptor type 3 | Homo sapiens (human) | Ki | 0.0008 | 1 | 1 |
| Somatostatin receptor type 4 | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
| Somatostatin receptor type 4 | Homo sapiens (human) | Ki | 0.1000 | 1 | 1 |
| Somatostatin receptor type 5 | Homo sapiens (human) | IC50 | 0.0022 | 1 | 1 |
| Somatostatin receptor type 5 | Homo sapiens (human) | Ki | 0.0001 | 1 | 1 |
| Sonic hedgehog protein | Homo sapiens (human) | IC50 | 0.8825 | 2 | 2 |
| Sonic hedgehog protein | Mus musculus (house mouse) | IC50 | 1.0057 | 3 | 5 |
| Sorbitol dehydrogenase | Homo sapiens (human) | IC50 | 121.8667 | 3 | 3 |
| Sortase A | Streptococcus mutans | IC50 | 18.7000 | 1 | 2 |
| Sphingomyelin phosphodiesterase | Bos taurus (cattle) | IC50 | 14.1000 | 1 | 1 |
| Sphingomyelin phosphodiesterase | Homo sapiens (human) | IC50 | 19.4200 | 2 | 2 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | IC50 | 0.4305 | 7 | 8 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | Ki | 0.2117 | 1 | 5 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | IC50 | 1.2602 | 8 | 9 |
| Sphingosine 1-phosphate receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.0200 | 1 | 1 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | Ki | 0.2117 | 1 | 5 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | IC50 | 2.4025 | 4 | 5 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | Ki | 0.2117 | 1 | 5 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | IC50 | 2.7575 | 3 | 4 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | Ki | 0.2117 | 1 | 5 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | IC50 | 1.0336 | 2 | 3 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | Ki | 0.2117 | 1 | 5 |
| Sphingosine kinase 1 | Homo sapiens (human) | IC50 | 7.1000 | 1 | 1 |
| Sphingosine kinase 2 | Homo sapiens (human) | IC50 | 766.0000 | 1 | 1 |
| Sphingosine-1-phosphate lyase 1 | Homo sapiens (human) | IC50 | 34.5000 | 2 | 2 |
| Sphingosine-1-phosphate lyase 1 | Mus musculus (house mouse) | IC50 | 52.4000 | 1 | 1 |
| Spike glycoprotein | Betacoronavirus England 1 | IC50 | 6.6733 | 1 | 3 |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | IC50 | 102.8000 | 2 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.6733 | 1 | 3 |
| Squalene monooxygenase | Rattus norvegicus (Norway rat) | IC50 | 15.2900 | 3 | 5 |
| Squalene--hopene cyclase | Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446 | IC50 | 0.0600 | 1 | 1 |
| SRSF protein kinase 1 | Homo sapiens (human) | IC50 | 0.1950 | 1 | 1 |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | IC50 | 2.2827 | 26 | 29 |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | IC50 | 0.0674 | 4 | 4 |
| Steroid 21-hydroxylase | Homo sapiens (human) | IC50 | 0.1642 | 2 | 2 |
| Steroid hormone receptor ERR1 | Homo sapiens (human) | IC50 | 0.0707 | 2 | 3 |
| Steroid hormone receptor ERR2 | Homo sapiens (human) | IC50 | 0.3950 | 1 | 1 |
| steroidogenic factor 1 | Homo sapiens (human) | IC50 | 67.5446 | 1 | 7 |
| Sterol O-acyltransferase 1 | Homo sapiens (human) | IC50 | 47.6500 | 4 | 4 |
| Sterol O-acyltransferase 1 | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 1 |
| Sterol O-acyltransferase 2 | Homo sapiens (human) | IC50 | 58.4000 | 2 | 2 |
| Steryl-sulfatase | Homo sapiens (human) | IC50 | 25.5004 | 2 | 2 |
| Stimulator of interferon genes protein | Homo sapiens (human) | IC50 | 108.6667 | 3 | 3 |
| Stimulator of interferon genes protein | Mus musculus (house mouse) | IC50 | 1.2000 | 1 | 1 |
| Stromelysin-1 | Homo sapiens (human) | IC50 | 9.6625 | 25 | 35 |
| Stromelysin-1 | Homo sapiens (human) | Ki | 0.0291 | 8 | 8 |
| Stromelysin-2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Structural capsid protein | Human immunodeficiency virus 1 | IC50 | 0.0467 | 1 | 1 |
| Substance-K receptor | Cavia porcellus (domestic guinea pig) | IC50 | 50.9600 | 1 | 10 |
| Substance-K receptor | Homo sapiens (human) | IC50 | 11.5872 | 1 | 8 |
| Substance-K receptor | Homo sapiens (human) | Ki | 3.8623 | 1 | 8 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 50.9600 | 1 | 10 |
| Substance-P receptor | Homo sapiens (human) | IC50 | 15.6560 | 1 | 1 |
| Substance-P receptor | Homo sapiens (human) | Ki | 8.5400 | 1 | 1 |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | IC50 | 20.4400 | 4 | 5 |
| Sucrase-isomaltase, intestinal | Rattus norvegicus (Norway rat) | IC50 | 156.0000 | 2 | 2 |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | Ki | 4.3500 | 1 | 2 |
| Sulfhydryl oxidase 1 | Homo sapiens (human) | IC50 | 5.4000 | 1 | 1 |
| SUMO-activating enzyme subunit 1 | Homo sapiens (human) | IC50 | 4.6000 | 2 | 2 |
| SUMO-activating enzyme subunit 2 | Homo sapiens (human) | IC50 | 4.6000 | 2 | 2 |
| SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | IC50 | 11.2000 | 2 | 2 |
| SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | IC50 | 11.2000 | 2 | 2 |
| Synaptic vesicle membrane protein VAT-1 homolog | Homo sapiens (human) | IC50 | 4.5100 | 2 | 2 |
| Synaptic vesicular amine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.0263 | 3 | 4 |
| Synaptojanin-1 | Homo sapiens (human) | IC50 | 8.4500 | 2 | 4 |
| Synaptojanin-2 | Homo sapiens (human) | IC50 | 2.2100 | 3 | 6 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Target of rapamycin complex 2 subunit MAPKAP1 | Homo sapiens (human) | IC50 | 0.0280 | 5 | 7 |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | IC50 | 0.0724 | 14 | 20 |
| Taste receptor type 2 member 31 | Homo sapiens (human) | IC50 | 11.3000 | 1 | 1 |
| Tat | Human immunodeficiency virus 1 | IC50 | 42.1290 | 1 | 1 |
| Telomerase reverse transcriptase | Homo sapiens (human) | IC50 | 40.5240 | 10 | 10 |
| Telomere resolvase ResT | Borreliella burgdorferi B31 | IC50 | 8.6700 | 1 | 1 |
| Testis-specific serine/threonine-protein kinase 1 | Homo sapiens (human) | IC50 | 0.0230 | 1 | 1 |
| Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | IC50 | 46.9400 | 3 | 8 |
| Testosterone 17-beta-dehydrogenase 3 | Rattus norvegicus (Norway rat) | IC50 | 0.0028 | 2 | 3 |
| TGF-beta receptor type-1 | Homo sapiens (human) | IC50 | 0.3755 | 13 | 13 |
| TGF-beta receptor type-1 | Mus musculus (house mouse) | IC50 | 0.1000 | 1 | 1 |
| TGF-beta receptor type-2 | Homo sapiens (human) | IC50 | 1.2500 | 2 | 2 |
| TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | Homo sapiens (human) | IC50 | 0.0140 | 4 | 4 |
| Thermolysin | Bacillus thermoproteolyticus | IC50 | 425.6667 | 3 | 3 |
| Thioredoxin glutathione reductase | Schistosoma mansoni | IC50 | 2.0100 | 1 | 1 |
| Thioredoxin reductase 1, cytoplasmic | Homo sapiens (human) | IC50 | 97.6750 | 5 | 8 |
| Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus (Norway rat) | IC50 | 73.4860 | 4 | 5 |
| Thioredoxin reductase 2, mitochondrial | Homo sapiens (human) | IC50 | 97.6750 | 5 | 8 |
| Thioredoxin reductase 2, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 166.0000 | 1 | 2 |
| Thioredoxin reductase 3 | Homo sapiens (human) | IC50 | 97.6750 | 5 | 8 |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | IC50 | 51.2480 | 2 | 10 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 10.3077 | 3 | 9 |
| Thymidine kinase | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 | 750.0000 | 1 | 2 |
| Thymidine kinase | Human alphaherpesvirus 1 strain SC16 | IC50 | 1,000.0000 | 1 | 1 |
| Thymidine kinase | Human herpesvirus 3 strain Dumas | IC50 | 833.3333 | 2 | 3 |
| Thymidine kinase | Macacine alphaherpesvirus 1 | IC50 | 451.0000 | 1 | 2 |
| Thymidine kinase 2, mitochondrial | Homo sapiens (human) | IC50 | 833.3333 | 2 | 3 |
| Thymidine kinase, cytosolic | Homo sapiens (human) | IC50 | 833.3333 | 2 | 3 |
| Thymidine kinase, cytosolic | Homo sapiens (human) | Ki | 15.0300 | 2 | 2 |
| Thymidine phosphorylase | Escherichia coli K-12 | IC50 | 0.0227 | 5 | 5 |
| Thymidine phosphorylase | Homo sapiens (human) | IC50 | 0.0311 | 12 | 12 |
| Thymidine phosphorylase | Escherichia coli K-12 | Ki | 0.0350 | 1 | 1 |
| Thymidine phosphorylase | Homo sapiens (human) | Ki | 0.0115 | 9 | 9 |
| Thymidylate kinase | Homo sapiens (human) | Ki | 214.0000 | 1 | 1 |
| Thymidylate kinase | Mycobacterium tuberculosis H37Rv | Ki | 220.6667 | 2 | 3 |
| Thymidylate synthase | Escherichia coli K-12 | IC50 | 11.4303 | 3 | 12 |
| Thymidylate synthase | Homo sapiens (human) | IC50 | 24.5031 | 28 | 43 |
| Thymidylate synthase | Lacticaseibacillus casei | IC50 | 121.2143 | 14 | 14 |
| Thymidylate synthase | Mus musculus (house mouse) | IC50 | 6.4061 | 16 | 22 |
| Thymidylate synthase | Homo sapiens (human) | Ki | 0.2356 | 4 | 4 |
| Thymidylate synthase | Lacticaseibacillus casei | Ki | 0.5500 | 1 | 1 |
| Thymidylate synthase | Mus musculus (house mouse) | Ki | 22.6700 | 2 | 2 |
| Thymidylate synthase | Escherichia coli | IC50 | 110.6812 | 13 | 16 |
| Thymidylate synthase | Escherichia coli LF82 | IC50 | 47.0000 | 1 | 2 |
| Thymidylate synthase | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 1 |
| Thyroid hormone receptor beta | Rattus norvegicus (Norway rat) | Ki | 0.0630 | 1 | 2 |
| Tissue alpha-L-fucosidase | Bos taurus (cattle) | IC50 | 37.5000 | 1 | 4 |
| Tissue factor | Homo sapiens (human) | IC50 | 23.5033 | 4 | 4 |
| Tissue-type plasminogen activator | Homo sapiens (human) | IC50 | 5.5637 | 2 | 3 |
| Toll-like receptor 2 | Mus musculus (house mouse) | IC50 | 69.2500 | 1 | 1 |
| Toll-like receptor 4 | Homo sapiens (human) | IC50 | 1.0400 | 1 | 1 |
| toll-like receptor 9 | Homo sapiens (human) | IC50 | 8.3620 | 1 | 1 |
| Toxin B | Clostridioides difficile | IC50 | 0.0172 | 1 | 1 |
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 | 41.7467 | 4 | 6 |
| TPA: protein transporter TIM23 | Saccharomyces cerevisiae S288C | IC50 | 3.5950 | 2 | 2 |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 | 28.5740 | 3 | 7 |
| Transcription factor 4 | Homo sapiens (human) | IC50 | 0.8000 | 1 | 1 |
| Transcription factor 7-like 2 | Homo sapiens (human) | Ki | 95.1000 | 7 | 7 |
| Transcription factor AP-1 | Homo sapiens (human) | IC50 | 0.0400 | 1 | 1 |
| Transcription factor ETV6 | Homo sapiens (human) | IC50 | 1.6292 | 2 | 2 |
| Transcription factor GATA-4 | Mus musculus (house mouse) | IC50 | 23.0000 | 1 | 2 |
| Transcription factor MafK | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
| Transcription factor p65 | Homo sapiens (human) | IC50 | 12.9233 | 14 | 26 |
| Transcription factor SOX-18 | Mus musculus (house mouse) | IC50 | 163.0000 | 2 | 2 |
| Transcription regulator protein BACH1 | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
| Transcriptional activator Myb | Gallus gallus (chicken) | IC50 | 16.7319 | 1 | 10 |
| Transcriptional activator protein LasR | Pseudomonas aeruginosa PAO1 | IC50 | 0.6400 | 1 | 1 |
| Transcriptional activator protein LuxR | Aliivibrio fischeri | IC50 | 40.0000 | 1 | 1 |
| Transient receptor potential cation channel subfamily A member 1 | Homo sapiens (human) | IC50 | 125.9465 | 1 | 2 |
| Transient receptor potential cation channel subfamily A member 1 | Rattus norvegicus (Norway rat) | IC50 | 46.7000 | 2 | 2 |
| Transient receptor potential cation channel subfamily M member 8 | Mus musculus (house mouse) | IC50 | 8.0000 | 2 | 2 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | IC50 | 28.5000 | 4 | 4 |
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0010 | 2 | 3 |
| Transient receptor potential cation channel subfamily V member 2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Transitional endoplasmic reticulum ATPase | Homo sapiens (human) | IC50 | 3.4188 | 4 | 4 |
| Translation factor GUF1, mitochondrial | Saccharomyces cerevisiae S288C | IC50 | 300.0000 | 1 | 1 |
| Translocator protein | Homo sapiens (human) | IC50 | 0.1645 | 3 | 3 |
| Translocator protein | Rattus norvegicus (Norway rat) | IC50 | 0.0082 | 12 | 14 |
| Translocator protein | Homo sapiens (human) | Ki | 0.0206 | 7 | 7 |
| Translocator protein | Rattus norvegicus (Norway rat) | Ki | 0.0048 | 14 | 14 |
| Transmembrane domain-containing protein TMIGD3 | Homo sapiens (human) | Ki | 0.0160 | 1 | 1 |
| Transmembrane protease serine 2 | Homo sapiens (human) | IC50 | 5.0095 | 2 | 4 |
| Transmembrane protease serine 2 | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
| Transmembrane protease serine 6 | Homo sapiens (human) | IC50 | 0.0180 | 1 | 1 |
| Transmembrane protease serine 6 | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
| Transporter | Rattus norvegicus (Norway rat) | IC50 | 0.4500 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 0.0001 | 1 | 1 |
| Transthyretin | Homo sapiens (human) | IC50 | 55.0250 | 2 | 8 |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | IC50 | 6.2726 | 7 | 8 |
| Trifunctional purine biosynthetic protein adenosine-3 | Mus musculus (house mouse) | IC50 | 20.0000 | 5 | 5 |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | Ki | 0.6112 | 4 | 4 |
| Triosephosphate isomerase | Oryctolagus cuniculus (rabbit) | Ki | 34.7525 | 1 | 4 |
| Trypanothione reductase | Trypanosoma cruzi | IC50 | 41.5000 | 2 | 4 |
| Trypsin | Sus scrofa (pig) | IC50 | 200.0000 | 1 | 1 |
| Trypsin-1 | Homo sapiens (human) | IC50 | 149.3943 | 5 | 8 |
| Trypsin-2 | Homo sapiens (human) | IC50 | 170.7291 | 4 | 7 |
| Trypsin-3 | Homo sapiens (human) | IC50 | 170.7291 | 4 | 7 |
| Tryptophan 2,3-dioxygenase | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | Ki | 0.0130 | 1 | 1 |
| Tubulin alpha-1A chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-1A chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin alpha-1A chain | Sus scrofa (pig) | IC50 | 2.6720 | 17 | 25 |
| Tubulin alpha-1A chain | Sus scrofa (pig) | Ki | 2.1800 | 1 | 1 |
| Tubulin alpha-1B chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-1B chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin alpha-1C chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-1C chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin alpha-3C chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-3C chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin alpha-3E chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-3E chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin alpha-4A chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin alpha-4A chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta chain | Sus scrofa (pig) | IC50 | 2.7162 | 13 | 21 |
| Tubulin beta chain | Sus scrofa (pig) | Ki | 2.1800 | 1 | 1 |
| Tubulin beta-1 chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-1 chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-2A chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-2A chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-2B chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-2B chain | Bos taurus (cattle) | IC50 | 470.9934 | 30 | 32 |
| Tubulin beta-2B chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-2B chain | Bos taurus (cattle) | Ki | 3.2000 | 1 | 1 |
| Tubulin beta-3 chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-3 chain | Homo sapiens (human) | IC50 | 18.2966 | 25 | 29 |
| Tubulin beta-4A chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-4A chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-4B chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-4B chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-6 chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-6 chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| Tubulin beta-8 chain | Homo sapiens (human) | GI50 | 0.0053 | 3 | 3 |
| Tubulin beta-8 chain | Homo sapiens (human) | IC50 | 20.4069 | 22 | 26 |
| tumor necrosis factor | Homo sapiens (human) | IC50 | 3.5298 | 2 | 2 |
| Type IV secretion-like conjugative transfer relaxase protein TraI | Escherichia coli SMS-3-5 | Ki | 0.0030 | 1 | 2 |
| type-1 angiotensin II receptor | Homo sapiens (human) | IC50 | 12.6380 | 1 | 2 |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | IC50 | 0.0073 | 1 | 1 |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | Ki | 1.7000 | 1 | 1 |
| Type-2 restriction enzyme BamHI | Bacillus amyloliquefaciens | IC50 | 300.0000 | 1 | 1 |
| Type-2 restriction enzyme EcoRI | Escherichia coli | IC50 | 300.0000 | 1 | 1 |
| Type-2 restriction enzyme HindIII | Haemophilus influenzae Rd KW20 | IC50 | 300.0000 | 1 | 1 |
| Type-2 restriction enzyme PstI | Providencia stuartii | IC50 | 300.0000 | 1 | 1 |
| Type-2 restriction enzyme ScaI | Streptomyces caespitosus | IC50 | 300.0000 | 1 | 1 |
| Tyrosinase | Homo sapiens (human) | IC50 | 29.5567 | 6 | 6 |
| Tyrosinase | Mus musculus (house mouse) | IC50 | 335.0767 | 1 | 3 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | GI50 | 1.5279 | 30 | 95 |
| Tyrosine-protein kinase ABL1 | Mus musculus (house mouse) | GI50 | 0.0010 | 1 | 1 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 | 24.6695 | 182 | 295 |
| Tyrosine-protein kinase ABL1 | Mus musculus (house mouse) | IC50 | 6.8751 | 4 | 7 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Ki | 1.0129 | 7 | 7 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | IC50 | 13.8050 | 6 | 8 |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | GI50 | 3.8512 | 2 | 4 |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | IC50 | 0.1082 | 9 | 10 |
| Tyrosine-protein kinase Blk | Mus musculus (house mouse) | IC50 | 0.0076 | 1 | 2 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | IC50 | 0.4386 | 115 | 126 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | Ki | 0.1466 | 3 | 3 |
| Tyrosine-protein kinase BTK | Mus musculus (house mouse) | IC50 | 2.5000 | 1 | 1 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | IC50 | 16.3526 | 11 | 24 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | IC50 | 0.2466 | 2 | 2 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | Ki | 0.0033 | 1 | 1 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | IC50 | 0.1820 | 2 | 2 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | Ki | 0.0060 | 1 | 1 |
| Tyrosine-protein kinase Fgr | Homo sapiens (human) | IC50 | 85.3254 | 6 | 6 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | IC50 | 0.6216 | 6 | 9 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | Ki | 0.0530 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 17.9596 | 15 | 21 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | GI50 | 4.6130 | 1 | 3 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | IC50 | 3.6801 | 7 | 20 |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | IC50 | 4.6670 | 17 | 20 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | GI50 | 8.9270 | 1 | 1 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | IC50 | 0.4431 | 34 | 37 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | Ki | 0.0002 | 3 | 3 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | GI50 | 5.0345 | 2 | 2 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | IC50 | 9.1743 | 55 | 60 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | Ki | 0.1324 | 4 | 4 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | IC50 | 76.7319 | 42 | 48 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | Ki | 2.5024 | 4 | 4 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | GI50 | 2.8428 | 2 | 4 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 21.4622 | 40 | 44 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | Ki | 0.0900 | 2 | 2 |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | IC50 | 4.2359 | 13 | 13 |
| Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | IC50 | 11.1000 | 1 | 1 |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | IC50 | 2.1233 | 3 | 3 |
| Tyrosine-protein kinase receptor TYRO3 | Homo sapiens (human) | IC50 | 5.0500 | 2 | 2 |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | IC50 | 0.2995 | 29 | 29 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | IC50 | 12.7681 | 9 | 15 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | Ki | 5.0000 | 2 | 2 |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | IC50 | 0.0650 | 12 | 14 |
| Tyrosine-protein kinase transforming protein Abl | Abelson murine leukemia virus | Ki | 10.0000 | 1 | 1 |
| Tyrosine-protein kinase transforming protein Fps | Fujinami sarcoma virus | Ki | 1.8000 | 1 | 1 |
| Tyrosine-protein kinase TXK | Homo sapiens (human) | IC50 | 0.0983 | 6 | 8 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | IC50 | 29.6094 | 13 | 17 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | Ki | 3.5840 | 1 | 3 |
| Tyrosine-protein kinase ZAP-70 | Homo sapiens (human) | IC50 | 26.0800 | 5 | 5 |
| Tyrosine-protein kinase ZAP-70 | Homo sapiens (human) | Ki | 8.2000 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 | 26.1819 | 19 | 21 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Ki | 4.2333 | 2 | 3 |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | IC50 | 70.1400 | 4 | 5 |
| Tyrosine-protein phosphatase non-receptor type 12 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | IC50 | 20.4233 | 3 | 3 |
| Tyrosine-protein phosphatase non-receptor type 22 | Homo sapiens (human) | IC50 | 14.9700 | 1 | 1 |
| tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 | 1.2950 | 2 | 2 |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | IC50 | 23.6333 | 3 | 3 |
| Tyrosine-protein phosphatase non-receptor type 7 | Homo sapiens (human) | IC50 | 75.7000 | 1 | 1 |
| tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 | 1.2400 | 1 | 1 |
| Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens (human) | IC50 | 6,055.3333 | 3 | 3 |
| Tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | IC50 | 55.9850 | 2 | 2 |
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | IC50 | 31.4000 | 1 | 5 |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | IC50 | 31.4000 | 1 | 5 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | IC50 | 74.5000 | 2 | 6 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Mus musculus (house mouse) | IC50 | 180.5000 | 1 | 2 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | IC50 | 42.7143 | 3 | 7 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Mus musculus (house mouse) | IC50 | 180.5000 | 1 | 2 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | IC50 | 31.4000 | 1 | 5 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 13.8392 | 2 | 4 |
| Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | IC50 | 11.2000 | 2 | 2 |
| Ubiquitin-like modifier-activating enzyme 1 | Mus musculus (house mouse) | IC50 | 1.5000 | 1 | 1 |
| Ubiquitin-like modifier-activating enzyme 6 | Homo sapiens (human) | IC50 | 1.4000 | 2 | 2 |
| Ubiquitin-like modifier-activating enzyme ATG7 | Homo sapiens (human) | IC50 | 5.5000 | 2 | 2 |
| UDP-glucose 4-epimerase | Homo sapiens (human) | IC50 | 37.5070 | 1 | 2 |
| UDP-glucose 6-dehydrogenase | Rattus norvegicus (Norway rat) | Ki | 288.0000 | 1 | 1 |
| UDP-glucose 6-dehydrogenase | Streptococcus pyogenes | Ki | 199.5000 | 2 | 2 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 111.2111 | 1 | 9 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 106.2250 | 3 | 16 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Ki | 39.7333 | 3 | 3 |
| UDP-glucuronosyltransferase 1A1 | Rattus norvegicus (Norway rat) | Ki | 100.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A10 | Homo sapiens (human) | Ki | 164.6500 | 2 | 2 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 100.5620 | 2 | 10 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Ki | 101.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A8 | Homo sapiens (human) | Ki | 23.0000 | 2 | 2 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 534.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 111.2111 | 1 | 9 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 111.2111 | 1 | 9 |
| UDP-N-acetylglucosamine 1-carboxyvinyltransferase | Escherichia coli K-12 | IC50 | 50.0000 | 1 | 4 |
| UDP-N-acetylglucosamine 1-carboxyvinyltransferase | Pseudomonas aeruginosa PAO1 | IC50 | 50.0000 | 1 | 4 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Urease | Canavalia ensiformis (jack bean) | Ki | 25.6600 | 1 | 1 |
| Urease subunit alpha | Helicobacter pylori 26695 | IC50 | 495.0460 | 8 | 15 |
| Urease subunit alpha | Helicobacter pylori 26695 | Ki | 4.7830 | 2 | 2 |
| Urease subunit beta | Helicobacter pylori 26695 | IC50 | 495.0460 | 8 | 15 |
| Urease subunit beta | Helicobacter pylori 26695 | Ki | 4.7830 | 2 | 2 |
| Uridine 5'-monophosphate synthase | Homo sapiens (human) | Ki | 0.0170 | 1 | 1 |
| Urokinase-type plasminogen activator | Homo sapiens (human) | IC50 | 17.0239 | 4 | 8 |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | IC50 | 3.3455 | 1 | 2 |
| Urokinase-type plasminogen activator | Homo sapiens (human) | Ki | 1.3560 | 1 | 1 |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | Ki | 9.3080 | 1 | 1 |
| Valosin-containing protein | Homo sapiens (human) | IC50 | 9.6700 | 3 | 3 |
| Vascular endothelial growth factor receptor 1 | Mus musculus (house mouse) | IC50 | 1.0400 | 1 | 1 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 | 1.6413 | 55 | 87 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | Ki | 0.0310 | 2 | 2 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | GI50 | 5.0250 | 4 | 6 |
| Vascular endothelial growth factor receptor 2 | Danio rerio (zebrafish) | IC50 | 0.7432 | 2 | 5 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 | 4.9653 | 300 | 465 |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | IC50 | 0.1849 | 5 | 11 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | Ki | 0.1882 | 9 | 10 |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | Ki | 0.0280 | 1 | 1 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | IC50 | 0.4881 | 26 | 39 |
| Vascular endothelial growth factor receptor 3 | Mus musculus (house mouse) | IC50 | 0.1112 | 2 | 8 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | Ki | 0.0170 | 1 | 1 |
| Vasopressin V1a receptor | Homo sapiens (human) | IC50 | 25.9250 | 1 | 1 |
| Vasopressin V1a receptor | Homo sapiens (human) | Ki | 10.4010 | 1 | 1 |
| Vasopressin V2 receptor | Homo sapiens (human) | IC50 | 20.3282 | 3 | 6 |
| Vif | Human immunodeficiency virus 1 | IC50 | 10.8200 | 1 | 1 |
| Virulence sensor histidine kinase PhoQ | Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 | IC50 | 261.0000 | 1 | 1 |
| Vitamin D3 receptor | Bos taurus (cattle) | IC50 | 0.0000 | 1 | 1 |
| Vitamin D3 receptor | Homo sapiens (human) | IC50 | 0.3401 | 19 | 19 |
| Vitamin D3 receptor | Rattus norvegicus (Norway rat) | Ki | 0.0001 | 11 | 11 |
| Vitamin K-dependent protein C | Homo sapiens (human) | IC50 | 2.0433 | 4 | 27 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 1,728.8805 | 13 | 13 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | IC50 | 52.3000 | 3 | 3 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | IC50 | 52.3000 | 3 | 3 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 35.4250 | 4 | 4 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 35.4250 | 4 | 4 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 35.4250 | 4 | 4 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | IC50 | 52.3000 | 3 | 3 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 8.0000 | 3 | 3 |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) | IC50 | 2.0000 | 2 | 2 |
| von Hippel-Lindau disease tumor suppressor | Homo sapiens (human) | IC50 | 0.0020 | 2 | 2 |
| WD repeat-containing protein 48 | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | IC50 | 26.8733 | 10 | 15 |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | IC50 | 171.9380 | 10 | 25 |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | Ki | 1.5500 | 1 | 2 |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | Ki | 1.2333 | 2 | 3 |
| XBP1 | Homo sapiens (human) | IC50 | 2.4300 | 1 | 1 |
| Zinc finger protein AEBP2 | Homo sapiens (human) | IC50 | 0.2400 | 1 | 1 |
| Zinc finger protein GLI1 | Homo sapiens (human) | IC50 | 26.1650 | 3 | 4 |
| Zinc finger protein GLI1 | Mus musculus (house mouse) | IC50 | 5.0000 | 1 | 1 |
| Zinc finger protein GLI2 | Mus musculus (house mouse) | IC50 | 5.0000 | 1 | 1 |
| Zinc metalloproteinase dpy-31 | Brugia malayi | IC50 | 199.5260 | 1 | 1 |
| Zinc metalloproteinase dpy-31 | Teladorsagia circumcincta | IC50 | 79.4328 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial | Homo sapiens (human) | EC50 | 0.0030 | 1 | 1 |
| 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase | Escherichia coli K-12 | Kd | 18.0000 | 1 | 1 |
| 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | Escherichia coli K-12 | Kd | 40,000.0000 | 1 | 1 |
| 26S proteasome regulatory subunit 6B | Homo sapiens (human) | Kd | 30.0000 | 1 | 78 |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Homo sapiens (human) | Kd | 0.0010 | 1 | 1 |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | Kd | 9.0373 | 4 | 60 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | EC50 | 0.0130 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Homo sapiens (human) | Kd | 19.3608 | 6 | 139 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Homo sapiens (human) | EC50 | 3.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Homo sapiens (human) | Kd | 8.8545 | 3 | 59 |
| 5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | EC50 | 3.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | EC50 | 3.0000 | 1 | 1 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | Kd | 28.5220 | 1 | 78 |
| 5'-AMP-activated protein kinase subunit gamma-2 | Homo sapiens (human) | Kd | 28.2206 | 1 | 77 |
| 7-dehydrocholesterol reductase | Homo sapiens (human) | Kd | 0.0010 | 1 | 1 |
| AarF domain-containing protein kinase 1 | Homo sapiens (human) | Kd | 29.0340 | 1 | 76 |
| Actin-related protein 2 | Homo sapiens (human) | Kd | 29.5834 | 1 | 72 |
| Actin-related protein 3 | Homo sapiens (human) | Kd | 29.2928 | 1 | 77 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | Kd | 18.9288 | 5 | 137 |
| Activin receptor type-1 | Homo sapiens (human) | Kd | 20.3039 | 4 | 141 |
| Activin receptor type-1B | Homo sapiens (human) | Kd | 20.3302 | 4 | 139 |
| Activin receptor type-2A | Homo sapiens (human) | Kd | 9.3820 | 3 | 59 |
| Activin receptor type-2B | Homo sapiens (human) | Kd | 20.4082 | 4 | 136 |
| Acyl-CoA dehydrogenase family member 10 | Homo sapiens (human) | Kd | 30.0535 | 1 | 71 |
| Acyl-CoA dehydrogenase family member 11 | Homo sapiens (human) | Kd | 29.2295 | 1 | 70 |
| Adenine phosphoribosyltransferase | Homo sapiens (human) | Kd | 29.4833 | 1 | 58 |
| Adenosine kinase | Homo sapiens (human) | Kd | 29.2886 | 1 | 76 |
| Adenosine receptor A1 | Cavia porcellus (domestic guinea pig) | EC50 | 0.0631 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | EC50 | 0.0740 | 17 | 17 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | EC50 | 13.7412 | 4 | 4 |
| Adenosine receptor A1 | Homo sapiens (human) | Kd | 0.7219 | 8 | 8 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Kd | 0.2951 | 1 | 1 |
| Adenosine receptor A2a | Homo sapiens (human) | EC50 | 0.0776 | 16 | 16 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | EC50 | 0.1807 | 3 | 3 |
| Adenosine receptor A2a | Homo sapiens (human) | Kd | 0.0032 | 1 | 1 |
| Adenosine receptor A2b | Homo sapiens (human) | EC50 | 1.4737 | 25 | 26 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | EC50 | 0.1300 | 1 | 1 |
| Adenosine receptor A2b | Homo sapiens (human) | Kd | 0.0100 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | EC50 | 17.4895 | 18 | 18 |
| Adenosine receptor A3 | Mus musculus (house mouse) | EC50 | 0.1880 | 1 | 1 |
| Adenylate kinase 2, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 80 |
| ADP/ATP translocase 2 | Homo sapiens (human) | Kd | 29.6212 | 1 | 78 |
| ADP/ATP translocase 3 | Homo sapiens (human) | Kd | 29.2273 | 1 | 77 |
| Albumin | Homo sapiens (human) | Kd | 39.8370 | 9 | 9 |
| Albumin | Rattus norvegicus (Norway rat) | Kd | 105.6000 | 3 | 3 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | EC50 | 4.0745 | 9 | 11 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | Kd | 10.2779 | 6 | 74 |
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | EC50 | 32.3000 | 1 | 1 |
| alkaline phosphatase, intestinal | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | EC50 | 0.0343 | 2 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 31.5000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Kd | 0.0126 | 1 | 2 |
| Alpha-1A adrenergic receptor | Oryctolagus cuniculus (rabbit) | Kd | 0.0101 | 1 | 2 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0079 | 3 | 3 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | EC50 | 0.0008 | 2 | 3 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 31.5000 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Kd | 0.0109 | 2 | 6 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0025 | 2 | 2 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 31.5000 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Kd | 0.0126 | 1 | 2 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0019 | 2 | 2 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0101 | 1 | 4 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0101 | 1 | 4 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0101 | 1 | 4 |
| Alpha-synuclein | Homo sapiens (human) | Kd | 3.5000 | 4 | 4 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | Kd | 0.1800 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | EC50 | 8.4100 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | EC50 | 3.3340 | 12 | 13 |
| Androgen receptor | Mus musculus (house mouse) | EC50 | 0.0061 | 2 | 2 |
| Androgen receptor | Homo sapiens (human) | Kd | 85.5302 | 4 | 4 |
| Angiopoietin-1 receptor | Homo sapiens (human) | Kd | 6.9905 | 4 | 61 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | EC50 | 28.8952 | 1 | 24 |
| Ankyrin repeat and protein kinase domain-containing protein 1 | Homo sapiens (human) | Kd | 8.5322 | 3 | 59 |
| AP2-associated protein kinase 1 | Homo sapiens (human) | Kd | 16.9963 | 9 | 148 |
| Apoptosis regulator BAX | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | EC50 | 0.1348 | 11 | 11 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Kd | 0.4100 | 5 | 7 |
| Aromatase | Rattus norvegicus (Norway rat) | EC50 | 0.2600 | 1 | 1 |
| Aryl hydrocarbon receptor | Mus musculus (house mouse) | EC50 | 78.0000 | 1 | 1 |
| Aryl hydrocarbon receptor | Mus musculus (house mouse) | Kd | 0.0900 | 1 | 1 |
| ATP-dependent 6-phosphofructokinase, platelet type | Homo sapiens (human) | Kd | 30.0000 | 1 | 72 |
| ATP-dependent Clp protease proteolytic subunit | Staphylococcus aureus subsp. aureus NCTC 8325 | EC50 | 13.5500 | 1 | 2 |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | Kd | 1.2000 | 1 | 1 |
| ATP-dependent RNA helicase DDX1 | Homo sapiens (human) | Kd | 29.6165 | 1 | 78 |
| ATP-dependent RNA helicase DDX3X | Homo sapiens (human) | Kd | 29.6210 | 1 | 78 |
| ATP-dependent RNA helicase DDX42 | Homo sapiens (human) | Kd | 30.0000 | 1 | 61 |
| ATP-dependent RNA helicase DHX30 | Homo sapiens (human) | Kd | 30.0000 | 1 | 53 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | EC50 | 9.4437 | 4 | 7 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Kd | 11.7208 | 1 | 5 |
| Atypical chemokine receptor 3 | Homo sapiens (human) | EC50 | 140.0000 | 1 | 1 |
| Atypical kinase COQ8A, mitochondrial | Homo sapiens (human) | Kd | 20.7279 | 4 | 140 |
| Atypical kinase COQ8B, mitochondrial | Homo sapiens (human) | Kd | 8.8593 | 3 | 59 |
| Aurora kinase A | Homo sapiens (human) | Kd | 16.9230 | 11 | 152 |
| Aurora kinase B | Homo sapiens (human) | Kd | 17.8009 | 4 | 135 |
| Aurora kinase C | Homo sapiens (human) | Kd | 5.3694 | 5 | 63 |
| Baculoviral IAP repeat-containing protein 2 | Homo sapiens (human) | EC50 | 0.0004 | 1 | 1 |
| Baculoviral IAP repeat-containing protein 2 | Homo sapiens (human) | Kd | 0.0104 | 1 | 1 |
| Baculoviral IAP repeat-containing protein 3 | Homo sapiens (human) | Kd | 0.0129 | 1 | 1 |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | EC50 | 0.0200 | 1 | 1 |
| Bcl-2-like protein 1 | Homo sapiens (human) | EC50 | 0.0233 | 3 | 3 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Kd | 0.0009 | 3 | 3 |
| bcl-2-like protein 11 isoform 1 | Homo sapiens (human) | EC50 | 350.0000 | 1 | 3 |
| Bcl-2-related protein A1 | Homo sapiens (human) | Kd | 1.0000 | 1 | 1 |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | Kd | 6.4045 | 5 | 61 |
| Beta-adrenergic receptor kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 77 |
| Beta-galactosidase | Escherichia coli | EC50 | 31.5000 | 1 | 1 |
| Bile acid receptor | Mus musculus (house mouse) | EC50 | 0.8500 | 1 | 1 |
| BMP-2-inducible protein kinase | Homo sapiens (human) | Kd | 17.4345 | 7 | 142 |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | Kd | 20.7886 | 4 | 136 |
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | Kd | 21.1380 | 3 | 116 |
| Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | Kd | 20.5054 | 4 | 134 |
| Breakpoint cluster region protein | Homo sapiens (human) | EC50 | 1.3135 | 4 | 10 |
| Breakpoint cluster region protein | Homo sapiens (human) | Kd | 23.1731 | 1 | 77 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | EC50 | 0.7093 | 4 | 6 |
| Bromodomain testis-specific protein | Homo sapiens (human) | Kd | 0.4040 | 7 | 10 |
| Bromodomain-containing protein 2 | Homo sapiens (human) | Kd | 0.0827 | 12 | 12 |
| Bromodomain-containing protein 3 | Homo sapiens (human) | Kd | 0.0599 | 10 | 10 |
| Bromodomain-containing protein 4 | Homo sapiens (human) | EC50 | 0.1203 | 3 | 3 |
| Bromodomain-containing protein 4 | Homo sapiens (human) | Kd | 0.1186 | 32 | 62 |
| Bromodomain-containing protein 7 | Homo sapiens (human) | Kd | 11.0000 | 1 | 1 |
| Bromodomain-containing protein 9 | Homo sapiens (human) | Kd | 17.0000 | 1 | 1 |
| Calcium-dependent protein kinase 1 | Plasmodium falciparum 3D7 | Kd | 7.8503 | 1 | 35 |
| Calcium/calmodulin-dependent protein kinase kinase 1 | Homo sapiens (human) | Kd | 8.1015 | 4 | 61 |
| Calcium/calmodulin-dependent protein kinase kinase 2 | Homo sapiens (human) | Kd | 19.0064 | 5 | 142 |
| Calcium/calmodulin-dependent protein kinase type 1 | Homo sapiens (human) | Kd | 8.2570 | 4 | 61 |
| Calcium/calmodulin-dependent protein kinase type 1D | Homo sapiens (human) | Kd | 7.9969 | 4 | 61 |
| Calcium/calmodulin-dependent protein kinase type 1G | Homo sapiens (human) | Kd | 11.0995 | 4 | 63 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | Kd | 7.8917 | 5 | 62 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | Kd | 8.6170 | 4 | 61 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | Kd | 19.2464 | 5 | 137 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | Kd | 18.5350 | 7 | 144 |
| Calcium/calmodulin-dependent protein kinase type IV | Homo sapiens (human) | Kd | 19.7161 | 4 | 136 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Kd | 21.7571 | 3 | 136 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | Kd | 20.8056 | 4 | 139 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | Kd | 29.5652 | 1 | 69 |
| cAMP-dependent protein kinase catalytic subunit PRKX | Homo sapiens (human) | Kd | 10.3691 | 4 | 62 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit | Homo sapiens (human) | Kd | 29.6007 | 1 | 75 |
| Cannabinoid receptor 1 | Homo sapiens (human) | EC50 | 0.0651 | 2 | 3 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 1.9953 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | EC50 | 0.1802 | 3 | 3 |
| Carbonic anhydrase 2 | Homo sapiens (human) | EC50 | 0.0010 | 1 | 1 |
| Casein kinase I isoform alpha | Homo sapiens (human) | Kd | 22.1515 | 4 | 118 |
| Casein kinase I isoform alpha-like | Homo sapiens (human) | Kd | 9.2241 | 2 | 54 |
| Casein kinase I isoform delta | Homo sapiens (human) | Kd | 19.9188 | 4 | 137 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | Kd | 19.2432 | 5 | 141 |
| Casein kinase I isoform gamma-1 | Homo sapiens (human) | Kd | 20.4104 | 5 | 136 |
| Casein kinase I isoform gamma-2 | Homo sapiens (human) | Kd | 20.1262 | 4 | 130 |
| Casein kinase I isoform gamma-3 | Homo sapiens (human) | Kd | 21.1636 | 4 | 141 |
| Casein kinase II subunit alpha | Homo sapiens (human) | Kd | 8.8536 | 3 | 59 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | Kd | 18.4291 | 4 | 133 |
| Catenin beta-1 | Homo sapiens (human) | Kd | 20.0000 | 1 | 1 |
| Cathepsin G | Homo sapiens (human) | EC50 | 0.0135 | 1 | 1 |
| Cell division control protein 2 homolog | Plasmodium falciparum 3D7 | Kd | 9.8086 | 1 | 35 |
| cell division cycle 42 (GTP binding protein, 25kDa), partial | Homo sapiens (human) | EC50 | 39.3205 | 2 | 2 |
| Cell division cycle 7-related protein kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 42 |
| Cellular retinoic acid-binding protein 1 | Mus musculus (house mouse) | Kd | 0.1002 | 2 | 4 |
| Cellular retinoic acid-binding protein 2 | Mus musculus (house mouse) | Kd | 0.1010 | 3 | 4 |
| cGMP-dependent protein kinase 1 | Homo sapiens (human) | Kd | 20.9496 | 4 | 138 |
| cGMP-dependent protein kinase 2 | Homo sapiens (human) | Kd | 9.0074 | 3 | 59 |
| Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase | Helicobacter pylori | Kd | 0.4500 | 1 | 1 |
| Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE | Paracoccus denitrificans | Kd | 5,000.0000 | 1 | 9 |
| Chain A, BCL-2-RELATED PROTEIN A1 | Homo sapiens (human) | EC50 | 350.0000 | 1 | 3 |
| Chain A, Bromodomain testis-specific protein | Homo sapiens (human) | Kd | 0.1901 | 1 | 1 |
| Chain A, Bromodomain-containing protein 4 | Homo sapiens (human) | Kd | 0.0490 | 1 | 1 |
| Chain A, Calmodulin-sensitive adenylate cyclase | Bacillus anthracis | Kd | 130.0000 | 1 | 1 |
| Chain A, Endoplasmin | Canis lupus familiaris (dog) | Kd | 0.2000 | 1 | 1 |
| Chain A, Fatty Acid-binding Protein, Brain | Homo sapiens (human) | Kd | 0.0534 | 1 | 2 |
| Chain A, Hth-type Transcriptional Regulator Ttgr | Pseudomonas putida | Kd | 0.0500 | 1 | 2 |
| Chain A, Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 0.0914 | 1 | 7 |
| Chain A, Neocarzinostatin | Streptomyces carzinostaticus | Kd | 0.0001 | 1 | 1 |
| Chain A, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Kd | 21.6000 | 1 | 1 |
| Chain A, Protocatechuate 3,4-dioxygenase alpha chain | Pseudomonas putida | Kd | 1,100.0000 | 1 | 1 |
| Chain A, Retinoic acid receptor beta | Homo sapiens (human) | Kd | 0.0020 | 1 | 1 |
| Chain A, RIO-type serine/threonine-protein kinase Rio1 | Archaeoglobus fulgidus | Kd | 0.0400 | 1 | 1 |
| Chain A, Transthyretin | Homo sapiens (human) | Kd | 0.9763 | 1 | 19 |
| Chain A, Troponin C, slow skeletal and cardiac muscles | Homo sapiens (human) | Kd | 1,100.0000 | 1 | 1 |
| Chain A, Vitamin D Nuclear Receptor | Homo sapiens (human) | Kd | 0.0006 | 1 | 1 |
| Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase | Helicobacter pylori | Kd | 0.4500 | 1 | 1 |
| Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE | Paracoccus denitrificans | Kd | 5,000.0000 | 1 | 9 |
| Chain B, DIHYDROFOLATE REDUCTASE | Escherichia coli | Kd | 0.1344 | 1 | 5 |
| Chain B, Protocatechuate 3,4-dioxygenase beta chain | Pseudomonas putida | Kd | 1,100.0000 | 1 | 1 |
| Chain B, Transthyretin | Homo sapiens (human) | Kd | 0.6633 | 1 | 6 |
| Cholecystokinin receptor type A | Homo sapiens (human) | EC50 | 0.2692 | 1 | 1 |
| Cholesteryl ester transfer protein | Homo sapiens (human) | Kd | 0.1600 | 1 | 2 |
| Choline-phosphate cytidylyltransferase A | Homo sapiens (human) | Kd | 30.0000 | 1 | 36 |
| Chromodomain-helicase-DNA-binding protein 4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 73 |
| Citron Rho-interacting kinase | Homo sapiens (human) | Kd | 19.2173 | 4 | 137 |
| Complement C5 | Homo sapiens (human) | Kd | 0.5700 | 1 | 1 |
| corticotropin releasing factor-binding protein | Homo sapiens (human) | EC50 | 31.2400 | 1 | 2 |
| corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | EC50 | 31.2400 | 1 | 2 |
| CREB-binding protein | Homo sapiens (human) | Kd | 9.6000 | 1 | 1 |
| Cyclin-C | Homo sapiens (human) | Kd | 0.3100 | 1 | 1 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | Kd | 28.2209 | 1 | 81 |
| Cyclin-dependent kinase 10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 23 |
| Cyclin-dependent kinase 11A | Homo sapiens (human) | Kd | 8.4326 | 3 | 59 |
| Cyclin-dependent kinase 11B | Homo sapiens (human) | Kd | 8.4774 | 3 | 59 |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | Kd | 28.8535 | 1 | 78 |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | Kd | 22.5354 | 2 | 112 |
| Cyclin-dependent kinase 14 | Homo sapiens (human) | Kd | 8.0309 | 3 | 59 |
| Cyclin-dependent kinase 15 | Homo sapiens (human) | Kd | 8.4760 | 2 | 40 |
| Cyclin-dependent kinase 16 | Homo sapiens (human) | Kd | 17.7894 | 6 | 140 |
| Cyclin-dependent kinase 17 | Homo sapiens (human) | Kd | 18.1443 | 4 | 131 |
| Cyclin-dependent kinase 18 | Homo sapiens (human) | Kd | 11.4544 | 4 | 68 |
| Cyclin-dependent kinase 19 | Mus musculus (house mouse) | EC50 | 0.0200 | 1 | 1 |
| Cyclin-dependent kinase 19 | Homo sapiens (human) | Kd | 7.5358 | 3 | 59 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | EC50 | 0.0010 | 1 | 1 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Kd | 19.9096 | 7 | 140 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | Kd | 20.3499 | 4 | 134 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | Kd | 19.2362 | 3 | 152 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | Kd | 27.8286 | 1 | 79 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Kd | 19.1039 | 4 | 137 |
| Cyclin-dependent kinase 8 | Mus musculus (house mouse) | EC50 | 0.0200 | 1 | 1 |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | Kd | 7.8913 | 5 | 61 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | Kd | 19.7787 | 4 | 139 |
| Cyclin-dependent kinase-like 1 | Homo sapiens (human) | Kd | 10.0000 | 1 | 35 |
| Cyclin-dependent kinase-like 2 | Homo sapiens (human) | Kd | 7.3883 | 2 | 40 |
| Cyclin-dependent kinase-like 3 | Homo sapiens (human) | Kd | 9.3095 | 2 | 40 |
| Cyclin-dependent kinase-like 5 | Homo sapiens (human) | Kd | 20.2354 | 3 | 85 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | Kd | 19.5677 | 5 | 137 |
| Cyclin-G-associated kinase | Homo sapiens (human) | Kd | 12.6366 | 17 | 170 |
| Cysteine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 29.5314 | 1 | 64 |
| Cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | EC50 | 8.4083 | 6 | 6 |
| Cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | Kd | 25.6000 | 1 | 1 |
| Cystic fibrosis transmembrane conductance regulator | Rattus norvegicus (Norway rat) | Kd | 40.0000 | 1 | 1 |
| Cytochrome c1, heme protein, mitochondrial | Homo sapiens (human) | Kd | 29.6321 | 1 | 81 |
| Cytochrome P450 1A1 | Homo sapiens (human) | EC50 | 8.8000 | 1 | 1 |
| Cytochrome P450 1A2 | Homo sapiens (human) | EC50 | 0.0005 | 1 | 1 |
| Cytochrome P450 1A2 | Rattus norvegicus (Norway rat) | EC50 | 0.0140 | 1 | 2 |
| Cytochrome P450 1B1 | Homo sapiens (human) | EC50 | 1.1000 | 1 | 1 |
| Cytochrome P450 2A13 | Homo sapiens (human) | Kd | 1.0150 | 1 | 2 |
| Cytochrome P450 2A6 | Homo sapiens (human) | Kd | 8.6000 | 1 | 2 |
| Cytochrome P450 2B6 | Homo sapiens (human) | EC50 | 1.3000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | EC50 | 0.0006 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | EC50 | 0.0012 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | EC50 | 2.2201 | 2 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Kd | 0.0037 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | EC50 | 4.3679 | 3 | 4 |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | Kd | 8.3048 | 6 | 64 |
| dCTP pyrophosphatase 1 | Homo sapiens (human) | Kd | 29.2864 | 1 | 79 |
| Death-associated protein kinase 1 | Homo sapiens (human) | Kd | 8.5157 | 3 | 59 |
| Death-associated protein kinase 2 | Homo sapiens (human) | Kd | 8.0687 | 5 | 62 |
| Death-associated protein kinase 3 | Homo sapiens (human) | Kd | 8.1030 | 6 | 81 |
| Delta-type opioid receptor | Homo sapiens (human) | EC50 | 26.4098 | 5 | 5 |
| Delta-type opioid receptor | Mus musculus (house mouse) | EC50 | 0.0030 | 1 | 2 |
| Delta(24)-sterol reductase | Homo sapiens (human) | Kd | 29.6394 | 1 | 82 |
| Deoxycytidine kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 80 |
| Dihydrofolate reductase | Escherichia coli K-12 | EC50 | 0.0010 | 1 | 1 |
| Dihydrofolate reductase | Escherichia coli K-12 | Kd | 0.3062 | 10 | 10 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | EC50 | 0.0550 | 1 | 1 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | Kd | 16.0914 | 9 | 150 |
| DNA (cytosine-5)-methyltransferase 3A | Mus musculus (house mouse) | Kd | 1.3000 | 6 | 6 |
| DNA damage-binding protein 1 | Homo sapiens (human) | EC50 | 0.0090 | 1 | 1 |
| DNA polymerase alpha catalytic subunit | Homo sapiens (human) | EC50 | 2.0000 | 1 | 1 |
| DNA repair and recombination protein RAD54-like | Homo sapiens (human) | EC50 | 16.5000 | 1 | 1 |
| DNA replication licensing factor MCM4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 77 |
| DNA topoisomerase 1 | Homo sapiens (human) | EC50 | 0.1731 | 3 | 5 |
| DNA topoisomerase 1 | Homo sapiens (human) | Kd | 0.0265 | 1 | 1 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | EC50 | 14.5625 | 3 | 4 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | Kd | 29.5528 | 1 | 66 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | EC50 | 14.5625 | 3 | 4 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | Kd | 30.0000 | 1 | 79 |
| DNA topoisomerase I | Leishmania donovani BPK282A1 | Kd | 645.0000 | 2 | 2 |
| DNA topoisomerase type IB small subunit | Leishmania donovani BPK282A1 | Kd | 380.0000 | 1 | 1 |
| DNA topoisomerase type IB small subunit | Leishmania major | EC50 | 0.6700 | 1 | 1 |
| DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | Kd | 0.0890 | 1 | 1 |
| DNA-binding protein Ikaros | Homo sapiens (human) | EC50 | 0.0455 | 1 | 2 |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | EC50 | 0.1180 | 1 | 1 |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | Kd | 1.8000 | 1 | 1 |
| DnaJ homolog subfamily A member 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 76 |
| Dual serine/threonine and tyrosine protein kinase | Homo sapiens (human) | Kd | 8.3126 | 1 | 35 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | Kd | 17.4709 | 9 | 142 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | Kd | 17.4999 | 7 | 140 |
| Dual specificity mitogen-activated protein kinase kinase 3 | Homo sapiens (human) | Kd | 20.9143 | 4 | 137 |
| Dual specificity mitogen-activated protein kinase kinase 4 | Homo sapiens (human) | Kd | 14.7744 | 4 | 87 |
| Dual specificity mitogen-activated protein kinase kinase 4 | Mus musculus (house mouse) | Kd | 0.0082 | 1 | 1 |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | Kd | 17.4914 | 2 | 113 |
| Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | Kd | 21.0369 | 4 | 138 |
| Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | Kd | 9.2872 | 2 | 36 |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | Kd | 16.7468 | 7 | 145 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | Kd | 17.9682 | 7 | 138 |
| Dual specificity protein kinase CLK3 | Homo sapiens (human) | Kd | 16.2286 | 6 | 102 |
| Dual specificity protein kinase CLK4 | Homo sapiens (human) | Kd | 17.2179 | 7 | 121 |
| Dual specificity protein kinase TTK | Homo sapiens (human) | Kd | 17.9003 | 6 | 118 |
| Dual specificity testis-specific protein kinase 1 | Homo sapiens (human) | Kd | 19.5155 | 4 | 123 |
| Dual specificity testis-specific protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 42 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | Kd | 20.4929 | 3 | 121 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Homo sapiens (human) | Kd | 14.0401 | 4 | 81 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Homo sapiens (human) | Kd | 7.8205 | 2 | 40 |
| Dynamin-like 120 kDa protein, mitochondrial | Homo sapiens (human) | Kd | 29.6244 | 1 | 78 |
| E3 ubiquitin-protein ligase Mdm2 isoform a | Homo sapiens (human) | EC50 | 0.5700 | 3 | 3 |
| E3 ubiquitin-protein ligase XIAP | Homo sapiens (human) | EC50 | 0.2082 | 4 | 4 |
| E3 ubiquitin-protein ligase XIAP | Homo sapiens (human) | Kd | 0.0527 | 1 | 1 |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | EC50 | 2.5324 | 3 | 5 |
| Egl nine homolog 1 | Homo sapiens (human) | EC50 | 50.0000 | 1 | 2 |
| eIF-2-alpha kinase GCN2 | Homo sapiens (human) | Kd | 7.9275 | 3 | 59 |
| EKC/KEOPS complex subunit TP53RK | Homo sapiens (human) | Kd | 29.2877 | 1 | 79 |
| Electron transfer flavoprotein subunit beta | Homo sapiens (human) | Kd | 29.5386 | 1 | 65 |
| Elongation factor Tu, mitochondrial | Homo sapiens (human) | Kd | 29.6354 | 1 | 81 |
| Endoplasmin | Canis lupus familiaris (dog) | EC50 | 0.1240 | 1 | 1 |
| Endoplasmin | Canis lupus familiaris (dog) | Kd | 2.8000 | 1 | 1 |
| Endoplasmin | Homo sapiens (human) | Kd | 0.5300 | 1 | 1 |
| Endoplasmin | Sus scrofa (pig) | Kd | 0.2000 | 2 | 2 |
| endoribonuclease toxin MazF | Escherichia coli str. K-12 substr. MG1655 | EC50 | 99.0000 | 2 | 4 |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | EC50 | 0.0713 | 1 | 1 |
| Env polyprotein | Human immunodeficiency virus 1 | EC50 | 100.0000 | 1 | 1 |
| Envelope glycoprotein | Ebola virus - Mayinga, Zaire, 1976 | EC50 | 0.0628 | 2 | 2 |
| Envelope glycoprotein | Ebola virus - Mayinga, Zaire, 1976 | Kd | 16.0000 | 2 | 2 |
| Ephrin type-A receptor 1 | Homo sapiens (human) | Kd | 17.0200 | 4 | 117 |
| Ephrin type-A receptor 2 | Homo sapiens (human) | Kd | 16.7085 | 6 | 148 |
| Ephrin type-A receptor 3 | Homo sapiens (human) | Kd | 6.4009 | 4 | 63 |
| Ephrin type-A receptor 4 | Homo sapiens (human) | Kd | 19.2244 | 5 | 139 |
| Ephrin type-A receptor 5 | Homo sapiens (human) | Kd | 18.4815 | 6 | 144 |
| Ephrin type-A receptor 6 | Homo sapiens (human) | Kd | 5.6264 | 5 | 67 |
| Ephrin type-A receptor 7 | Homo sapiens (human) | Kd | 18.3732 | 6 | 130 |
| Ephrin type-A receptor 8 | Homo sapiens (human) | Kd | 6.4204 | 5 | 64 |
| Ephrin type-B receptor 1 | Homo sapiens (human) | Kd | 6.6017 | 5 | 66 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | Kd | 19.3953 | 4 | 135 |
| Ephrin type-B receptor 3 | Homo sapiens (human) | Kd | 20.3688 | 4 | 140 |
| Ephrin type-B receptor 4 | Homo sapiens (human) | Kd | 18.3527 | 5 | 140 |
| Ephrin type-B receptor 6 | Homo sapiens (human) | Kd | 19.6112 | 3 | 117 |
| Epidermal growth factor receptor | Homo sapiens (human) | EC50 | 1.2396 | 27 | 48 |
| Epidermal growth factor receptor | Homo sapiens (human) | Kd | 7.2231 | 49 | 765 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | Kd | 14.7410 | 9 | 145 |
| Estrogen receptor | Homo sapiens (human) | EC50 | 0.5143 | 18 | 26 |
| Estrogen receptor | Mus musculus (house mouse) | EC50 | 55.9410 | 1 | 2 |
| Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 | 90.4772 | 1 | 10 |
| Estrogen receptor | Homo sapiens (human) | Kd | 0.0047 | 1 | 1 |
| Estrogen receptor | Ovis aries (sheep) | Kd | 3.2800 | 1 | 2 |
| Estrogen receptor beta | Homo sapiens (human) | EC50 | 0.3376 | 17 | 26 |
| Estrogen receptor beta | Mus musculus (house mouse) | EC50 | 55.9410 | 1 | 2 |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 | 90.4772 | 1 | 10 |
| Estrogen receptor beta | Ovis aries (sheep) | Kd | 3.2800 | 1 | 2 |
| Estrogen-related receptor gamma | Homo sapiens (human) | EC50 | 0.4250 | 2 | 3 |
| Eukaryotic initiation factor 4A-I | Homo sapiens (human) | EC50 | 0.0039 | 2 | 2 |
| Eukaryotic initiation factor 4A-I | Homo sapiens (human) | Kd | 0.1560 | 1 | 1 |
| Eukaryotic peptide chain release factor GTP-binding subunit ERF3B | Homo sapiens (human) | Kd | 30.0000 | 1 | 19 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | Kd | 22.5034 | 2 | 112 |
| eukaryotic translation initiation factor 2-alpha kinase 3 isoform 1 precursor | Homo sapiens (human) | EC50 | 55.7000 | 2 | 2 |
| Eukaryotic translation initiation factor 4E | Homo sapiens (human) | Kd | 0.0005 | 1 | 1 |
| Eukaryotic translation initiation factor 5B | Homo sapiens (human) | Kd | 30.0000 | 1 | 53 |
| Exosome RNA helicase MTR4 | Homo sapiens (human) | Kd | 30.0000 | 1 | 75 |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | Kd | 1,497.5000 | 4 | 4 |
| Ferrochelatase, mitochondrial | Homo sapiens (human) | EC50 | 5.0119 | 1 | 1 |
| Ferrochelatase, mitochondrial | Homo sapiens (human) | Kd | 22.6256 | 2 | 92 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | EC50 | 0.0210 | 1 | 1 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Kd | 19.7574 | 5 | 144 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | Kd | 6.8194 | 5 | 63 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | EC50 | 0.0300 | 1 | 1 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | Kd | 7.8316 | 7 | 120 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | Kd | 9.1814 | 3 | 59 |
| Flavin reductase (NADPH) | Homo sapiens (human) | Kd | 1.3802 | 1 | 2 |
| Focal adhesion kinase 1 | Homo sapiens (human) | Kd | 19.6965 | 6 | 138 |
| Forkhead box protein O3 | Homo sapiens (human) | Kd | 1,730.0000 | 1 | 1 |
| Free fatty acid receptor 1 | Homo sapiens (human) | EC50 | 23.8500 | 2 | 2 |
| G protein-activated inward rectifier potassium channel 1 | Homo sapiens (human) | EC50 | 100.0000 | 2 | 2 |
| G protein-activated inward rectifier potassium channel 1 | Rattus norvegicus (Norway rat) | EC50 | 3.0790 | 1 | 1 |
| G protein-activated inward rectifier potassium channel 2 | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| G protein-activated inward rectifier potassium channel 4 | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| G protein-coupled receptor kinase 4 | Homo sapiens (human) | Kd | 8.1430 | 2 | 40 |
| G protein-coupled receptor kinase 6 | Homo sapiens (human) | Kd | 29.4323 | 1 | 50 |
| G-protein coupled bile acid receptor 1 | Homo sapiens (human) | EC50 | 5.5200 | 1 | 2 |
| G-protein coupled receptor 35 | Homo sapiens (human) | EC50 | 8.7640 | 2 | 10 |
| G-protein coupled receptor 84 | Homo sapiens (human) | EC50 | 2.8027 | 20 | 24 |
| G-protein coupled receptor 84 | Mus musculus (house mouse) | EC50 | 4.2700 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Galanin receptor type 2 | Homo sapiens (human) | EC50 | 55.7000 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | EC50 | 0.0190 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Kd | 0.0020 | 1 | 1 |
| Gamma-butyrobetaine dioxygenase | Homo sapiens (human) | Kd | 4.1000 | 2 | 2 |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | EC50 | 0.0005 | 1 | 1 |
| General transcription and DNA repair factor IIH helicase subunit XPD | Homo sapiens (human) | Kd | 28.9157 | 1 | 80 |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | EC50 | 3.4460 | 2 | 2 |
| Glucocorticoid receptor | Homo sapiens (human) | EC50 | 0.0278 | 44 | 44 |
| Glucocorticoid receptor | Mus musculus (house mouse) | EC50 | 0.0046 | 2 | 2 |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0196 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | Kd | 0.0290 | 1 | 1 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Kd | 3.6400 | 1 | 1 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 1.0704 | 2 | 2 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | EC50 | 1.0704 | 2 | 2 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | EC50 | 1.0704 | 2 | 2 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | EC50 | 1.0704 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| Glutamine synthetase | Homo sapiens (human) | EC50 | 0.0320 | 1 | 1 |
| glutathione S-transferase, partial | Homo sapiens (human) | EC50 | 1.7500 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Homo sapiens (human) | EC50 | 1.0900 | 1 | 2 |
| Glycine--tRNA ligase | Homo sapiens (human) | Kd | 29.6301 | 1 | 81 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Kd | 29.6696 | 1 | 80 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | Kd | 29.6332 | 1 | 76 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | Kd | 19.7829 | 4 | 137 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Kd | 20.0617 | 4 | 139 |
| glycogen synthase kinase-3 beta isoform 1 | Homo sapiens (human) | EC50 | 166.4802 | 1 | 8 |
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | Kd | 0.0007 | 2 | 3 |
| GTP-binding nuclear protein Ran | Homo sapiens (human) | Kd | 29.6299 | 1 | 79 |
| GTP-binding protein (rab7) | Canis lupus familiaris (dog) | EC50 | 41.2100 | 1 | 1 |
| Guanine nucleotide-binding protein G(i) subunit alpha-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 67 |
| Heat shock cognate 71 kDa protein | Homo sapiens (human) | Kd | 59.3462 | 1 | 4 |
| Heat shock factor protein 1 | Homo sapiens (human) | EC50 | 1.8500 | 2 | 2 |
| heat shock protein 90 | Candida albicans | EC50 | 1.4810 | 1 | 1 |
| Heat shock protein 90, putative | Plasmodium falciparum 3D7 | Kd | 0.2435 | 2 | 2 |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | EC50 | 0.1835 | 15 | 19 |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | Kd | 29.9384 | 19 | 19 |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | EC50 | 0.4095 | 10 | 12 |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | Kd | 38.9870 | 11 | 13 |
| Heme oxygenase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 75 |
| Heparanase | Homo sapiens (human) | Kd | 1,000.0000 | 1 | 1 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | EC50 | 0.0420 | 1 | 1 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | Kd | 13.6483 | 11 | 214 |
| Heterogeneous nuclear ribonucleoprotein A1 | Homo sapiens (human) | Kd | 3.5609 | 2 | 3 |
| hexokinase HKDC1 | Homo sapiens (human) | EC50 | 38.8000 | 1 | 1 |
| hexokinase-1 isoform HKI | Homo sapiens (human) | EC50 | 41.9000 | 1 | 1 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | Kd | 17.4086 | 7 | 128 |
| High mobility group protein B1 | Homo sapiens (human) | Kd | 0.2620 | 2 | 2 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | EC50 | 25.0013 | 2 | 2 |
| Histone deacetylase 1 | Homo sapiens (human) | EC50 | 10.2880 | 12 | 16 |
| Histone deacetylase 1 | Homo sapiens (human) | Kd | 0.1646 | 2 | 5 |
| Histone deacetylase 11 | Homo sapiens (human) | EC50 | 12.5420 | 7 | 10 |
| Histone deacetylase 2 | Homo sapiens (human) | EC50 | 9.1209 | 10 | 14 |
| Histone deacetylase 2 | Homo sapiens (human) | Kd | 0.1957 | 1 | 4 |
| Histone deacetylase 3 | Homo sapiens (human) | EC50 | 9.1141 | 10 | 14 |
| Histone deacetylase 4 | Homo sapiens (human) | EC50 | 11.4123 | 8 | 11 |
| Histone deacetylase 5 | Homo sapiens (human) | EC50 | 12.5420 | 7 | 10 |
| Histone deacetylase 6 | Homo sapiens (human) | EC50 | 784.9185 | 14 | 18 |
| Histone deacetylase 6 | Homo sapiens (human) | Kd | 0.3000 | 1 | 1 |
| Histone deacetylase 7 | Homo sapiens (human) | EC50 | 11.4079 | 8 | 11 |
| Histone deacetylase 7 | Homo sapiens (human) | Kd | 36.0000 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | EC50 | 10.6030 | 9 | 12 |
| Histone deacetylase 8 | Homo sapiens (human) | Kd | 2.8700 | 4 | 4 |
| Histone deacetylase 9 | Homo sapiens (human) | EC50 | 11.4135 | 8 | 11 |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | Kd | 0.3000 | 1 | 1 |
| HLA class I histocompatibility antigen, A alpha chain | Homo sapiens (human) | Kd | 21.2000 | 1 | 1 |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | Kd | 7.6094 | 2 | 40 |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | Kd | 6.7028 | 2 | 40 |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | Kd | 6.5354 | 2 | 40 |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | Kd | 4.6407 | 2 | 40 |
| Hormonally up-regulated neu tumor-associated kinase | Homo sapiens (human) | Kd | 8.2470 | 2 | 40 |
| Hsf1 protein | Mus musculus (house mouse) | EC50 | 1.6500 | 1 | 2 |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | EC50 | 0.0713 | 1 | 1 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 homolog | Mus musculus (house mouse) | Kd | 1.0000 | 1 | 1 |
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Homo sapiens (human) | Kd | 9.0085 | 2 | 40 |
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | Kd | 9.6025 | 2 | 40 |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | Kd | 19.2545 | 4 | 136 |
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 70 |
| Insulin receptor | Homo sapiens (human) | Kd | 20.3473 | 6 | 142 |
| Insulin receptor-related protein | Homo sapiens (human) | Kd | 8.9456 | 3 | 59 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | Kd | 20.8276 | 5 | 142 |
| Integrin alpha-L | Homo sapiens (human) | Kd | 12.9000 | 1 | 1 |
| Integrin-linked protein kinase | Homo sapiens (human) | Kd | 29.1739 | 1 | 71 |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | Kd | 8.1731 | 3 | 59 |
| Interleukin-1 receptor-associated kinase 1 | Homo sapiens (human) | Kd | 21.2107 | 3 | 118 |
| Interleukin-1 receptor-associated kinase 3 | Homo sapiens (human) | Kd | 18.9853 | 4 | 139 |
| Interleukin-1 receptor-associated kinase 4 | Homo sapiens (human) | Kd | 22.2061 | 2 | 114 |
| Interleukin-10 | Homo sapiens (human) | EC50 | 0.2200 | 1 | 1 |
| Interstitial collagenase | Homo sapiens (human) | Kd | 51.8000 | 1 | 1 |
| Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens (human) | EC50 | 0.8132 | 3 | 3 |
| Isoleucine--tRNA ligase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 47 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | EC50 | 0.0000 | 1 | 1 |
| Kappa-type opioid receptor | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | EC50 | 0.8700 | 1 | 1 |
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
| L-ornithine N(5)-monooxygenase | Aspergillus fumigatus Af293 | Kd | 1.4000 | 2 | 2 |
| LacZ protein (plasmid) | Escherichia coli | EC50 | 40.0000 | 1 | 3 |
| LAP4 | Saccharomyces cerevisiae (brewer's yeast) | EC50 | 0.9860 | 1 | 1 |
| large T antigen | Betapolyomavirus macacae | EC50 | 47.9300 | 1 | 1 |
| Leucine-rich repeat serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 7.6978 | 2 | 70 |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | Kd | 6.9734 | 3 | 59 |
| Leukotriene C4 synthase | Cavia porcellus (domestic guinea pig) | Kd | 9.3151 | 1 | 35 |
| LIM domain kinase 1 | Homo sapiens (human) | Kd | 19.0324 | 5 | 139 |
| LIM domain kinase 2 | Homo sapiens (human) | Kd | 19.9011 | 4 | 138 |
| Long-chain-fatty-acid--CoA ligase 5 | Homo sapiens (human) | Kd | 29.4379 | 1 | 53 |
| Luciferin 4-monooxygenase | Photinus pyralis (common eastern firefly) | EC50 | 0.0100 | 1 | 1 |
| Lymphocyte antigen 96 | Homo sapiens (human) | Kd | 419.5000 | 1 | 2 |
| Lysine--tRNA ligase | Homo sapiens (human) | Kd | 3.1623 | 1 | 1 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | EC50 | 0.0540 | 1 | 1 |
| Lysosomal acid glucosylceramidase | Homo sapiens (human) | EC50 | 2.5000 | 1 | 1 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | Kd | 3.2128 | 9 | 66 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | EC50 | 0.9000 | 1 | 1 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | Kd | 21.9584 | 3 | 117 |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | Kd | 20.1637 | 4 | 138 |
| MAP kinase-activated protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 29 |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | Kd | 20.7872 | 4 | 131 |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 7.5202 | 3 | 59 |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 5.7614 | 4 | 66 |
| MAP/microtubule affinity-regulating kinase 3 | Homo sapiens (human) | Kd | 19.4836 | 5 | 137 |
| MAP/microtubule affinity-regulating kinase 4 | Homo sapiens (human) | Kd | 20.5409 | 4 | 133 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | EC50 | 0.5214 | 2 | 2 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | Kd | 4.0845 | 34 | 513 |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | Kd | 19.5344 | 4 | 137 |
| matrix metalloproteinase 1, partial | Homo sapiens (human) | EC50 | 5.6500 | 1 | 1 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | Kd | 2.1000 | 1 | 1 |
| Megakaryocyte-associated tyrosine-protein kinase | Homo sapiens (human) | Kd | 9.8375 | 2 | 40 |
| melanocortin receptor 4 | Homo sapiens (human) | EC50 | 50.0000 | 1 | 1 |
| Membrane-associated progesterone receptor component 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 55 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | Kd | 20.4644 | 5 | 142 |
| MEP2 | Saccharomyces cerevisiae (brewer's yeast) | EC50 | 337,300.0000 | 1 | 1 |
| Microtubule-associated serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 8.5790 | 2 | 40 |
| Midasin | Homo sapiens (human) | Kd | 30.0000 | 1 | 78 |
| Mineralocorticoid receptor | Homo sapiens (human) | EC50 | 0.0010 | 2 | 2 |
| Misshapen-like kinase 1 | Homo sapiens (human) | Kd | 16.5104 | 3 | 76 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | Kd | 21.2676 | 6 | 142 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | Kd | 19.1303 | 6 | 140 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | Kd | 19.2934 | 7 | 138 |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | Kd | 9.6246 | 4 | 61 |
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | Kd | 9.8300 | 2 | 40 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | EC50 | 2.0233 | 3 | 3 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 18.2748 | 12 | 149 |
| Mitogen-activated protein kinase 15 | Homo sapiens (human) | Kd | 20.5508 | 4 | 143 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | Kd | 21.5108 | 4 | 139 |
| Mitogen-activated protein kinase 4 | Homo sapiens (human) | Kd | 9.2339 | 3 | 59 |
| Mitogen-activated protein kinase 6 | Homo sapiens (human) | Kd | 8.8246 | 4 | 61 |
| Mitogen-activated protein kinase 7 | Homo sapiens (human) | Kd | 20.0859 | 4 | 134 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | Kd | 20.2377 | 6 | 143 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | Kd | 19.1674 | 6 | 146 |
| Mitogen-activated protein kinase kinase kinase 1 | Homo sapiens (human) | Kd | 20.9181 | 3 | 117 |
| Mitogen-activated protein kinase kinase kinase 10 | Homo sapiens (human) | Kd | 9.1658 | 3 | 59 |
| Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens (human) | Kd | 18.9699 | 5 | 138 |
| Mitogen-activated protein kinase kinase kinase 12 | Homo sapiens (human) | Kd | 8.3909 | 1 | 35 |
| Mitogen-activated protein kinase kinase kinase 13 | Homo sapiens (human) | Kd | 8.1435 | 2 | 40 |
| Mitogen-activated protein kinase kinase kinase 15 | Homo sapiens (human) | Kd | 9.1625 | 2 | 40 |
| Mitogen-activated protein kinase kinase kinase 19 | Homo sapiens (human) | Kd | 3.2921 | 2 | 40 |
| Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens (human) | Kd | 20.9333 | 3 | 117 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | Kd | 17.3896 | 4 | 139 |
| Mitogen-activated protein kinase kinase kinase 3 | Homo sapiens (human) | Kd | 21.4785 | 3 | 117 |
| Mitogen-activated protein kinase kinase kinase 4 | Homo sapiens (human) | Kd | 20.0534 | 5 | 142 |
| Mitogen-activated protein kinase kinase kinase 5 | Homo sapiens (human) | Kd | 21.3235 | 4 | 136 |
| Mitogen-activated protein kinase kinase kinase 6 | Homo sapiens (human) | Kd | 22.6688 | 3 | 113 |
| Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (human) | Kd | 6.2430 | 4 | 42 |
| Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens (human) | Kd | 8.2411 | 3 | 59 |
| Mitogen-activated protein kinase kinase kinase kinase 1 | Homo sapiens (human) | Kd | 18.3310 | 4 | 133 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens (human) | Kd | 20.2156 | 3 | 119 |
| Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens (human) | Kd | 18.3835 | 5 | 140 |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | Kd | 17.9680 | 4 | 138 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens (human) | Kd | 16.4535 | 6 | 146 |
| Mitotic checkpoint serine/threonine-protein kinase BUB1 | Homo sapiens (human) | Kd | 28.7687 | 1 | 70 |
| Mixed lineage kinase domain-like protein | Homo sapiens (human) | Kd | 0.2170 | 1 | 1 |
| mu opioid receptor, partial | Homo sapiens (human) | EC50 | 32.0000 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | EC50 | 0.0080 | 1 | 1 |
| Mu-type opioid receptor | Homo sapiens (human) | EC50 | 50.3100 | 2 | 2 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0070 | 1 | 1 |
| Multifunctional protein ADE2 | Homo sapiens (human) | Kd | 29.6857 | 1 | 78 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | EC50 | 0.7800 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | EC50 | 0.7800 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | EC50 | 0.7800 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | EC50 | 0.7800 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | EC50 | 0.7800 | 1 | 2 |
| Muscle, skeletal receptor tyrosine-protein kinase | Homo sapiens (human) | Kd | 7.9171 | 3 | 59 |
| Myocilin | Homo sapiens (human) | Kd | 41.6000 | 1 | 1 |
| Myosin light chain kinase 2, skeletal/cardiac muscle | Homo sapiens (human) | Kd | 7.3745 | 5 | 62 |
| Myosin light chain kinase 3 | Homo sapiens (human) | Kd | 22.4402 | 2 | 107 |
| Myosin light chain kinase family member 4 | Homo sapiens (human) | Kd | 8.7757 | 3 | 59 |
| Myosin light chain kinase, smooth muscle | Gallus gallus (chicken) | Kd | 9.0381 | 1 | 19 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | Kd | 19.4718 | 5 | 144 |
| Myosin-10 | Homo sapiens (human) | Kd | 29.5126 | 1 | 60 |
| Myosin-14 | Homo sapiens (human) | Kd | 30.0000 | 1 | 73 |
| Myosin-IIIa | Homo sapiens (human) | Kd | 9.5259 | 3 | 59 |
| Myosin-IIIb | Homo sapiens (human) | Kd | 9.2915 | 3 | 59 |
| Myotonin-protein kinase | Homo sapiens (human) | Kd | 7.9344 | 3 | 59 |
| NAD kinase | Homo sapiens (human) | Kd | 1.7800 | 1 | 1 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | Homo sapiens (human) | Kd | 30.0000 | 1 | 76 |
| NEDD8-activating enzyme E1 catalytic subunit | Homo sapiens (human) | EC50 | 1.5767 | 2 | 3 |
| NEDD8-activating enzyme E1 regulatory subunit | Homo sapiens (human) | EC50 | 1.5767 | 2 | 3 |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | EC50 | 10.0000 | 2 | 2 |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | EC50 | 10.0000 | 2 | 2 |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | EC50 | 7.0500 | 2 | 2 |
| Neuronal acetylcholine receptor subunit alpha-7 | Rattus norvegicus (Norway rat) | EC50 | 5.0210 | 2 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | EC50 | 10.0000 | 2 | 2 |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | EC50 | 10.0000 | 2 | 2 |
| Nociceptin receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0034 | 1 | 1 |
| Non-receptor tyrosine-protein kinase TNK1 | Homo sapiens (human) | Kd | 18.1166 | 4 | 138 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | EC50 | 5.4167 | 2 | 3 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | Kd | 17.1168 | 6 | 176 |
| NPYLR7B | Aedes aegypti (yellow fever mosquito) | EC50 | 7.1793 | 1 | 3 |
| NS5 | Zika virus | EC50 | 0.8769 | 6 | 6 |
| NT-3 growth factor receptor | Homo sapiens (human) | Kd | 7.0349 | 3 | 59 |
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | Kd | 8.4527 | 3 | 59 |
| NUAK family SNF1-like kinase 2 | Homo sapiens (human) | Kd | 19.5204 | 4 | 129 |
| Nuclear factor erythroid 2-related factor 2 | Homo sapiens (human) | EC50 | 7.2183 | 6 | 6 |
| Nuclear factor erythroid 2-related factor 2 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | EC50 | 55.9410 | 1 | 1 |
| Nuclear hormone receptor family member daf-12 | Caenorhabditis elegans | EC50 | 67.5260 | 1 | 1 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | EC50 | 29.7500 | 2 | 4 |
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | EC50 | 8.9372 | 12 | 27 |
| Nuclear receptor subfamily 1 group I member 2 | Rattus norvegicus (Norway rat) | EC50 | 1.3500 | 1 | 4 |
| Nuclear receptor subfamily 4 group A member 1 | Homo sapiens (human) | Kd | 0.4275 | 4 | 4 |
| Nuclear receptor subfamily 4 group A member 2 | Homo sapiens (human) | EC50 | 0.0100 | 1 | 1 |
| Nucleolar GTP-binding protein 1 | Homo sapiens (human) | Kd | 29.5776 | 1 | 71 |
| Nucleoside diphosphate kinase B | Homo sapiens (human) | Kd | 30.0000 | 1 | 8 |
| nucleotide-binding oligomerization domain-containing protein 1 isoform 1 | Homo sapiens (human) | EC50 | 2.1100 | 1 | 1 |
| nucleotide-binding oligomerization domain-containing protein 2 isoform 1 | Homo sapiens (human) | EC50 | 20.0000 | 1 | 2 |
| Obg-like ATPase 1 | Homo sapiens (human) | Kd | 29.5386 | 1 | 65 |
| ORF73 | Human gammaherpesvirus 8 | EC50 | 75.0000 | 1 | 1 |
| Oxysterols receptor LXR-alpha | Homo sapiens (human) | EC50 | 17.0953 | 2 | 3 |
| Oxysterols receptor LXR-beta | Homo sapiens (human) | EC50 | 17.3880 | 2 | 3 |
| oxysterols receptor LXR-beta isoform 1 | Homo sapiens (human) | EC50 | 67.5260 | 1 | 1 |
| oxytocin receptor | Homo sapiens (human) | EC50 | 11.4680 | 1 | 1 |
| P2X purinoceptor 1 | Rattus norvegicus (Norway rat) | EC50 | 1.0000 | 1 | 1 |
| P2X purinoceptor 2 | Rattus norvegicus (Norway rat) | EC50 | 10.4000 | 1 | 1 |
| P2X purinoceptor 3 | Homo sapiens (human) | EC50 | 8.9500 | 2 | 2 |
| P2X purinoceptor 4 | Rattus norvegicus (Norway rat) | EC50 | 100.0000 | 1 | 1 |
| P2X purinoceptor 5 | Rattus norvegicus (Norway rat) | EC50 | 4.0000 | 1 | 1 |
| P2X purinoceptor 6 | Rattus norvegicus (Norway rat) | EC50 | 100.0000 | 1 | 1 |
| P2X purinoceptor 7 | Homo sapiens (human) | EC50 | 92.0000 | 1 | 1 |
| P2Y purinoceptor 1 | Meleagris gallopavo (turkey) | EC50 | 10.0000 | 1 | 1 |
| P2Y purinoceptor 11 | Homo sapiens (human) | EC50 | 16.0000 | 1 | 1 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | EC50 | 4.0000 | 1 | 1 |
| P2Y purinoceptor 2 | Homo sapiens (human) | EC50 | 48.0000 | 1 | 1 |
| P2Y purinoceptor 4 | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| PAS domain-containing serine/threonine-protein kinase | Homo sapiens (human) | Kd | 29.4642 | 1 | 54 |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | EC50 | 0.0364 | 1 | 1 |
| Peptidyl-prolyl cis-trans isomerase FKBP1B | Homo sapiens (human) | Kd | 0.0002 | 1 | 1 |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Kd | 0.8000 | 1 | 1 |
| Peripheral plasma membrane protein CASK | Homo sapiens (human) | Kd | 8.1770 | 1 | 35 |
| Peroxisomal acyl-coenzyme A oxidase 1 | Homo sapiens (human) | Kd | 29.0521 | 1 | 63 |
| Peroxisomal acyl-coenzyme A oxidase 3 | Homo sapiens (human) | Kd | 29.6487 | 1 | 78 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | EC50 | 52.1778 | 9 | 9 |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | EC50 | 33.6807 | 3 | 3 |
| Peroxisome proliferator-activated receptor delta | Homo sapiens (human) | EC50 | 36.5550 | 2 | 2 |
| Peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Kd | 27.6200 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 | 27.6651 | 25 | 27 |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | EC50 | 113.9280 | 5 | 10 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Kd | 70.6667 | 3 | 3 |
| Phenylalanine--tRNA ligase beta subunit | Homo sapiens (human) | Kd | 29.6105 | 1 | 77 |
| Phosphatidylethanolamine-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 64 |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 | Homo sapiens (human) | Kd | 0.2000 | 1 | 1 |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | EC50 | 0.0467 | 2 | 3 |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | Kd | 9.3305 | 4 | 42 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta | Homo sapiens (human) | Kd | 8.8878 | 3 | 41 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma | Homo sapiens (human) | Kd | 8.9708 | 2 | 40 |
| Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha | Homo sapiens (human) | Kd | 8.8798 | 3 | 59 |
| Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma | Homo sapiens (human) | Kd | 9.0291 | 1 | 35 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | EC50 | 0.2644 | 6 | 9 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | Kd | 9.3490 | 26 | 438 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | EC50 | 0.0295 | 2 | 4 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | Kd | 8.8438 | 5 | 43 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | EC50 | 0.0428 | 3 | 5 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | Kd | 8.8452 | 5 | 43 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | EC50 | 0.0590 | 2 | 4 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | Kd | 8.8429 | 5 | 43 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Kd | 29.5619 | 1 | 68 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 beta | Homo sapiens (human) | Kd | 8.8564 | 3 | 59 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Homo sapiens (human) | Kd | 21.6034 | 2 | 113 |
| Phospholipid hydroperoxide glutathione peroxidase | Homo sapiens (human) | EC50 | 16.5220 | 2 | 2 |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Homo sapiens (human) | Kd | 18.2431 | 6 | 142 |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform | Homo sapiens (human) | Kd | 7.2595 | 5 | 62 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | EC50 | 0.3851 | 2 | 2 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | Kd | 3.1788 | 10 | 66 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | Kd | 13.6909 | 12 | 152 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | EC50 | 3.1587 | 9 | 15 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | Kd | 0.7751 | 5 | 7 |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | EC50 | 0.0107 | 3 | 6 |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | Kd | 0.0210 | 3 | 5 |
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | Kd | 10.0000 | 1 | 1 |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | Kd | 8.1700 | 2 | 6 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | EC50 | 12.5420 | 7 | 10 |
| Polycomb protein EED | Homo sapiens (human) | Kd | 5.8850 | 3 | 4 |
| Polypeptide N-acetylgalactosaminyltransferase 2 | Homo sapiens (human) | Kd | 0.9240 | 1 | 1 |
| Polyphenol oxidase 2 | Agaricus bisporus | EC50 | 14.8000 | 1 | 1 |
| POsterior Segregation | Caenorhabditis elegans | EC50 | 122.0887 | 1 | 3 |
| Probable ATP-dependent RNA helicase DDX6 | Homo sapiens (human) | Kd | 30.0000 | 1 | 78 |
| Procathepsin L | Homo sapiens (human) | EC50 | 28.8952 | 1 | 24 |
| Progesterone receptor | Homo sapiens (human) | EC50 | 0.6252 | 16 | 16 |
| Progesterone receptor | Homo sapiens (human) | Kd | 0.0004 | 1 | 1 |
| Programmed cell death protein 4 | Homo sapiens (human) | EC50 | 0.0500 | 1 | 1 |
| Prolyl hydroxylase EGLN2 | Homo sapiens (human) | EC50 | 50.0000 | 1 | 2 |
| Prolyl hydroxylase EGLN3 | Homo sapiens (human) | EC50 | 50.0000 | 1 | 2 |
| Prosaposin | Homo sapiens (human) | Kd | 6.9000 | 2 | 2 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Kd | 8.3459 | 1 | 35 |
| Protease | Human immunodeficiency virus 1 | Kd | 0.0095 | 5 | 5 |
| Protein cereblon | Homo sapiens (human) | EC50 | 1.4599 | 4 | 7 |
| Protein delta homolog 1 | Homo sapiens (human) | Kd | 8.0200 | 1 | 5 |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | EC50 | 0.0920 | 1 | 1 |
| Protein farnesyltransferase subunit beta | Mus musculus (house mouse) | EC50 | 0.0410 | 4 | 5 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | EC50 | 3.4460 | 2 | 2 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Mus musculus (house mouse) | EC50 | 0.0410 | 4 | 5 |
| Protein kinase C alpha type | Homo sapiens (human) | EC50 | 850.0048 | 2 | 2 |
| Protein kinase C alpha type | Homo sapiens (human) | Kd | 27.5808 | 3 | 85 |
| Protein kinase C beta type | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Protein kinase C beta type | Homo sapiens (human) | Kd | 29.6194 | 1 | 78 |
| Protein kinase C delta type | Homo sapiens (human) | EC50 | 5.1099 | 4 | 4 |
| Protein kinase C delta type | Homo sapiens (human) | Kd | 20.4889 | 4 | 140 |
| Protein kinase C epsilon type | Homo sapiens (human) | EC50 | 8.1265 | 3 | 3 |
| Protein kinase C epsilon type | Homo sapiens (human) | Kd | 8.5648 | 3 | 59 |
| Protein kinase C eta type | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Protein kinase C eta type | Homo sapiens (human) | Kd | 8.8539 | 3 | 59 |
| Protein kinase C gamma type | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | Kd | 23.3534 | 2 | 111 |
| Protein kinase C theta type | Homo sapiens (human) | EC50 | 3.4832 | 3 | 3 |
| Protein kinase C theta type | Homo sapiens (human) | Kd | 19.4739 | 4 | 131 |
| Protein kinase C zeta type | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Protein kinase C zeta type | Homo sapiens (human) | Kd | 30.0000 | 1 | 43 |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | Kd | 5.9333 | 1 | 3 |
| Protein mono-ADP-ribosyltransferase PARP11 | Homo sapiens (human) | Kd | 10.0000 | 1 | 2 |
| Protein mono-ADP-ribosyltransferase PARP12 | Homo sapiens (human) | Kd | 10.0000 | 1 | 2 |
| Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | Kd | 10.0000 | 1 | 2 |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | Kd | 7.6333 | 1 | 3 |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | EC50 | 0.0107 | 3 | 6 |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | Kd | 0.3243 | 2 | 3 |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | Kd | 0.3053 | 1 | 3 |
| Protein mono-ADP-ribosyltransferase PARP8 | Homo sapiens (human) | Kd | 10.0000 | 1 | 2 |
| Protein mono-ADP-ribosyltransferase PARP9 | Homo sapiens (human) | Kd | 3.1000 | 1 | 1 |
| Protein polybromo-1 | Homo sapiens (human) | Kd | 12.9000 | 1 | 1 |
| Protein Tat | HIV-1 M:B_HXB2R | EC50 | 1.2150 | 1 | 2 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | Kd | 19.7398 | 4 | 137 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | Kd | 18.3502 | 5 | 143 |
| Prothrombin | Homo sapiens (human) | Kd | 0.0387 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | Kd | 9.4015 | 17 | 283 |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | EC50 | 0.0058 | 1 | 1 |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | Kd | 8.6531 | 3 | 59 |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | Kd | 0.0071 | 3 | 9 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Kd | 17.7193 | 9 | 147 |
| Purine nucleoside phosphorylase | Mycobacterium tuberculosis H37Rv | Kd | 79.4328 | 1 | 1 |
| Putative heat shock protein HSP 90-beta 2 | Homo sapiens (human) | Kd | 29.6483 | 1 | 78 |
| Putative nucleoside diphosphate kinase | Homo sapiens (human) | Kd | 30.0000 | 1 | 4 |
| Pyridoxal kinase | Homo sapiens (human) | Kd | 29.5183 | 1 | 78 |
| Pyruvate kinase PKM | Homo sapiens (human) | EC50 | 0.0009 | 2 | 2 |
| Rab-like protein 3 | Homo sapiens (human) | Kd | 29.6067 | 1 | 64 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | Kd | 20.8339 | 4 | 136 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | Kd | 20.6676 | 4 | 136 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | Kd | 20.8754 | 4 | 135 |
| Rac1 protein | Homo sapiens (human) | EC50 | 54.0175 | 2 | 2 |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | EC50 | 0.6010 | 1 | 1 |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | Kd | 7.9408 | 3 | 59 |
| Ras guanyl-releasing protein 3 | Homo sapiens (human) | EC50 | 0.0820 | 1 | 1 |
| ras protein, partial | Homo sapiens (human) | EC50 | 30.0000 | 2 | 2 |
| Ras-related C3 botulinum toxin substrate 1 | Homo sapiens (human) | Kd | 30.0000 | 1 | 5 |
| Ras-related protein Rab-10 | Homo sapiens (human) | Kd | 30.0000 | 1 | 73 |
| Ras-related protein Rab-27A | Homo sapiens (human) | Kd | 30.0000 | 1 | 79 |
| Ras-related protein Rab-2A | Canis lupus familiaris (dog) | EC50 | 30.0000 | 1 | 1 |
| Ras-related protein Rab-6A | Homo sapiens (human) | Kd | 29.5895 | 1 | 73 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | EC50 | 0.1293 | 6 | 7 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | Kd | 6.4696 | 7 | 68 |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | Kd | 7.5977 | 2 | 40 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | Kd | 6.2933 | 5 | 45 |
| Receptor-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 7.6928 | 8 | 64 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 14.9801 | 5 | 144 |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 22.8685 | 4 | 80 |
| Receptor-interacting serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 8.3902 | 2 | 40 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | Kd | 7.0369 | 43 | 491 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 | 43.5770 | 2 | 4 |
| regulator of G-protein signaling 16 | Homo sapiens (human) | EC50 | 2.2400 | 1 | 1 |
| regulator of G-protein signaling 19 | Homo sapiens (human) | EC50 | 2.0600 | 1 | 1 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | EC50 | 2.5900 | 1 | 1 |
| Regulatory protein E2 | human papillomavirus 11 | Kd | 20.1000 | 1 | 1 |
| Regulatory protein E2 | Human papillomavirus 16 | Kd | 70.5000 | 1 | 1 |
| Regulatory protein E2 | Human papillomavirus type 1a | Kd | 207.0300 | 4 | 5 |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | EC50 | 0.0002 | 1 | 1 |
| Renin | Homo sapiens (human) | EC50 | 0.0033 | 1 | 1 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | EC50 | 30.2878 | 2 | 26 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | Kd | 220.0000 | 1 | 1 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | EC50 | 28.8952 | 1 | 24 |
| Replicase polyprotein 1ab | Human coronavirus 229E | EC50 | 30.2878 | 2 | 26 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | EC50 | 23.6866 | 5 | 31 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | EC50 | 27.7619 | 3 | 29 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Kd | 15.8200 | 3 | 5 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Kd | 24.5000 | 1 | 1 |
| Retinoic acid receptor alpha | Homo sapiens (human) | EC50 | 0.6216 | 29 | 41 |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | EC50 | 0.0082 | 3 | 3 |
| Retinoic acid receptor alpha | Homo sapiens (human) | Kd | 0.0701 | 12 | 21 |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | Kd | 0.0110 | 1 | 2 |
| Retinoic acid receptor beta | Homo sapiens (human) | EC50 | 0.5370 | 27 | 42 |
| Retinoic acid receptor beta | Mus musculus (house mouse) | EC50 | 0.0012 | 3 | 3 |
| Retinoic acid receptor beta | Homo sapiens (human) | Kd | 0.1894 | 13 | 22 |
| Retinoic acid receptor beta | Mus musculus (house mouse) | Kd | 0.0100 | 1 | 2 |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | EC50 | 0.0004 | 2 | 2 |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | Kd | 0.0175 | 1 | 2 |
| Retinoic acid receptor gamma | Homo sapiens (human) | EC50 | 0.6501 | 23 | 35 |
| Retinoic acid receptor gamma | Homo sapiens (human) | Kd | 0.3697 | 14 | 25 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | EC50 | 0.3790 | 35 | 47 |
| Retinoic acid receptor RXR-alpha | Mus musculus (house mouse) | EC50 | 0.7725 | 3 | 4 |
| Retinoic acid receptor RXR-alpha | Rattus norvegicus (Norway rat) | EC50 | 0.0900 | 2 | 3 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | Kd | 0.2377 | 18 | 35 |
| Retinoic acid receptor RXR-alpha | Mus musculus (house mouse) | Kd | 0.5160 | 1 | 2 |
| Retinoic acid receptor RXR-beta | Homo sapiens (human) | EC50 | 0.8881 | 11 | 17 |
| Retinoic acid receptor RXR-beta | Mus musculus (house mouse) | EC50 | 0.3470 | 3 | 4 |
| Retinoic acid receptor RXR-beta | Homo sapiens (human) | Kd | 0.0167 | 2 | 3 |
| Retinoic acid receptor RXR-beta | Mus musculus (house mouse) | Kd | 0.2292 | 4 | 6 |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | EC50 | 0.8877 | 10 | 16 |
| Retinoic acid receptor RXR-gamma | Mus musculus (house mouse) | EC50 | 0.2272 | 4 | 5 |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | Kd | 0.0728 | 3 | 5 |
| Retinoic acid receptor RXR-gamma | Mus musculus (house mouse) | Kd | 0.1030 | 3 | 4 |
| Retinol-binding protein 4 | Homo sapiens (human) | EC50 | 2.3720 | 1 | 1 |
| Retinol-binding protein 4 | Homo sapiens (human) | Kd | 0.1560 | 1 | 1 |
| RGS7, partial | Homo sapiens (human) | EC50 | 2.3600 | 1 | 1 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | Kd | 22.0624 | 3 | 120 |
| Rho-associated protein kinase 2 | Homo sapiens (human) | Kd | 21.7676 | 3 | 119 |
| Rhodopsin kinase GRK1 | Homo sapiens (human) | Kd | 7.8692 | 2 | 40 |
| Rhodopsin kinase GRK7 | Homo sapiens (human) | Kd | 7.6379 | 2 | 40 |
| Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | Kd | 16.4647 | 7 | 195 |
| Ribosomal protein S6 kinase alpha-2 | Homo sapiens (human) | Kd | 8.7617 | 8 | 122 |
| Ribosomal protein S6 kinase alpha-3 | Homo sapiens (human) | Kd | 20.1057 | 6 | 141 |
| Ribosomal protein S6 kinase alpha-4 | Homo sapiens (human) | Kd | 16.8442 | 7 | 195 |
| Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | Kd | 17.0721 | 9 | 204 |
| Ribosomal protein S6 kinase alpha-6 | Homo sapiens (human) | Kd | 17.0345 | 7 | 198 |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | Kd | 22.0058 | 3 | 111 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | Kd | 26.1917 | 1 | 79 |
| RNA cytidine acetyltransferase | Homo sapiens (human) | Kd | 30.0000 | 1 | 80 |
| RNA-directed RNA polymerase | | EC50 | 50.0000 | 1 | 1 |
| RuvB-like 2 | Homo sapiens (human) | Kd | 22.0000 | 1 | 1 |
| S-adenosylmethionine synthase isoform type-2 | Homo sapiens (human) | Kd | 30.0000 | 1 | 73 |
| Septin-9 | Homo sapiens (human) | Kd | 29.6343 | 1 | 82 |
| Serine hydroxymethyltransferase, cytosolic | Homo sapiens (human) | Kd | 16.9000 | 1 | 1 |
| Serine palmitoyltransferase 1 | Homo sapiens (human) | EC50 | 0.0495 | 1 | 1 |
| Serine-protein kinase ATM | Homo sapiens (human) | EC50 | 0.0280 | 1 | 1 |
| Serine/threonine-protein kinase 10 | Homo sapiens (human) | Kd | 14.9404 | 6 | 144 |
| Serine/threonine-protein kinase 16 | Homo sapiens (human) | Kd | 19.5475 | 6 | 140 |
| Serine/threonine-protein kinase 17A | Homo sapiens (human) | Kd | 7.1702 | 5 | 65 |
| Serine/threonine-protein kinase 17B | Homo sapiens (human) | Kd | 7.8710 | 5 | 63 |
| Serine/threonine-protein kinase 24 | Homo sapiens (human) | Kd | 17.7725 | 4 | 110 |
| Serine/threonine-protein kinase 25 | Homo sapiens (human) | Kd | 8.5912 | 3 | 59 |
| Serine/threonine-protein kinase 26 | Homo sapiens (human) | Kd | 19.7521 | 4 | 136 |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 20.2408 | 4 | 140 |
| Serine/threonine-protein kinase 3 | Mus musculus (house mouse) | Kd | 0.1900 | 1 | 2 |
| Serine/threonine-protein kinase 32A | Homo sapiens (human) | Kd | 8.7437 | 1 | 35 |
| Serine/threonine-protein kinase 32B | Homo sapiens (human) | Kd | 9.3600 | 3 | 59 |
| Serine/threonine-protein kinase 32C | Homo sapiens (human) | Kd | 10.0000 | 3 | 59 |
| Serine/threonine-protein kinase 33 | Homo sapiens (human) | Kd | 7.4705 | 3 | 59 |
| serine/threonine-protein kinase 33 isoform a | Homo sapiens (human) | EC50 | 17.3900 | 1 | 3 |
| Serine/threonine-protein kinase 35 | Homo sapiens (human) | Kd | 7.5604 | 2 | 40 |
| Serine/threonine-protein kinase 36 | Homo sapiens (human) | Kd | 7.5582 | 4 | 61 |
| Serine/threonine-protein kinase 38 | Homo sapiens (human) | Kd | 15.8762 | 3 | 58 |
| Serine/threonine-protein kinase 38-like | Homo sapiens (human) | Kd | 15.8057 | 5 | 89 |
| Serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 19.5190 | 6 | 138 |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | Kd | 29.2492 | 1 | 77 |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | EC50 | 0.0350 | 1 | 1 |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | Kd | 30.0000 | 1 | 35 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | EC50 | 0.7030 | 5 | 6 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | Kd | 15.3264 | 10 | 200 |
| Serine/threonine-protein kinase BRSK1 | Homo sapiens (human) | Kd | 9.0528 | 3 | 59 |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | Kd | 8.8287 | 3 | 59 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | EC50 | 0.0021 | 1 | 1 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | Kd | 20.9057 | 4 | 140 |
| Serine/threonine-protein kinase Chk2 | Homo sapiens (human) | Kd | 8.2847 | 2 | 40 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | Kd | 8.3590 | 3 | 59 |
| Serine/threonine-protein kinase D2 | Homo sapiens (human) | Kd | 19.4082 | 4 | 137 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | EC50 | 0.0095 | 1 | 1 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | Kd | 19.1241 | 4 | 138 |
| Serine/threonine-protein kinase DCLK1 | Homo sapiens (human) | Kd | 8.3188 | 3 | 59 |
| Serine/threonine-protein kinase DCLK2 | Homo sapiens (human) | Kd | 8.7258 | 3 | 59 |
| Serine/threonine-protein kinase DCLK3 | Homo sapiens (human) | Kd | 7.8529 | 3 | 59 |
| Serine/threonine-protein kinase ICK | Homo sapiens (human) | Kd | 21.8920 | 3 | 110 |
| Serine/threonine-protein kinase LATS1 | Homo sapiens (human) | Kd | 20.1630 | 4 | 141 |
| Serine/threonine-protein kinase LATS2 | Homo sapiens (human) | Kd | 8.5681 | 3 | 59 |
| Serine/threonine-protein kinase MAK | Homo sapiens (human) | Kd | 9.0829 | 2 | 40 |
| Serine/threonine-protein kinase MARK1 | Homo sapiens (human) | Kd | 9.0527 | 3 | 59 |
| Serine/threonine-protein kinase MARK2 | Homo sapiens (human) | Kd | 19.2078 | 5 | 138 |
| Serine/threonine-protein kinase MRCK alpha | Homo sapiens (human) | Kd | 20.7724 | 5 | 137 |
| Serine/threonine-protein kinase MRCK beta | Homo sapiens (human) | Kd | 20.8996 | 4 | 137 |
| Serine/threonine-protein kinase MRCK gamma | Homo sapiens (human) | Kd | 20.5531 | 4 | 130 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | EC50 | 0.0002 | 1 | 1 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | Kd | 8.2741 | 6 | 41 |
| Serine/threonine-protein kinase mTOR | Mus musculus (house mouse) | EC50 | 0.0011 | 1 | 2 |
| Serine/threonine-protein kinase N1 | Homo sapiens (human) | Kd | 19.4521 | 4 | 136 |
| Serine/threonine-protein kinase N2 | Homo sapiens (human) | Kd | 20.2596 | 4 | 135 |
| Serine/threonine-protein kinase N3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 49 |
| Serine/threonine-protein kinase Nek1 | Homo sapiens (human) | Kd | 21.2353 | 4 | 138 |
| Serine/threonine-protein kinase Nek11 | Homo sapiens (human) | Kd | 9.1803 | 1 | 35 |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | Kd | 20.3668 | 6 | 140 |
| Serine/threonine-protein kinase Nek3 | Homo sapiens (human) | Kd | 23.2858 | 2 | 114 |
| Serine/threonine-protein kinase Nek4 | Homo sapiens (human) | Kd | 10.0000 | 1 | 35 |
| Serine/threonine-protein kinase Nek5 | Homo sapiens (human) | Kd | 9.9542 | 3 | 59 |
| Serine/threonine-protein kinase Nek6 | Homo sapiens (human) | Kd | 10.0000 | 3 | 59 |
| Serine/threonine-protein kinase Nek7 | Homo sapiens (human) | Kd | 18.4582 | 4 | 107 |
| Serine/threonine-protein kinase Nek9 | Homo sapiens (human) | Kd | 20.6713 | 4 | 137 |
| Serine/threonine-protein kinase NIM1 | Homo sapiens (human) | Kd | 9.1625 | 2 | 40 |
| Serine/threonine-protein kinase NLK | Homo sapiens (human) | Kd | 20.6603 | 4 | 139 |
| Serine/threonine-protein kinase OSR1 | Homo sapiens (human) | Kd | 9.1915 | 2 | 40 |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | Kd | 8.8739 | 3 | 59 |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | Kd | 20.4198 | 4 | 129 |
| Serine/threonine-protein kinase PAK 3 | Homo sapiens (human) | Kd | 8.6018 | 3 | 59 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | Kd | 20.5416 | 4 | 140 |
| Serine/threonine-protein kinase PAK 5 | Homo sapiens (human) | Kd | 8.9212 | 3 | 59 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | Kd | 16.9987 | 4 | 97 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | EC50 | 5.0050 | 2 | 2 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | Kd | 20.4861 | 6 | 138 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | EC50 | 5.0050 | 2 | 2 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | Kd | 17.8858 | 5 | 108 |
| Serine/threonine-protein kinase pim-3 | Homo sapiens (human) | EC50 | 5.0050 | 2 | 2 |
| Serine/threonine-protein kinase pim-3 | Homo sapiens (human) | Kd | 8.2398 | 3 | 59 |
| Serine/threonine-protein kinase PknB | Mycobacterium tuberculosis H37Rv | Kd | 8.9340 | 1 | 35 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Kd | 18.8465 | 4 | 110 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | Kd | 9.0390 | 2 | 40 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | Kd | 9.6646 | 3 | 59 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Kd | 17.2771 | 6 | 142 |
| Serine/threonine-protein kinase PRP4 homolog | Homo sapiens (human) | Kd | 8.8373 | 2 | 40 |
| Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | Kd | 12.1212 | 4 | 69 |
| Serine/threonine-protein kinase RIO1 | Homo sapiens (human) | Kd | 8.3826 | 3 | 59 |
| Serine/threonine-protein kinase RIO2 | Homo sapiens (human) | Kd | 7.2522 | 3 | 41 |
| Serine/threonine-protein kinase RIO3 | Homo sapiens (human) | Kd | 7.6008 | 4 | 67 |
| Serine/threonine-protein kinase SBK1 | Homo sapiens (human) | Kd | 8.3017 | 1 | 35 |
| Serine/threonine-protein kinase Sgk3 | Homo sapiens (human) | Kd | 8.9320 | 1 | 35 |
| Serine/threonine-protein kinase SIK1 | Homo sapiens (human) | Kd | 7.4827 | 3 | 59 |
| Serine/threonine-protein kinase SIK2 | Homo sapiens (human) | Kd | 18.2000 | 4 | 135 |
| Serine/threonine-protein kinase SIK3 | Homo sapiens (human) | Kd | 21.3093 | 3 | 120 |
| Serine/threonine-protein kinase STK11 | Homo sapiens (human) | Kd | 20.9693 | 4 | 138 |
| Serine/threonine-protein kinase TAO1 | Homo sapiens (human) | Kd | 20.5941 | 4 | 122 |
| Serine/threonine-protein kinase TAO2 | Homo sapiens (human) | Kd | 22.0692 | 2 | 111 |
| Serine/threonine-protein kinase TAO3 | Homo sapiens (human) | Kd | 21.2189 | 3 | 119 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | Kd | 21.4972 | 3 | 122 |
| Serine/threonine-protein kinase TNNI3K | Homo sapiens (human) | Kd | 7.1552 | 4 | 60 |
| Serine/threonine-protein kinase tousled-like 1 | Homo sapiens (human) | Kd | 9.2405 | 3 | 59 |
| Serine/threonine-protein kinase tousled-like 2 | Homo sapiens (human) | Kd | 9.3744 | 3 | 59 |
| Serine/threonine-protein kinase ULK1 | Homo sapiens (human) | Kd | 21.7082 | 3 | 115 |
| Serine/threonine-protein kinase ULK2 | Homo sapiens (human) | Kd | 8.0334 | 2 | 40 |
| Serine/threonine-protein kinase ULK3 | Homo sapiens (human) | Kd | 21.5777 | 3 | 123 |
| Serine/threonine-protein kinase ULK3 | Mus musculus (house mouse) | Kd | 0.7050 | 1 | 4 |
| Serine/threonine-protein kinase VRK2 | Homo sapiens (human) | Kd | 9.0849 | 1 | 35 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | Kd | 22.1726 | 3 | 117 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 | Homo sapiens (human) | Kd | 29.6068 | 1 | 76 |
| Sex hormone-binding globulin | Homo sapiens (human) | Kd | 8.0906 | 1 | 5 |
| Short transient receptor potential channel 5 | Homo sapiens (human) | EC50 | 0.0076 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | EC50 | 30.0000 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 30.0000 | 2 | 2 |
| Signal recognition particle receptor subunit alpha | Homo sapiens (human) | Kd | 30.0000 | 1 | 64 |
| Signal transducer and activator of transcription 1-alpha/beta | Homo sapiens (human) | Kd | 0.7000 | 1 | 1 |
| signal transducer and activator of transcription 1-alpha/beta isoform alpha | Homo sapiens (human) | EC50 | 2.0600 | 1 | 1 |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | EC50 | 10.0000 | 5 | 5 |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | Kd | 1.5280 | 1 | 1 |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | EC50 | 0.8300 | 1 | 1 |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | Kd | 8.2000 | 2 | 4 |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | Kd | 0.1800 | 1 | 1 |
| Smoothened homolog | Homo sapiens (human) | EC50 | 0.0025 | 2 | 2 |
| Smoothened homolog | Mus musculus (house mouse) | EC50 | 0.0034 | 2 | 2 |
| Smoothened homolog | Homo sapiens (human) | Kd | 0.0975 | 1 | 1 |
| SNF-related serine/threonine-protein kinase | Homo sapiens (human) | Kd | 9.7326 | 1 | 35 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | EC50 | 1.4500 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | EC50 | 110.5757 | 1 | 3 |
| Sodium/bile acid cotransporter | Homo sapiens (human) | Kd | 64.3000 | 1 | 1 |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | EC50 | 0.9539 | 20 | 21 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 2 |
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | Kd | 1.9600 | 1 | 1 |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | EC50 | 1.7449 | 12 | 13 |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | EC50 | 1.4356 | 6 | 7 |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | EC50 | 1.3227 | 9 | 10 |
| Spike glycoprotein | Betacoronavirus England 1 | EC50 | 28.8952 | 1 | 24 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | EC50 | 28.8952 | 1 | 24 |
| SRSF protein kinase 1 | Homo sapiens (human) | Kd | 8.4172 | 3 | 59 |
| SRSF protein kinase 2 | Homo sapiens (human) | Kd | 8.8485 | 3 | 59 |
| SRSF protein kinase 3 | Homo sapiens (human) | Kd | 8.1970 | 2 | 40 |
| STAT3, partial | Homo sapiens (human) | EC50 | 55.7000 | 1 | 1 |
| STE20-like serine/threonine-protein kinase | Homo sapiens (human) | Kd | 16.2974 | 6 | 144 |
| STE20-related kinase adapter protein alpha | Homo sapiens (human) | Kd | 28.9438 | 1 | 78 |
| STE20/SPS1-related proline-alanine-rich protein kinase | Homo sapiens (human) | Kd | 9.1470 | 2 | 40 |
| Stimulator of interferon genes protein | Homo sapiens (human) | EC50 | 100.0000 | 6 | 6 |
| Stimulator of interferon genes protein | Mus musculus (house mouse) | EC50 | 49.5500 | 4 | 4 |
| Stimulator of interferon genes protein | Homo sapiens (human) | Kd | 157.0000 | 1 | 1 |
| Stimulator of interferon genes protein | Mus musculus (house mouse) | Kd | 34.4925 | 3 | 4 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 | 33.8392 | 2 | 14 |
| Stromelysin-1 | Homo sapiens (human) | Kd | 25,000.0000 | 1 | 1 |
| Structural maintenance of chromosomes protein 1A | Homo sapiens (human) | Kd | 29.5826 | 1 | 71 |
| Structural maintenance of chromosomes protein 2 | Homo sapiens (human) | Kd | 29.2476 | 1 | 78 |
| Substance-K receptor | Rattus norvegicus (Norway rat) | EC50 | 0.1800 | 1 | 1 |
| Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial | Homo sapiens (human) | Kd | 29.5589 | 1 | 68 |
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a | Homo sapiens (human) | EC50 | 91.1550 | 1 | 2 |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | EC50 | 0.0002 | 1 | 1 |
| Taste receptor type 2 member 16 | Homo sapiens (human) | EC50 | 20,000.0000 | 2 | 2 |
| Taste receptor type 2 member 46 | Homo sapiens (human) | EC50 | 8.6000 | 1 | 1 |
| Testis-specific serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 9.3220 | 3 | 59 |
| TGF-beta receptor type-1 | Homo sapiens (human) | Kd | 20.1693 | 4 | 139 |
| TGF-beta receptor type-2 | Homo sapiens (human) | Kd | 19.5292 | 4 | 134 |
| Thyroid hormone receptor-associated protein 3 | Homo sapiens (human) | Kd | 30.0000 | 1 | 65 |
| Toll-like receptor 7 | Homo sapiens (human) | EC50 | 8.2200 | 6 | 6 |
| Toll-like receptor 8 | Homo sapiens (human) | EC50 | 270.0000 | 1 | 1 |
| TRAF2 and NCK-interacting protein kinase | Homo sapiens (human) | Kd | 17.1964 | 6 | 138 |
| Transcription factor AP-1 | Homo sapiens (human) | EC50 | 0.8100 | 2 | 2 |
| transcription factor p65 isoform 1 | Homo sapiens (human) | EC50 | 55.9410 | 1 | 1 |
| Transient receptor potential cation channel subfamily A member 1 | Homo sapiens (human) | EC50 | 11.3529 | 15 | 24 |
| Transient receptor potential cation channel subfamily A member 1 | Mus musculus (house mouse) | EC50 | 22.0000 | 1 | 1 |
| Transient receptor potential cation channel subfamily A member 1 | Rattus norvegicus (Norway rat) | EC50 | 3.4782 | 4 | 4 |
| Transient receptor potential cation channel subfamily M member 6 | Homo sapiens (human) | Kd | 10.0000 | 1 | 35 |
| Transient receptor potential cation channel subfamily M member 8 | Mus musculus (house mouse) | EC50 | 4.2500 | 1 | 2 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | EC50 | 170.0000 | 1 | 2 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Kd | 19.9526 | 1 | 1 |
| Translocator protein | Homo sapiens (human) | Kd | 0.0081 | 3 | 3 |
| Translocator protein | Rattus norvegicus (Norway rat) | Kd | 0.0013 | 2 | 2 |
| Transmembrane prolyl 4-hydroxylase | Homo sapiens (human) | EC50 | 50.0000 | 1 | 2 |
| Transmembrane protease serine 2 | Homo sapiens (human) | EC50 | 27.7794 | 2 | 25 |
| Transthyretin | Homo sapiens (human) | EC50 | 15.8000 | 1 | 2 |
| Transthyretin | Homo sapiens (human) | Kd | 3.1000 | 5 | 8 |
| Tubulin alpha-1A chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-1A chain | Sus scrofa (pig) | EC50 | 0.5200 | 1 | 1 |
| Tubulin alpha-1A chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin alpha-1A chain | Rattus norvegicus (Norway rat) | Kd | 5.5309 | 1 | 19 |
| Tubulin alpha-1A chain | Sus scrofa (pig) | Kd | 14.9360 | 5 | 5 |
| Tubulin alpha-1B chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-1B chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin alpha-1C chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-1C chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin alpha-3C chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-3C chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin alpha-3E chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-3E chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin alpha-4A chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin alpha-4A chain | Homo sapiens (human) | Kd | 93.3772 | 3 | 5 |
| Tubulin beta 8B | Homo sapiens (human) | Kd | 0.5790 | 1 | 1 |
| Tubulin beta chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta chain | Sus scrofa (pig) | EC50 | 0.5200 | 1 | 1 |
| Tubulin beta chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta chain | Sus scrofa (pig) | Kd | 14.9360 | 5 | 5 |
| Tubulin beta-1 chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-1 chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-2A chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-2A chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-2B chain | Bos taurus (cattle) | EC50 | 0.8300 | 1 | 1 |
| Tubulin beta-2B chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-2B chain | Bos taurus (cattle) | Kd | 8.2000 | 2 | 2 |
| Tubulin beta-2B chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-3 chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-3 chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-4A chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-4A chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-4B chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-4B chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-6 chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-6 chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Tubulin beta-8 chain | Homo sapiens (human) | EC50 | 13.0402 | 4 | 4 |
| Tubulin beta-8 chain | Homo sapiens (human) | Kd | 77.9108 | 4 | 6 |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | Kd | 0.0430 | 1 | 2 |
| Type-2 angiotensin II receptor | Homo sapiens (human) | Kd | 0.0403 | 2 | 3 |
| Tyrosine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 29.6442 | 1 | 75 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | EC50 | 1.1942 | 5 | 11 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Kd | 6.3481 | 47 | 883 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | Kd | 15.8607 | 9 | 150 |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | Kd | 4.6453 | 4 | 61 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | EC50 | 0.0383 | 2 | 3 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | Kd | 17.9072 | 7 | 141 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | Kd | 19.6211 | 5 | 143 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | Kd | 19.0422 | 5 | 140 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | Kd | 20.4563 | 4 | 140 |
| Tyrosine-protein kinase Fgr | Homo sapiens (human) | Kd | 12.2308 | 6 | 97 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | Kd | 15.7367 | 7 | 144 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | Kd | 18.1135 | 6 | 141 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | Kd | 16.8543 | 5 | 139 |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | Kd | 8.7025 | 5 | 63 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | EC50 | 4.0720 | 3 | 4 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | Kd | 17.6882 | 8 | 177 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | EC50 | 1.2747 | 3 | 3 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | Kd | 13.5972 | 6 | 90 |
| Tyrosine-protein kinase JAK2 | Mus musculus (house mouse) | EC50 | 0.1860 | 1 | 1 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | Kd | 6.5646 | 6 | 64 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | Kd | 15.0354 | 7 | 145 |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | Kd | 16.3776 | 6 | 141 |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | Kd | 13.1315 | 5 | 83 |
| Tyrosine-protein kinase receptor Tie-1 | Homo sapiens (human) | Kd | 5.8122 | 3 | 59 |
| Tyrosine-protein kinase receptor TYRO3 | Homo sapiens (human) | Kd | 7.9209 | 5 | 61 |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | Kd | 5.9229 | 4 | 60 |
| Tyrosine-protein kinase Srms | Homo sapiens (human) | Kd | 8.3110 | 3 | 59 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | EC50 | 60.9286 | 3 | 7 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | Kd | 20.3940 | 4 | 138 |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | Kd | 19.0638 | 6 | 139 |
| Tyrosine-protein kinase TXK | Homo sapiens (human) | Kd | 7.5636 | 4 | 61 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | Kd | 17.2039 | 5 | 139 |
| Tyrosine-protein kinase ZAP-70 | Homo sapiens (human) | Kd | 9.3831 | 3 | 59 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Kd | 6.0800 | 1 | 1 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase | Homo sapiens (human) | Kd | 29.6184 | 1 | 75 |
| UMP-CMP kinase | Homo sapiens (human) | Kd | 28.6958 | 1 | 46 |
| Uncharacterized aarF domain-containing protein kinase 5 | Homo sapiens (human) | Kd | 29.3916 | 1 | 48 |
| Uncharacterized protein FLJ45252 | Homo sapiens (human) | Kd | 26.1185 | 1 | 76 |
| Uncharacterized serine/threonine-protein kinase SBK3 | Homo sapiens (human) | Kd | 9.2460 | 2 | 40 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | Kd | 4.7316 | 6 | 62 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | EC50 | 1.0833 | 3 | 3 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | Kd | 5.0080 | 8 | 69 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | Kd | 5.1811 | 8 | 68 |
| vasopressin V1a receptor | Homo sapiens (human) | EC50 | 12.0700 | 1 | 1 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1 | 79 |
| Vitamin D-binding protein | Homo sapiens (human) | Kd | 0.0240 | 1 | 1 |
| Vitamin D3 receptor | Bos taurus (cattle) | EC50 | 0.0001 | 2 | 2 |
| Vitamin D3 receptor | Homo sapiens (human) | EC50 | 0.0394 | 36 | 36 |
| Vitamin D3 receptor | Mus musculus (house mouse) | EC50 | 0.1000 | 1 | 1 |
| Vitamin D3 receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0002 | 7 | 7 |
| Vitamin D3 receptor | Homo sapiens (human) | Kd | 0.0001 | 1 | 1 |
| Vitamin D3 receptor | Sus scrofa (pig) | Kd | 0.0001 | 1 | 1 |
| Vitamin D3 receptor A | Danio rerio (zebrafish) | EC50 | 0.0055 | 1 | 1 |
| Vitamin D3 receptor A | Danio rerio (zebrafish) | Kd | 1.2000 | 1 | 1 |
| Voltage-dependent anion-selective channel protein 2 | Homo sapiens (human) | Kd | 0.1000 | 1 | 1 |
| voltage-dependent T-type calcium channel subunit alpha-1H isoform a | Homo sapiens (human) | EC50 | 3.9900 | 1 | 1 |
| Wee1-like protein kinase | Homo sapiens (human) | Kd | 20.3826 | 6 | 142 |
| Wee1-like protein kinase 2 | Homo sapiens (human) | Kd | 8.8615 | 3 | 42 |
| Zinc finger protein Aiolos | Homo sapiens (human) | EC50 | 0.0545 | 1 | 2 |
| Zinc finger protein mex-5 | Caenorhabditis elegans | EC50 | 110.5757 | 1 | 3 |